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Abstract 
Research on sustainable technologies has accelerated during the past two decades to 
find alternative energy sources and combat envi ronmental  pollution, as well as to 
find alternative cancer treatments.  One of the most intensively researched areas to 
achieve this, is the development of new sources of solar energy conversion and 
utilisation.  
 
The first chapter gives a summary of various solar cell technologies and photovoltaic 
conversion devices, and also highlights some potential medicinal applications of the 
prepared complexes described in this work. It states the aim and objectives of this 
investigation, and concludes with the hypothesis. Chapter 2 gives a summary of the 
Cu-catalysed [3+2] cycloaddition reaction between an aryl azide and aryl alkene, 
known as the “click reaction”. It describes work to date on various types of addition 
reactions, the role of Cu(I) catalysts and the use of various solvents.  
 
In Chapter 3 the literature review continues with a discussion of the dye solar cell 
compounds (DSSC) themselves, and focuses on the synthesis of a range of organic 
ligands (L1-L9). The final literature review Chapter 4 gives a summary of biological 
activities of bioinorganic compounds used as medicinal drugs, in particular as 
anticancer agents. 
 
All the ligands and organo-transition metal complexes synthesized in this 
investigation, were characterised comprehensively by 1H-, 13C-, DEPT, 1H- 1H COSY, 
1H- 13C HQMC NMR, mass spectroscopy, FT-IR measurements, melting point 
determinations, UV-VIS absorbance determinations, fluorescence spectroscopy, X-
ray crystallography, magnetic susceptibility and conductivity measurements, with 
finally quantum yield calculations. The strategy was to first synthesize a series of nine 
ligands of the type 1,2,3-triazol-4-yl-pyridine (PYTA) (Chapter 6), and couple them 
to eight different transition metals (Chapter 6). These were compared to consider the 
effects of electron withdrawing and electron donating substituents on the various 
ligands on the properties, and specifically the fluorescence yields/properties, and the 
geometries of the final metal complexes. Finally, the chloro ligands were replaced by 
isothiocyanato ones and the comparison repeated for selected complexes (Chapter 8). 
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The investigation yielded a number of new and interesting results. In Chapter 6 a new 
series of PYTA ligands were readily and easily prepared through a convenient click 
chemistry approach. X-ray crystallography clearly indicated that the 1,2,3-triazole 
part had an azo-character. A novel crystal structure analysis of ligand L4 revealed that 
it had a unique one-dimensional zig-zag chain structure in the solid state, which was 
stabilised by intermolecular hydrogen bonds and stacking π-π interactions between 
the phenyl rings.  
 
In Chapter 7 the structural analysis indicated that complexes of the [M(L3)2(Cl)2] type 
were a rare example of the coexistence of two trans–coordinated Cl anions in the axial 
position. It was further demonstrated that the direct connection at the N8 position of 
the triazolyl ring of a 4-substituted phenyl substituent had a significant influence on 
the geometry of both the ligands and their corresponding M-complexes. The 
coplanarity of the organic framework led to slip-stacked π–π interactions between any 
two molecules of a complex.  Additionally, it was shown that the nature of the pendant 
substituent (X = CH3, OCH3, COOH, F, Cl, CN, H, CF3) could affect the electronic 
properties of the organo-metallic complexes. It was demonstrated that the pyridine 
and triazole rings occupied the equatorial plane, whereas the metal-Cl atoms are in 
the axial plane, except for Mn(II) and Cd(II) complexes where the metal-Cl atoms lay 
in the equatorial plane. A further new contribution was that the triazole and pyridine 
nitrogens from each of the ligands in the equatorial plane were trans to each other.  
Finally, it was proven that weak intermolecular interactions via (C–H–Cl), (C–H...N) 
and (C–H...O) resulted in an ordered three dimensional supramolecular structure in 
which the molecules adopted a head-to-tail orientation stabilised by hydrogen 
bonding and π…π stacking.  
 
In Chapter 8, a structural analysis indicated that the complexes [Zn(L3)2(NCS)2] and 
[Cd(L3)2(NCS)2] were rare examples of the coexistence of two trans–coordinated 
NCS anions in the axial positions in the mononuclear triazole-based octahedral 
configuration. This is in contrast to what is found in wide band ruthenium 
photosensitisers (e.g. N3 and N719) that are efficient photosensitisers, where the 
isothiocyanato groups are cis to each other. It was also proven that the substitution of 
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the chloro ligand by an isothiocyanato group in order to enhance the fluorescence of 
these complexes, failed to produce the desired effect. Finally, in Chapter 9, the 
remarkable structural resemblance of these novel compounds to bio-inorganic 
molecules with anticancer properties (such as cisplatin) indicated that compounds 
with the linkers bound to Co and Cu showed the maximum activity against some 
cancer cells, with a higher preference to target and kill colon cancer cells. This is a 
promising new development in the fight against cancer. Chapter 9 gives a final 
summary of the main findings and contributions of this work.  
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Chapter 1 : Solar Photovoltaic (PV) Technologies 
 
1.1 Introduction 
The world’s fossil fuel resources are unable to sustain our current energy requirements 
beyond the next few decades. Therefore, the need for inexpensive alternatives has become 
urgent. Solar radiation is the single most abundant energy source of our planet. For many 
millennia, humanity relied solely on renewable forms of solar energy, making use of direct 
forms like lighting or heat, and indirect forms like biomass or wind. With the explosion of 
the world population at the beginning of the 20th century and its growing energy demand, 
humans started to tap non-renewable fossil forms of ancient biomass like oil, gas and coal 
[1]. Our dependence on the burning of fossil fuels actually is a curse, which causes 
geopolitical tensions, environmental damage, and puts our climate at stake [2]. One of the 
biggest challenges ahead of human kind is to replace the fossil fuel with renewable energy 
sources while keeping pace with the worldwide increasing thirst for energy because of 
rising demand, especially from developing countries. This challenge requires a low-cost 
solution, using abundantly available raw materials. The sun is an obvious source of clean 
and cheap energy, already used by nature to sustain almost all life on earth. even before 
the industrial revolution, human life quality was greatly affected by the availability of 
energy. The escalated consumption of conventional sources of energy is leading to 
forecasted energy and environmental crises. Renewable energy sources such as solar 
energy are considered as a feasible alternative because “more energyfrom sunlight strikes 
earth in 1 hour than all of the energy consumed by humans in an entireyear”. [3] 
Harvesting just a fraction of the solar energy reaching the earth may solve many problems 
associated with both the energy and global environment [4]. Therefore, harnessing the 
power of the sun with photovoltaic technologies is very attractive and potentially scalable. 
Indeed, solar farms are already providing electricity within many countries such as Spain, 
Germany, Portugal, USA, India and UAE.  It is likely that solar energy will be used in 
conjunction with other renewable energy technologies and not on its own. Up to now, 
commercially available photovoltaic technologies are based on inorganic materials, which 
require high costs and highly energy consuming preparation methods. In addition, several 
of these materials, like CdTe, are toxic and have a low natural abundance. Organic 
photovoltaics can avoid this problem. However, the efficiencies of organic-based 
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photovoltaic cells are still at the moment a long way behind those obtained with purely 
inorganic based photovoltaic technologies. Conventional organic photovoltaic devices use 
donor and acceptor types of organic materials, which form a heterojunction favouring the 
separation of the excitation into two carriers. These carriers are then transported to the 
electrodes by the same organic materials that are used for the generation of the excitation. 
A material for classical organic photovoltaic devices should thus have both good light 
harvesting properties and good carrier transporting properties, which is a difficult task to 
achieve. On the other hand, the dye-sensitised solar cell (DSSC) technology separates the 
two requirements as the charge generation is done at the semiconductor-dye interface and 
the charge transport is done by the semiconductor and the electrolyte. Spectral properties 
optimisation can be done by modifying the dye alone, while carrier transport properties 
can be improved by optimising the semiconductor and the electrolyte composition. To 
obtain such compounds, organic moieties have been added on to metal cores producing 
bio-inorganic compounds. 
 
Another critical problem facing modern society is medical health care, and the 
increasing number of the human population suffering from various cancers. Cancer 
has long been known to mankind, but the treatment thereof has been met with various 
degrees of success, and depends to a large degree on the type of cancer and the very 
early diagnosis thereof. In the last few decades, bio-inorganic molecules have shown 
diverse anticancer activities. The mechanisms of action for these molecules seem to 
be interaction with DNA. These agents have received much attention and generated 
increased interest in medicinal inorganic chemistry and have been found useful in 
treatment of cancers, psoriasis and various anemias [5]. Several ruthenium complexes 
have been developed as an alternative to cis-platin as potential anticancer agents, 
because they display lower toxicity than their platinum counterparts [6-9]. Studies on 
DNA-binding of any such complexes are crucial in development of nucleic acid 
interaction, chemotherapy and photodynamic treatment. Considerable efforts have 
gone into studying the binding mode, sites and affinities which could lead to 
opportunities to discover important information on site–specific DNA probes. 
Therefore, a study to modify the main ligand is quite significant for understanding the 
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DNA–binding and action mechanisms of selected suitable organometal complexes 
[10-12]. Triazoles from “click chemistry” are convenient ligands for the formation of 
promising organometallic complexes bearing combined triazole-amine or triazole-
carboxylate moieties with different chelation modes. One triazole-amine platinum 
complexes that exhibited selective cytotoxicity against breast cancer cells lines was 
recently reported [13-15]. 
 
1.2 Photovoltaic cells 
Photovoltaics (PV), also referred to as solar cells, convert sunlight directly into 
electricity. In 1839, Becguerel discovered the photo-voltaic effect [16]. Adams and 
Day found that solid selenium displays the photo-voltaic effect [17].  The first 
photovoltaic cell was created by Fritz in 1883, however, the efficiency was less than 
1% [18]. Einstein published further information about the photovoltaic effect in 1904 
but again the efficiency was less than 1% [19]. A 11% increase in efficiency was 
achieved by workers at the Bell Telephone Laboratories (1954) [20-22]. Currently 
there are three types of photovoltaic cells and are described in Scheme 1.1.
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Scheme 1.1: Illustrated the three types of photovoltaic cells used in different 
applications [23]. 
 
 
The best laboratory efficiencies from various materials and a number of photovoltaic 
technologies over the last 35 years have been collected by the National Renewable 
Energy Laboratory (NREL) in the US and the data are plotted in Figure 1.1. The data 
show two relatively new entries; dye-sensitised solar cells (DSCs) and organic 
photovoltaic cells [24]. 
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Figure 1.1: Statistics of efficiency for different kinds of solar cells [24].
 6 
 
PV cell technologies are divided into three generations, depending on the basic 
material that they contain: 
 
• First-generation PV systems are based on the wafer-based crystalline silicon (c-Si) 
technology, either single crystalline (sc-Si) or multi-crystalline (mc-Si). Crystalline 
silicon cells are classified into three main types depending on how the Si wafers are 
made. They are: 
• Monocrystalline (Mono c-Si) sometimes also called single crystalline (sc-Si) 
• Polycrystalline (Poly c-Si), sometimes referred to as multi-crystalline (mc-Si) 
• EFG ribbon silicon and silicon sheet-defined film growth (EFG ribbon-sheet c-Si) 
[25, 26]. 
 
The crystalline silicon solar cells have numerous advantages such as, high efficiency 
than that of other solar cells and easy availability which forced the producers to use 
them as a potential material for solar cells [27]. 
 
• Second-generation PV systems are based on thin-film technology and include three 
families: 
 
1) Amorphous (a-Si) and micromorph silicon (a-Si/μc-Si). 
2) Cadmium-Telluride (CdTe)3) Copper- Indium-Selenide (CIS) and Copper-Indium- 
Gallium-Diselenide (CIGS) 
• Third-generation PV systems with concentrating PV (CPV) and organic PV cells 
have not yet been commercialised (e.g. multi-junction concentrating PV) and are 
concepts still in need of basic R&D (e.g. quantum-structured PV cells). Third-
generation PV technologies can be classified into four types including; concentrating 
PV (CPV), dye-sensitised solar cells (DSSC) and organic solar cells [28]. 
• Concentrating PV (CPV). 
• Dye-sensitised solar cells (DSSC). 
• Organic solar cells. 
• Novel and emerging solar cell concepts. 
 
Table 1.1:  illustrations an overview and comparison of major PV technologies 
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Table 1.1: An overview and comparison of major PV technologies [27]. 
  1st Generation  2nd Generation   3rd Generation    
Technology Units Single 
crystalline 
silicon (Si)  
Poly 
Crystalline 
(sc-Si) silicon   
 (pc-Si) 
Amorphous 
Silicon  
(a-Si) 
Copper 
Gallium 
Diselenide 
(CIS/CIGS) 
Cadmium  
  Telluride 
Solar cell 
III-V Compound  
Multi junction 
Concentrated  
PV(CPV) 
Dye-
Sensitise
d 
(DSSC) 
Organic 
or 
Polymer  
 (OPV) 
Best research solar 
cell efficiency  at AM 
1.5 
% 24.7 10.4 
13.2 Tandem 
Single junction 20.3 16.5 43.5 
 
11.1 11.1 
Confirmed solar cell  
efficiency at AM 1.5 
% 20-24 14-18 6-8 10-12 8-10 
 
36-41 8.8 8.3 
Commercial PV 
module  
efficiency at AM1.5 
% 15-19 13-15 5-8 7-11 8-11 
 
25-30 1-5 1 
Commercial PV 
module  
efficiency at AM1.5 
% 
 
15-19 
 
13-15 
 
5-8 
 
7-11 
 
8-11 
 
25-30 
 
1-5 
 
1 
 
Confirmed maximum 
PV Module efficiency 
% 23 
 
16 
 
7.1/10.0 
 
12.1 
 
11.2 
 
25 
 
- 
 
- 
 
Current PV module 
cost 
USD/W < 1.4 < 1.4 ~ 0.8 ~ 0.9 ~ 0.9 - - - 
Market share in 2009 % 83 3 1 13 - - - - 
Market share in 2010 % 87 2 2 9 - - - - 
Maximum PV module  
output 
W 
 
 320 
 
300 
 
120 
 
120 
 
120 
 
- 
 
- 
 
PV module size m2 2.0 1.4-2.5 1.4 0.6-1.0 0.72 - - - 
Area needed per KW m2 7 8 15 10 11 - - - 
State of 
commercialization 
Mature 
with large 
scale 
production 
 
Mature with 
large scale 
production 
Early 
deployment 
phase, medium 
scale 
production 
Early phase, 
small scale 
production 
 
Early 
deployment 
phase, medium 
scale 
production 
Early 
deploymen
t phase, 
small scale 
production 
Just 
commercialised, 
small scale 
production 
R&D  
phase 
 
R&D  
phase 
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The main advantages and disadvantages solar cell technologies are presented in Table 
1.2 [26, 29]. 
 
Table 1.2: presented advantages and disadvantages of photovoltaic cells 
technologies 
 
Advantages of PV Cells Disadvantages of PV Cells 
Modular “custom-made” energy, can be designed  
for any application from watch to a multi-megawatt 
power plant and not requiring large building infrastructure. 
High initial costs 
Renewable technology Efficiency can be poor but improving 
No use of fuels and water costs Sunlight variability and seasonality 
low operation and maintenance (O&M) costs Requires large surface area since power  
density in sunlight can be low as  
1,000 watts/m2 
Environmentally friendly (no emissions of   carbon  
gases and other harmful compounds 
no noise, no moving parts, clean energy, safe, highly  
reliable, flexible, quiet to operate, renewable,  
domestically available 
PV generates direct current: special DC  
appliances or inverters are needed in off- 
grid applications energy storage is needed,  
such as batteries 
PV operates even in cloudy weather conditions PV cannot work without light 
long lifetime, up to 30 years large area needed for large scale  
applications 
minimal maintenance requirements cannot operate all the time 
 
A solar PV system is powered by many crystalline or thin film PV modules. 
Individual PV cells are interconnected to form a PV module. This takes the form of a 
panel for easy installation. Figure (1.2) illustrates common PV module technologies 
[30]. 
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Mono-crystalline        Poly-crystalline          Flexible amorphous                CIGS 
thin film 
silicon                          silicon                       thin film 
 
                                 
                                            organic solar cells thin film 
  
Figure 1.2: Common PV module technologies 
 
 
 
Photo-voltaics are one of the fastest growing renewable energy technologies and it is 
expected that it will play a major role in the global electricity generation mix.   
 
1.2.1 Mechanism of Photovoltaic (P-N junction) cells  
P-N junction photovoltaic (PV) cells are created from p-type semiconductors (having 
excessive electron holes (positive)) and N-type semiconductors (having excessive 
electron charge carriers (negative)).  When solar light hits the PV cell, two types of 
electrons are produced, negatively and positively charged, within the semiconductors.  
The negatively charged electrons are attracted to the N-type semiconductor whilst the 
positively charged electrons are attracted to the P-type semiconductor.  The potential 
difference across the two semiconductors allows the generation of a current if a load 
(e.g. light bulb) is placed between the two electrodes [31]. A pictorial representation 
of this mechanism is depicted in Figure 1.3. 
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Figure 1.3: A typical structure of Si-based solar cell panel with metal contacts 
and anti-reflection coating [32]. 
 
1.2.2 Mechanism of Dye sensitised photovoltaic cells 
Dye-sensitised solar cells (DSSC) mimic photosynthesis by utilising light absorbing 
pigements (in nature this is chlorophyll).  In p-n junction PV cells the semiconductors 
provides photoelectrons, charge carrier separation and transportation, whilst in the 
DSSC PV cells the semiconductor is used for charge transport and the photoelectrons 
are created by the separate photosensitive dye.  Charge separation is formed at the 
surface between dye, semiconductor and electrolyte (normally an organic hole 
transport material).  The basic design of the DSSC involves semiconductor structures 
formed between a photo-sensitised anode and an electrolyte. The semiconductor 
nanocrystals antennae that harvest the sunlight (photons) and the dye molecule 
perform charge separation (photocurrent), mimicking natural photosynthesis [33]. 
DSSC was introduced by O’Regan and Grätzel in 1991 [33, 34].  These cells are low-
cost materials and are simple to manufacture. They release electrons from metals 
covered by a light absorbing pigment. The exposure to UV light and the use of a liquid 
electrolyte makes the cells prone to degradation and freezing respectively over time. 
Broadband dyes and electrolytes have 12% efficiency [35], compared to 4% to 5% of 
DSSC commercial efficiencies due to the presence of few dyes that can absorb a broad 
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spectral range. The advantage of incorporating nanomaterials in DSSCs makes them 
able to accommodate thousands of organic dyes. 
The mechanism of the primary steps to convert photons into current for dye sensitised 
solar cell (DSSC) is demonstrated in Figure 1.4. 
 
Figure 1.4: Schematic energy diagram and operating principle of DSSC [36] 
                      
The primary processes that occur in a DSSC for the solar energy–to–current 
conversion are given below: 
 
1. Photosensitises (such as Ru complexes) adsorbed on a suitable substrate (TiO2) 
surface absorb the incident photon flux. 
2. The photosensitsers are excited from the ground state (S) to the excited state (S∗) 
owing to the MLCT transition. The excited electrons are injected into the conduction 
band of the TiO2 electrode, resulting in the oxidation of the photosensitiser. 
 
S + hν → S∗                            (1) 
S∗ → S+ + e− (TiO2)                (2) 
 
3. Injected electrons in the conduction band of TiO2 are transported between TiO2 
nanoparticles with diffusion toward the back contact (TCO) and consequently reach 
the counter electrode through the external load and wiring. 
4. The oxidized photosensitiser (S+) accepts electrons from the I− ion redox mediator, 
regenerating the ground state (S), and I− is oxidized to the oxidized state, I3
−. 
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S+ + e− →S                     (3) 
5. The oxidized redox mediator, I3
−, diffuses toward the counter electrode and is re-
reduced to I− ions. 
I3
− + 2e− → 3I−              (4) 
 
Overall, electric power is generated without permanent chemical transformation. The 
performance of a DSSC is predominantly based on four energy levels of the 
components: the excited state (approximately LUMO) and the ground state (HOMO) 
of the photosensitiser, the Fermi level of the TiO2 electrode, which is located near the 
conduction band level, and the redox potential of the mediator (I−/I3
−) in the 
electrolyte. The photocurrent obtained from a DSSC is determined by the energy 
difference between the HOMO and the LUMO of the photosensitiser, analogous to 
the band gap, Eg, for inorganic semiconductor materials. The smaller the HOMO–
LUMO energy gap, the larger the photocurrent will be because of the utilization of 
the long wavelength region in the solar spectrum. The energy gap between the LUMO 
level and the conduction-band level of TiO2, ΔE1, is important, and the energy level 
of the LUMO must be sufficiently negative with respect to the conduction band of 
TiO2 to inject electrons effectively. In addition, substantial electronic coupling 
between the LUMO and the conduction band of TiO2 also leads to effective electron 
injection. The HOMO level of the complex must be sufficiently more positive than 
the redox potential of the I−/I3
− redox mediator to accept electrons effectively (ΔE2). 
The energy gaps, ΔE1 and ΔE2, must be larger than approximately 200mV as driving 
force for each of the electron transfer reactions to take place with optimal efficiency 
[37]. The voltage in the DSSC is developed by the energy gap between the Fermi level 
of a TiO2 electrode and the redox potential of the I
−/I3
− in the electrolyte. The 
conduction band level of the TiO2 electrode and the redox potential of I
−/I3
− were 
estimated to be −0.5V versus normal hydrogen electrode (NHE) and 0.4V versus 
NHE, respectively, as shown in Figure 1.4. [36], (or −0.7V versus saturated calomel 
electrode (SCE) and 0.2V versus SCE, respectively [37, 38]). Thus, in the case of a 
DSSC using a TiO2 electrode and I
−/I3
− redox mediator, the maximum voltage is 
expected to be approximately 0.9V, depending on the electrolyte component because 
the Fermi level of the TiO2 electrode depends on the electrolyte components and their 
concentrations. 
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In contrast to conventional p-n-type solar cells, the mechanism of a DSSC does not 
involve a charge-recombination process between electrons and holes because 
electrons are only injected from the photosensitiser into the semiconductor and a hole 
is not formed in the valence band of the semiconductor. In addition, charge transport 
takes place in the TiO2 film, which is separated from the photon absorption site (i.e. 
the photosensitiser). Thus, effective charge separation is expected. This photon-to-
current conversion mechanism in a DSSC is similar to the mechanism for 
photosynthesis in nature, in which chlorophyll functions as the photosensitiser and 
charge transport occurs in the membrane. 
 
A part of this investigation will focus on a new class of organic dyes synthesised from 
1,2,3-triazole compounds, synthesised using “click chemistry”, in combination with 
various base metals to form classical organometallic complexes.   These complexes 
will be tested as DSSC cells and thus demonstrate, as a proof of concept, their 
feasibility within the field. 
1.4 Current Cancer incidence and trends 
Cancer is a group of diseases involving uncontrolled and abnormal growth of cells, 
which potentially can invade or spread to other parts of the body.  In 2011 in the UK 
more than 33 000 people were diagnosed with cancer (around 910 people every day). 
The is 1 in 35 for men and 1 in 20 for women risk of developing cancer up to the age 
of 50 years. A common approach for discovery of agents with anticancer activity start 
with the empiric screening for antiproliferative or cytotoxic effects in human cancer 
cell lines. Generally, the most commonly used anticancer chemotherapeutic drugs 
work by inhibiting cell division (mitosis) by different mechanisms. There are 
numerous methods used to treat the cancer such as surgery, chemotherapy, 
immunotherapy and radiotherapy. The aim of any cancer treatment is to remove 
cancerous cells in order to prevent them from growing and spreading. Chemotherapy 
treatment involves drugs, which aim to kill cancer cells. Chemotherapy drugs have 
been used to combat cancers. These differ in their chemical structure and their actions 
within the human body. The most common chemotherapy drugs used are alkylating 
drugs such as nitrogen mustards, alkyl sulphonates, triazines, nitrosoureas, 
ethylenimine derivatives and metal salts containing platinum [39]. The incorporation 
of metal complexes with platinum central atoms such as Cisplatin or carboplatin into 
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cancer drugs may improve the effectiveness of the drug. However, cancer treatment 
efficacy suffers from side effects and resistance phenomena to the latter drugs. These 
problems in e.g. platinum-based anti-cancer therapy have stimulated increased 
research efforts in the search for novel non-platinum containing metal species. The 
bio-inorganic molecules designed in this thesis have a remarkable similarity in the 
structures to anticancer agents therefore the latter section of this investigation will 
focus on the potential anti-cancer properties of the photochemical compounds 
synthesised and characterised in this work. 
 
1.5 Motivation for current investigation 
There is a demand for electricity due to the growing populations and expanding 
economies. Electricity generation depends on burning fossil fuels, which cause 
pollution to the environment upon their emission of greenhouse gases. Strategies have 
been developed to reduce greenhouse gas emissions involved in the production of 
electricity. Hence, renewable energy sources have been developed in order to replace 
fossil fuels in the production of electricity. PV systems are an attractive tool in 
renewable energies as it does not produce greenhouse gases and relies on clean, safe 
and renewable energy. PV systems such as dye-sensitised solar cell (invented in 1991) 
are less expensive, more efficient with the advantage of being fabricated from 
abundant non-toxic materials with simple manufacturing processes. This thesis 
intends to focus partly on the development of the dye-sensitised solar compounds by 
synthesising a range of potential luminescent organotransition metal complexes, and 
their characterisation for further use in dye solar cells. Furthermore, the potential of 
the various synthesised organometallic complexes will be investigated as potential 
anti-cancer compounds to increase the current limited arsenal of medicines that can 
successfully treat cancer and overcome it. In both approaches it will be attempted to 
increase knowledge and make a new and novel contribution to the current field of 
photochemical compounds and their applications.  
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1.6 Aim and objectives of the investigation 
Inorder to accomplish the goals of this investigation, the following objectives will be 
pursued: 
1. Synthesis of transition metal complexes  
2. Characterisation of the physical properties of the complexes. 
3. Characterisation of the optical, fluorescent and crystallographic properties of the 
complexes to predict their suitability or not for DSSC. 
4. Evaluation of the complexes as potential anticancer agents. 
1.7 Hypothesis 
Careful ligand design and systematic variation of the metal centre can tune and 
optimise the optical absorption properties of a new series of chromophores and 
potentially useful anti-cancer drugs. 
1.8 Summary 
This chapter introduces the scientific areas that this research project will focus on.  
The next chapter elaborates on click chemistry and synthesis of organometallic 
complexes, particularly those involving triazoles. 
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Chapter 2 : THE CYCLOADDITION (CUAAC) “CLICK” 
REACTION 
 
2.1 Introduction 
In this work, a design for a new series of chromophores using click chemistry will be 
proposed.  This will include preparation of transition metal complexes to test as photo-
sensitisers for potential use in DSSCs and medicinal drug applications. The synthesis 
of photosensitisers will be undertaken using the CuAAC (copper catalyzed azide-
alkyne cycloaddition) reaction (a “click reaction”) to generate a five membered 
triazole ring. 
2.2 Click Chemistry 
In 2001, K. Barry Sharpless defined the very useful and “green” concept of “click 
chemistry”, with the aim of binding two molecular building blocks together in a facile, 
selective, high yielding reaction under mild water-tolerant conditions with little or no 
byproducts [1]. The most used “click” reaction that can fulfill these conditions is by 
far the Cu (I)-catalyzed azide/alkyne cycloaddition (CuAAC). Other “click” reactions 
are the thiol-ene, oxime, Diels-Alder, Michael addition and pyridyl sulfide reactions 
[1, 2]. 
He elaborated on the stringent criteria that the reactions must meet in order to classify 
the process as click chemistry.  The criteria (and advantages of click chemistry) are 
listed below: 
1. Modular 
2. Wide in scope 
3. High yielding 
4. Stereospecific (but not necessarily enantiospecific) 
5. Harmless byproducts 
6. Stable 
7. Show large thermodynamic driving force. 
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6. Simple reaction conditions 
7. Readily available starting materials 
9. Use of no solvent, or benign (water) or easily removed 
10. Simple product isolation (non-chromatographic) 
The following are reactions, which exemplify the characteristics of click chemistry: 
 
Table 2.1. Presented the summary of typical click reactions [3]. 
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Table 2.1: Summary of Typical Click Reactions [3] 
Classifications Mechanism Reagent A Reagent B Notes on reaction 
Copper catalyzed reactions Cu-catalyzed [3+2] azide-alkyne cycloaddition 
(CuAAC) 
azide alkyne 2 h at 60 °C in H2O 
Copper-free reactions Strain-promoted [3+2] azide-alkyne cycloaddition 
(SPAAC) 
azide cyclooctyne 1 h at RT 
 [3+2] Huisgen cycloaddition azide activated alkyne 4 h at 50 °C 
 [3+2] cycloaddittion azide electron-deficient alkyne 12 h at RT in H2O 
 [3+2] cycloaddittion azide aryne 4 h at RT in THF with crown ether or 24h at RT in 
CH3CN 
 Diels–Alder retro-[4+2] cycloaddition tetrazine alkene 40 min at 25 (100% yield) N2 is the only by-product 
 1,3-dipolar cycloaddition (photoclick) tetrazole alkene few mi n UV irradiation and then overnight at 4 °C 
 hetero-Diels–Alder cycloaddition dithioester diene 10 min at RT 
 [4+2] Diels–Alder reaction anthracene maleimide 2 days at reflux in toluene 
 reaction radical addition (thio click) thiol alkene 30 min UV (quantitative conv.) or 24 h UV 
irradiation (>96%) 
 Michael addition thiol enone 24 h at RT in CH3CN 
 Michael addition thiol maleimide 1 h at 40 °C in THF or 16 h at RT in dioxane 
 Nucleophilic substitution thiol para-fluoro overnight at RT in DMF or 60 min at 40 °C in DMF 
 Nucleophilic substitution amine para-fluoro 20 min MW at 95 °C in NMP as solvent 
Thiol-based condensation CBT 1,2-aminothiol pH=7.4 in PBS 
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2.3 Triazoles 
Triazoles are a group of compounds regarded as azoles with the molecular formula 
C2H3N3 [4].  They contain a characteristic ring structure of five-membered nitrogen 
heterocyclic atoms in addition to one other non-carbon atom of either nitrogen, sulfur 
or oxygen [4]. The aromatic structures of azoles constitute two double bonds, Figure 
2.1. 
 
 
 
 
 
Figure 2.1: The chemical structure of azole five-membered nitrogen heterocyclic 
ring compounds [4]. 
 
There are two isomeric chemical compounds related to triazoles. The two isomers are 
given in Figure 2.2 
 
Figure 2.2: The isomeric forms of triazole [2-5]. 
 
A 1,2,3-triazole structure contains three adjacent nitrogen atoms with three available 
substitution sites found at positions 1, 4 and 1, 5 Figure 2.2. The planar unsaturated 
ring of atoms in the 1,2,3-triazole makes it a building block for more complex 
compounds [5]. The development of 1,2,3-triazoles for drug discovery and industrial 
use has been shown to be very versatile. The uses for triazoles have been found in 
various areas and are continuously growing. 
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The synthesis of 1,2,3-triazoles is distinctive in that there are a multitude of methods 
by which to achieve the preferred outcome. Depending on the application of the 
desirable product, an acceptable procedure likely already exists. The three most 
common methods for the synthesis of 1,2,3-triazoles all contain elements from the 
Huisgen 1,3-dipolar azide- alkyne cycloaddition (AAC) [6]. Those methods include: 
(1)-The regiospecific, copper-calayzed azide-alkyne cycloaddition (CuAAC) [7, 8] 
(2)-The strain-promoted, metal free AAC of cyclooctynes [9] and (3)-The ruthenium-
catalyzed azide-alkyne (RuAAC) of both terminal and internal alkynes [10]. These 
three methods as well as our contributions to the CuAAC will be described carefully 
within this chapter. 
 
2.4 [3+2] cycloaddition reactions, Huisgen 1, 3-dipolar cycloadditions 
The synthesis of complex heterocyclic compounds in a stereospecific manner is an 
important area of organic chemistry. The syntheses of a number of heterocyclic 
compounds are based upon cycloaddition reactions. Recently, asymmetric [3 + 2] 
cycloaddition reactions using chiral organocatalysts mediated by different metals 
have provided new methods for the construction of stereochemically complex 
heterocyclic compounds. Specifically, [3 + 2] cycloaddition is an excellent approach 
for the synthesis of many types of five-membered ring systems starting from a 3-atom 
and a 2-atom precursor. 
Generally speaking, [3 + 2] cycloaddition is a broad concept that includes 1,3-dipolar 
cycloadditions which provide a very efficient way to synthesise complex natural 
products and medicinal molecules [11]. In other words, cycloaddition reactions that 
involve 1,3-dipoles reacting with 𝜋-bonds of dipolarophiles to give five-membered 
rings which are called [3 + 2] cycloaddition reactions [12]. A 1,3-dipole usually 
contains heteroatoms and four 𝜋-electrons which are distributed over three atoms, 
such as azide, diazoalkane, nitrous oxide, nitrile imine, nitrile ylide, nitrile oxide, 
azomethine imine, azoxy compound, azomethine ylide, as well as nitrone, carbonyl 
oxide and ozone [13]. A 1,3-dipolar cycloaddition reaction can also be described as 
involving at least one mesomeric state structure that represents a charged dipole and 
a dipolarophile. The dipolarophiles usually are alkene or alkyne derivatives. In 1864, 
Griss described organic azides as a new class of compounds [14]. Organic azides 
belong to the propargyl-allenyl category of dipoles as shown in Figure 2.3. 
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                                  (a)                                              (b) 
Figure 2.3: The two possible resonance forms (a) or (b) to the electronic 
structure of azide isomers [15]. 
 
The first reaction between azide and alkyne yielding 1,2,3-triazole (Figure 2.4) was 
reported at the end of the 19th century [16]: keeping an ester solution of phenyl azide 
(1) and dimethyl ether of acetylenedicarboxylic acid (2) in the light or heating it in a 
sealed ampoule (8 h at 100°C), Michael obtained the corresponding triazole (3). 
 
 
 
 
 
 
Figure 2.4: The first synthesis of 1,2,3-triazole by the cycloaddition reaction [16]. 
At the end of the 1950s/early 1960s, Huisgen developed the general concept of 1,3-
dipolar cycloaddition [17, 18], a variant of which is the reaction between azides and 
alkynes. 
Huisgen 1, 3-dipolar cycloadditions [19] are exergonic combining procedures that aim 
to integrate two unsaturated reactants to yield a wide range of five-membered 
heterocyclic compounds [20]. The cycloaddition of azides and alkynes to give 
triazoles [21] is an effective method for the latter generation. Unfortunately, the high 
risks involved in the development of organic azides have kept chemists from refining 
and studying this method in detail. Cycloaddition is a faster and more selective 
procedure for the production of 1,3-dipoles other than azide. This is due to its three-
atom dipole structure, which makes it free of side reactions.   
 
The reaction between azides and alkynes was actively studied. However, the fact that 
the interaction between asymmetric or terminal alkynes with azides (4) yields a 
mixture (frequently, hardly separable) of two triazole isomers interfered with its wide 
application, for example in the case of terminal alkynes (5), such as these 1,4- (6) and 
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1,5-disubstituted (7) triazoles Figure 2.5. The ratio of the products strongly depended 
on the type of substituents R1 and R2 in compounds (4) and (5) and the reaction 
conditions. However, it was impossible to obtain only one of the triazole isomers. 
 
Figure 2.5: The addition of the azides to the terminal alkynes [22]. 
 
The disadvantage of this approach was that using an unsymmetric alkyne would lead 
to different regioisomeric products Figure 2.6. Since there was not a universal method 
that would guarantee regioselectivity from these reactions, the problem of how to 
favour the formation of the 1,4- versus the 1,5-disubstituted products became a focus 
of much research. 
 
 
 
 
 
 
Figure 2.6: Example of regio-isomeric products when using an asymmetric 
alkyne [7]. 
A breakthrough took place in the 21st century when, in 2002, the groups of Meldal 
[7] and Sharpless [8]. Discovered that copper(I) compounds were able to efficiently 
catalyze this reaction with terminal alkynes, making the reaction itself regiospecific, 
i.e., the reaction yielded exclusively 1,4_disubstituted 1,2,3_triazoles (6) (see Figure 
2.5). 
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2.5 The copper(I)-catalyzed alkyne-azide cycloaddition (CuAAC) “click” 
reaction 
 
In 2002, the research groups of Fokin and Sharpless [8] and of Meldal et al. [7] 
independently reported the efficient Cu(I) catalysis of the azide/alkyne cycloaddition.  
The Huisgen reaction produces a mixture of 1,4 and 1,5-disubstitution products, 
whereas the CuAAC reaction of terminal alkynes is completely selective in the 
formation of the 1,4-disubstituted triazoles shown in Figure 2.7, with a variety of 
Cu(I) catalysts or precursors of Cu(I) catalysts [7, 8].  
 
Thus, the CuAAC reaction has become very popular a “click” reaction, and more than 
1000 research articles including many reviews [22-39] have been published on 
CuAAC since the Meldal and Fokin–Sharpless publications of 2002. The reasons for 
its success are that this “click” reaction is so easy to carry out and widely applicable. 
Indeed, it is unaffected by a variety of functional groups and can be achieved with 
many sources of Cu(I) catalysts and solvents, including aqueous ones. By completely 
changing the mechanism, the Cu(I) catalysts easily overcome the activation barrier 
that is high in the non-catalyzed Huisgen reaction (for instance 105kJ. mol−1 for the 
reaction between methylazide and propyne [40]). 
 
Huisgen 1, 3-dipolar cycloaddition of azide and alkynes 
 
 
Figure 2.7: Huisgen 1, 3-dipolar cycloadditions and CuAAC reaction [8]. 
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Comparison of the thermal reaction between benzyl azide and phenyl propargyl ether 
with the reaction of the same substrates but catalysed by copper shows the value of 
such catalysis (Figure 2.8). The thermal reaction ends in the production of two 
disubstituted triazole isomers. On the other hand, the reaction catalysed by copper 
exclusively yields the 1,4-isomer in 91% yield after 8 hours [8]. 
 
 
 
 
 
 
 
 
Figure 2.8: Thermal and Cu(I)-catalyzed 1,3-dipolar cycloadditions [8]. 
 
2.5.1 The Cu(I) catalysts and pre-catalysts 
An extensive variety of copper catalysts can be used for the CuAAC reaction provided 
that some Cu(I) species is generated [7, 8]. It is essential to keep the Cu(I) 
concentration at its maximum in order to facilitate the reaction. The pre-catalyst can 
be a Cu(II) salt (usually CuSO4) with a reducing agent (usually sodium ascorbate), a 
Cu(I) compound (preferably CuBr or CuOAc), together with a base or amine ligand 
and a reducing agent in order to inhibit aerobic oxidation to Cu(II), or a Cu(0) 
compound (wire, turnings, powder, or nanoparticles) [41, 42], the surface of which 
forms the required Cu(I) species. Some cupric salts or complexes such as Cu(OAc)2 
without added reductant also work as pre-catalysts, because they are strong oxidants 
that are reduced to catalytically active Cu(I) species by alkynes, as for instance in the 
well-known Glaser coupling [17, 23, 43]. The solvent is very flexible from organic to 
aqueous media, which is remarkable. The most common conditions are those reported 
by the Fokin and Sharpless group in 2002 using CuSO4 and 10 equiv. sodium 
ascorbate in an aqueous solvent such as water + an alcohol (t-BuOH, MeOH or EtOH) 
in order to solubilize the substrate and retain the favourable aqueous medium (only 2 
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equiv. sodium ascorbate are generally used). These aqueous conditions are very useful 
for biochemical conjugations as well as for organic syntheses.  
2.5.2. Solvents used in the CuAAC reaction 
The variety of solvents used in the CuAAC reaction, is one of the most remarkable 
features of this reaction. The numerous solvents include non-coordinating solvents 
such as toluene, chloroform and dichloromethane, weakly coordinating solvents such 
as THF, pyridine, and dioxane, polar solvents such as acetone, MeCN, DMF, DMSO, 
alcohols, and aqueous solvents including mixtures of water with an alcohol, acetone, 
THF, MeCN, DMSO, dioxane, biphasic media mixing water with dichloromethane, 
and other mixtures of two or even three solvents [7]. The CuSO4 + sodium ascorbate 
catalyst and the Cu(0) catalysts were used with a variety of aqueous solvents, whereas 
Cu(I) catalysts are used in a non-aqueous solvent most of the time. A key role of the 
solvent or solvent mixture is to solubilize the substrates and Cu(I) catalyst in order to 
ensure rapid reactions. Polar solvents favour the heterocycle bond formation step and 
the solubility of the substrate and catalysts, but if the solvents are coordinating, they 
can inhibit or slow down the required metal–substrate coordination. Therefore, DMF 
is an optimal solvent for the CuBr catalyst without additional ligand. In the presence 
of polyamine ligands, toluene gives good results, because it provides solubilisation of 
both catalyst and substrates without inhibiting substrate coordination. 
 
2.5.3 Mechanism of CuAAC 
Copper(I) compounds were able to efficiently catalyze this reaction with terminal 
alkynes, making the reaction itself regiospecific, i.e., the reaction yielded exclusively 
1,4-disubstituted 1,2,3-triazoles (6). This is because the catalysis dramatically 
changes the reaction mechanism. While the thermal Huisgen 1,3-dipolar 
cycloaddition is a concerted process, the reaction with the involvement of monovalent 
copper is a stepwise one. The following mechanism for this reaction was proposed [8, 
40]: alkyne (5) and catalyst (8) yield copper acetylenide (9) followed by the 
attachment of azide (4), thecyclization of the formed intermediate (10) into the 
structure (11) with the subsequent ring narrowing, the formation of the triazole copper 
derivative (12), and the final hydrolysis of the copper–carbon bond in Scheme. 2.1. In 
this reaction pathway, the energy of the intermediates is considerably decreased, 
elevating the overall transformation rate by seven to eight orders of magnitude as 
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compared with the concerted process. The reaction received an abbreviated name, 
CuAAC, i.e., Cu(I) catalyzed azide–alkyne cycloaddition. The CuAAC reaction, also 
referred to as the Huisgen–Meldal–Sharpless reaction, which specifically yields 1,4-
disubstituted 1,2,3-triazoles (6) under mild conditions proceeds in a wide range of 
solvents, including water, appeared to be the exclusively effective method for 
combinatorial chemistry.  
 
 
Scheme 2.1: The mechanism of Cu(I) catalyzed azide and terminal alkyne 
cycloaddition (CuAAC); L, monovalent ligands [8, 40]. 
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2.5 Copper-free click chemistry 
The strain-promoted 1, 3-dipolar cycloaddition of cyclooctynes and azides, also 
termed as the Cu-free click reaction, is a bioorthogonal reaction that enables the 
conjugation of two molecules in an aqueous and otherwise complex chemical 
environment through the formation of a stable triazole (Figure 2.9). This reaction 
possesses extreme selectivity and biocompatibility. 
The cycloaddition of the azide with alkynes requires activation of the corresponding 
alkyne compound. This can be achieved either by catalysis with copper(I), usually 
termed click chemistry, or through ring-strain. The copper-catalysed click reaction 
between azides and terminal alkynes is ideal for numerous applications, but due to the 
cytotoxic effects of the heavy metal, the application of the copper(I)-catalysed azide 
alkyne cycloaddition (CuAAC) in living systems is very limited, making the strain-
promoted variant the more preferable choice [44]. It was discovered by Wittig and 
Krebs, who observed the rapid reaction of cyclooctyne with phenyl azide providing a 
single product, the triazole (13) (Figure 2.9) [45].
 
 
 
 
 
 
 
 
Figure 2.9: Reaction of cyclooctyne with phenyl azide to triazole 13 [45].  
 
In 2004 Bertozzi and co-workers rediscovered this observation and since the reaction 
of the first substituted cyclooctyne (14) with azides was published, this class of 
reactions was named the strain-promoted azide alkyne cycloaddition (SPAAC) [9]. 
While the reaction rate of (14) Ewas only moderately increased compared to linear 
alkynes, many new cyclooctyne compounds with strongly improved kinetics have 
been produced since then, as shown in Figure 2.10. 
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Figure 2.10: Cyclooctyne derivatives for bioorthogonal reactions [9]. 
 
The attachment of one or two electron withdrawing fluorine substituents to the 
cyclooctyne ring resulted in a significant increase of the reaction rates of the 
compounds (15) and (16) compared to (14) [46-47]. Boons and co-workers have 
reported the synthesis of the even faster dibenzocyclooctynes (17) and (18), whose 
reactivities are enhanced by the additional ring strain provided by the two phenyl rings 
[48-49]. The introduction of a nitrogen atom into the 8-ring of a dibenzocyclooctyne 
further elevates the ring strain due to the shorter carbon-nitrogen bond and therefore 
additionally improves the reaction rates of dibenzoazacyclooctyne (19) and 
dibenzoazacyclooctynone (20) [50-51]. 
 
2.6 The ruthenium-catalyzed azide-alkyne cycloaddition 
In 2005, the group of Fokin and co-workers discovered a novel catalyst for click 
chemistry, and utilised various ruthenium complexes to produce either the 1,4- or the 
1,5- disubstituted triazole selectively in “ideal” 100% yield, suggesting complete 
regiochemical control, e.g. the [pentamethylcyclopentadienyl ruthenium(II)] 
complexes (Cp*Ru), such as [Cp*RuCl(PPh3)2] (Scheme 2.2). Cp*Ru complexes 
present 1,5-substituted 1,2,3-triazoles [52] in contrast to other catalysts. Moreover, 
they can work on both terminal and internal alkynes alike [53]. Figure 2.11 shows an 
example of this reaction. Limited information is available on the role of Ru(II) 
complexes in click chemistry.   
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Figure 2.11: A (Cp*Ru) catalyst in the click reaction exclusively forms 1,5-
substituted 1,2,3-triazoles. 
 
Scheme 2.2: Ruthenium-Catalyzed Cycloaddition of Benzyl Azide to 
Phenylacetylene. 
 
 
 
In 2008, the ruthenium catalyzed method to afford 1,5-disubstituted 1,2,3-trioazoles 
was reported by Fokin and co-workers [10]. A search for the catalysts revealed that 
pentamethylcyclopentadienyl ruthenium chloride [Cp*RuCl] complexes are capable 
to catalyse the cycloaddition of azides to terminal alkynes regioselectively leading to 
1,5-disubstituted 1,2,3-triazoles. Furthermore, RuAAC can also be used with internal 
alkynes (Figure. 2.12), providing fully substituted 1,2,3-triazoles, which compares 
with CuAAC. 
 
Figure 2.12: The ruthenium-catalyzed 1,3-dipolar cycloaddition [10]. 
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In contrast to the CuAAC, terminal and internal alkynes work in the RuAAC, causing 
the formation of completely substituted 1,2,3-triazoles and providing key mechanistic 
understanding. Ruthenium - acetylide species are not formed at all or if they do form, 
they are not part of the catalytic cycleshown in (Scheme 2.3). The [Cp*RuCl] 
(pentamethylcyclopentadienyl ruthenium chloride) catalyst was found to be most 
reactive and its reactivity was referred to the Cp* ligands ability to stabilise the higher 
oxidation states of ruthenium. The orientation of the R groups in the activated 
complex results in the 1,5-disubstituted product. The proposed reaction mechanism 
was examined computationally employing DFT calculations and indicate that the 
[Cp*RuCl]-catalyzed reactions of azides with alkynes involve an irreversible 
oxidative coupling of azide and alkyne to give ruthenacycles, followed by a rate-
determining reductive elimination.  
 
 
Scheme 2.3: Proposed intermediates in the catalytic cycle of the RuAAC 
reaction [10]. 
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2.7 Summary 
This chapter focuses on the synthetic strategies to produce metal-ligand complexes, 
particularly the “green” concept of “click chemistry”. This concentrated the efforts on 
triazole modified ligands using the CuAAC reaction.  Key mechanisms are discussed.  
The next chapter is a literature review of sensitisers for use in solar cells. 
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Chapter 3 : LITERATURE REVIEW: SENSITISERS 
FOR DSSC 
3.1 Dye sensitisers 
Dye sensitises serve as solar energy absorbers in DSSC makes them very efficient at 
harvesting light and converting photoelectric energy. The latter phenomenon depends 
on the capacity of the molecules to absorb incident photons, the conversion of such 
photons into electro-hole pairs as well as charge separation and collection [1]. An 
efficient photosensitiser must display three critical characteristics: first, an intense 
absorption in the visible region. This is followed by strong adsorption onto the 
semiconductor surface and the conduction band of the semiconductor must have an 
effective electron injection. Linearity and a rapid regeneration by the mediator layer 
would guarantee the recombination of electrons in the ground and excited states. 
 
As one of the most crucial factors that influence the performance of DSSC, the 
sensitising dyes involve various types of molecules from synthetic metal complexes 
[2] to natural dyes [3]. Also, a tremendous number of new synthetic metal-free organic 
dyes [4, 5] have been developed and employed as sensitisers in DSSCs. Among them 
Ru(II)-based complex dyes remain dominant in photoelectronic conversion efficiency 
[6]. However, the inconvenient purification and high cost of Ru-based dyes limit their 
development compared to the metal-free organic dyes. Even though none of the pure 
organic dyes has surpassed the conversion efficiency of the Ru-based sensitisers at 
present [7], they still have attracted considerable attention. A large number of studies 
have been devoted to design novel structural dyes, to clarify the relationship between 
the structure and properties and to optimise the DSSC devices [5, 8]. 
 
The positions of the energy levels in the sensitiser are of great importance. A small 
gap between the levels leads to the possibility to harvest more low energy photons. 
This enables the cell to have a high photocurrent output. However, the different 
electron transfers in the cell need enough driving force to proceed. The excited state 
oxidation potential of the dye, which is referred to as the lowest unoccupied molecular 
orbital (LUMO) of the dye, has to be sufficiently higher (more negative) than the 
conduction band edge of the semiconductor for efficient electron injection. At the 
same time the ground state oxidation potential or the highest occupied molecular 
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orbital (HOMO) of the dye needs to be lower (more positive) than the redox potential 
of the redox couple in the electrolyte for efficient regeneration of the oxidized dye. 
Several reviews describing the development of sensitisers for DSSCs, including both 
organic and inorganic dyes, have been published during the last few years [9 - 11]. 
 
The sensitisers used in DSSC can be subdivided into organic and inorganic dyes. 
Inorganic dyes include metal and ruthenium complexes in addition to osmium, metal 
porphyrin, phthalocyanine and inorganic quantum dots, while organic dye can be 
natural or synthetical. Unlike organic dyes, inorganic dyes are more stable at higher 
temperatures. 
 
3.2 Metal-complex sensitisers 
The wide absorption and photovoltaic nature of metal complexes make them suitable 
for DSSC applications. Such types of complex sensitisers usually have anchoring 
ligands and ancillary ligands. Anchoring ligands are responsible for the complexes 
adsorption onto the semiconductor surface and are also chromophoric groups. 
Ancillary ligands are not directly attached onto the semiconductor surface and can be 
used for tuning the overall properties of the complexes. Polypyridinic complexes of d6 
metal ions show intense metal to ligand charge transfer (MLCT) bands in the visible 
region, with potential interest for promoting charge injection processes to the 
conduction band of wide band gap semiconductors, such as TiO2, SnO2 and ZnO. The 
energies of the (MLCT) states can be altered systematically by modifying the 
anchoring ligands as well as by changing the ancillary ligands or their substituents.  
 
The wide possibilities to tune the MLCT energy resulted in the preparation of many 
different compounds that have been investigated for semiconductor sensitization. 
Among them, the best light-to-electricity conversion efficiency has been achieved by 
using ruthenium(II) polypyridyl complexes as TiO2 sensitisers in dye-sensitized solar 
cells.  In fact, a ruthenium bipyridine complex was used in the first efficient DSSC 
cell example reported in the breakthrough article by Grätzel and O’Regan in 1991 
[11]. A metal complex consists of a central metal ion with an ancillary binding 
molecule bearing at least one anchoring group. The absorption of light in the 
discernible element of the solar spectrum is caused by a charge transfer process from 
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a metal to a ligand (MLCT). Thus, the central metal ion is critical for the complex in 
which ancillary binding molecules, typically bipyridines or terpyridines, can be used 
with different substituents (alkyl, aryl, heterocycle, etc.). The purpose of this is to 
improve the photovoltaic performance by altering the original photophysical and 
electrochemical properties. In order to enable the injection of the excited electron into 
the conduction band (CB) of the semiconductor anchoring groups can be used to 
attach the dye. The adjustment of energy levels of the MLCT to enhance electron 
injection and dye regeneration kinetics can be done on any part of the new structure.  
 
3.2.1 Ruthenium complex dyes 
Ruthenium DSCs were first reported in 1991 by O’Regan and Grätzel [11]. These first 
ruthenium dye DSCs achieved 7.1% conversion efficiency (Figure 3.1). However, the 
structure of the ruthenium dye was complicated and contained three ruthenium metal 
centres. In 1993, Nazeeruzzin et al. published DSCs with 10.3% conversion [12], 
using a ruthenium dye sensitiser N3 (Figure 3.1). N3 contained one ruthenium center 
and was thus simpler than the ruthenium dye reported in 1991. The family of 
complexes [{(4,4’-CO2H)2(bipy)}2RuX2] (bipy=2,2’-bipyridyl; X=Cl, Br, I, CN, 
NCS) all perform well [12]. For example, the dye [{(4,4’-CO2H)2bipy}2Ru(NCS)2] 
(N3) and the doubly deprotonated analogue N719 shown in Figure 3.2 give a solar-
to-electrical energy conversion efficiency of over 10%. Use of a terpyridyl ligand led 
to the so-called “black dye” shown in Figure 3.2, which gives a very high IPCE 
(incident photon to current conversion efficiency) across the wavelength range 400–
700 nm and a cell efficiency of over 10% [13, 14]. 
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Figure 3.1: A ruthenium dye reported in Nature (1991) by Dr. O’Regan and 
Prof. Grätzel [11]. 
 
The most efficient DSSCs are based on ruthenium dyes. These were originally 
produced by the Grätzel group, and are known as N3, N719 and ‘black’ dyes [13, 14] 
(Figure 3.2). The metal-ligand charge transfer (MLCT) transition that mediates how 
the photoelectric charge is injected into TiO2 makes these dyes more durable and 
superior at harvesting light. In the ruthenium complexes the charge transfer is faster 
and more effective. This allows electrons to merge with the oxidised dye instead of 
entering into the circuit to yield energy [1].  
 
Considering that the efficiency of conversion in absorbed atoms is particularly high, 
most research to date has been focused on enhancing the absorption of incident light 
by altering the molecular structure of the dye. The main objective of this modification 
is to increase the extent to which photons are absorbed within a functional wavelength 
(as measured by the molar extinction coefficient, ε) and/or to increase the functional 
wavelength in itself near infrared (N-IR) [1, 12, 15]. 
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Figure 3.2: The chemical structures of the ruthenium-based dyes N3, N719 and 
‘black dye’ developed by the Grätzel group [16, 17]. 
Among these complexes, polypyridyl ruthenium sensitisers have outstanding redox 
properties and good responses to natural visible sunlight. Using a semiconductor film 
electrode with either a carboxylate or a phosphonate group, sensitisers are attached to 
the surface allowing the injection of electrons into the band of the semiconductor. In 
the case of the polypyridyl ruthenium dye, the number of metal centres determines 
the extent of light adsorption of the sensitisers. Whereas carboxylate polypyridyl 
ruthenium dye and phosphonate ruthenium dye bear similar metal centres, hence the 
polynuclear bipyridyl ruthenium dye is clearly different. The carboxylate polypyridyl 
ruthenium dye shows an in level constitution and that allows quantitative electron 
injection into the conduction band of the semiconductor. 
 
N3 and its tetrabutylammonium salt N719 (also known as black dye) are the most 
efficient amongst this type of sensitisers. N719 is considered the standard for dye 
sensitised solar cells, for instance. Recently, other ruthenium-based dyes such as 
amphiphilic ruthenium (Z907), and high-molar-extinction-coefficient ruthenium 
sensitisers (K19) have been the focus of extensive research for carboxylate 
polypyridyl ruthenium sensitisers. Both the molecular configuration and photovoltaic 
performance of solar cells are shown in Figure 3.3 and Table 3.1 [18 - 31]. 
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Figure 3.3: The chemical structures of the several ruthenium dye complexes [14, 
18 - 31]. 
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Table 3.1: Absorption spectra and photoelectric performance of different polybipyridyl ruthenium (II) complexes. 
Dye Abs/nm 
(ε /103 m2 mol−1) 
IPCE 
Incident photon-to-
current efficiency 
Jsc/mA·cm−2 
short circuit 
current 
Voc/mV 
open circuit 
voltage 
FF 
fill 
factor 
η/% efficiency Ref. 
 
N3 
N719 
Black Dye 
Black Dye 
Z907 
Z907 
K8 
K19 
N945 
Z910 
K73 
K51 
HRS-1 
Z955 
534(1.42) 
532(1.4) 
605(0.75) 
— 
526(1.22) 
526(1.22) 
555(1.80) 
543(1.82) 
550(1.89) 
543(1.70) 
545(1.80) 
530(1.23) 
542(1.87) 
519(0.83) 
83% 
85% 
80% 
80% 
72% 
72% 
77% 
70% 
80% 
80% 
80% 
70% 
80% 
80% 
18.2 
17.73 
20.53 
20.9 
13.6 
14.6 
18 
14.61 
16.5 
17.2 
17.22 
15.40 
20 
1 6.37 
720 
846 
720 
736 
721 
722 
640 
711 
790 
777 
748 
738 
680 
707 
0.73 
0.75 
0.704 
0.722 
0.692 
0.693 
0.75 
0.671 
0.72 
0.764 
0.694 
0.685 
0.69 
0.693 
10 
11.18 
10.4 
11.1 
6.8 
7.3 
8.64 
7.0 
9.6 
10.2 
9.0 
7.8 
9.5 
8.0 
[12] 
[18] 
[19] 
[20,21] 
[22,23] 
[22] 
[24] 
[25] 
[26] 
[27] 
[28] 
[29] 
[30] 
[31] 
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Different from carboxylate polypyridyl ruthenium sensitisers, which are easy to desorb in 
solutions with low pH, phosphonate polypyridyl ruthenium sensitisers are attached to the 
surface of the semiconductor by a phosphonate group. This makes it difficult to detach even 
at high pH. On the other hand, because of their non-planar conjugation, the injection of 
electrons is not as efficient.  
 
The phosphonate polypyridyl ruthenium dye (complex 1) displays a 15-nanosecond lifetime 
in the excited state. Interestingly, it has a Langmuir adsorption coefficient of 8×106, which is 
significantly higher than other dyes including the N3 [32] and 70% photon-current conversion 
efficiency at a wavelength of 510 nm. On the other hand, the phosphonate polypyridyl 
ruthenium analogue of Z907 achieves photon-current conversion efficiency levels slightly 
higher than solar cells [31]. These polynuclear complexes exhibiting an antenna effect which 
have been employed to increase absorption coefficients due to their antenna-like properties. 
Nevertheless, the antenna does not occur at longer wavelengths because of the marked 
decrease of absorption coefficients and the IPCE spectrum (Incident photon-to-current 
efficiency) of ruthenium charge-transfer sensitisers’ decrease strongly. In addition, these 
types of sensitisers are bulky and occupy more space on the TiO2 surface while penetrating at 
lower rates into small cavities in relation to monocuclear compounds. Thus, the increased 
absorption coefficients that polynuclear compounds display are not always translated into an 
improved light absorption on the TiO2 electrode because of their reduced surface frequency 
on the non-porous TiO2 [33]. The binding of bipyridine and two thiocyanato (NCS) groups to 
N3 allows it to absorb up to800 nm in radiation. However, N3 does not show high Voc (open 
circuit voltage) despite its high Jsc (short circuit current). The presence of H+ at the two 
carboxyl groups in the N3 dye, different from N719 for instance, which has 
tetrabutylammonium (TBA+), allows it to supply a maximum of four protons per dye turning 
the Ecb (conduction-band-edge energy level) more positive. The fill factor (FF) is essentially 
a measure of quality of the solar cell, and is defined as the ratio of the maximum power output 
per unit area to the product of Voc and Jsc. Several factors can influence the FF, such as a 
high inner resistance (e.g. a bad counter electrode), which will give a low fill factor and a 
decreased overall efficiency. Typical fill factors range from 0.5 to 0.82 
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Another dye with a similar adsorption performance than the N3 and N719 is the N749 dye, 
known as black dye. Its absorption coefficient is slightly lower at 860 nm and demands thicker 
TiO2 electrodes for molecule adsorption. Thicker electrodes represent a drawback in electron 
transport and open circuit voltage, considering that the Jsc and Voc values might drop. The 
performance of N749 is not as high as its counterpart; the N719. The hydrophobic alkyl chains 
attached to one of the bipyridine ligands in the Z907 allows it to keep water molecules away 
turning the dye more stable in the long-term, which is a considerable advantage over the dyes 
N3 and N719. Remarkably, the performance of the DSSCs with Z907 is stable up to 1000 h 
under light irradiation. This has made amphiphilic ruthenium dyes and high-molar-extinction-
coefficient ruthenium sensitisers very appealing in scientific research. Table 3.1 displays the 
photovoltaic performance of the solar cells. 
 
The reaction of a polypyridyl ligand with ruthenium trichloride produces ruthenium 
polypyridyl complexes [34]. The reaction to yield 2, 2’-bipyridine and 2, 2’:6’, 2”-terpyridine 
is given in Scheme 3.1. 
 
Scheme 3.1: Synthesis of polypyridyl ligands [34]. 
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3.2.2 Other metal-complex sensitisers 
Ruthenium complexes have provided the highest efficiencies to date and have therefore been 
widely studied. However, there are still many problems to be addressed in terms of their low 
molar extinction coefficient, ruthenium metal and high synthetic cost, and therefore other 
metal complexes have also been investigated. Considerable effort has been put into 
substituting Ru with other transition as Os (II), Pt (II), Re (I) Cu (I), and Fe (II). Osmium (Os 
(II)) complexes show promising photosensitiser properties for DSCs because of their 
prominent metal-to-ligand charge transfer (MLCT) absorption band in comparison with the 
Ru complex. Lewis et al. were able to develop a class of (Os) polypyridines [35 - 37] by 
substituting the Ru metal ion with Os. The results were the dyes [Os(H2L’)2(CN) 2] and 
[Os(H2L’)2(SCN)2], Figure 3.4. These dyes show a wider light response area and similar 
photovoltaic performances than the DSCs. It was later proven that the slower electron transfer 
from iodide electrolyte to the osmium dye cation results in lower photocurrent efficiency in 
Os complexes [38 - 40]. 
 
 
                 [Os(H2L’)2(CN)2]             [Os(H2L’)2(SCN)2 ]                       [ OsH2dcbpyCl] 
 
Figure 3.4: The chemical structures of the (Os) polypyridines dyes [37 - 39]. 
 
 
Platinum and copper have been also tested, but with poor results. Islam et al. synthesised 
square planar platinum (II) diimine dithiolate (Figure 3.5) complexes that can also efficiently 
sensitise nanocrystalline TiO2 [39, 40]. They reached efficiencies up to 3%. However, 
recombination and aggregation problems typical of these platinum (II) complexes seem to 
stop these sensitisers from being more efficient. 
 
 46 
 
 
 
Figure 3.5: The chemical structures of the square planar platinum (II) diimine 
dithiolate complexes [39] 
Cu (I) complexes Figure 3.6 were investigated by Sauvage and co-workers because of their 
similar photophysical properties to Ru complexes [43, 44]. Up to now the best efficiencies of 
2.3% have been reached by Constable and co-workers [45]. 
 
 
 
Figure 3.6: Chemical structures of the Cu(I) complexes [45]. 
 
Ferrere and co-workers engineered Fe(II) complexes for possible DSC applications, such as 
the  [Fe(II)(2,2’-bipyridine)2(CN)2] these showed lower efficiency rates with IPCE values of 
only 10-11% in DSCs, Figure 3.7 [46 - 48]. 
 
Figure 3.7: The chemical structures of the [Fe(II)(2,2’-bipyridine-4,4'-dicarboxylic 
acid)2(CN)2]  complex [46 - 48]. 
 
Chlorotricarbonyl rhenium (I) complexes based on benzathiazole derivatives are shown in 
Figure 3.8. In relation to similar rhenium (I) 2, 2’-bipyridine compounds, these show red-
shifted absorption as well as solar energy conversion efficiency rates around 1.5% 
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Figure 3.8: The chemical structures of the chlorotricarbonyl rhenium (I) complexes [49 
- 50]. 
3.2.3 Porphyrin sensitisers in DSSCs 
Emulation of the extraordinary chlorophyll-based photosynthetic light harvesting apparatus 
has inspired researchers to investigate synthetically prepared porphyrin dyes as sensitisers for 
dye-sensitised light harvesting applications and they remain one of the most frequently 
studied dyes. They are attractive for such purposes, as their synthesis is relatively 
straightforward and their optical and electronic properties can be tuned via chemical 
modification of the porphyrin core, the number of porphyrin units and the linker between the 
core and the inorganic oxide. Figure 3.9 shows the molecular structure of a basic 
phthalocyanine (special polypyridine complexes). In this figure, R means a radical like t-
butyl, n-hexil, n-octyl, and in some cases R can be a substituted amine, and M means a 
metallic cation. 
 
 
Figure 3.9: The chemical structures of tetrakis(4-carboxyphenyl)porphyrin 
(phthalocyanine) [51]. 
 
A further strategy for avoiding the use of expensive ruthenium in DSC dyes is to use 
complexes containing inexpensive metals. Large π-aromatic molecules, such as porphyrins 
and phthalocyanines, are attractive potential candidates for thin, low-cost, efficient DSCs, 
because of their photostability and high light-harvesting capability. Porphyrins show strong 
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absorption and emission in the visible region, as well as tunable redox potentials. These 
properties mean they have many potential applications, in areas such as optoelectronics, 
catalysis, and chemo-sensing. Self-assembled porphyrin molecular structures play a key role 
in solar energy research, because the photosynthetic systems of bacteria and plants contain 
chromophores based on porphyrins, which efficiently collect and convert solar energy into 
chemical energy. Various artificial photosynthetic model systems have been designed and 
synthesised in order to elucidate the factors that control the photoinduced electron-transfer 
reaction. Inspired by efficient energy transfer in naturally occurring photosynthetic reaction 
centres, numerous porphyrins and phthalocyanines have been synthesised and tested in 
DSCs.Campbell et al. have reported zinc porphyrin dyes (Figure 3.10) which has conversion 
efficiencies of 7.1% [52]. A recently reported series of zinc porphyrin dyes with donor– 
acceptor (D–A) substituents exhibit promising photovoltaic properties with a conversion 
efficiency of 6.8% (YD-2, Figure 3.11 [53].  Bessho et al. optimised the fabrication method 
for YD-2-sensitised DSCs, resulting in the achievement of an 11% solar-to-electric power 
conversion efficiency under standard conditions (AM 1.5G, 100 mW/cm-2 intensity) [54], 
which is the highest conversion efficiency for a DSC using a ruthenium-free dye so far. 
 
 
 
Figure 3.10: The chemical structures of the zinc porphyrin dyes [52]. 
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Figure 3.11: The chemical structures of the porphyrin dye YD-2 [53]. 
 
3.3 Metal-free dyes 
Metal-free dyes include natural organic dyes and synthetically organic dyes. 
 
3.3.1 Organic dyes 
Ruthenium complex dyes are capable of delivering DSCs with high photo-energy conversion 
efficiencies. However, because ruthenium is a rare and expensive metal, ruthenium dyes are 
not suitable for cost-effective, environmentally friendly photovoltaic systems. This limits the 
range of applications for these complexes, and makes the development of DSCs that use metal-
free, organic dyes essential for their practical use. As a consequence, a lot of work appeared 
to date in the literature aimed at the optimization of the design of metal-free dyes, and organic 
sensitizers with higher efficiencies. The general structural architecture of these dyes is usually 
composed of a push-pull system of the type donor-π bridge-acceptor (D-π-A) such as shown 
in Figure 3.12. This configuration permits an easy design of new structures with extended 
absorption spectra, adjusted HOMO and LUMO levels and ensures the necessary separation 
of charges within the molecule. Upon adsorption of light, there is a transfer of charge from 
subunit D to subunit A via the π-bridge. The electron is then injected into the conduction 
band through the electron acceptor group A by the excited dye.  
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Figure 3.12: Push-pull system of the type donor-π bridge-acceptor (D-π-A) [55]. 
 
The ideal structure of the metal free dyes sensitiser is represented pictorially in the Scheme 
3.2  
 
Scheme 3.2: The ideal structure of the metal free dyes sensitiser. 
 
Significant work has been put into manipulating organic dyes in order to optimise DSC 
performance. Organic dyes, including coumarin, indoline, tetrahydroquinoline, triarylamine, 
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carbazole, squaraine, perylene, oligothiophene have been studied as sensitizers for DSCs and 
shown remarkable efficiency  
 
As a donor system, triarylamines are the most studied, thanks to their great stability, electron 
mobility, strong donating ability and aggregation resistance due to non-planar molecular 
configuration. Replacement of the phenyl ring that is directly conjugated with the bridge with 
a heteroaromatic ring, such as a thiophene, can increase the donating strength and reduce 
aromatic stabilisation [56]. Concerning the spacer, in order to broaden the absorption spectra 
of the sensitizers in the visible and near-IR region, one strategy is to introduce more conjugate 
bridges between the donor and acceptor. The π-conjugated linker plays an important role, not 
only in tuning and modifying the optical properties of DSSC devices under the sunlight 
radiation, but also in controlling the intra-molecular electron-transfer and electron injection 
from the excited dye to the conduction band of the semiconductor. Starting from the double 
bond, several bridges are employed in the dyes, such as triple bonds, aromatic and 
heteroaromatic rings. Among these, thiophene is an appealing linker extensively used in the 
literature as single unit or condensed in more complex structures thanks to its electron-donor 
ability. However, a lot of activity in this field is still devoted to the research of an ideal bridge, 
which will be able to give broad red-shifted absorption spectra, but also a good electronic 
connection between A and D unit.  
 
The properties of the organic sensitisers can be modified by incorporating different groups 
into the molecule. By choosing the right design, the sensitiser can be tuned in order to increase 
the long wavelength absorption, achieve a high extinction coefficient, and shift the energy 
levels to improve the performance of the solar cell. Organic dyes have the benefits of higher 
extinction coefficients, easier structural modification, and provide less environmental 
problems compared to many of the transition metal complexes. On the other hand, they have 
drawbacks such as relatively narrow absorption bands, higher tendency to aggregate, and often 
stability problems. Recently, numerous organic dyes for high-efficiency DSCs have been 
reported. New organic dyes with efficiencies over 5% (Figure 3.13) include hemicyanine dye, 
polyene diphenylaniline dye, thienylfluorene dye, phenothiazine dye, thienothiophene-
thiophene-derived dye, phenyl conjugated polyene dye, N,N-dimethylaniline-cyanoacetic 
acid, oligothiophene dye, coumarin dye, indoline dye and oligo-phenylenevinylene-unit dye. 
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Hemicyanine dye (η = 5.1%)  [57]           Polyene-diphenylaniline dye (η =5.1%) [58] 
 
 
 
Thienylfluorene dye (η = 5.23%) [59]                 Phenothiazine dye (η =5.5%)  [60] 
 
 
 
                                    Thienothiophene-thiophene-derived dye (η = 6.23%) [61] 
 
 
Phenyl-conjugated polyene dye (η = 6.6%) [62]    N,N-dimethylaniline-cyanoacetic acid 
(η = 6.8%) [63, 64]. 
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Oligothiophene dye (η = 7.7%) [65]          Oligo-phenylenevinylene- dye (η = 9.1%) [66] 
 
Coumarin dye (η= 8.2%)  [67]                         Indoline dye (D149) (η = 9.03%) [68]     
 
Figure 3.13: Molecular structure of several organic dyes with efficiencies over 5% 
 
3.3.2 Natural dyes 
Natural dyes as sensitisers for DSSCs are promising alternatives to organic dyes, which have 
been found in fruits, flower petals, leaves and bark. They offer environmental friendliness, 
low-cost production, simple preparation techniques and widely available, easily extracted, 
and are biodegradable [69, 70]. In addition, as natural dyes contain many various constituents 
they exhibit wider absorption spectra in comparison to chemical synthesis dyes [71-73] 
However, the use of natural dyes in dye-sensitised solar cells often has low conversion 
efficiency in comparison to ruthenium polypyridyl complex dyes [74]. Therefore, there is a 
need to prepare chemical synthetic dyes that encompass high efficiency along with low 
toxicity. 
 
3.3.2.1 Plant pigmentation 
Plant pigmentation is the result of the interaction of the pigment in the plant with sunlight. 
Changes in pigmentation are directed to alter the wavelength reflected by the plant. The 
 54 
 
human visual abilities can detect wavelengths between approximately 430 and 680 nm. 
Pigments are determined by both the wavelength of maximum absorbance (λmax) and the 
colour perceived by the observer. Table 3.2 illustrates the classification of plant pigments 
based on their type and occurrence [68]. 
Table 3.2: Pigments in plants. 
Pigment  Common type  Occurrence  
Betalains       Betacyanins   
Betaxanthins 
Caryophyllales and some fungi. 
Carotenoids   Carotenes 
 
Xanthophylls   
Photosynthetic plants and bacteria. 
Retained from the diet by some birds, 
fish and Crustaceans. 
Chlorophyll   Chlorophyll   All photosynthetic plants 
Flavonoids Anthocyanin 
Aurones 
Chalcones 
Flavonols 
Proanthocyanidins 
Widespread and common in plants 
including angiosperms,  
 
Gymnosperms, ferns and 
bryophytes. 
 
Table 3.3 summarises the photoelectrochemical specifications of DSSCs for a variety of 
natural dyes as photosensitisers amongst these dyes a highest efficiency of η = 1.70 % was 
obtained with an extract of Red turnip Figure 3.14 shows the molecular structure of several 
natural dyes used in DSSCs. Natural dyes are useful as they can be potentially efficient, cheap 
and biodegradable. 
 
Table 3.3: Photo-electrochemical parameters of natural dye based DSSCs 
 
Dye Jsc (mA cm−2) Voc (V) FF η (%) Ref. 
Rosella 
Blue pea 
Mixed rosella-blue pea 
Black rice 
Capsicum 
Rosa xanthina 
Kelp 
Erythrina variegate 
1.63 
0.37 
0.82 
1.14 
0.23 
0.64 
0.43 
0.78 
0.40 
0.37 
0.38 
0.55 
0.41 
0.49 
0.44 
0.48 
0.57 
0.33 
0.47 
0.52 
0.63 
0.52 
0.62 
0.55 
0.37 
0.05 
0.15 
– 
– 
– 
– 
– 
[75] 
 
 
[76] 
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Bixin 
Annatto 
Norbixin 
Crocetin 
Crocin 
Fruit of Calafate 
Syrup of Calafate 
Skin of Jaboticaba 
Red Sicilian orange 
Purple eggplant extract 
Dragon fruit 
Pomegranate juice 
Red turnip 
Wild Sicilian prickly pear 
Sicilian Indian fig 
Bougainvillea 
Shisonin 
Shisonin and chlorophyll 
Chlorophyll 
Hibiscus surattensis 
Sesbania grandiflora 
Hibiscus rosasinesis 
Nerium olender 
Ixora macrothyrsa 
Rhododendron arboretum 
zeylanium 
Table (3) Continued 
1.10 
0.53 
0.38 
2.84 
0.45 
6.20 
1.50 
7.20 
3.84 
3.40 
0.20 
0.20 
9.50 
8.20 
2.70 
2.10 
3.56 
4.80 
3.52 
5.45 
4.40 
4.04 
2.46 
1.31 
 
1.15 
 
0.57 
0.56 
0.53 
0.43 
0.58 
0.47 
0.38 
0.59 
0.34 
0.35 
0.22 
0.40 
0.43 
0.38 
0.38 
0.30 
0.55 
0.53 
0.43 
0.39 
0.41 
0.40 
0.41 
0.40 
 
0.40 
 
0.59 
0.66 
0.64 
0.46 
0.60 
0.36 
0.20 
0.54 
0.50 
0.40 
0.30 
0.45 
0.37 
0.38 
0.54 
0.57 
0.51 
0.51 
0.39 
0.54 
0.57 
0.63 
0.59 
0.57 
 
0.64 
 
0.37 
0.19 
0.13 
0.56 
0.16 
– 
– 
– 
– 
– 
0.22 
1.50 
1.70 
1.19 
0.50 
0.36 
1.01 
1.31 
0.59 
1.14 
1.02 
1.02 
0.59 
0.30 
 
0.29 
 
 
[77] 
 
[78] 
 
 
[79] 
 
[80] 
 
[81] 
[82] 
[83] 
 
 
 
[84] 
 
 
[85] 
 
 
 
Dye Jsc (mAcm−2) Voc (V) FF η (%) Ref. 
Begonia 
Tangerine peel 
Rhododendron 
Fructus lyciia 
Marigold 
Perilla 
Herba artemisiae scopariae 
China loropetal 
Yellow rose 
Flowery knotweed 
Bauhinia tree 
0.63 
0.74 
1.61 
0.53 
0.51 
1.36 
1.03 
0.84 
0.74 
0.60 
0.96 
0.54 
0.59 
0. 59 
0.69 
0.54 
0.52 
0.48 
0.52 
0.61 
0.55 
0.57 
0.72 
0.63 
0.61 
0.47 
0.83 
0.70 
0.68 
0.63 
0.57 
0.63 
0.66 
0.24 
0.28 
0.57 
0.17 
0.23 
0.50 
0.34 
0.27 
0.26 
0.21 
0.36 
[86] 
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Petunia 
Lithospermum 
Violet 
Chinese rose 
Mangosteen pericarp 
Rose 
Lily 
Coffee 
Broadleaf holly leafbase 
Red Bougainvillea glabra 
Violet Bougainvillea glabra 
Red Bougainvillea spectabilis 
Violet Bougainvillea  
spectabilis 
Spinach 
Ipomoea 
Bongainvillea brasiliensis 
Garcinia   suubelliptica 
Ficus reusa 
 
0.85 
0.14 
1.02 
0.90 
2.69 
0.97 
0.51 
0.85 
1.19 
2.34 
1.86 
2.29 
1.88 
0.47 
0.91 
5.00 
6.48 
7.85 
10.9 
0.62 
0.34 
0.50 
0.48 
0.67 
0.60 
0.50 
0.56 
0.61 
0.26 
0.23 
0.28 
0.25 
0.55 
0.54 
0.25 
0.32 
0.52 
0.50 
0.61 
0.59 
0.65 
0.62 
0.63 
0.66 
0.67 
0.69 
0.65 
0.74 
0.71 
0.76 
0.73 
0.51 
0.56 
0.36 
0.33 
0.29 
0.27 
0.32 
0.03 
0.33 
0.27 
1.17 
0.38 
0.17 
0.33 
0.47 
0.45 
0.31 
0.48 
0.35 
0.13 
0.28 
0.45 
0.69 
1.18 
1.49 
 
 
 
 
 
 
 
 
 
 
[87] 
 
 
 
[88] 
 
[89] 
 
 
 
 
           Rosella (η= 0.37) (%)                              Bixin (η= 0.37) (%) 
 
                                                       Shisonin (η= 1.01) (%) 
Figure 3.14: The chemical structures of several natural dyes used in DSSCs [75, 77, 84]. 
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3. 3.2.2 The performance of a natural dye based DSSC 
The generation of natural-dye based DSSCs is inefficient (Table 3.3) due to the low 
interaction between the dye and TiO2. The long R group makes the steric hindrance interfere 
with the binding of the oxide surface of the TiO2. This results in inappropriate adsorption onto 
the TiO2 film and poor transfer of electrons from the dye onto the conduction band of the 
TiO2. The extract must have a particular intensity and light absorption since a shorter distance 
between the dye skeleton and the TiO2 surface facilitates the transfer of electrons [75]. 
 
The nature of the interaction between the TiO2 and the dye is critical for the efficiency of 
DSSCs. Natural dyes present low Voc values due to the poor recombination pathways of 
electron/dye cations and the acidic dye adsorption environment [83]. Since the presence of 
H+ determines the transfer of ions to TiO2 and the level of proton adsorption results in a 
positive shift of the Fermi level of the TiO2, there is a limit to the maximum photovoltage that 
can be conveyed by the cells. The higher the charge-transfer in the TiO2/dye/electrolyte 
resistance the more significant the decrease in Jsc [86]. Hence, the addition of carboxyl groups 
and the modification of the structure of natural dyes are pivotal to achieve higher levels of 
efficiency from natural dyes based DSSCs. The occupying of free space between the iodine 
solution and TiO2 semiconductor film surface is known as dye aggregation. This is a known 
problem with dyes that impedes the electron injection and low efficiency [80]. 
 
There are thus many aspects of dye structure, synthesis and application which need to be 
considered for successful application in any DSCC. 
 
3.4. Summary 
The literature review within this chapter covers the background and current research 
highlights in the development of organic and organometallic compounds for use within dye 
sensitised solar cells.  Chapter 4 will focus on the use of organometallic complexes within 
cancer therapy.   
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Chapter 4 : Anticancer activities of bio-inorganic compounds 
 
4.1 Introduction  
Cancer comprises a group of diseases involving uncontrolled and abnormal growth of cells, 
which can potentially be invaded or it be spread to other parts of the body [1, 2]. Cancer starts 
with genetic changes in one cell or a small group of cells. The change is called mutation [3, 
4]. Mutation can change the normal DNA sequence, and the most common mechanism of this 
process implies that one base is replaced by another during the replication process. Sometimes 
mutations can arise from a modification in the base, deletion of the base or addition of another 
base. This is quite a common process and the DNA repair mechanism generally fixes it. When 
this does not happen, a misfolded protein can be the result of mutations.  It can happen by 
chance when a cell is dividing or it can be caused by the biological processes inside the cell. 
It can be also triggered by external factors, such as through chemicals in tobacco smoke, UV 
radiation and toxins. In the majority of cases, these mutations are overcome by the cell repair 
machinery and the damage is not occurred further [5-7]. Healthy cells produce signals by 
controlling cells division, and if the mutation of the erroneous signals cannot be repaired, then 
the cell enters into senescence (apoptosis). However, if the apoptotic signalling is not working 
and /or the repairing mechanism is faulty, then cells may start to multiply and grow in excess 
forming a lump, which is called a tumour.  
The cell cycle is a series of phases that both normal cells and cancer cells go through in order 
to form new cells. The cell cycle has 5 phases, which are labelled below using letters and 
numbers. 
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Figure 4.1: A schematic representation including the stages G0, G1, S, G2 and M of cell 
cycle [8]. 
After a cell reproduces, the 2 new cells are identical. Each of the 2 cells made from the first 
cell, can go through this cell cycle again when new cells are needed. 
G0 phase (resting stage): The cell has not started to split. Cells spent much of their lives in 
this stage. Depending on the type of cell, G0 can last from a few hours to a few years. When 
the cell gets a signal to reproduce, it moves into the G1 phase. 
G1 phase: During this phase, the cell starts making more proteins and growing larger, so the 
new cells will be of normal size. This phase lasts about 18 to 30 hours. 
S phase: In the S phase, the chromosomes containing the genetic code (DNA) are copied so 
that both of the new cells formed, will have matching strands of DNA. The S phase lasts about 
18 to 20 hours. 
G2 phase: In the G2 phase, the cell checks the DNA and gets ready to start splitting into 2 
cells. This phase lasts from 2 to 10 hours. 
M phase (mitosis): In this phase, which lasts only 30 to 60 minutes, the cell essentially splits 
into 2 new cells. The cell cycle is important because many chemotherapy drugs work only on 
cells that are actively reproducing (not cells that are in the resting phase, G0). Some drugs 
actually attack cells in a particular phase of the cell cycle (the M or S phases, for example) 
[9]. 
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In 2011, in the UK, more than 331,000 people were diagnosed with cancer (around 910 people 
every day). The risk of developing cancer up to the age of 50 years is 1 in 35 for men and 1 
in 20 for women. Cancer can be developed at any age and the incidence has risen by 23% in 
males and by 43% in females since mid-1970s [10-12], (Cancer Research Statistics UK). The 
sixth most common and the third lethal cancer in the world is liver cancer with 782.000 new 
cases diagnosed in 2012. Development of this type of cancer is mainly linked to an unhealthy 
lifestyle, alcohol consumption and also Hepatitis B and C infections [13-15] (World Cancer 
Research Fund International). A total of 4348 people in the UK were diagnosed with liver 
cancer in 2011, which accounts for 1% of all cancer cases (Cancer Research, Key Statistics). 
 
Colorectal cancer was the fourth most common cancer in the UK in 2011 and accounted for 
13.6% of all new cases of cancer in that year. It is the third most common cancer in both 
males and females.  In 2011, there were 41,581 new cases of colorectal cancer in the UK: 
23,171 (56%) in men and 18,410 (44%) in women, giving a male: female ratio of 14:11. Most 
cases of colorectal cancer occur in older men and women. Age specific incidence rates in UK 
between 2009 and 2011 shows that an average 43% of new cases were diagnosed in people 
aged 75 years and over, and 95% were diagnosed in those aged 50 and over [16]. About 50% 
of patients diagnosed with colorectal cancer survive for at least 5 years after diagnosis [17]. 
Countries with the highest incidence rates include Australia, New Zealand, Canada, US and 
parts of Europe. Colorectal cancer is mainly a disease of developed countries with a Western 
culture [18-19].  Almost two-thirds (66%) of all bowel cancers are cancer of the colon and 
over one-third (34%) are cancers of the rectum (Cancer Research, Bowel Cancer statistics). 
Treatment modalities for colorectal cancer include surgery, radiotherapy, chemotherapy and 
targeted therapy [20]. Chemotherapy drugs, which are useful in treatment of colorectal 
cancer, include Capecitabine, Fluorouracil, Irinotecan, Oxaliplatin, Raltitrexed and UFT [21]. 
 
Hepatic cancer is now ranked as the 18th most common cancer in England. Incidence has 
increased by 70% among males and 60% among females since 2003. Over 80% of liver cancer 
cases worldwide are due to hepatitis B or C infection. Alcohol is another risk factor for hepatic 
cancer [22]. Studies evaluating the use of cytotoxic chemotherapy for the treatment of 
advanced liver cancer, have shown low response rates and no improvement in patients’ 
survival [23]. Examples of chemotherapeutic drugs used in the treatment of liver cancer 
include Doxorubicin, Cisplatin and Fluorouracil [24]. Malignant tumours (cancer) have the 
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capability of invading tissues and cells can be spread (radiate) to distant sites in the body [25].  
Treating hepatic cancer can be a difficult.  There are four stages, namely A in which resection, 
transplant or heat can reverse it to achieve a cure of it. If it is diagnosed in stage B or C, there 
is no cure, but chemotherapy allows survival by stopping the cancer spreading into other 
organs. If the diagnosis is done at stage D, palliative care is the only option. 
 
Cancer has an impact worldwide and there are debates in relation to the question “do we have 
more cancers” or “we have better diagnosis”. It seems the answer lies in between the two 
questions. It has been postulated by the majority of researchers that current cancers are result 
of our lifestyle choices such as drinking alcohol, cigarette smoking, meat consumption, 
environmental contamination, etc. Our life expectancy, thanks to antibiotics, vaccines and 
sanitation, has increased dramatically. It is also important to point out that mutations in the 
DNA are more common with ageing, so an older population will have more chances of 
developing cancer later in life. Better diagnostic techniques have allowed the detection of 
cancers earlier on, thus giving way to improved treatment outcomes.  
 
A common approach for discovery of agents with anticancer activity, starts with the empiric 
screening for antiproliferative or cytotoxic effects in human cancer cell lines [19-21, 26]. 
Generally, the most commonly used anticancer chemotherapeutic drugs work by inhibiting 
cell division (mitosis) by different mechanisms such as damaging DNA or inhibiting cellular 
metabolism. There are numerous methods used to treat the cancer, such as surgery, 
chemotherapy, immunotherapy and radiotherapy. The aim of any cancer treatment is to 
remove cancerous cells in order to prevent them from growing and spreading. Radiotherapy 
is a treatment involving the use of high-energy radiation to destroy cancer cells. It can be 
given externally (X-rays) or through gamma rays, at the affected area or internally (involves 
radioactive material placed inside of the body) [27-30].  
 
Immunotherapy treatment uses the body’s own immune system to work harder in order to 
attack cancer cells. It uses materials either made by the body or in a laboratory to improve, 
target or restore immune system functions (monoclonal antibodies, interferons, and 
interleukins) [31-33]. Chemotherapy treatment involves drugs, which aim to destroy cancer 
cells. Chemotherapy drugs can be divided into several groups, based on factors such as how 
they work, their chemical structure and their relationship to any another drug.  There are 
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different methods of chemotherapy [34, 35]. Chemoembolisation delivers a chemotherapeutic 
agent directly to a tumour and thus minimise exposure to healthy tissue. This method reduces 
side effects and maximises the cancer – killing properties of the drugs. During 
chemoembolisation a drug is injected through a catheter directly into a tumour using image 
guidance. The chemotherapy drugs are mixed with particles called microspheres, which block 
the flow of blood to the tumour. Without blood supply, the tumour no longer has the oxygen 
and nutrients it needs to grow. This method is primarily used for the treatment of liver cancer. 
There are also other ways of receiving chemotherapy such as intravenously (IV), orally, as an 
injection or intraperitomeally (directly into the abdomen or peritomeal cavity) or topically 
[36]. Another treatment, called photodynamic therapy, involves a drug sensitive to light. Once 
given to the patient, light at a particular wavelength is applied, and the drug will produce 
reactive oxygen species that will kill the surrounding cells. It is generally applicable for 
cancers of the skin (not melanoma), gullet, head, neck, mouth, eyes and lungs [37-38]. The 
most common chemotherapy drugs used are alkylating drugs such as nitrogen mustards, alkyl 
sulphonates, triazines, nitrosoureas, ethylenimine derivatives and metal salts containing 
platinum [39, 40]. The treatment of colon cancer depends on its stage. If the cancer did not 
spread to distant sites, surgery is usually the primary treatment in conjunction with 
chemotherapy. In more advanced stages, the surgery is followed by adjuvant chemotherapy 
with drugs containing platinum compounds such as Folfox [41], (leucovorin and oxaliplatin) 
or CapeOx (capecitabine and oxaliplatin) [42, 43].  
 
The development of metal complexes with platinum central atoms, such as cisplatin or 
carboplatin, had a massive impact on current cancer treatments. However, the spectrum of 
cancers that can be treated with platinum agents is narrow and treatment efficacy suffers from 
side effects and resistance phenomena. These problems in platinum-based anti-cancer therapy 
have stimulated increased research efforts in the search for novel non-platinum containing 
metal species as cytostatic agents. Preclinical and clinical trials showed promising results for 
complexes with iron, cobalt or gold central atoms. Compounds with titanium, ruthenium or 
gallium central atoms have already been evaluated in phase I and phase II trials [44]. These 
metals when used in photodynamic therapy, can produce reactive oxygen species that can kill 
the surrounding cells, though a different mechanism, therefore they have promising activities 
[45]. 
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4.2 Chemotherapeutic anticancer agents 
4.2.1 Platinum compounds and derivatives - based anticancer agents 
Transition metal ion complexes have been widely considered, particularly because of their 
photophysical properties and potential biological applications and antitumor potential [45-
48]. The first complex observed and investigated in this regard was cisplatin (cis-
diamminedichloroplatinum(II)).  This complex was synthesised for the first time in 1844 by 
Michele Peyrone [49]. Figure 4.2 gives a schematic representation of the compound. 
 
 
 
 
 
 
Figure 4.2: Cisplatin, cis-diamminedichloridoplatinum(II) [50-52]. 
 
The tumour-inhibiting qualities of this substance were discovered more than a century later 
by Rosenberg in 1969 [53]. In 1971 cisplatin entered clinical experiments shortly after its 
discovery and since then has become a highly active drug for treating testicular tumours, 
ovarian carcinomas, bladder tumours, neck and head cancer. Successful applications also 
occurred in cases of lung cancers, oesophageal cancer, lymphomas, breast cancer and other 
tumour types [54]. In spite of cisplatin’s success as an anticancer drug, it also has some 
disadvantages. Its applicability is still restricted to a comparatively narrow scope of tumours, 
because some tumours have a natural resistance to cisplatin. There are also significant 
problems in terms of the toxicity of cisplatin and its limited solubility in aqueous solution, 
which restricts it, administration intravenously [55]. 
4.2.2. Cisplatin analogues as marketed platinum anticancer drugs 
Over 3000 platinum compounds have been synthesised and screened for their biological 
activity [56]. Of these, less than 30 compounds have entered clinical trials [57]. Attempts to 
improve new anticancer platinum drugs have faced difficulties in overcoming the problems 
of cisplatin in actual clinical tests. At present, only four platinum drugs (anologues of 
cisplatin) are registered and marketed drugs (cisplatin, carboplatin, oxaliplatin and 
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nedaplatin) Figure 4. 3 and only one compound (oxaliplatin) has been approved by the FDA 
(Food and Drug Administration) for colorectal cancer [58]. 
 
 
Figure 4.3: Molecular structure of some selected platinumdrugs: (a) Carboplatin, (b) 
Oxaliplatin, Nedoplatin and Labopltin [44, 59]. 
 
The platinum family of chemotherapeutics, which includes the parent compound cisplatin and 
its derivatives carboplatin and oxaliplatin, are among the most commonly prescribed 
anticancer agents, with global sales of over $670 million in 2004 [60]. 
 
Some derivatives of cisplatin complex exhibited excellent cytotoxicity, such as a platinum(II) 
complex with an acridinylthiourea ligand. This complex (4) was reported and exhibited 
excellent cytotoxicity against a leukemia cell line (Figure 4.4) [61, 62]. On the other hand, 
the derivatives of cis-amminedichloro(2-methylpyridine)-platinum(II) (AMD473 (5), shown 
in Figure 4.4, exhibited high antitumor efficacy against cisplatin-resistant mouse sarcoma 180 
(S-180cisR) cell lines [63] 
 
 
 
 
 
 
 
 
Figure 4.4: Structures of Pt(II) complexes (4) with acridinylthiourea ligand (5), with 2-
phenylpyridine ligand. 
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4.2.3. Palladium anticancer chemistry 
Palladium (Pd) chemistry is analogue to that of platinum (Pt). Therefore, Pd complexes (II) 
are expected to display antitumor activities analogous to those of Pt. Several attempts have 
been made to synthesise Pd (II) complexes with such activities, as Pd complexes are probable 
to have less kidney toxicity than Pt complexes [64]. Graham et al. (1979) and Rau et al. (1996) 
have synthesised several palladium complexes with promising activity against tumour cell 
lines. Different types of monodentate ligands were applied in the synthesis of these complexes 
[65-66].  Furthermore, several research groups have focused on the preparation of Pd(II) 
complexes bearing bidentate ligands as a approach to stabilise these compounds and to 
prevent any possible cis-trans isomerism [67] (see Figure 4.5). 
 
The discovery of the cytotoxic activity of cisplatin and its analogue carboplatin has led to an 
extensive search for new biologically active metal drugs. Several cisplatin related platinum 
based drugs have been synthesised, however, high general toxicity and development of 
platinum-resistance to the drug have become major obstacles to its efficacy. Most of the 
palladium complexes are less cytotoxic compared to their platinum analogues, and the latest 
studies have proved that Pd metal still holds some interest as anticancer compounds with 
desirable properties, as depicted in Figure 4.5 [68-78]. 
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Figure 4.5: Molecular structure of selected anticancer Palladium(II) complexes 
containing different types of nitrogen monodentate and bidentate ligands (5-14). 
In inorganic complexes, the central metal ions play a significant role in the improvement of 
anticancer metallodrug. The palladium complexes resulting from diamines, amine-imine, di-
imines [79-83], have been found to possess excellent cytotoxicity. Metal complexes derived 
from click chelators are known for their cytotoxicity [84] and have displayed good versatility 
in the radiolabelling of biomolecules [85]. Improvement of palladium (II) metallodrugs is of 
importance due to the similarity in the coordination behaviour of platinum (II) and palladium 
(II) [86-99]. Diverse triazole functionalities, e.g. (2-pyridyl)-substituted 1,2,3-triazoles, are 
renowned for their metal binding properties [100-102] and can easily be added simply by the 
famous click reaction procedure [103]. 
Trivedi et al. (2012) have synthesised a number of carbohydrate containing pyridyl 1,2,3-
triazole ligands by using the ‘click reaction’ of 2-ethynyl pyridine with the appropriate azides 
[104]. The pyridyl triazole containing benzyl group 2e was prepared according to a literature 
procedure [105]. The palladium complexes were formed by the reaction of pyridyl triazole 
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ligands with [Pd(COD)Cl2] in dichloromethane. The complexes have been examined for their 
cytotoxic activity and demonstrated anticancer properties in various cell line, including e.g. 
A549 (human alveolar adenocarcinomacells), Neuro2a (mouse neuroblastoma cells), HeLa 
(cervical carcinoma cancer cells), MDA-MB-231(human breast adenocarcinoma cells) and 
MCF7 (human breast adenocarcinoma cells). The complexes exhibited significant 
cytotoxicity, while the ligands were non-toxic on the tested cell lines, except ligand 2b, which 
revealed considerably cytotoxicity with IC50 values ranging from 11.9-43.7 μM [106]. 
 
4.3 Other metals compounds and derivatives non-platinum anticancer agents 
4.3.1 Ruthenium complexes 
Other metal-based compounds have been synthesised in an effort to replace platinum 
compounds as anticancer agents, with much focus placed on ruthenium-based compounds 
because of their lower general toxicity compared to platinum anticancer compounds [107- 
110]. Ruthenium-DMSO complexes are believed to have great potential because of their 
selectivity for solid tumour metastases and low host toxicity [111]. A number of ruthenium 
complexes have been established which offer a significantly higher degree of selectivity 
towards cancerous cells than the leading commercially available platinum derived drugs. 
They also resulted in reduced damage to healthy tissues [112]. Currently two ruthenium 
complexes (NAMI, NAMI-A and KP1019), shown in Figure 4.6, are in clinical trials. The 
first typical of ruthenium (III) complex [HIm]-Trans-[RuCl4(DMSO)(Im)] (NAMI-A) where 
[Cl = Chloride ion, Im = imidazole, DMSO = dimethylsulfoxide)]. This complex, improved 
by Sava et al. in Trieste, possesses outstanding antimetastatic properties [113]. The second, 
complex is [HInd] trans-[RuCl4(Ind)2], where (Ind = indazole). KP1019, another 
ruthenium(III) compound prepared by Keppler et al. in 1989 displayed very encouraging 
antitumor properties in clinical trials [114]. 
Various other ruthenium complexes with oxidation states of Ru(II), Ru(III) and Ru(IV), 
display antitumor activities, especially against metastatic cancers [115]. However, several of 
these compounds are very insoluble in aqueous solution, which is necessary to allow efficient 
administration and transport. Solubility has been increased by using dialkyl sulfoxide 
derivatives. Some of organometallic ruthenium complexes of the type [Ru(η6-arene)-(en)Cl]+ 
(where arene., biphenyl or tetrahydroanthracene; en = ethylenediamine) also exhibited 
promising in vitro and in vivo activity, towards cisplatin-resistant cell lines (Figure 4.6) [116-
118]. 
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Figure 4.6: Representative structures of some ruthenium complexes with monodentate 
ligands tested as anticancer drugs. 
 
4.3.2 Gold complexes as anticancer agents 
A number of gold compounds, widely used as anti-infective and anti-tubercular agents [119], 
have been screened as anticancer agents. Serratrice et al. reported the synthesis of a series of 
Au(I)/Au(III) complexes with imidazolate derivatives ranging from monodentate, bidentate 
to tridentate nitrogen donor ligands such as 2-phenylimidazole, 2-(2′-pyridyl)imidazole, and 
2,6-bis(benzimidazol-2-yl)pyridine, as well as phosphane groups, namely triphenylphosphine 
ligands such as 16, 17 and 18 shown in Figure 4.7 [120]. These complexes were evaluated 
against ovarian and breast carcinoma cell lines and the Au(I) dinuclear complexes 17 and 18 
exhibited higher cytotoxicity than cisplatin.   
 
Che and co-workers recently (2013) prepared a series of cationic Au(III) complexes with both 
N-heterocyclic carbine (NHC), N^N^N 2,6-bis(imidazol-2-yl)pyridine (H2IPI) and 2,6-
bis(benzimidazol-2-yl)pyridine (H2BPB) ligands  to be used as both thiol ‘‘switch-on’’ anti-
cancer agents and fluorescent probes, e.g the Au(III) complex 19 in Figure 4.7.  Complex 20 
displayed the highest in vitro cytotoxicity among the examined complexes (Figure 4.7), 
against human cervical epithelioid carcinoma (HeLa) xenografts [121].  Ronconi et al. have 
demonstrated that the Au(III)-dithiocarbamate complex 21 shown in Figure 4.7 exhibited 
promising anticancer properties with negligible toxic side-effects. The application of gold 
complexes, particularly gold(I) derivatives, in medicine has been termed “chrysotherapy” and 
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are also used to decrease inflammation and treat patients with rheumatoid arthritis [122].  A 
series of new 2-phenylpyridine Au(III) complexes of the general formula [Au(ppy)X] with 
various thiolate ligands has been synthesised and characterised (where X = (SCN), (NCS), tlc 
(thiolactate), tsc (thiosalicylate), dmp (2,3-dimercapto-1-propanol), dms (2,3-
dimercaptosuccinic acid), cys (cysteine)). These complexes have been screened in vitro 
against human leukemia and mouse tumour cell lines, and exhibited more cytotoxicity than 
cisplatin [123]. 
 
Figure 4.7: The chemical structures of Au(I) /Au(III) complexes with imidazolate 
derivatives (16-18). Au(III) complexes with N-heterocyclic carbene ligands (19-20) and 
(21) Au(III) dithiocarbamate complex. 
 
4.3.3 Titanium complexes as anticancer 
Titanocene dichloride (Cp2TiCl2) [124], and β-diketonato complexes of Ti such as budotitane 
[125] (Figure 4:8), were some of the first anticancer metal complexes used in clinical trials 
as anticancer drugs [126]. Both complexes bear two labile ligands and hydrolyse rapidly in 
water. On the other hand, the nature of their active species and the mechanism of action 
remained unresolved. Hence, current studies focus on water soluble but stable Ti(IV) 
antitumor complexes [127] 
 
Glasner et al. (2011) reported a series of C1 symmetrical Salan titanium (IV) complexes with 
differently substituted aromatic rings. Usually, one ring is para-nitrated, which led to 
enhanced solubility in a biological environment and another is in the ortho position. Para-
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halogenated rings led to increases in both the cytotoxicity and hydrolytic stability [128]. 
These complexes exhibited particularly high anticancer activity (Figure 4.8), ∼30-fold more 
than that of cisplatin. Good examples are Ti(IV)-Salan complexes with of differently 
substituted aromatic rings such as 22 and 23 [129]. These hybrid complexes are highly stable 
and have much higher anticancer activity than C2 symmetrical Ti(IV)-Salan analogues (24-
26) and cisplatin. A further related benefit of the hybrid complexes is their higher solubility 
in DMSO. The structural parameters of the ligand play an important role towards the 
cytotoxicity of the complexes. For example, complex 28, which consist of para substituted 
chlorine, were found to be much more active than complex 29, which consist of ortho 
substituted chlorine. This example illustrate how highly cytotoxic Ti(IV) complexes can be 
obtained by fine-tuning structural parameters of the ligand. The same research group has 
extended their study to trans-Ti(IV) complexes containing the salophen ligand (Figure 4.8) 
[130]. These complexes exhibited high hydrolytic stability and high cytotoxicity against 
different carcinoma cells. 
 
Figure 4.8: Ti anticancer drugs used in human clinical trials. (A): Titanocene 
dichloride, (B): budotitane. Symmetrical Ti(IV) Salan complexes (22–26). Trans-Ti(IV) 
complexes consisting of salophen ligand (28 and 29). 
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4.3.4 Copper complexes as anticancer agents 
Copper is one of the most remarkable elements for many biomedical applications. Copper 
compounds display a wide group of biological actions, e.g containing anti-inflammatory, anti-
proliferative, and others. It also displays a preference for radioisotopes, suitable for nuclear 
imaging and radiotherapy, rapidly progress in nanotechnology opened new possibilities for 
design of copper based drugs and medical materials [131]. In medicinal chemistry, copper 
complexes showed encouraging potential treatments [132]. Copper-based complexes as 
anticancer drugs have been selected on the basis that endogenous metals may be less toxic 
for normal cells than towards cancer cells. On the other hand, copper can also be toxic due to 
its redox activity. The changed metabolism of cancer cells and differential response among 
normal and tumour cells to copper are the basis for evolution of copper complexes with 
antineoplastic features. Copper is fundamentally a suitable element for most aerobic 
organisms, where it works as a structural and catalytic cofactor. For that reason, it can be 
involved in numerous biological pathways [133-135]. Considerable attention has been given 
to research regarding the mechanisms of absorption [136-138], distribution [139-141] 
metabolism, and excretion of copper in support of its role in the treatment of cancer and other 
diseases [142-144]. The essential features of the chemistry and biochemistry of copper, the 
role of this metal in medicine [145- 150], the pathology and treatment of Menkes and 
Wilson’s disease [151-152] and the chelation therapy approach in neurodegenerative 
disorders by copper [153], have been extensively surveyed in recent review articles.  Copper 
forms a rich diversity of coordination complexes with oxidation states Cu(II) and Cu(I), but 
very few examples of copper(III) compounds are reported [154]. The coordination chemistry 
of copper is controlled by Cu(II) derivatives. A number of bonding modes have been detected 
for thiosemicarbazones (TSCs) in their neutral or anionic forms, and depending on the 
substituents, they can behave as N, S bidentate, N, S, D (D = N, O) tridentate, or N2, S, D (D 
= O, S) tetradentate ligands. The antitumor activity of copper-(TSCs), has been described as 
early as in 1960s [154-155] and new developments are still in progress [156-167]. 
 
 Rosu et al. reported new Cu(II) complexes of the bidentate (κ2N,S-TSCs) ligand adducts. 
These Cu(II) complexes have a general formula of [Cu(L1)Cl(H2O)], [Cu(HL1)(H2O)2SO4], 
[Cu(L1)(H2O)2NO3], and [Cu(L1)(H2O)2(OCOCH3)] with 2-hydroxy-8-propyl-tricyclo-
[7.3.1.0.2,7] tridecane-13-one (R = n-propyl and furyl) thiosemicarbazone (HL1) derivatives 
as ligands (Figure 4:9). 
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Figure 4.9: Proposed structures of copper metal complexes. 
 
The ligands and the formed complexes were screened for them in vitro antibacterial effects 
against four different microorganisms and for the effects on HeLa cell proliferation. All the 
complexes examined showed antiproliferative activity [168].  There are also numerous 
copper(II) compounds with a 1,2,4-triazole moiety that demonstrated an extensive range of 
biological and pharmacological activities [169-170], among them the Cu(II) complex of 4-
amino-1,4-dihydro-3-(2-pyridyl)-5-thioxo 1,2,4-triazole (HL) ligand [Cu(L)Cl2] which was 
screened for its cytotoxicity in human cancer cells [171-173].  
 
4.4 Triazole based compounds 
4.4.1 Background of 1,2,3-triazole ring used in medicinal chemistry 
Medicinal chemists considered the synthesis of 1,2,3-triazole as an important category of 
nitrogen heterocycles in the field of medicinal and material chemistry based on heterocyclic 
compounds. The 1,4-disubstituted derivatives are the most common triazoles synthesized by 
means of 1,3-dipolar cycloaddition reactions (1,3-DCRs) and form the backbone of medicinal 
chemistry due to their importance and demonstrated wide range of numerous interesting 
biological activities. In the early part of the twentieth century researchers started working on 
the possibility of using 1,2,3-triazolo[4,5-d] pyrimidines (8-azapurines) for the treatment of 
cancer and malignant tumors [174-175]. 1,2,3-Triazoles cause peptidomimetic inhibition of 
tyrosinase, an enzyme which causes the browning of plant based foodstuffs and human skin 
diseases [176]. 
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The click chemistry approach invented by Sharpless [177] using copper (I)-catalyzed 
azidealkyne cycloaddition (CuAAC) has resulted in the production of large number of 1, 4-
disubstituted 1,2,3-triazoles in very high yields [178]. The copper(I)-catalyzed azidealkyne 
cycloaddition (CuAAC) yielded 1,2,3-triazole as one of the key structural units found in a 
large variety of bioactive molecules used in the different areas of the science, such as 
bioconjugation [179], oligonucleotide synthesis [180] construction of bolaamphiphilic 
structures [181], DNA labelling [182] and drug discovery [183].  
 
The characteristics of 1,2,3-triazoles make them pharmaceutically important molecules. They 
are stable against reduction and oxidation, as well as against hydrolysis in acidic and basic 
conditions. This is an indication of high aromatic stabilisation and relative resistance to 
metabolic degradation [184]. Moreover, the1,2,3-triazole ring has a high dipole moment [185] 
and this feature enables it to participate actively in hydrogen bond formation, as well as in 
dipole – dipole and π - π stacking interaction with an aromatic ring such as a phenyl ring 
[186]. The two nitrogen atoms N(2) and N(3) can form hydrogen bonds with hydrogen bond 
donors or coordinate with metal ions, which could be favourable in binding easily with 
biological targets [187] and also improves their solubility. Moreover, the1,2,3-triazoles are 
very stable under physiological conditions. Among nitrogen containing compounds, 1,2,3-
triazole compounds increasingly attract attention in drug discovery. The similarity of the two 
moieties can be seen in the size (distances between substituents are 3.8 -- 3.9 Å in amides and 
5.0 - 5.1 Å in 1,2,3-triazoles), the dipolar moment (amide ~ 4 Debye, while for 1,2,3-triazole 
~ 5 Debye), and the H-bond acceptor capacity (Scheme 4.1) [188]. The 1,2,3-triazole rings 
have sp2-hybridized nitrogen atoms N(2) and N(3), which can act as weak hydrogen bond 
acceptors or donors of a lone pair of electrons. Furthermore, the strong dipole moment of 
1,2,3-triazole ring polarizes the C(5) proton to such a degree that it can function as a 
hydrogen-bond donor similar to the amide NH. Additionally, the 1,2,3-triazole ring has a 
large dipole that could align with that of the other amides in a given peptide secondary 
structure [189]. However, unlike amides, 1,2,3-triazoles are very stable against hydrolysis. 
Because of the ability of 1,2,3-triazoles to function as rigid linking units that imitate the atom 
replacement and electronic properties of a peptide bond without the susceptibility to 
hydrolysis, many known 1,2,3-triazoles possess biological activity. 
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Scheme 4.1: Hypothesis on how triazoles could act as non-classic bioisosteres of amides 
[190] 
 
Substances acting against the hepatitis C virus (HCV) [191] and compounds such as 
benzodiazepine and adenosine receptors exhibited inhibiting properties [192-193]. Some 
biologically active compounds are presented in Figure 4.10. 
 
 
Figure 4.10: Molecules containing 1,2,3-triazole showing different applications. 
 
When attached to a carbohydrate core, triazole derivatives have found applications as 
antibacterial, antihelmintic, antifungal and anticancer properties [194]; antiviral drugs [195, 
196] and inhibitors of glycosidases [197-198]. Over the past few years, 1,2,3-triazole 
molecules have been synthesised as useful chemotherapeutic agents for various diseases [199]. 
A novel series of new chalcone-pyrrolo [2,1-c] [1,4]benzodiazepine (PBD) derivatives were 
made using alkane spacers and linked through a 1,2,3-triazole moiety. The synthesised 
compounds showed a promising anticancer activity with MIC ranging from <0.1-2.92 μM. 
The compound in Figure 4.11 was found to be the most effective with MIC-values ranging 
from 0.12-2.03 μM against different cancer cell lines [200]. 
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Figure 4.11: Molecule containing 1,2,3-triazole showing anticancer activates. 
4.5 Compounds with a combination of metals and triazole moieties 
Gautier et al. (2008) reported a series of 1,2,3-triazole ligands for platinum complexes. It is 
noteworthy that most of the synthesis of Pt(II) N, N or N, O complexes of biological interest 
are conducted in water, and proved that the click chemistry is a beneficial tool for the facile 
building of a series of potentially chelating triazole ligands for platinum. The structures of 
Pt(II) complexes chelates that coordinate through one triazole nitrogen atom and one 
exocyclic functionality (amine or carboxylate) are depicted in Scheme 4.2. The ligands can 
be divided into two categories: “regular” click ligands, in which the C4 substituent chain 
participates with N3 for chelation, and the isomeric counterparts, “inverse” click ligands, in 
which the chelation involves N2 and the substituent chain at N1. The regular and inverse 
ligands are expected to form five- and six-membered complexes, respectively. 
 
Scheme 4.2: Schematic representation of synthetic for triazoles and complexes [201]. 
The neutral cis dichloro diamino complex A, as presented in Scheme 4.3, exhibited interesting 
cytotoxicity against breast cancer cells, which is comparable to that of cisplatin. In contrast, 
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the cationic complex B in Scheme 4.3 showed no such activities, which is in accordance with 
the accepted structure activity relationship of platinum drugs [202, 203]. 
 
 
Scheme 4.3: Synthesis of regular N, N complexes. 
 
On the other hand, the behaviour of the N, O ligand which is coordinate with Pt(II) by using 
a different mole ratio(stoichiometry) of the ligand as presented in Scheme 4.4, yielded the 
complexes C, D and E with no cytotoxicity activity. 
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Scheme 4.4: Synthesis of regular N, O complexes [201]. 
4.6 Summary 
From the brief overview supplied in the discussion above, it is obvious that another potential 
lucrative area for 1,2,3-triazole ligands is in the potential application as medicinal drugs, and 
in particular as anticancer agents when combined with selected metal atoms. To date a number 
of metal-ligand complexes with single or double N-atom bonds have been prepared and 
tested, some with more success than others. In the metal-1,2,3-triazole ligand category, work 
to date has been limited to Pt and Pd complexes. In the investigations described in this thesis, 
various new metal-1,2,3-triazole ligand complexes will be synthesised and evaluated for their 
potential anticancer applications in addition to considering them for potential dye solar cell 
compounds and devices. These light sensitive compounds can be used in photodynamic 
therpy with a light source to destroy cancer cells. Photodynamic therapy includes a drug 
sensitive to light. Once given to the patient, light at a particular wavelength is applied and the 
drug will produce reactive oxygen species that will kill the surrounding cells. It is normally 
relevant for cancers of the skin (not melanoma), gullet, head, neck, mouth, eyes and lungs. 
Chapter (6) will describe the synthesis and characterisation of just such a series 1,2,3-triazoles 
prepared in this investigation. 
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Chapter 5 : Instrumentation and Experimental Techniques  
5.1 General reagents and solvents 
 
Caution: Aryl amines should be treated as potential carcinogens and all azides considered 
potentially explosive and treated with care. 
Precursors and solvents were purchased from Alfa Aesar, Sigma/Aldrich or Fisher Scientific 
and purified where appropriate or otherwise used as received. Dimethylsulphoxide (DMSO; 
spectrophotometer grade), hydrochloric acid, ammonium hydroxide, 4-aminobenzonitrile, 4-
aminobenzoic acid, 2-ethynylpyridine, sodium azide, copper chloride, cobalt chloride, nickel 
chloride, cadmium chloride, phenylacetylene, iron chloride and sodium ascorbate were 
obtained from Sigma Aldrich. Dichloromethane, hexane, methanol, chloroform, ethyl acetate, 
diethyl ether, ethanol, magnesium sulphate (anhydrous) were purchased from Fisher 
Scientific. 4-Chloroaniline, tert–butanol, aniline, sodium nitrite and magnesium chloride 
were boughtfrom Aldrich and 4-fluoroanline, 4-methylaniline, 4-(trifluoromethyl)aniline 
hydrochloride from Alfa Aesar.  
 
5.2 General Instrumentation and Characterisation Methods  
 
1H 13C, COSY, 13C–1H correlated NMR spectra were recorded on an ECS-400 MHz, JEOL 
multi nuclear F.T spectrometer with Optiplex 380 Delta 5.02 software, with tetramethylsilane 
(TMS) as an internal standard for 1H NMR analysis. Chemical shifts are reported in ppm 
downfield from tetramethylsilane (TMS), at 298 K with coupling constants (J) reported in 
Hertz (Hz). Standard abbreviations indicating multiplicity were used as follows: m = 
multiplet, t = triplet, d = doublet and s = singlet. 
Accurate mass spectrometry data, of samples, was collected at the EPSRC (engineering and 
Physical Sciences Research Council) mass spectrometry service centre, University of Wales, 
Swansea Thermofisher LTQ Orbitrap XL; HRMS (N-NSI) or (P+NSI) Positive or Negative 
ion (nano-electrospray) spectrometer, while the ionisation was electrospray (ESI+ and ES-) 
Thermofisher LTQ Orbitrap XL was used to analyse volatile molecules in the mass range m/z 
50–2000 or m/z 200–4000 Daltons. Positive Electrospray (ESI-MS) mass spectra time of 
flight (TOF) (MALDI-TOF), were recorded on Voyager instrument DE-STR used to analyse 
volatile molecules in the mass range 200 to 200000 Daltons. Facility at Swansea University 
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and at the Department of Chemistry at University of Sheffield using (HRMS TOF/(ESI+)). 
The instrument used was the ‘WATERS LCT premier’, the ionisation was electrospray 
(ESI+), the solvent was Water/Acetonitrile (1:3), (water: acetonitrile = 1:3). All strucral 
characteristion spectra are presented in the Appendices. 
 
Single-crystal X-ray diffraction data and analyses were performed in the Chemical 
Crystallography Laboratory at the EPSRC National Crystallography Service, School of 
Chemistry, University of Southampton, United Kingdom. Single crystal diffraction data were 
collected using either a Nonius-kappa CCD area detector mounted at the window of an FR591 
rotating anode generator (Mo Kα, λ=0.71073A); Rigaku Saturn 724+ area detector mounted 
at the window of an FR-E+ rotating anode generator (Mo Kα, λ=0.71073Å) equipped with 
HF Varimax optics (100µm focus). 
 
Fourier transform infrared spectra (ATR-FTIR IR) and (FTIR) were recorded using a smart 
diamond ATR attachment on a Thermo-Nicolet FT-IR Spectrophotometer (AVATAR 320) 
over the range 4000 to 400 cm-1. 
 
Electronic spectra and UV-VIS spectra were recorded in 1cm2 path length quartz cell in a 
Perkin-Elmer Lambda 40 spectrophotometer from 245-1000 nm, by dilution of a 10-3M stock 
solution in DMSO at 294K. Fluorescence measurements were undertaken in 1cm2 path length 
quartz cuvettes on solutions with an absorbance < 0.1 au using a Hitachi fluorescence 
spectrophotometer, and the data analysed using the Hitachi FL solution software. The 
fluorescence quantum yield was determined by (1,1':4'1"- terphenyl; PTP ) dye as a reference 
with The ligand, complexes and the reference dye were excited at 276 nm, maintaining nearly 
equal absorbance (0.0954), and the emission spectra were recorded from 285 to 800 nm. All 
experiments were carried out at a concentration of (1 x 10-6 M). 
 
Melting points were determined with a Stuart Scientific melting point – SMP1 (Bibby, UK) 
apparatus. Preparative thin layer chromatography plates Analtech (PTLC) were undertaken 
on 20 x 20 CM 2000 microns 12 x 12 cm silica plates, 2mm thick (ANALTECH), eluted with 
EtOAc/hexane (1:1) unless otherwise stated. After development the plates were examined 
under UV- 254nm, the individual band removed, then extracted with a suitable solvent, 
filtered to remove the solid silica and the filtrate evaporated under vacuum to give the pure 
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product. Thin layer chromatography plate Analtech, Inc. 75 Blue Hen Drive Newark, DE 
19713 WWW.analtech.com 20x20 CM 2000 MICRONS.  
Gas chromatography electron impact mass spectroscopy (GCEIMS) was carried out in house 
on a Hewlett Packard (HP), model 5890GC interfaced to a HP 5972 mass selective detector 
(MSD) quadropole spectrometer with mass fragmentation by electron impact (EI) ionisation. 
Gas chromatographic separation was undertaken on a RTX – 5MS column, (15m x 0.25mm 
x 0.25μm Restek; Cat no. 12620), helium gas carrier, column head pressure = 7psi, inlet temp, 
275 oC and injector, 1 μl.  
Conductivity measurements were carried out using aqueous DMSO solutions (1.0 x 10-3 M) 
at 294K using a Hanna digital conductivity meter (model EC 214) with a conductivity 
electrode, type H1 76300 Conductivity measurements were carried out by using 10-3M 
concentrations of the complexes in DMSO (294 K)  
 
Following instructions from the manufacturer. Magnetic susceptibility of complexes were 
recorded at room temperature (294K) using a magnetic susceptibility balance (Johnson 
Matthey Catalytic Systems Division Equipment).  
 
Bioligal activity studies were carried out on two human tumour cell lines, HepG2: Hepatoma 
Cells (hepatic carcinoma from a 15 years old child) (Cyprotex) and HCT116: Colorectal 
Cancer Cell (gift from Kids Can) at the school of environmental and life sciences Salford 
university. 
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Chapter 6 : SYNTHESIS OF (1,2,3-TRIAZOL-4-YL)-
PYRIDINE LIGANDS VIA A CLICK APPROACH 
 
6.1 Introduction  
The initial objective of this work, as previously stated, was to prepare novel metal complexes 
using bidentate ligands ((1,2,3-triazol-4-yl)-pyridine based) which were synthesised via the 
Cu(I)-catalysed alkyne–azide (CuAAC) (‘click chemistry’) reaction from a wide range of 
substrates. It was intended to assess the potential applications of these metal complexes in 
dye-based solar cells and for screening as potential anti-cancer drugs. During the course of 
this project a paper was published detailing the synthesis of the ligands, how the metal 
complexes and their X-ray structures were determined and what a novel packing pattern they 
displayed.  
During the course of this research, many of the synthesised ligands have not been reported 
before, nor have they been characterised. Knowledge of their structure and characteristics is 
important to be able to estimate whether the coupling of these ligands to metallic ions would 
yield the required photochemical performance of the intended dye solar cells. The novelty of 
this work has been highlighted in the paper published in Acta Crystallographica Section B, 
70, 379–389 (2014). 
 
6.1.1 Synthesis of 4-(4-phenyl-1H-[1, 2,3]-triazol-1-yl)benzoic acid (L1) 
Before embarking on this task, the click ligand 4-(4-phenyl-1H-[1,2,3]-triazol-1-yl)benzoic 
acid (L1) was targeted as a model compound to validate the conditions used to successfully 
effect the Cu-catalysed regioselective click reaction between 4-azidobenzoic acid and 
commercially available phenylacetylene (Scheme 6.1). 
 
 
Scheme 6.1: Proposed preparation route for 4-(4-phenyl-[1H-1,2,3]-triazol-1-yl)benzoic 
acid (L1). 
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4-Azidobenzoic acid was chosen for use in this reaction in view of its easy preparation, from 
4-aminobenzoic acid [1-3], as shown in the Scheme 6.2 (see below) using the Sandmeyer 
reaction.   
 
Scheme 6.2: Synthetic route for the preparation of arylazides.  
 
The subsequent click reaction (Scheme 6.1) was undertaken as detailed in the experimental 
section (6.3.1.1) using THF/H2O as a solvent. The compound, 4-(4-phenyl-1H-[1,2,3]-triazol-
1-yl)benzoic acid (L1), was obtained as a colourless solid in 70% yield. The structure was 
confirmed by NMR and HRMS spectra. After successful demonstration of the “click” 
reaction it was decided to prepare 2-(4-phenyl-[1,2,3]triazol-1-yl)pyridine (structure (I) in 
scheme 6.3), a bidentate ligand, which will form metal complexes with our desired properties. 
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6.1.2 Synthesis of 2-(4-phenyl-1H-1,2,3triazol-1-yl)pyridine ligand (I) 
The synthesis of the titled bidentate ligand was attempted, as shown in Scheme 6.3, using the 
click reaction between 2-azidopyridine and phenylacetylene. 
 
 
Scheme 6.3: Proposed preparation route for 2-(4-phenyl-1H-1,2,3]triazol-1-yl)pyridine 
(I).  
Whilst phenylacetylene was commercially available, 2-azidopyridine had to prepared either 
by the conversion of 2-fluoropyridine with NaN3 in DMSO at 100
oC [4], or by the conversion 
of 2-fluoropyridine to 2-hydrazine pyridine with hydrazine hydrate, followed by diazotization 
with NaNO2/HCl and NaN3 [5], as shown in Scheme 6.4 
 
Scheme 6.4: Preparation route for 2-azidopyridine. 
 
2-azidopyridine was successfully prepared using both these two methods and yielded crude 
2-azidopyridine, as confirmed by NMR and IR, with the azide peak centered at 2130(vs) cm-
1 and 2100(vs) cm-1 as reported in the literature [6]. The 2-azidopyridine was reacted with 
phenylacetylene (see Scheme 6.3) to produce the desired click ligand 2-(4-phenyl-
[1,2,3]triazol-1-yl)pyridine(I) under similar conditions which were used to successfully 
prepare ligand L1 (6.3.1.1.) Scheme 6.1.  However, on organic work up of the reaction 
mixture, the only product identified was a remnant of the starting material with no evidence 
of the formation of the desired click product (I).  
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Heterocyclic azides such as 2-azidopyridine spontaneously cyclise as reported in the literature 
to the fused tetrazolo [1,5-a]pyridine, which is in equilibrium with the azide as shown in 
Scheme 6.5 [7]. This has been described in the literature as a tautomerism, as an 
azidomethine-tetrazole (imideamide-tetrazole) equilibrium, as a 1,5-dipolar cyclisation and a 
valence isomerisation [6-11]. 
 
 
 
 
 
 
 
However, the position of the equilibrium is important with regard to the formation of the click 
product via the [3+2] cycloaddition reaction mechanism (chapter 2, Scheme 2.1), as this 
requires the azide structure and its dipolar character rather than a tetrazole structure to form 
the transition state (Scheme 2.1 (10) for product formation). The failure to form the desired 
click product as expected, based on Scheme 6.3, suggested that 2-azidopyridine might exist 
predominantly as the tetrazole in (Scheme 6.5). However, the literature in regard to the 
position of the azide ↔ terazole equilibrium was controversial. Spectroscopic studies on 
solute-solvent studies favoured the azide form exclusively and the absence of an equilibrium 
[7]. Computational ab initio calculations [12] indicated that the presence of electron 
withdrawing groups on the pyridine shifted the equilibrium from the tetrazole towards the 
azide. IR absorptions studies of the 2-azidopyridine group however, indicated that the major 
equilibration isomer of this compound is the tetrazolo [1,5-a]pyridine (Scheme 6.5) [11, 13], 
as reported for the solid state [14-19].  
 
The literature indicated that the 2-azidopyridine equilibrium favoured the tetrazolo [1,5-a] 
pyridine isomer Scheme 6.5 both in solution and in the solid state, except for the publication 
of Rafie et al. [7], which indicated that the compound existed exclusively as the azide in 
solution. As the method of preparation could influence the equilibrium, it was decided to 
prepare 2-azidopyridine according to the method of Rafie et al. [7], i.eby diazotisation of 2-
aminopyridine with (i) NaNO2/HCl, and then (ii) NaN3. However, the 2-azidopyridine when 
used in the click reaction with phenylacetylene again failed to give 2-(4-phenyl-[1,2,3]triazol-
Scheme 6.5: Equilibrium tautomerism between 2-azidopyridine and its tetrazole 
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1-yl)pyridine (I). After six months of research effort in trying to achieve the above research 
objective, it was decided to abandon the preparation of this click ligand via this approach.  
It is noteworthy that upon completion of our research, a paper was published by Zhang et al. 
in 2012 [19], reporting the successful preparation of derivatives of this type above (6.1.2.) 
using a Cu(I)-acetate catalyst with 5-substituted-2-azidopyridine having electron 
withdrawing groups (NO2, CN, CO2Et) to shift the position of the tetrazole ↔ azide 
equilibrium to effect the azide-alkyne cycloaddition reaction. Tetrazolo [1,5-a]pyridine is 
formed by the conjugation of the terminal nitrogen of the azide group with the nitrogen at 1-
position of the pyridine ring with subsequent electron transfer to satisfy the positive charge 
on the azide group (Scheme 6.5). The presence of an electron withdrawing group on the 5-
position of the 2-azido pyridine causes the electron pair on the nitrogen to conjugate now with 
the electron withdrawing group at the 5-position to stabilise its positive character so 
preventing the competing reaction the formation of tetrazolo [1,5-a]pyridine. 
 
6.1.3 Preparation of aryl azides 
In order to synthesise alternative ligands a general procedure was required for the preparation 
of aryl azides and this is elaborated in the earlier scheme (Scheme (6.2). The synthetic route 
involved the use of the Sandmeyer reaction (a) where an aromatic primary amine was 
converted under acid conditions with NaNO2 into a diazonium salt in situ, followed by 
nucleophilic substitution of the diazonium salt with NaN3 to give the azido compound [20-
22]. A range of 4-substituted aryl azides A1– A9 (see Table. 6.1) were synthesised with the 
aim of producing a series of click ligands containing electron donating (R= CH3, OCH3) and 
electron withdrawing groups (R = F, Cl, CN, CF3, COOH) and whose Hammett substituent 
constants (σρ) covered the range between -0.27 to 0.66.  Experimental details are described 
in Appendix 1 and the yields obtained reported in Table 6.1. These compounds have been 
previously reported in the literature and characterised by NMR, GC-MS and IR [23-37].  
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Table 6.1: Chemical structure and nomenclature of aryl azide reagents (A1-A9). 
Code Compound IUPAC nomenclature Yield % 
Literature 
reference 
 
A1and A4 
 
 
        4-azidobenzoic acid      69 
 
24-26 
 
 
A2 
 
       1-azido-4-methylbenzene        71 
 
24-25 
 
 
A3 
 
 
1-azido-4-methoxybenzene 79 
 
24-26 
 
 
A5 
 
 
1-azido-4-fluorobenzene 90 
 
22, 31, 37 
 
 
A6 
 
 
1-azido-4-chlorobenzene 83 
 
32-34 
 
 
A7 
 
 
4-azidobenzonitrile 
 
90 
 
 
35-36 
 
 
A8 
 
 1-azidobenzene 79 
 
23-25 
 
 
A9 
 
 
1-azido-4-(trifluoromethyl)benzene 
 
91 
 
 
24, 37 
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The significance of the Hammett constant is that a plot of the properties of the click ligands 
against the substituent constants (σρ) would allow substituent effects on the property of the 
ligand or complex to be assessed in a quantitative manner under certain conditions and allow 
us to obtain an overview of compounds rather than examining them in isolation. 
 
6.1.4 Synthesis of click ligands (L2- L9) 
Due to the aforementioned problems in synthesisng 2-(4-phenyl-1H-1,2,3triazol-1-yl) 
pyridine ligand it was decided to focus on the preparation of the analogue of the desired 
product 2-(1-p-tolyl-1H-[1,2,3]-triazol-4-yl)-pyridine (L2) using the click reaction as shown 
in Scheme 6.6.   
 
 
Scheme 6.6: Preparation route for 2-(1-p-tolyl-1H-[1,2,3]-triazol-4-yl)-pyridine (L2).   
 
The synthesis of 2-(1-p-tolyl-1H-[1,2,3]-triazol-4-yl)-pyridine (L2) (see experimental section 
6.3.1.2), required the reaction of commercially available 2-ethynylpyridine with our 
previously prepared 1-azido-4-methylbenzene (A2) under click conditions using CuSO4/Na-
ascorbate in water/tert–butyl alcohol at room temperature(RT), as shown in Scheme 6.6. The 
click product 2-(1-p-tolyl-1H-[1,2,3]-triazol-4-yl)-pyridine (L2) was isolated after removal of 
insoluble copper salts using celite and organic workup to give (L2) as a yellow solid in 74% 
yield. Recrystallisation from CH2Cl2: CH3OH (1:1) gave the product as a colourless solid 
with mp 128-129oC; Lit 128-129oC [38]. The structure was confirmed by NMR and HRESMS 
[38], as well as for the first time by single crystal X-ray analysis. 
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Having established the methodology for the preparation of compound L2, the work was 
extended to prepare a range of related 2-pyridyl-[1,2,3]-triazole ligands L3- L9 as shown in 
Table. 6.2, by reaction of the appropriate 4-substituted aryl azides A1–A9 (Table. 6.1) with 
2-ethynylpyridine under click reaction conditions as shown in Scheme 6.7. 
 
 
Scheme 6.7: Preparation route for 2-pyridyl-[1,2,3]-triazoleligands L1-L9. 
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Table 6.2: Chemical structure and nomenclature of click 1,2,3-triazole ligands (L1-L9). 
Code Structure IUPAC nomenclature Yield 
(%) 
Literature 
reference 
 
L1 
 
4-(4-phenyl-1H-[1,2,3-triazol]-1-
yl)benzoic acid 
71 46 
 
L2 
 
2-(1-p-tolyl-1H-[1,2,3]-triazol-4-yl)-
pyridine 
70 38 
 
L3  
2-(1-(4-methoxyphenyl)-1H-[1,2,3]-
triazol-4-yl)pyridine 
93 39,40,41 
 
L4  
4-(4-(pyridin-2-yl)-1H-[1,2,3-triazol]-
1-yl)benzoic acid 
79 novel 
 
L5 
 
2-(1-(4-fluorophenyl)-1H-[1,2,3-
triazol]-4-yl)pyridine  
83 novel 
 
L6 
 
2-(1-(4-chlorophenyl)-1H-[1,2,3-
triazol]-4-yl)pyridine 
81 45 
 
L7 
 
4-(4-(pyridin-2-yl)-1H-[1,2,3-triazol]-
1-yl)benzonitrile 
91 novel 
 
 L8 
 
2-(1-phenyl-1H-[1,2,3-triazol]-4-
yl)pyridine 
80 42,43,44 
 
 L9 
 
2-(1-(4(trifluoromethyl)phenyl)-1H-
[1,2,3]-triazol-4yl)pyridine 
78 novel 
 
The click ligands L1 and L2- L9 in Table 6.2 were prepared as shown in Schemes 6.1 and 
Schemes 6.7 using the appropriate aryl azide and obtained in good yields varying from 70-93 
%. They were characterised by NMR, HRMS, IR and X-ray analysis as described in section 
5.2.2. Click ligands L2 [38], L3 [39-41], and L8 [42-44] were previously reported in the 
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literature and compound L6 [45] was prepared in 2013, in 94% yield, as a yellow solid. The 
click products L1- L9 isolated by us, were all colourless solids after recrystallisation. 
 
6.2 Results and discussion 
 
Comparative spectroscopic techniques have been used to study the properties of ligands L1-
L9. 
6.2.1. FTIR spectra 
Infrared (ATR-FTIR-IR) spectra were recorded using a smart diamond ATR attachment on a 
Thermo-Nicolet FT-IR Spectrophotometer (AVATAR 320) over the range 4000 to 400 cm-1. 
The FTIR spectral data of ligands L1-L9 are visually presented as an overlay of the IR spectra 
of L1-L9, as shown in Figure 6.1. These significant peaks for ligands L1-L9 are tabulated in 
Table 6.3. 
 
Table 6.3: IR frequencies (cm-1) of the ligands (L1-L9) 
Ligand ν(C-H)triaz ν(C=N)py ν(C=C)Ar ν(C=C)triaz ν(N-N)triaz ν(N=N)triaz ν(C-N) ν(C=O) 
L1 3125 1605 1605, 1573 1557 1177,1035 1520 1229 1682 
L2 3118 1597 1592, 1566 1549 1144,1036 1517 1233  
dL3 3142 1604 1592,1574 1549 1154,1022 1515 1258  
L4 3141 1603 1588, 1573 1553 1151,1036 1517 1240 1687 
L5 3152 1589 1572, 1549 1515 1149,1035 1516 1235  
L6 3132 1602 1589, 1570 1550 1146,1037 1501 1236  
eL7 3120 1601 1572, 1549 1511 1147,1032 1511 1235  
L8 3116 1599 1591, 1567 1544 1147,1035 1502 1237  
L8 3122 1615 1593, 1570 1547 1105,1027 1528 1337  
 
d ν(C-OMe): 1257 cm-1, ῡ =1022cm-1 ; e ν(C≡N): 2230 cm-1 
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Figure 6.1: ATR-FT-IR absorption spectral data of the ligands (L1- L9).
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Table 6.3 shows the characteristic bands common to all bond types present in click 
ligands L1-L9. The bands in the region ῡ = 3116-3151cm-1 were assigned to the 
stretching of the ν(C-H) bond of the triazole ring [38-48] and that at ῡ = 1615-1598 
cm-1 to the stretching of the ν(C=N) bond of free pyridine that shifts on coordination 
to the metal to higher wavenumbers, indicating a new compound was obtained. The 
two bands at region ῡ = 1605-1549 cm-1 were, attributed to the two characteristic 
stretching peaks of the ν(C=C)Ar bond which occur as a pair of peaks in substituted 
benzenes. The bands observed at region 1557-1511 cm-1 were attributed to stretching 
of the ν(C=C)triaz bond of the triazole ring [49, 50] and the ῡ = 1520-1500cm-1 to the 
ν(N=N) stretching vibration [51, 52]. The band at ῡ = 1258-1220cm-1 is attributed to 
the ν(C-N) stretching bond [53], and the bands around ῡ = 1145cm-1 and ῡ = 1036cm-
1were assigned to the ν(N-N) bond of the triazole ring [54]. The pair of bands in the 
range at ῡ = 962-977cm-1 were assigned to ν(N–N=N) stretching vibration [55, 56] of 
the triazole ring. In addition, substituent specific bands were identified for ligands, L1 
and L4 at 1682 and 1687 cm-1 respectively, for the ν(C=O) stretching of the COOH 
group and ῡ =2230 cm-1for the ν(C≡N) stretching of the nitrile group of L7. Two bands 
at ῡ = 1257 cm-1 andῡ =1022cm-1 were assigned for the ν(C-O) stretching of the 
methoxy group of L3 [53].  
 
6.2.2 Hammett Plot Using UV-Vis Data 
A plot of the λ maxvs the σp substituent constant for all ligands gave a concave upward 
deviation in the Hammett plot with a negative slope for the electron donating groups 
and a positive slope for electron withdrawing groups. This is a change in mechanism 
in which electron donating groups decrease the positive charge at the triazole ring. 
However, electron withdrawing groups enhance the positive charge (see Figure 6.2) 
at this centre. There were three substituents (H, CF3 and COOH) which are outliers 
on the plot. 
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Figure 6.2: Hammett plot of correlations of the λ max of L2-L9 ligands vs. σp 
values for the Hammett substituent parameters electron donor and withdrawing 
para substituents (R = H, Me, OMe, Cl, F, CN, COOH, and CN). 
 
 
Figure 6.3: Hammett plot of absorbance maximum of L2-L9 ligands vs. σp values 
for the electron donor and withdrawing para substituents (R = H, Me, OMe, Cl, 
F, CN, COOH, and CN). 
In the series L2-L9, the maximum absorption of both bands measured in DMSO (1x10-
6M), gives a linear correlation the between the Hammett σρ constant for the substituent 
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on the p-position of the phenyl group (Figure 6.3). The two substituents which are 
outliers (COOH and CN) are not included in the plot. This suggests that compounds 
with these substituents act as stronger acids than one would have predicted from their 
values. When electron withdrawing due to mesomeric effects can be extended to the 
reaction centre via “through conjugation”, the result is an even more stabilized 
species. These types of correlation between the Hammett σρ constant in relation to the 
substituent of the p-position and the relevant UV absorption frequencies were reported 
previously in literature [57-58]. 
Table 6.4: The absorption maxima λ max vs the Hammett parameter of the σρ 
substituent correlation in DMSO (C= 1 X10-6M). 
 
Compound Substituent 
   in para 
postion 
σρ λ max(nm) Absorbance ε/10-6 M 
dm3. mol-1.cm-1 
L2 CH3 -0.17 283 0.1051 15100 
L3 OCH3 -0.27 285 0.1052 15200 
L4 COOH 0.45 291 0.0814 81400 
L5 F 0.06 283 0.0994 99400 
L6 Cl 0.23 284 0.0957 95700 
L7 CN 0.66 292 0.0975 97500 
L8 H 0 284 0.0975 97500 
L9 CF3 0.54 288 0.0932 93200 
  
6.2.3 NMR spectra 
The 1H- and 13C-NMR spectra for each ligand were assigned in comparison with 
spectra of previously reported triazoles [38-47], and supported by 2-dimensional 
spectra (1H–1HCOSY and 13C–1H HMQC) to confirm the proposed assignments. The 
chemical shift (δ) of the 1H- (C-H) and 13C-NMR (=CH) of the triazole moiety have 
been tabulated for ligands L1-L9 in Table 6.5. This is also shown in Figure 6.4, which 
indicates that the proton from the triazole ring position shifts according to the 
substituent in the para-position of the phenyl ring, 
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Figure 6.4: The overlayed spectra of the (C-H) triazole from the 1H NMR for ligands L1-L9 in CDCl2 solutions.
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The effect of the electron withdrawing substituents on the phenyl ring manifested 
itself in shifts of the C-H-triazole peak of the 1H-1,2,3-triazole system, which was 
observed in the range between 8.54-9.46 ppm in the 1H-NMR and 119.69-120.48 ppm 
in the 13C-NMR spectra of ligands L2-L9. These values are tabulated in Table 6.5 with 
literature values reported for triazole ligands with a NO2 and NH2 substituent included 
[45]. To ascertain whether there was a relationship between the shifts in the C-H-
triazole1H-NMR peak and the substituents present on the phenyl ring, a Hammett type 
plot was undertaken on the data. Figure 6.5 shows the plot of the shift of δ(C-H) 
triazole in ppm for ligands L2-L9 and literature reported ligands (NH2 andNO2) against 
the Hammett σ substituent constant [59]. A linear relationship with positive slope 
(0.18) was observed between δ(C-H) and the σp substituent constant for the ligands, 
with R2=0.97. L4 (COOH) and the NO2 substituent were outliers and were excluded 
from the linear regression fit. The plot Figure 6.5 suggests that COOH and NO2 groups 
act as much stronger electron withdrawing groups than expected via the inductive 
effect based on their σp constant. They therefore cause greater deshielding of the (C-
H) of the triazole ring and higher acidity. 
Table 6.5: The 1H- and 13C-NMR spectra of the C-H-triazole ligands (L1- L9). 
 
Ligand Formula Solvent 1H-NMR δ(C-H) 
(triazole) 
13CNMR(=CH) 
(triazole) 
σρ constant (-σρ) 
[53] 
L1 C15H10N3O2 DMSO- d6 9.42 H9 119.62 (C9)  
L2 C14H12N4 CD2Cl2 8.55 H8 120.09 (C8) -0.17 
L3 C14H12N4O CD2Cl2 8.54 H11 120.64 (C11) -0.27 
L4 C14H10N4O2 DMSO- d6 9.46 H11 121.41 (C11) 0.45 (0.77) 
L5 C13H9FN4 CD2Cl2 8.58 H7 120.48 (C7) 0.06 
L6 
 L6* 
C13H9ClN4 
C13H9ClN4 
CD2Cl2 
CDCl3 
8.60 H11 
8.62 
120.42(C11) 
119.9 [28] 
0.23 
0.23 
L7 C14H9N5 CD2Cl2- d6 8.70 H16 120.23 (C16) 0.66 
L8 C13H10N4 CD2Cl2 8.62 H1 120.41 (C1) 0 
L9 C14H9F3N4 CD2Cl2 8.70 H11 119.69(C11) 0.54 
NO2 [30] C14H9N4 DMSO 9.57 122.3 0.78 (1.27) 
NH2 [45] C14H9N4 DMSO- d6 8.48 121.1 -0.66 
 
L6* = A value obtained from literature [43]. 
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Figure 6.5: A plot of δ(C-H) ppm of triazole against the Hammett's para 
substituent constant [σρ]. 
Deviation from the plot by electron withdrawing groups such as the NO2 and COOH, 
can occur due to mesomeric effects, if these effects can be extended to the reaction 
centre via “through conjugation” to result in a more stabilised species.  
 
Scheme 6.8: Resonance structures proposed for 2-pyridyl-1,2,3-triazole ligands 
L2- L9. 
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The electron distribution of the click ligands L2, L3, L5-L9 is influenced by the 
resonance structure (a) when R is an electron withdrawing group and structures (b) 
when R: is an electron donating group (see Scheme 6.8). However, the marked 
deviation of the δ(C-H) and the σp substituent constant for ligands L4 (COOH) and 
the NO2 ligand (Figure 6.5), indicates that these electron withdrawing groups have a 
significant mesomeric contribution (structure c). The use of the modified -σp 
substituent constant for NO2 (1.27) and COOH (0.77) that corrects for the mesomeric 
contribution of the substituent, failed to correct the deviation of these ligands from a 
linear relationship. This indicates the δ(C-H) triazole proton was significantly more 
acidic than expected. This may be due to structure (c) where conjugation resulted in 
the positive charge being localised on the triazole nitrogen adjacent to the triazole-H 
as shown in Scheme 6.8 [60]. 
 
Figure 6.6: A plot of 13C δ (C=C) ppm shift for the triazole carbon against the 
Hammett's para substituent constant [σρ]. 
A plot of the 13C δ(C=Ctriazole) vs the σp substituent constant for all ligands gave a 
concave upward deviation in the Hammett plot with a negative slope for electron 
donating groups and positive slope for electron withdrawing groups. This indicates a 
change in mechanism in which donating groups decrease the positive charge on the 
triazole ring (b; Scheme 6.8), whilst electron withdrawing groups (a and c; Scheme 
6.8) enhance the positive charge (see Figure 6.6) at this centre. There were two 
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substituents which acted as outliers (CF3 and CN) and these are not depicted on and 
considered for the graph. 
6.2.4 Mass spectra 
The mass spectroscopic pattern presented here were experimentally observed and 
both positive and negative ion nano-electrospray (NSI) mass spectra were used to 
measure the mass of the ligands L2-L9 are shown in Scheme 6.9. The high resolution 
mass spectra obtained for compounds L2-L9were identical to the fragments reported 
in the literature for compounds L2, L3 and L6, [38-47] with the formation of a 
metastable ion (M+H)+ relative abundance (100%), Table 6.6 that subsequently 
fragmented by pathways A, B & C, as shown in Scheme 6.9. 
 
Scheme 6.9: Dominant fragments detected in the mass spectra pattern of ligands.  
Pathway (A) involves the loss of a nitrogen molecule to give the (M-N2)
+ species, 
seen for ligands L2, L3, L5-L9 using positive ion nano-electrospray. In the case of L4, 
negative ion nano-electrospray was used and this species was not observed. The other 
species observed was the molecular ion plus sodium (M+Na)+ pathway (B) and the 
dimeric molecular ion plus sodium (2M+Na)+ pathway (C), a result of the use of 
sodium in the matrix solution. Table 6.6 shows the molecular weight and relative 
abundance of each species identified for ligands L2-L9. 
Table 6.6: MS (P+NSI) species observed experimentally for ligands L2, L3, L5-L9 
and MS (N-NSI) of L4. 
Ligand [M-N2]+ [M+H]+(100%) [M+Na]+ 
 
[2M+Na]+ Ref and other 
fragments 
L2 209 (22%) 237 259 (7%) 495 (18%) [39] 
L3 224 (15%) 253  527 (14%) [41] 
L4  265(M-H)-  531(9%) (2M-H)-  
L5 213 (35%) 241 263 (14%) 503 (24%) 362(5%); 391(2%) 
L6 229 (25%) 257 279 (6%) 535 (9%) [43] 
L7 220 (55%) 248 270 (29%) 517 (33%)  
L8 195 (37%) 223 245 (8%) 467 (13%) [44] 
L9 263 (22%) 291  603 (9%) 391 (6%) 
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6.2.5 Molecular structure 
The general numbering scheme shown in Figure 6.7 is used to discuss the ligand 
structures. This sequence is not necessarily maintained in the next chapters when the 
syntheses of different metal complexes are described. This is due to the X-ray 
crystallographic investigation and the description of atomic bonds and angles that 
were carried out elsewhere and not in-house. A new different numbering system will 
therefore be introduced in the next two chapters. 
 
 
Figure 6.7: General numbering of ligands L2-L9.  
 
 
The X-ray crystallographic structures of the ligands L2-L9 are depicted in Table 6.7 
and the crystallographic data is presented in Table 6.8, with selected bond lengths and 
angles given in Table 6.9. The eight structures L2-L9 are similar, and the presence of 
substituents on the 4 position of the phenyl ring causes variation in the bond distances 
and angles of the triazole moiety. The effect that substituents (electron withdrawing 
or electron donating) on the 4-position of the phenyl arm (R = H, CH3, OCH3, F, Cl, 
CN, CF3) have on photophysical properties, will be highlighted using experimental 
and theoretical studies. 
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Table 6.7: The molecular structures of ligands L2- L9. 
Ligands Formula molecular structures Yield  
 
L2 
 
C14H12N4 
 
 
 
70 
 
L3 
 
C14H12N4O 
 
 
 
93 
 
L4 
 
C14H10N4O2 
  
 
 
79 
 
L5 
 
C13H9FN4 
 83 
 
L6 
 
C13H9ClN4 
 
 
 
81 
 
L7 
 
C14H9N5 
 
 
 
91 
 
L8 
 
C13H10N4 
 
 
80 
 
L9 
 
C14H9F3N4 
 
 
 
 
75 
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Table 6.8: Details of crystal structure determinations for L2- L9. 
a1 Σ(||Fo| - |Fc||)/Σ|Fo|; wR2 = [Σw(|Fo| - |Fc|)2/Σw(Fo)2]1  
Ligand L2 L3 L4 L5 L6 L7 L8 L9 
Empirical formula C14H12N4 C14H12N4O C14H10N4O2 C13H9FN4 C13H9ClN4 C14H9N5 C13H10N4 C14H9F3N4 
Mr 236.28 252.28 266.26 240.24 256.69 247.26 222.25 290.25 
Temp/K 120(2) 100(2) 100(2) 120(2) 120(2) 100(2) 120(2) 120(2) 
Cryst. syst. Monoclinic Triclinic Monoclinic Monoclinic Monoclinic Monoclinic Monoclinic Monoclinic 
Space group P21 P1 P21/c P21/c C2/c C2/c P21/c P21/c 
a/Å 5.7797(5) 3.7837(4) 10.5970(17) 12.2013(3) 16.0000(11) 16.0427(19) 22.6348(5) 5.7460(1) 
b/Å 6.7414(4) 10.8502(16) 14.471(2) 7.9798(2) 5.9258(2) 5.8677(6) 5.82500(10) 7.2076(2) 
c/Å 15.0259(12) 15.2200(17) 7.7343(12) 11.6329(3) 24.3829(17) 24.487(3) 17.8421(4) 15.2997(4) 
α/° 90.00 109.226(11) 90.00 90.00 90.00 90.00 90.00 103.045(2) 
β/° 92.359(4) 97.056(6) 90.121(6) 104.043(2) 93.109(8) 92.354(8) 113.007(1) 98.768(2) 
γ/° 90.00 91.514(9) 90.00 90.00 90.00 90.00 90.00 92.290(2) 
V/Å3 584.96(8) 584.03(12) 1186.0(3) 1098.94(5) 2308.4(2) 2303.1(5) 2165.32(8) 608.25(3) 
Z 2 2 4 4 8 8 8 2 
Rint 0.0555 0.0617 0.0576 0.0314 0.0497 0.0605 0.0567 0.0351 
Dcalcd/mg /m-3 1.341 1.435 1.491 1.452 1.477 1.426 1.364 1.585 
Refln (all/ind) 9647/2622 6395/2617 5844/2705 13725/2510 11996/2636 9891/2638 35200/4956 14232/2785 
μ/mm-1 0.084 0.096 0.105 0.104 0.316 0.092 0.087 0.131 
R1/wR2 
(obsd data: F22σ(F2))a 
0.0482/ 0.1130 0.0534/0.1074 0.0624/0.149 0.0382/0.080 0.0450/0.1125 0.0459/0.1147 0.0456/0.1021 0.0398/0.1046 
R1/wR2 
(all data)a 
0.0716/ 0.1244 0.0734/0.1161 0.0966/0.1606 0.0441/091 0.0765/0.1371 0.0562/0.1206 0.0545/0.1077 0.0459/1.028 
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Table 6.9: Comparison of selected bond lengths (Å) and angles [°] of ligands. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 L2 L3 L4 L5 L6 L7 L8 L9 
N1N2 1.368(2) 1.355(4) 1.355(3) 1.3605(13) 1.359(2) 1.3578(17) 1.3601(18) 1.364(6) 
N2N3 1.311(3) 1.302(4) 1.299(3) 1.3107(15) 1.315(3) 1.3083(17) 1.312(2) 1.310(7) 
C8-N1 1.349(3) 1.350(5) 1.346(3) 1.3527(14) 1.351(3) 1.3551(17) 1.357(2) 1.36(17) 
C1N1 1.433(3) 1.422(5) 1.425(3) 1.4310(15) 1.423(3) 1.4256(18) 1.431(2) 1.422(7) 
C8-C9 1.366(3) 1.362(2) 1.378(3) 1.3733(17) 1.371(3) 1.373(2) 1.372(2) 1.366(8) 
C9C10 1.469(3) 1.463(5) 1.465(3) 1.4689(16) 1.465(3) 1.4694(19) 1.469(2) 1.459(8) 
N3 - C9 1.367(3) 1.365(5) 1.366(3) 1.3660(15) 1.369(3) 1.3680(18) 1.371(2) 1.370(7) 
C14N4 1.336(3) 1.336(5) 1.340(3) 1.3381(16) 1.336(3) 1.3389(19) 1.342(2) 1.324(7) 
C8H8 0.9500 0.9500 0.9300 0.9300 0.9300 0.9500 0.9500 0.9300 
N3N2N1 107.06(17) 107.0(3) 107.24(19) 107.35(9) 107.28(17) 107.24(11) 107.24(12) 107.8(5) 
N2N3C9 108.89(17) 109.2(3) 109.3(2) 109.01(10) 108.87(17) 109.09(12) 108.92(13) 108.7(5) 
C14N4C10 116.5(2) 117.0(3) 118.5(2) 117.32(11) 116.68(19) 116.85(13) 116.82(15) 117.8(5) 
N4-C10-C9 116.55(18) 115.9(3) 118.6(2) 115.5(10) 115.94(19) 115.59(12) 116.28(14) 117.2 (5) 
N3-C9-C10 121.09(19) 122.7(3) 120.5(2) 122.85(11) 121.89(19) 122.05(12) 121.96(14) 122.7(5) 
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6.2.5 X-ray crystallographic structures 
Single-crystal X-ray diffraction analyses were performed in the Chemical 
Crystallography Laboratory at the National Crystallography Service, School of 
Chemistry, University of Southampton, United Kingdom. Crystals used for X-ray 
analysis were produced in house via the slow evaporation of ligands in a variety of 
solvents and different conditions, see Appendix (2). The molecular structure of L8 
where R=H is used as a model example for the discussion of all the other structures. 
The molecular structure of ligand L8 was determined by single crystal X-ray 
diffraction (Figure. 6.8). Crystallographic data are presented in Table 6.8 and selected 
bond lengths with bond angles are reported in Table 6.9. 
The crystallographic data for L8 was collected at 100(2)K on a RigakuSaturn 724+ 
area detector mounted at the window of an FR-E+ Mo-Kα rotating anode radiation 
source (λ= 0.71075 Å)single crystal X-ray diffractometer. Cell determination, data 
collection, data reduction, cell refinement and empirical absorption correction were 
implemented using the CrystalClear-SM Expert 2.0 r13 (Rigaku, 2011). The structure 
was solved by direct methods using SUPERFLIP [61]. The structures were refined 
with full-matrix least-squares techniques on F2 using the SHELXL-97 program 
package [62], with the graphicsprogram OLEX2 [63]. MERCURY 3.1 was used to 
generate graphics [64]. All non-hydrogen atoms were refined by isotropic 
displacement parameters and hydrogen atoms were added at calculated positions. The 
crystallographic data and selected bond lengths and selected bond angles for the 
ligand L8 are summarised in Table 6.9. Ligand L8 was crystallised by slow evaporation 
in a hot (DMSO: CH3CN: CH3OH) solution under ambient conditions. Single-crystal 
X-ray diffraction analysis reveals that it crystallises in the monoclinic P21/c space 
group and indicates four molecules per unit cell as Z = 4 of L8 (See Table 6.8). In the 
structure of L8 the pyridine ring adopting an almost “anti” conformation with respect 
to the triazole ring and this is also observed in similar compounds with the nitrogen 
atom of the pyridine ring with ligands L2- L9. 
The angle between the least square planes of the triazole and pyridine rings is 16.7(3)°. 
This value is analogous to what has been previously reported for other such 1,2,3-
triazole ligands [65]. The twisting of the triazole ring with respect to the phenyl ring 
is about 29.7(2)°, as has been previously reported [42, 65]. This value is much smaller 
compared to the phenyl substituted derivative for other 1,2,3-triazole ligands studied 
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previously. The N2-N3 distance of the 1,2,3-triazole unit at 1.312(2)Å is shorter than 
the neighbouring distance (N3-C9 and N1-N2) bonds, 1.371(2) and 1.3601(18)Å 
respectively, thus confirming the azo character of the triazolyl entity (see Table 6.9) 
[42]. The bond distance of C8-C9 of 1.372(2)Å is longer than the bond distance of C8-
N1 and N3-C9 observed to be 1.357(2)Å and 1.371(2)Å, respectively. 
For L4, dominant intermolecular hydrogen bonding interactions between the hydrogen 
of the carboxylic moiety and the nitrogen atom of the pyridyl group were observed, 
with bond distance for the O1-H1…N1i of 2.626(3)A˚. The bond lengths for O-H and 
H-N1i are 0.82Å and 1.82Å, respectively. The angles for the O1-H1…N1i is 167.2. 
The bond lengths and angles of these intermolecular hydrogen bonds between the 
donor and accepter fragments are summarised in Table 6.10. The crystal structure of 
L4 exhibits intermolecular contact patterns, which result in it adopting a unique 
packing arrangement dominated by C-H···O and N hydrogen bonding. This hydrogen 
bonding’s occurred via O1-H1···N1, C3-H3···N9, C11-H11···O1 and C11-H11···O2 
interactions. The hydrogen – bonded chains are linked with the chains from the other 
layer. The strong O-H…N hydrogen bond formed between the carboxylic acid and 
pyridyl groups and the C-H···O hydrogen bond formed between the carboxylic acid 
and proton-pyridyl groups are dominant to the interactions. These resulted in the 
formation of one-dimensional zig-zag chains of molecules (see Figure 6.8). These 
interactions were observed between adjacent molecules. Therefore, such molecules 
are further assembled into infinite 1-D supramolecular chains which are governed by 
the O–H···N hydrogen bonding interactions between the triazole and pyridyl units of 
neighboring molecules with COOH group from neighboring molecules (Figure.6.9). 
This in accordance with results reported previously for other triazole compounds 
having a carboxylic group moiety [66-68].  
 
The closest intermolecular interactions between the different layers are weak π…π 
contacts. The overlap between phenyl and phenyl rings in adjacent molecules cause it 
adopt to an offset face to face-slipped – type parallel alignment where the rings are 
parallel displaced with respect to one another and exhibiting a centroid–centroid 
distance of 4.665Å. The plane–plane distance is 3.76Å. This is a higher value than 
accepted for the typical phenyl and phenyl rings π…π stacking interaction [69, 70]. 
The title compound L4 is stabilised by intermolecular hydrogen bonding interactions 
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and intermolecular π…π stacking interactions between the phenyl rings in the solid 
state as shown in (Figure 6.9). 
 
Table 6.10: Hydrogen bonding interaction parameters; D = donor and A = 
acceptor (Å, °) in L4. 
 
D-H...A/interactions D–H (Å) H–A (Å) D–A (Å) Angle (  ͦ) 
O1–H1...N1 0.820 1.820(2) 3.626 (2) 167.2 
C3–H3...N9 0.930 2.477(2) 3.344 (2) 155.3 
C11–H11...O1 0.930 3.088(3) 3.787(8) 130.4 
C11–H11...O2 0.930 2.564(2) 3.525(3) 131.4 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.8: The packing arrangement adopted in crystals of the L4 ligand, 
viewed along the b-axis of the main hydrogen-bonding motif of carboxylic acid - 
pyridyl contact, which show the formation of a one-dimensional zig-zag chain. 
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Figure 6.9: (A) A pair of L4 connected molecules arranged around a centre of symmetry, which shows the overlap between the phenyl 
rings with the intermolecular π…π stacking interactions shown with green dashed lines. (B) Hydrogen bonding interactions shown with 
blue dashed lines for C–H…O and C–H…N within an infinite 1-D zig-zag chain. The molecules are viewed along the crystallographic b-
axis. 
 123 
 
This alternation in bond length would support the increased bond length of L4 
(1.3780Å) determined from the X-ray structure when compared to the other ligands 
in the series L2-L9. This is shown by the plot of C8-C9 triazole bond length in A˚ 
against the Hammett's σρ substituent constant (see Figure 6.10).  
 
The plot ignoring two points (COOH, CN) shows a concave downwards deviation in 
the Hammett plot with a positive slope for donating groups. This indicates that 
increased electron density results in the C8-C9 triazole bond length becoming shorter 
and therefore enhancing the double bond character of the bond. Electron withdrawing 
groups result in a negative slope which reduce the double bond character of the C8-C9 
triazole bond and cause it to become longer. A concave downwards deviation in the 
Hammett plot is characteristic of a change in the rate determining step (see Scheme 
6.8) where the contribution of structure b changes over to a and c [65]. 
 
 
Figure 6.10: A plot of the carbon-carbon bond length C8-C9 (A˚) of ligands L2-L9 
against the Hammett para substituent constant [σρ]. 
 
This is in agreement with the NMR data, in which the chemical shift of the 1H NMR 
of the (C-H) triazole for L4 shows more acidic character compared with that observed 
for other ligands, in agreement with earlier reports in literature [68]. 
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6.3 General Experimental Procedures and Characterisationof the Ligands  
6.3.1 Synthesis and characterisation of click (1,2,3-triazol-4-yl)-pyridine ligands 
6.3.1.1 Synthesis and characterisation of 4-(4-phenyl-1H-[1,2,3-triazol]-1-yl) 
benzoic acid (L1) 
To a stirred solution of 4-azidobenzoic acid (0.65g; 3.98mmol) and phenyl acetylene 
1.2eq (0.6g; 4.78mmol) dissolved in a mixture of THF (20ml) and water (10ml), was 
added a solution of CuSO4.5H2O (0.184g; 7.36mmol) dissolved in water (5ml). To 
this was added dropwise a freshly prepared solution of Na-ascorbate (0.291g; 
14.68mmol) in water (5ml) and the solution left to stir at RT for 24h.  The THF was 
removed under vacuum and DCM (100ml) added to the residue with stirring for a 
further 30min, and then aqueous ammonia solution (15%) (100ml) was added. After 
stirring at RT for 10min, the organic phase was washed with water (2x100ml), filtered 
through celite, dried over MgSO4 and evaporated under vacuum to give a colourless 
solid with yield of (0.75g; 71%), mp. 344-346°C. ATR/IR: ῡ(cm-1): 3125, 1682,1605, 
1557, 1520, 1427, 1408, 1293, 1229, 1177, 1092, 1024, 992, 860, 808, 753, 684. 
1HNMR data δH/ppm (400MHZ, DMSO-d6): 13.04 (1H, bs, COOH), 9.42 (1H, s, H9), 
8.20-8.11 (4H, m, H2, H6, H3, H5), 7.97-7.95 (2H, dd, J = 7.79Hz, H11, H15),7.54-7.50 
(2H, t,1JHH = 7.79Hz, H12, H14), 7.42-7.39 (1H, t, JHH = 7.27 Hz, H13); 
13CNMR 
(100.63MHZ, D6MSO-d6) δC/ppm: 119.57(C2, C6), 119.62 (C9), 125.29 (C11, C15), 
128.32 (C13), 128.96 (C12, C14), 129.91 (C1), 130.70 (C4), 131.04 (C3, C5), 139.35 
(C8), 147.48 (C10`), 166.33 (COOH) (C7). These assignments were confirmed using, 
DEPT 13C (135°), 1H-1H COSY and 1H-13C HMQC two dimensional correlations. 
HRMS (N-NSI): [M-H]- (100%): m/z = 264.0778 calculated for (C15H10N3O2); found 
264.0774 [46]. 
6.3.1.2 Synthesis and characterisation of 2-(1- p-tolyl)-1H-[1,2,3-triazol]-4-yl)-
pyridine (L2) 
 
A mixture of 1-azido-4-methylbenzene (0.75g; 5.63mmol) and 2-ethynylpyridine 
(0.69g; 6.75mmol, 1.2eq) was dissolved in a 1:1 mixture of water/tert–butyl alcohol 
(100ml). After stirring for 20 min, a solution of CuSO4.5H2O (0.41g; 1.64mmol) in 
water (10ml) was added dropwise followed with a freshly prepared solution of Na-
ascorbate (0.37g; 1.85mmol) in water (5ml). The mixture was allowed to stir for 24h 
at RT, and then an aqueous ammonia solution (15%; 50ml) was added. The mixture 
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was stirred for a further 20min, and then extracted with dichloromethane (2x100ml). 
The organic phase was washed twice with water (2x100ml) and filtered through celite 
to remove trapped Cu(I)-salts ([Cu(NH3)6]
+). The combined organic layer was washed 
with brine (2x100ml), and then dried over MgSO4. The organic solvent was removed 
under vacuum to give the crude product as a bright yellow a solid with yield of (0.98g; 
74%); Recrystallisation from a mixture of CH2Cl2: CH3OH (1:1) gave the product as 
colourless crystals (0.93g; 70%), mp. 128-129°C. ATR/IR: ῡ(cm-1): 3128, 3099, 2947, 
2919, 1597, 1592, 1566, 1549, 1471, 1271, 1238, 1212, 1176, 1148, 1031, 998, 813, 
784 and 745. 1HNMR data δH/ppm (400MHZ, CD2Cl2- d2): 8.60-8.58 (1H, ddd, 1JHH 
= 0.92Hz , 2JHH = 1.83Hz, 
3JHH = 5.04Hz, H14), 8.57 (1H, s, H8), 8.21-8.18 (1H, td,
1JHH 
= 0.92Hz , 2JHH = 1.37Hz, 
3JHH = 7.79Hz , H11), 7.82-7.77 (1H, dt, 
1JHH = 1.83Hz, 
2JHH  
= 7.79Hz, H12), 7.70-7.67 (2H, d, JHH = 8.70Hz, Ar-H2,6), 7.35-7.33 (2H, d, JHH = 
8.24Hz, Ar-H3,5), 7.26-7.23 (1H, ddd, 
1JHH = 1.37Hz, 
2JHH = 4.58Hz, 
3J = 7.33, H13), 
2.41 (3H, s, CH3, H7); 
13CNMR (100.63MHZ, CD2Cl2-d2) δC/ppm: 21.14 (C7), 120.34 
(C11), 120.37 (C8), 120.56 (C3,C5), 123.26 (C13), 130.56 (C2,C6), 135.05 (C4), 137.13 
(C12), 139.40 (C1), 149.14 (C9), 149.89 (C14), 150.48 (C10). These assignments were 
confirmed using DEPT 13C (135°), 1H-1H COSY and 1H-13C HMQC two dimensional 
correlations. HRMS (P+NSI): [M+H]+ (100%): m/z = 237.1135 calculated for 
(C14H13N4); found  237.1133.The fragment of the molecular ion plus H
+ (M+H)+ [(M-
N2)+H]
+ (15%): calculated for (C14H13N2); found  m/z = 209.1133 [38]. Slow 
evaporation of a (1:1) CH2Cl2:CH3OH solution of the ligand yielded crystals suitable 
for X-ray diffraction analysis. 
6.3.1.3 Synthesis and characterisation of 2-[1-(4-methoxyphenyl)-1H-[1,2,3-triazol]-
4-yl]-pyridine(L3) 
The method used was similar to that for (L2), but with 1-azido-4-methoxy benzene 
(1g, 6.70mmol) instead of 1-azido-4-methylbenzene. The quantities of the other 
reagents were adjusted accordingly. An identical work-up procedure gave the required 
compound as a bright yellow solid (1.60g; 95%). The product was purified by silica 
gel column chromatography (95:5 CH2Cl2/MeOH) to give an off-white solid with 
yield of (1.57g; 93%); Rf = 0.43 (2:1 EtOAc/PE), mp. 129-130°C.  ATR/IR: ῡ(cm-1): 
3142, 3006, 2844, 1604, 1592 1574, 1549, 1551, 1515, 1275, 1258, 1237, 1174, 1089, 
1023, 996, 823 and 777. 1HNMR data δH/ppm (400MHZ, CD2Cl2-d2): 8.60-8.58  (1H, 
d, JHH = 4.24 Hz, H2), 8.53 (1H, s, H11),  8.20 -8.18 (1H, d, JHH = 7.90Hz, H5), 7.83 -
7.79 (1H, dt,1JHH = 1.72Hz, 
2J = 7.79Hz, H4), 7.74-7.70 (2H, d, JHH = 9.27Hz, H13,17), 
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7.28-7.24 (1H, ddd, 1JHH = 0.92Hz, 
2JHH = 4,92Hz,
3JHH = 7.44Hz, H3), 7.08-7.06 (2H, 
d, JHH = 9.16Hz, Ar-H14,16), 3.88 (3H, s, CH3, H19); 
13CNMR (100.63MHZ, CD2Cl2-
d2) δC/ppm: 56.06 (C19), 115.17 (C14, C16 -Ar), 120.64 (C11), 120.42 (C5), 122.45 (C13, 
C17 -Ar), 123.35 (C3), 130.89 (C12), 137.25 (C4), 149.18 (C7), 149.97 (C2), 150.62 
(C6), 160.38 (C15). These assignments were confirmed using DEPT
 13C (135°), 1H-1H 
COSY and 1H-13C HMQC two dimensional correlations. HRMS (P+NSI): [M+H]+ 
(100%): m/z = 253.1084 calculated for (C14H13N4O); found 253.1082. Slow 
evaporation of a 1:1 CH2Cl2:CH3OH solution of the ligand yielded crystals suitable 
for X-ray diffraction analysis [39-41]. 
6.3.1.4 Synthesis and characterisation of 4-(4-(pyridin-2-yl)-[1H-1,2,3-triazol]-1-
yl)benzoic acid (L4) 
The method used was analogous to that for (L2), but with 4-azido benzoic acid (1g, 
6.13mmol) instead of 1-azido-4-methylbenzene. The quantities of the other reagents 
were adjusted accordingly. An identical work-up procedure gave the required 
compound as a colourless solid (1.29g; 79%). Recrystallisation from a mixture of 
DMSO: CH3OH: CH3CN (2:8:8) gave a colourless solid with yield of (1.24g; 76%); 
mp. 337-339°C. ATR/IR: ῡ(cm-1): 3141, 3003, 1687, 1603, 1588, 1573, 1549, 1553, 
1403, 1302, 1269, 1240,1258, 1174, 1089, 1023, 991, 856, 768 and 692. 1HNMR data 
δH/ppm (400MHZ, D6MSO-d6): 13.27 (1H, s, H18), 9.46 (1H, s, H11), 8.69-8.67 (1H, 
d, JHH = 4.02Hz, H2), 8.22-8.13 (5H, m, Ar -H13,17,14,16,4), 7.99-7.94 (1H, dt, 
1JHH = 
1.93Hz, 2JHH = 7.63Hz, H3), 7.44-7.41 (1H, dd, 
1JHH = 6.48Hz, 
2JHH = 7.25Hz, H5);
 
13CNMR (100.63MHZ, D6MSO-d6) δC/ppm: 119.94 (C5, C14, C16-Ar), 121.41 (C11), 
123.48 (C3), 130.17 (C15), 131.03 (C13, C17 -Ar), 137.37 (C4), 139.46 (C12), 148.43 
(C7), 149.26 (C6), 149.72 (C2), 166.39 (C18). These assignments were confirmed using 
DEPT 13C (135°C), 1H-1H COSY and 1H-13C HMQC two dimensional correlations. 
HRMS (N-NSI): [M-H]- (100%): calculated for (C14H9N4O2) m/z = 265.0731; found 
265. 0723. Slow evaporation of a (1:4:4) DMSO: CH3OH: CH3CN solution of the 
ligand yielded crystals suitable for X-ray diffraction. 
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6.3.1.5 Synthesis and characterisation of 2-(1-(4-fluorophenyl)-1H-[1, 2, 3-triazol]-
4-yl)pyridine (L5) 
The method used was analogous to that for (L2), but with 1-azido-4-fluorobenzene 
(0.80g, 5.83mmol) instead of 1-azido-4-methylbenzene. The quantities of the other 
reagents were adjusted accordingly. An identical work-up procedure gave the required 
compound as a colourless solid. Recrystallisation from a mixture of CH2CL2: CH3OH 
(1:1) gave a colourless solid with yield of (1.17g; 83%), mp 178-180°C. ATR/IR:  
ῡ(cm-1): 3151, 3072, 3025, 1598, 1572, 1549, 1515, 1472, 1405, 1359, 1300, 1220, 
1189, 1163, 1150, 1101, 1035, 994, 844, 782 and 782. 1HNMR data δH/ppm 
(400MHZ, CD2Cl2-d2): 8.60-8.59 (1H, dd, JHH 4.58Hz, H13), 8.58 (1H, s, H7),  8.20-
8.18 (1H, d, JHH = 7.79 Hz, H10), 7.84-7.78 (3H, m, H11, Ar-H2,6), 7.73-7.70 (td, 
1JHH 
= 2.29Hz, 2JHH = 3.21 Hz,
 3JHH = 9.16Hz), 7.29-7.24 (3H, m, H12, Ar-H3,5) 7.07-7.04 
(td, 2JH-F, 
1JHH = 1.83Hz,
 2JHH = 3.66Hz, 
3JHH = 8.70Hz,); 
13CNMR (100.63MHZ, 
CD2Cl2-d2) δC/ppm: 116.98-117.20 (2JC-F = 23.00Hz, C3, C5, Ar), 120.48 (C7), 120.69 
(C10), 122.85-122.93 (d, J
3
C-F = 8.63 Hz, C2,C6, Ar), 123.51 (C12), 133.82 (C1), 137.29 
(C11), 149.51 (C8), 150.02 (C13), 150.37 (C9), (161.65-164.12) J
1
C-F = 248.24Hz, (C4). 
These assignments were confirmed using DEPT 13C (135°), 1H-1H COSY and 1H-13C 
HMQC two dimensional correlations. HRMS (P+NSI): [M+H]+ (100%): m/z = 
241.0884 calculated for (C13H10N4F); found 241.0885. The second fragment of the 
molecular ion plus H+ (M+H)+ calculated for (C13H10N2F) [(M-N2)+H]
+ (35%); found 
m/z = 213.0823. Slow evaporation of a (1:1) C3H6O:CH3OH solution of the ligand 
yielded crystals suitable for X-ray diffraction analysis. 
6.3.1.6 Synthesis and characterisation of 2-(1-(4-chlorophenyl)-1H-[1,2,3-triazol]-4-
yl)pyridine (L6) 
The method used was similar to that for (L2), but with 1-azido-4-chlorobenzene 
(0.65g, 4.23mmol) instead of 1-azido-4-methylbenzene. The quantities of the other 
reagents were adjusted accordingly. An identical work-up procedure gave the required 
compound as a colourless solid. Recrystallisation from a mixture of C3H6O: CH3OH 
(1:1) gave a colourless solid with yield of (0.87g; 81%), mp. 203-205 °C. ATR/IR: 
ῡ(cm-1): 3132, 3058, 1602 1589, 1570, 1570, 1550, 1473, 1440, 1421, 1399, 1355, 
1236, 1174, 1145, 1114, 1091, 1037, 996, 817, 779 and 739. 1HNMR data δH/ppm 
(400MHZ, CD2Cl2-d2): 8.60 (1H, s, H11), 8.59-8.58 (1H, ddd, 
1JHH = 0.92Hz, 
2JHH = 
1.83 Hz, 3JHH = 5.04Hz, H2), 8.20-8.18 (1H, dd, 
1J = 0.92Hz,2JHH = 7.79Hz, H5), 7.83-
7.76 (3H, m, H4, Ar-13,17), 7.56-7.52 (2H, d, JHH = 9.16Hz, Ar-H14,16), 7.28-7.25 (1H, 
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ddd, 1JHH = 0.92 Hz, 
2JHH = 5.04Hz, 
3JHH = 7.79Hz, H3); 
13CNMR (100.63MHZ, 
CD2Cl2-d2) δC/ppm: 120.42(C11), 120.57(C5), 122.04 (Ar-C13,17), 123.54 (C3), 130.33 
(Ar-C14,16), 134.80 (C12), 136.01 (C15) 137.30 (C4), 149.57 (C7), 150.00 (C2), 150.26 
(C6). These assignments were confirmed using DEPT 
13C (135°), 1H-1H COSY and 
1H-13C HMQC two dimensional correlations.  HRMS (P+NSI): [M+H]+ (100%): m/z 
=257.0589 calculated for (C13H9N4Cl); found 257.0590. The second fragment of the 
molecular ion plus H+ (M+H)+ [(M+H)-(N2)]
+ (25%); found m/z = 229.0528 
calculated for (C13H9N2Cl). Slow evaporation of a (1:1) C3H6O:CH3OH solution of 
the ligand yielded crystals suitable for X-ray diffraction analysis [45]. 
6.3.1.7 Synthesis and characterisation of 4-(4-(pyridin-2-yl)-1H-[1,2,3-triazol]-1-
yl)benzonitrile (L7) 
The method used was analogous to that for (L2), but with 4-azido-benzonitrile 
(1g,6.70mmol) instead of 1-azido-4-methylbenzene. The quantities of the other 
reagents were adjusted accordingly. An identical work-up procedure gave the required 
compound as a colourless solid. Recrystallisation from a mixture of CH2Cl2: CH3OH 
(1:1) gave a colourless solid with yield of (1.57g, 91%), mp. 244-246°C. ATR/IR: 
ῡ(cm-1): 3120, 3079, 2229, 1601, 1572, 1572, 1549, 1511, 1470, 1446, 1351, 1274, 
1235, 1178, 1147, 1032, 998, 849, 782, and 742. 1HNMR data δH/ppm (400MHZ, 
CD2Cl2-d2): 8.70 (1H, s, H16), 8.62-8.60 (1H, ddd, 
1JHH = 0.92Hz, 
2JHH = 1.83Hz, 
3JHH 
= 5.04Hz, H14), 8.22-8.20 (1H, d, JHH = 7.79Hz, H15), 8.01-7.99 (2H, d, JHH = 9.16Hz, 
Ar-H3,1), 7.89-7.87 (2H, d, JHH  = 8.70Hz, Ar-H7,10), 7.86-7.82 (1H, dt, 
1J = 1.83Hz, 
2J = 7.79Hz , H18), 7.39-7.28 (1H, ddd, 
1JHH = 0.92Hz, 
2JHH = 4.58Hz, 
3JHH = 7.79Hz, 
H19); 
13CNMR (100.63MHZ, CD2Cl2-d2) δC/ppm: 112.77 (C12), 118.21 (C5), 120.23 
(C16), 120.65 (C15), 120.93 (C3, C11 -Ar), 123.73 (C19), 134.84 (C7, C10 -Ar), 137.39 
(C18), 140.21 (C6), 149.93 (C17), 150.02 (C9), 150.12 (C14). These assignments were 
confirmed using DEPT 13C (135°C), 1H-1H COSY and 1H-13C HMQC two 
dimensional correlations. HRMS (P+NSI): [M+H]+ (100%): m/z = 248.0931 
calculated for (C14H9N5); found 248.0933. The fragment of the molecular ion plus 
H+(M+H)+ [(M-N2)+H]
+ (55%); found m/z =220.0871 calculated for C14H9N3. Slow 
evaporation of a (1:1) CH2Cl2:CH3OH solution of the ligand yielded crystals suitable 
for X-ray diffraction analysis. 
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6.3.1.8 Synthesis and characterisation of 2-(1-phenyl-1H-[1,2,3-triazol]-4-
yl)pyridine (L8) 
The method used was analogous to that for (L2), but with 1-azidobenzene (0.80g, 
5.83mmol) instead of 1-azido-4-methylbenzene. The quantities of the other reagents 
were adjusted accordingly. An identical work-up procedure gave the required 
compound as a pale yellow solid with yield of (1.17g; 84%). Recrystallisation from a 
mixture of CH2Cl2:CH3OH (1:1) gave a colourless solid with yield of (1.12g; 80 %), 
mp. 88-90°C (lit. 81-91°C [28]). ATR/IR: ῡ(cm-1): 3116, 3051, 3001, 1599, 1591, 
1567, 1544, 1502, 1471, 1405, 1354, 1237, 1189, 1147, 1091, 1035, 913, 843, 792, 
and 756. 1HNMR data δH/ppm (400MHZ, CD2Cl2-d2): 8.62 (1H, S, H1), 8.61-8.59 
(1H, ddd, 1JHH = 0.92Hz, 
2JHH = 1.83Hz, 
3JHH = 5.04Hz, H7), 8.21-8.19  (1H, dt,
1JHH = 
0.92Hz, 2JHH = 2.29Hz, 
3JHH = 8.24Hz, H4), 7.84-7.79 (3H, m, H5, Ar-H9,13), 7.59 -
7.55 (2H, d, JHH = 7.73Hz, Ar-H10,12), 7.50-7.45 (1H, ttt, 
1JHH = 0.92Hz, 
2JHH = 
1.73Hz, 3JHH = 7.73Hz, H11), 7.28-7.24 (1H, ddd, 
1JHH = 1.73Hz, 
2JHH = 5.04Hz, 
3J = 
7.33Hz, H6); 
13CNMR (100.63MHZ, CD2Cl2-d2) δC/ppm: 120.41 (C1), 120.41 (C4), 
120.72 (C9, C13-Ar), 123.35 (C6), 129.12 (C11), 130.11 (C10, C12-Ar), 137.18 (C5), 
137.39 (C8), 149.29 (C2), 149.92 (C7), 150.39 (C3). These assignments were 
confirmed using DEPT 13C (135°C), 1H-1H COSY and 1H-13C HMQC two 
dimensional correlations. HRMS (P+NSI): [M+H]+ (100%): m/z = 223.0978 
calculated for (C13H10N4); found 223.0977. The fragment of the molecular ion plus 
H+ (M+H)+ [(M-N2)+H]
+ (35%); found m/z =195.0915 calculated for (C13H10N2). 
Slow evaporation of a (1:1) CH2Cl2:CH3OH solution of the ligand yielded crystals 
suitable for X-ray diffraction analysis [42-44]. 
6.3.1.9 Synthesis and characterisation of 2-(1-(4-(Trifluoromethyl)phenyl)-1H-
[1,2,3-triazol]-4-yl)pyridine (L9) 
The method used was similar to that for (L2), but with 1-azido-4-
trifluoromethylbenzene (0.5g, 2.67mmol) instead of 1-azido-4-methylbenzene. The 
quantities of the other reagents were adjusted accordingly. An identical work-up 
procedure gave the required compound as a colourless solid with a yield of (0.613g; 
78%).  Recrystallisation from a mixture of CH2Cl2:CH3OH (1:1) gave a colourless 
solid with yield of, (0.582g; 75%), mp. 168-170°C. ATR/IR: ῡ(cm-1): 3122, 3060, 
1615, 1593, 1570, 1547, 1528, 1472, 1409, 1322, 1279, 1237, 1191, 1161, 1104, 1066, 
1027, 991, 847, 785, 746 and 694. 1HNMR data δH/ppm (400MHZ, CD2Cl2-d2): 8.70 
(1H, s, H11), 8.61-8.60 (1H, ddd, 
1JHH = 0.95Hz, 
2JHH = 1.83Hz, 
3J = 5.04Hz, H2), 8.2-
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8.19 (1H, dd, 1JHH = 0.92Hz, 
2JHH = 7.79Hz, H5), 8.01-7.99 (2H, d, JHH = 8,70Hz, Ar-
H13,17), 7.85-7.78 (3H, m, H4,14,16), 7.30-7.26 (1H, ddd,
 1JHH = 1.37Hz,
 2JHH = 5.04Hz, 
3JHH = 7.33Hz, H3); 
13CNMR (100.63MHZ, CD2Cl2-d2) δC/ppm: 119.69 (C11), 120.29 
(C13, C17-Ar), 119.43, 122.14, 124.85, 127.27 (q, 
1JC-F = 270.20Hz, C-F3 (C18)), 
120.51 (C5), 123.85 (C3), 127.11, 127.14, 127.18, 127.21 (q, J
3
C-F = 3.83Hz, C14, C16- 
Ar), 130.28, 130.61, 130.94, 131.27 (q, 2JC-F = 32.59Hz, C-CF3 (C15)), 137.04 (C4), 
139.31 (C12), 149.39 (C7), 149.51 (C6), 149.55(C2). These assignments were 
confirmed using DEPT 13C (135°), 1H-1H COSY and 1H-13C HMQC two dimensional 
correlations. HRMS (P+NSI): [M+H]+ (100%): m/z = 291.0852 calculated for 
(C14H9N4F3); found 291.0853.The fragment of the molecular ion plus H
+ (M+H)+ 
[(M-N2)+H]
+ (20%); found m/z = 263.0794 calculated for (C14H9N2F3). Slow 
evaporation of a (1:1) C3H6O:CH3OH solution of the ligand yielded crystals suitable 
for X-ray diffraction analysis. 
6.4 Conclusion 
In summary, a series of bi-dentate 2-pyridyl-1,2,3-triazole ligands bearing a 4-
substituted phenyl arm (some of which are novel (L4, L7, L5, L9) at the time of writing 
this thesis), were synthesised from a variety of organic azides and alkynes via a simple 
cycloaddition reaction (literature method) under neat conditions and investigated. 
This method was also applied to generating a large number of novel complexes of bis-
triazoles (49). A total of four years was spent synthesizing and characterising all the 
compounds reported in the thesis.  
 
The L2, L3, L8, L6 ligands were described recently in the literature [38-47], with 
different functional groups (electron rich and withdrawing substituents) on the 
triazole heterocycle. In this work, it was demonstrated that the nature of the pendant 
arm (R = CH3, OCH3, COOH, F, Cl, CN, H, CF3) could affect the electronic properties 
of the triazole moiety and the formation of metal complexes. Pyridine triazole ligands 
(PYTA) are readily prepared through a convenient click chemistry approach where 
thecopper(I)-catalyzed 1,3-dipolar cycloaddition is undertaken between 2-
ethynylpyridine and an aryl azide prepared using standard procedures (see Appendix 
(1)) [23-26]. The reaction proceeds under mild conditions and affords the ligands 
regio-selectively in good yields. X-ray crystallography clearly indicates that the 1,2,3-
triazole have an azo- character while the 1,2,4-triazole has an azine character. 
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These initial results can be considered promising, because they open up a new area 
for the modulation of the photophysical properties of pyridine-triazole ligands 
conjugated to a π-system. The exploration of the crystal structure of the ligand 
L4reveals a one-dimensional zig-zag chain structure in the solid state, which is 
stabilised by intermolecular hydrogen bonds and π-π stacking interactions between 
the phenyl rings.  
The success of these reactions highlights the need for future work in this area, which 
should include:  
 
1-Design and synthesis of new 1,2,3-triazoles by using various other azides or using 
multi-azide as a starting material (i.e. bis(azide) or tris(azide) ). 
2-Studying the photophysical properties of the new 1,2,3-triazole ligands. 
3-Computational studies for the formation of simple and complex 1,2,3-triazoles. 
The yields have been reported in each specific synthesis report, and the novelty of the 
work has been reported in the Acta Crystallographica B paper that was published. 
  
The next chapter focuses on the coupling of these bidentate (1,2,3-triazol-4-yl)-
pyridine ligands to different transation metal to prepare a variety of organometallic 
complexes to be characterised and tested for dye solar cells and /or used in anticancer 
screening to determine their toxicity against selected cell lines. 
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Chapter 7 : METAL COMPLEXES WITH CLICK (1,2,3- 
TRIAZOL-4-YL)-PYRIDINE LIGANDS 
 
7.1 Introduction 
After successfully synthesising a new series of bidentate (1,2,3-triazol-4-yl)pyridine  
ligands (see table 6.2), their ability to form metal-ligand complexes were investigated. 
The complex formation can occur with nitrogen from the pyridyl and nitrogen group 
of the 1,2,3-triazole unit (see Scheme 7.1). The first row transition metals were chosen 
due their availability and cost effectiveness and as alternatives to ruthenium metal, 
which is currently popular in solar cell dye research. The complexes were prepared in 
a 1:2 mole ratio of metal - ligand and characterised by different techniques such as: 
FT-IR, HRMS, NMR, UV-Vis, absorbance and fluorescence spectra, magnetic 
moments, conductivity measurements, melting points and X-ray molecular structure 
analysis. X-ray molecular structures revealed the coordination of the complexes 
which, in the majority of cases, had distorted octahedral geometry. In view of the large 
number of complexes prepared (49), the L3 ligand complexes were selected with eight 
metal(II) ions see Table 7.1, based on the quality and abundance of the results 
obtained (X-ray quality crystals, crystallographic data and good yields) and also the 
Cu(II) complexes with ligands L2-L9 as representative examples for detailed 
discussion in this chapter. The characterisation data for the other complexes are 
presented in the Appendices (2).  
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7.2 Results and discussion 
7.2.1 Synthesis of (1,2,3-triazol-4-yl)pyridine ligand metal complexes 
The general approach for the synthesis of all the metal complexes carried out was 
according to a standard literature procedure, with small modifications as necessary. 
Appropriate metal chloride amounts (1equiv.), were reacted with all ligands (2 equiv.) 
under the same conditions. CH3OH and DCM were used as solvents and the mixtures 
were stirred at RT for 8-10h. The solvent was removed under vacuum and the solid 
mass recovered and then washed with several volumes of cold methanol and diethyl 
ether [1]. This approach was used to prepare metal complexes between ligands L2, L3, 
L4, L5, L6, L7, L8 and L9 with the first row transition metal chlorides (Mn(II), Fe(II), 
Co(II), Ni(II), Cu(II) and Zn(II)), the second row transition metal chloride of Cd(II) 
and the third row transition metal chloride of Pt(II). Except in cases of the complexes 
of ligand L4 where DMSO was used as a solvent, all the other reactions employed 
methanol and dichloro-methane.  The reactions were refluxed for 24h. This is due to 
fact that L4 ligand has a carboxylic group that is poorly soluble in many organic 
solvents. Similar observations were reported for btp 2,6-Bis(1-(4-(carboxy)benzyl)-
1,2,3-triazol-4-yl)pyridine [1]. This method was very satisfactrory  and good yields 
ranging from 74-91% (see Table 7.1 for exact yields) were obtained. 
 
 
Where, R = L2 = CH3, L
3 = OCH3, L
4 = COOH, L5 = F, L6 = Cl, L7 = CN, L8 = H and 
L9 = CF3 
Scheme 7.1: Synthesis of the various metal complexes [2]
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Table 7.1: Molecular structure, formula weight and yield of the metal-L3 
complexes. 
Molecular structure Formula weight   Sample code Yield (%) 
 
C28H24Cl2N8O2Mn [MnL
3(1-2)] 82 
 
C28H24Cl2N8O2Fe [FeL
3(1-2)] 83 
 
C28H24Cl2N8O2Co [CoL
3(1-2)] 77 
 
C28H24Cl2N8O2Ni [NiL
3(1-2)] 74 
 
C28H24Cl2N8O2Cu [CuL
3(1-2)] 91 
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C28H24Cl2N8O2Zn [ZnL
3(1-2)] 77 
 
C28H24Cl2N8O2Cd [CdL
3(1-2)] 80 
 
C28H24Cl2N8O2Pt [PdL
3(1-2)] 78 
7.2.2 FTIR spectral data for L3 complexes 
An overlay of the IR spectra of L3 and its various metal complexes is presented in 
Figure 6.1. The aim of these measurements is to observe any shift which may occur 
to the characteristic bands for the functional groups upon complex formation. The IR 
spectra of the metal complexes exhibited bands with appropriate shifts due to complex 
formation (see Table 7.2). The ν(C=N) stretching band of the pyridine moiety is 
observed at the value around 1604cm-1 for the free ligand, which is shifted to higher 
wavenumbers in the complexation depending on the nature of the metals ion. The 
bands are shifted to around 1630-1606cm-1 for the various complexes. It is interesting 
to observe that the MN(PY) (pyridine nitrogen-cadmium complex) bond length is 
longer (as shown in the crystal structure) than the other metals. This difference is 
reflected in the vibrational energies in the FTIR spectrum in terms of the MN(PY) 
bond which is shifted to higher wavenumbers compared to the other metal complexes 
(Figure 7.1). 
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Figure 7.1: FTIR spectra of the L3 ligand with its various metal complexes. 
 
The IR spectra of the metal complexes exhibited bands shift due to complex formation 
(see Table 7.2). This indicate coordination of the nitrogen of the C=N pyridine moiety 
to the different metal atoms. The ν(C=C) bands of phenyl ring for the complexes, 
which usually appear as two absorptions are around 1602-1591cm-1 and 1514-
1518cm-1, compared with those at 1596 and 1515cm-1 in the free ligand [3-4]. The 
ν(C=N) absorption band of the triazole moiety around 1574cm-1 in the free ligand is 
detected around 1572-1586cm-1 in the metal complexes, while the ν(C=C) absorption 
band of the triazole moieties which appear at 1552cm-1 in the free ligand is detected 
around 1551-1565cm-1 in the metal complexes, as indicated in Table (7.2).  Moreover, 
the ν(N=N) stretching absorption band for the triazole ring appeared around 1430-
1400cm-1 [5-7], the ν(N=N-N) absorption band of triazole moiety is observed at 997-
983cm-1[8]. The important characteristics bands are presented in Table (7.2). 
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Table 7.2: IR frequencies in wavenumber (cm-1) units of the ligands (L3) and the 
metal-L3complexes. 
 
7.2.3 Magnetic moments, electronic absorption spectra and conductivity 
measurements 
The introduction to magnetic susceptibility is given in Physical Appendix 
(Chapter11.2.6). The calculated µeff values, conductivity measurements and UV-Vis 
spectral data for the L3-complexes are listed in Table (7.3).  
 
Compound ν(C=N)py, ν(C=C)Ar, 
ν(C=N)triaz conj. 
ν(C=C)triaz ν(N-N)triaz ν(C=C)Ar ν(C-N) 
L3 1604, 1592, 1574 1552 1154,1022 1515 1258 
[Mn(L3)2Cl2] 1607, 1596, 1576 1555 1157,1030 1518 1254 
[Fe(L3)2Cl2] 1607, 1597, 1572 1556 1147,1028 1518 1261 
[Co(L3)2Cl2] 1609, 1597, 1574 1557 1146,1028 1518 1254 
[Ni(L3)2Cl2] 1612, 1597, 1576 1551 1147,1028 1519 1263 
[Cu(L3)2Cl2] 1618, 1608, 1597,1572 1558 1149,1026 1517 1250 
[Zn(L3)2Cl2] 1610, 1594, 1573 1557 1141,1027 1514 1253 
[Cd(L3)2Cl2] 1630, 1602,1573 1565 1156,1030 1519 1268 
[Pt(L3)2Cl2] 1616, 1600,1592 1576 1169,1010 1511 1257 
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                  Table 7.3: UV-Vis spectral data of L3 complexes in DMSO solutions. 
Compound 
Band Position 
λmax(nm) 
Wave number (cm-1) 
Extinction coefficient 
ɛmax (dm3mol-1cm-1) 
Assignment µeff B.M 
Conductivity 
M (Ω-1cm2mol-1) 
L3 285 35087 24375, (4x10-6M) Intra - ligand, π→π*,n→ π*   
[Mn(L3)2Cl2] 
258, 291 
352, 
369 
390 
38759, 34364 
28409, 
27100 
25641 
6210,3059, (5x10-6M) 
32, (1x10-3M) 
30, (1x10-3M) 
21, (1x10-3M) 
Intra - ligand, π→π*, n→ π* 
CT 
6A1g → 4T1g 
5.32 52 
[Fe(L3)2Cl2] 
257, 291 
333 
922 
39062, 34364 
30030 
10845 
35500, 17500, (6x10-6M) 
3810, (8x10-5M) 
65, (8x10-5M) 
Intra – ligand, π→π, n→π* 
CT 
5T2g → 5E2g 
5.07 54 
[Co(L3)2Cl2] 
257, 292 
615 
677 
38910, 34246 
16260 
14771 
26625, 11000, (8x10-6M) 
38, (1x10-3M) 
61, (1x10-3M) 
Intra - ligand  π→π*, n→ π* 
4T1g (F)  → 4T1g (P) 
4T1g (F) → 4A2g (F) 
3.97 42 
[Ni(L3)2Cl2] 
257, 291 
407 
660 
39682, 34364 
24570 
15151 
30000, 18167 (6x10-6M) 
61, (1x10-3M) 
43, (1x10-3M) 
Intra-ligand π→π*,n→π* 
A2g (F) → 3T1g (p) 
3A2g (F) → 3T1g (F) 
2.73 54 
[Cu(L3)2Cl2] 
257, 287 
892 
39682, 34843 
11210 
39200, 19800, (5x10-6M) 
97, (1x10-3M) 
Intra - ligand  π→π*, n→ π* 
2B1g → 2B2 g 
1.69 24 
[Zn(L3)2Cl2] 257, 291 39682, 34364 41333, 13833, (6x10-6M) Intra - ligand  π→π*, n→ π* diamagnetic 12 
[Cd (L3)2Cl2] 258, 286 38759, 34965 43332, 42308, (2.6x10-6 Intra - ligand  π→π*, n→ π* diamagnetic 18 
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7.2.4 UV-Vis Spectral data for L3 complexes 
 
In the studies the UV-Vis spectral data were performed on the complexes, with the 
general formula [M(Ln)2Cl2]. The complexes were prepared in DMSO (where: M= 
Mn(II), Fe(II), Co(II), Ni (II), Cu(II), Zn(II) and Cd(II); n = 2 = CH3, 3 = OCH3, 4 = 
COOH, 5 = F, 6 = Cl, 7 = CN, 8= H, 9 = CF3). These studies covered different 
concentrations of the complexes. Varying and increasing the concentration allows one 
to observe the forbidden d-d transitions.  In general, the electronic spectra of the metal 
ion with different ligands having various substituents (R= CH3, OCH3, COOH, F, Cl, 
CN, H, CF3) display an analogous pattern for d-d transitions, and indicate that the 
substituents imposed have no-effect on the splitting of the d-d orbitals. The final 
concentration of each complex is shown in Table 7.3. The UV-Vis spectral data for 
all complexes, Figures, are depicted in Physical Appendix (Chapter 11 see sections 
11.2.2 to 11.2.5). 
 
 
7.2.5 Conductivity measurements 
Conductivity measurements were carried out by using 10-3M concentrations of the 
complexes in DMSO (294 K) following instructions from the manufacturer. The 
molar conductivities of the complexes ranged from 6 -77 Ω-1cm2mol-1 at 294 K. The 
low values indicate that the chloride anions bind to the metal ions as co-ligands and 
do not ionize. The low conductivity values are indicative of the complexes having 1:2 
metals - ligand stoichiometry of the type ML2Cl2, where L acts as a bidentate ligand 
[9]. The higher values than expected for the [M] values are usually due to the possible 
displacement of one chlorine atom ligand by a one molecule of the solvent DMSO in 
the complexes and produced intermediate behaviour [ML2(Cl)(DMSO)]. Cl between 
those of non-electrolytes and 1:1 electrolyte. Similar behaviours were observed for 
several complexes, mainly measured in DMSO solvent, because this solvent is a 
strong donor with profitable steric properties [10, 11]. 
 
7.2.6 Magnetic moment measurements 
The calculated μeff values for the L3- complexes are listed in Table 7.3 and an 
introduction to the subject is detailed in Physical Appendix 11.2.6. Magnetic 
susceptibility measurements were conducted as per instructions from the manufacturer. 
Magnetic susceptibility measurements were performed using Guoy's method [76] 
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7.2.7 Fluorescence emission spectral data for L3 and its complexes 
The fluorescence spectra of the trizole-based ligand and its various metal M(II) 
complexes [M = Mn(II), Fe(II), Co(II), Ni(II), Cu(II), Zn(II) and Cd(II)], were 
investigated in DMSO at room temperature (294 K). See Chapter 11 Physical 
Appendix (11.2.7-11.2.10) for an introduction to fluorescence. Weakly fluorescence 
intensity with a low quantum yield was observed. The fluorescence and quantum yield 
was determined by using 1,1':4'1"-terphenyl (PTP) dye as a reference.  This standard 
was chosen because its wavelength was nearest to that of the ligand and the complexes 
synthesised. The ligand, complexes and the reference dye were excited at 276nm, 
maintaining nearly equal absorbance (0.0954), and the emission spectra were 
recorded from 285 to 550nm. All experiments were carried out at a concentration of 
1x10-6 M. The fluorescence spectrum of the free p-terphenyl when excited at 276nm 
showed a maxima band at 345nm and 332nm with fluorescence intensity 2720nm and 
a Stokes shift of Δλ = 69nm and 2218nm with a Stokes shift of Δλ = 56nm. The 
quantum yield was Φf= 1.0 at a concentration of (1x10-6 M) [12], as shown in Figure 
7.2.  
 
 
Figure 7.2: The fluorescence emission spectrum of PTP in DMSO, excited at 276 
nm (C= 1X10-6M). 
 
The free L3 ligand emits a weak fluorescence spectrum when excited at 276nm and 
showed maxima bands at 345nm and 332nm with fluorescence intensity 89 and a 
Stokes shift of Δλ = 56nm and intensity 104 with a Stokes shifts of Δλ = 59nm.These 
can be attributed to a (π→π*) transition and LLCT transfer. The quantum yield was 
Φf= 0.04 at a concentration of 1x10-6 M [13-16] as shown in Figure 7.3. 
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Figure 7.3: The fluorescence emission spectrum of L3 in DMSO excited at 276 
nm (C= 1X10-6M). 
Overall the fluorescence emission spectra of the complexes with the L3 ligand is 
presented in Figure 7.4 and showed a weak fluorescence relative to the standard PTP. 
The Stokes shift, fluorescence intensity and quantum yield of the metal complexes 
having the general formula [M(L3)2Cl2] where [M = Mn(II), Fe(II), Co(II), Ni(II), 
Cu(II), Zn(II) and Cd(II)] are listed in Table 7.4. Furthermore, the emission spectra 
for the complexes is depicted in Figure 7.4 and were characterised by the emission 
band around 345-346nm. The quenching of the fluorescence is related to the 
complexation of the ligand by transition metal ions and is a rather common 
phenomenon, which is explained by processes such as magnetic perturbation, redox 
activity, and electronic energy transfer or by the solvent effect [17-18]. Additionally, 
upon complexation of the ligand, the maximum photoluminescence peak shifted to 
344-346 nm with a wavelength excitation of 276nm. This emission band probably 
originates from a (π→π*) transition, which can be assigned to ligand-to-ligand charge 
transfer (LLCT). 
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Figure 7.4: The fluorescence emission spectra of L3 ligand and complexes in DMSO excited at 276 nm (C= 1X10-6M). 
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Table 7.4: Photoluminescence spectra of the ligand L3 and its various complexes 
in DMSO (10-6 M); samples were excited at λmax (ex) = 276 nm. 
 
 
The trend of Table 7.4 shows that the quantum yield of the complexes is low compared 
to the standard PTP and that the complexes have similar properties amongst them.   
 
7.2.7.1 The fluorescence emission spectral data for Cu(II) complexes with L2-L9 
ligands 
The optical properties of the Cu(II) complexes with various ligands L2 - L9 were 
studied and investigated by using UV/Vis and fluorescence spectroscopy were 
recorded in DMSO solutions, and excited at wavelengths corresponding to at 276nm 
for (L2 - L9) complexes and 281nm for L4 complexes repectively.  
Compound Intensity 
 
Emissions 
  ( λem)nm, C=1X10-6 M 
 
Stokes shift 
(Δλ)nm 
 
Quantum yield % 
(Φf) 
PTP 
2720 
2218 
332 
345 
56 
69 
1.0 
 
L3 
89 
104 
332 
345 
56 
69 
 
0.040 
 
[Mn(L3)2Cl2] 
65 
74 
332 
346 
56 
70 
 
0.032 
 
[Fe(L3)2Cl2] 
88 
103 
332 
346 
56 
70 
 
0.045 
 
[Co(L3)2Cl2] 
    89 
104 
332 
346 
56 
70 
 
0.050 
[Ni(L3)2Cl2] 
89 
102 
331 
345 
55 
69 
 
0.041 
 
[Cu(L3)2Cl2] 
63 
74 
332 
346 
56 
67 
 
0.034 
 
[Zn(L3)2Cl2] 
58 
68 
332 
345 
56 
69 
 
0.047 
[Cd(L1)2Cl2] 
70 
82 
332 
346 
41 
55 
 
0.037 
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The fluorescence spectra of the Cu(II) complexes, depicted in Figure 7.5, showed 
weak fluorescence. Quantum yields, emission maxima intensity and Stokes shifts of 
Cu(II) complexes are summarised in Table 7.5. 
 
The fluorescence spectrum of the [Cu(L4)2Cl2] complex yield maximum emission 
peaks at 399nm, 421nm and 443nm (under 281 nm excitation). Stokes shifts at 
123,145 and 167nm respectively, occurred when the same Cu complexes have 
different ligands. The emission of the complex may be attributed to the ligand-centred 
π → π̽ LLCT (ligand-to-ligand charge transfer), MLCT (metal-to-ligand charge 
transfer ) or intraligand π → π̽ transitions. These shifts may be attributed to the 
difference in the excited state between the ligands and Cu complex [14-16].  The 
triazole as dyes can be easily designed for specific sensors as needed. The electron 
donating/withdrawing capacity of the modified groups on the triazole can also be used 
to help design dyes. Using Hammett sigma plots, such as Figures 7.6 and 7.7, 
comparisons were made to the UV-VIS maximum absorption and wavelength. The 
trends in these optical properties of the complexes are influenced by the electron 
donating/withdrawing groups on the trizaole ligands which affect the conjugated π-
electron system. These trends clearly show that substituents can enhance or decrease 
the optical properties performance of a dye, with potential to lead to the development 
of promising materials for potential DSSCs. 
  
 148 
 
Table 7.5: Optical properties of the Cu Complexes with ligands (L2-L9) in 
DMSO, excited at 276-281 nm (C= 1X10-6 M). 
 
 
Compound Intensity 
Emissions 
 ( λem)nm, C=1X10-6 M 
Stokes shift 
(Δλ)nm 
 
Quantum yield % 
(Φf) 
PTP 
2720 
2218 
332 
345 
56 
69 
 
1.0 
 
[Cu(L2)2Cl2] 
14 
15 
303 
331 
17 
45 
 
0.010 
 
[Cu(L3)2Cl2] 
15 
63 
74 
303 
332 
346 
13 
41 
59 
 
0.034 
 
[Cu(L4)2Cl2] 
11 
79 
86 
48 
303 
399 
421 
443 
27 
123 
145 
167 
 
0.054 
 
[Cu(L5)2Cl2] 
13 
25 
302.5 
344.5 
16.5 
58.5 
 
0.010 
[Cu(L6)2Cl2] 
12 
12 
12 
303 
332 
343 
15 
44 
57 
 
0.0079 
 
[Cu(L7)2Cl2] 
12 
26 
18 
303 
345 
374 
4 
46 
75 
 
0.016 
 
[Cu(L8)2Cl2] 
23 
99 
110 
309 
332 
345 
24 
47 
60 
 
0.053 
[Cu(L9)2Cl2] 
12 
13 
14 
302 
331 
344 
15 
44 
57 
 
0.0095 
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Figure 7.5: The UV-Vis and fluorescence emission spectra of Cu(II) with ligands (L2-L9) in DMSO excited at 276-281 nm (C= 1X10-6M). 
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Figure 7.6: Hammett plot of absorbance maximum of Cu complexes with ligand 
(L2-L9) vs. σp values of the para substituent in DMSO (C= 1X10-6M). 
 
Figure 7.7: Hammett plot of wavelength of Cu complexes with ligands (L2-L9) vs. 
σp values of the para substituent in DMSO (C= 1X10-6 M). 
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7.2.8 Mass spectra for complexes 
Of the available mass spectral techniques, positive ion TOF- electrospray (TOF MS 
ES+), (TOF-MOLDI-MS) and positive ion nano-electrospray (PSI) proved to be the 
most satisfactory techniques for the analysis and measurement of poorly soluble high 
MW metal complexes, such as these formed with ligands L2-L9. However, the 
molecular ion peak [M(Ln)2Cl2]
+, which corresponds to the molecular weight of the 
metal complexes, is not observed and the value is due to it being unstable. Only the 
secondary fragment ions were observed and the value is after the loss of one or more 
chlorine anions, ligand or metal atom using this approach. The high resolution mass 
spectra (HRMS) is observed and the value is were therefore undertaken on the highest 
MW secondary fragment ion peak [M(Ln)2Cl]
+ produced after loss of a chloride anion, 
from the molecular ion. Therefore, the structures of these complexes have been 
determined on the HRMS of the secondary fragment ion [M(Ln)2Cl]
+. Figure 7.8 is an 
example spectrum showing these different fragmentation species for the [Cu(L3)2Cl2] 
complex, while the calculated mass spectrum of complex [Cu(L3)2Cl2] is presented in 
Figure 7.9. 
 
Figure 7.8: TOF MS ES (+) mass spectrum of the complex [Cu(L3)2Cl2].      
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Figure 7.9: The calculated mass spectrum of the complex [Cu(L3)2Cl2] 
The mass spectroscopic pattern is observed and the value for the ratio of 1:2 (M:L) 
metal complexes formed with ligands L2- L9 by positive ion TOF- electrospray, are 
shown in Scheme 7.2. The molecular ion as stated was not observed, but eight 
secondary fragments were seen which were ascertained to have been formed by one 
of six different pathways, generalised and depicted in Scheme 7.2.  The initial loss of 
either a chloride anion gives [M(Ln)2Cl]
+ or two chloride ions yield [M(Ln)2]
+, which 
was the base peak (100%) in some cases, eg. the Cu complex (see Table 7.6). Similar 
fragments pattern observations were reported recently for bis [1-(cyclohexyl)-4-(2-
pyridyl)-1,2,3-triazole] with NiBr2 [19]. 
Loss of a chloride anion and a ligand fragment(-Cl+C10H11N3O) gave [M(L
n)pyCl]+ 
via pathway A, where the pyridine fragment of the ligand remained coordinated to the 
metal  as shown in Scheme 7.2. This peak was the base peak (100%) for the Mn(II), 
Fe(II), Co(II) and Ni(II) complexes, see eg. Table 7.6 Loss of two chloride anions, the 
methoxy group from the ligand and one ligand (-L3 + Cl2 + (OCH3)) gives the [M(L
n)]+ 
fragment via pathway B, which was the base peak (100%), in the case of the Zn 
complex in Table 7.6. In some cases, such as complexes of Co(II) and Ni(II), both 
pathways A and B, shown in Scheme 7.2, were operative. Loss of MLCl2 from the 
molecular ion gives the penultimate fragment (Ln)+ which could undergo further loss 
of a nitrogen molecule to give a (Ln*-N2)+ fragment.   Loss of the X substituent of the 
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ligand or part of the substituent from (Ln)+ gives rise to the (Ln*)+ fragment as depicted 
in Scheme 7.2. In the final pathway observed, the value involved the loss of a ligand, 
two chlorides and a nitrogen molecule (L+ Cl2+ N2) to give the [M(L
n)]+ fragment 
and the value is observed in the cases of Mn(II) and Ni(II). 
 
Scheme 7.2: The major fragments is observed and the values in the mass spectra 
for the metal complexes of general formula [M(Ln)2Cl2]. 
 
The Ln* fragment identified occurs by loss of the X substituent where X = F, Cl, 
OCH3, etc. or in the case of the methoxy substituent, by rearrangement through the 
loss of a CH3 cation (see Scheme 7.3). In the general formula [M(L
n)2Cl2] (M = 
Mn(II), Fe(II), Co(II), Ni(II), Cu(II), Zn(II), Cd(II); Ln = the ligands have various 
substituents such as (CH3, OCH3, COOH, F, Cl, CN, H, CF3) and n = (2= CH3, 3= 
OCH3, 4= COOH, 5= F, 6= Cl,7= CN, 8= H, 9= CF3). The generalised fragments and 
their relative abundances for the metal complexes [M(L3)2Cl2] are shown in Table 7.6. 
The molecular ion peak fragmentation patterns of the [M(L3)2Cl]
+ (D) are detected at 
m/z (100%) due to the fragment ion patterns [M-Cl+C10H11N3O]
+, which  could be 
corresponding to the rearrangement in the molecule as illustrated in Scheme 7.3. It is 
attributed to the loss of a part of the ligand, while the pyridine ring remains intact and 
is followed by the loss of a CH3 cation group. As a result, the para -quinine ion is 
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formed. This is in accordance with fragmentation rearrangement results reported for 
para-methoxyphenyl azide and para-anisidine [20]. 
 
 
Scheme 7.3: The major fragments detected in the mass spectrum of the metal 
complexes of [M(L3)2Cl2] where: M= [Mn(II), Fe(II), Co(II) and Ni(II)]. 
 
The fragmentation results and spectra for other complexes are included in the 
Appendix 2 Tables and Figures. Only in the case of complexes with L4 positive ion 
(TOF-MOLDI-MS) had to be used to measure the complexes.  
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Table 7.6: TOF MS ES+ species is observed and the value is for the complexes with L3. 
 
 
 
Complexes  
  
 Fragmentation (%)     
[M]+ [M(L)2Cl]+. [M(L)2]+. [M- Cl+C10H11N3O]+ [M- L3+Cl2+(OCH3)]+ [L3] +. [L-N2] +. [M(L)2]+. Other peak 
[Mn(L3)2Cl] 594(95%) 
 
405.5 (100%) 
 
  279.5 (40%) 
[M- (L3+Cl2+N2)]+ 
 
[Fe(L3)2Cl2] 595(80%) 
 
405.8 (100%) 
 
253(30%) 225(50%)   
[Co(L3)2Cl2] 598(90%)  
 
407.5 (100%) 281.5 (100%)     
[Ni(L3)2Cl2] 597(70%)  
 
407.0 (90%) 281.0 (100%)  224(50%) 224 (50%) 
[M- (L3+Cl2+N2)]+ 
 
[Cu(L3)2Cl2] 602(10%)   567.1(100
%) 
 
284.0 (30%) 253(20%) 225(50%)  351 (5%) [M-(L3+Cl2)]+ 
[Zn(L3)2Cl2] 603(60%) 567.1 
(20%) 
 
284 (100%) 253(30%) 225(50%)  602.1 (15%) 
[M- (Cl2 + CH3)] + 
[Cd(L3)2Cl2] 653(10%) 
  
284.0 (100%) 253(50%) 225(100%)  567.1 (40%) 
[M-(Cl +(C2H6O2) + N2)]+ 
[Pt(L3)2Cl2] 725.1413 
(100%) 
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7.2.9 1H-13C, 1H-1H COSY, HMQC two dimensional correlation spectroscopy and 
D.E.P.T NMR spectra for the complexes 
All assignments were confirmed using DEPT-13C (θ = 135 °), 1H-1H COSY and 1H-
13C HMQC two dimensional correlation spectroscopy. The 1H-13C and DEPT NMR 
analysis were used to characterise the structure of ligand L3. The samples were 
recorded in CD2Cl2 solutions (see chapter 6 section 6.3.1.3). 
 
The 1H and 13C-NMR spectra for each complex were assigned in accordance with the 
NMR spectra of L3 triazoles, supported by 2-dimensional spectra (1H–1HCOSY, 13C–
1H HMQC) to confirm the proposed assignments. The chemical shift (δ) of the 1H- 
(C-H) and 13C-NMR (C=CH) for the triazole moiety of the Zn(II) and Cd(II) 
complexes are listed in Tables 7.7 and 7.8. 
 
7.2.9.1 1H NMR spectrum for [Zn(L3)2Cl2] 
The 1H NMR spectrum for [Zn(L3)2Cl2] in DMSO-d6 solution is shown in Figure 
7.10. The spectrum displays one set of signals, thus indicating the present of one 
isomer in solution.  The spectrum shows a chemical shift at δ = 9.05ppm (1H, S) 
which is attributed to C11; 11-H triazole proton shifted downfield relative to its position 
in the “free” ligand L3, which indicates complexation to Zn(II) ions. This yield Δδ = 
0.53ppm in comparison with the chemical shift of L3. The downfield shift can be 
attributed to the reduction in the electron density of the triazole ring (the lone pair of 
electrons on the nitrogen triazole contributes to the metal upon complex formation).  
The pyridine proton resonances are shifted in accordance with their proximity to the 
metal centre. The proton H2 closest to the Zn(II) centre is shifted downfield, which 
could also be related to the participation of the pyridine nitrogen atom in the binding 
to the metal. This signal is slightly shifted downfield compared to that detected in the 
free ligand of L3, and yield Δδ = 0.04ppm. The full assignment of signals are 
summarised in Table 7.7. These finding are in accordance with that reported for 
ferrocene triazole pyridine complexes [21-23]. 
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7.2.9.2 13C NMR and DEPT spectra for [Zn(L3)2Cl2] 
The 13C NMR spectrum for [Zn(L3)2Cl2], Figure 7.10, shows a chemical shift at δ = 
120.75ppm, which is assigned to C11 of the triazole. This gives a value of Δδ = 
0.18ppm in comparison with the chemical shift of L3. Signals at δ = 121.60 and 
114.63ppm, are related to the para benzene substitution (C14,16; C13,17), respectively. 
The chemical shift of the CH3 group of the methoxy moiety appears as expected at δ 
= 55.29ppm [24-25]. The full assignment of signals are summarised in Table 7.7. 
DEPT-13C is presented in Figure 7.12. 1H-13C HMQC correlation and 1H-1H COSY 
spectra of [Zn(L3)2Cl2] in DMSO-d6 are displayed in Figure 7.13 and 7.14, 
respectively. 
 
 
Figure 7.10: 1H NMR spectrum of [Zn(L3)2Cl2] in DMSO-d6. 
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Figure 7.11: 13C NMR spectrum of [Zn(L3)2Cl2] in DMSO-d6. 
 
Figure 7.12: 13C NMR and DEPT NMR spectrum of [Zn(L3)2Cl2] in DMSO-d6. 
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Figure 7.13: 2D 1H-13C HMQC correlation spectrum of [Zn(L3)2Cl2] in DMSO-
d6. 
 
 
Figure 7.14: 2D 1H-1HCOSYcorrelation spectrum of [Zn(L3)2Cl2] in DMSO-d6. 
 160 
 
7.2.9.3 1H NMR spectrum for [Cd(L3)2Cl2] 
 
The 1H NMR spectrum for [Cd(L3)2Cl2] in DMSO-d6 solution is depicted in Figure 
7.15.  The spectrum shows a chemical shift at δ = 9.08ppm (1H, S), which is attributed 
to the C11; 11-H of the triazole proton. This gives a value of Δδ = 0.55ppm in 
comparison with the free ligand L3. The assignment of signals are summarised in 
Table 7.8. 
 
 
Figure 7.15: 1H NMR spectrum of [Cd(L3)2Cl2] in DMSO-d6. 
 
7.2.9.4 13C NMR and DEPT spectra for [Cd(L3)2Cl2] 
The 13C-NMR spectrum for [Cd(L3)2Cl2], Figure 7.16, exhibits a chemical shift at δ = 
121.17ppm, which assigned to C11 of the triazole. This gives a value of Δδ = 0.25ppm 
compared with the chemical shift of L3. Signals at δ = 121.62 and 114.64ppm are 
related to (C14,16; C13,17), respectively. The CH3 group of the methoxy moiety appears 
as expected at δ = 55.29ppm. The assignment of signals are summarised in Table 7.8. 
DEPT-13C is presented in Figure 7.17.  1H-13C HMQC correlation and 1H-1H COSY 
spectra of [Cd(L3)2Cl2] in DMSO-d6 are shown in Figures 7.18 and 7.19, respectively. 
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Figure 7.16: 13C NMR spectrum of [Cd(L3)2Cl2] in DMSO-d6. 
 
 
Figure 7.17: 13C NMR and DEPT NMR spectrum of [Cd(L3)2Cl2] in  
DMSO-d6. 
 162 
 
 
Figure 7.18: 2D1H-13C HMQC correlation spectrum of [Cd(L3)2Cl2] in DMSO-
d6. 
 
 
Figure 7.19: 2D 1H-1HCOSYcorrelation spectrum of [Cd(L3)2Cl2] in DMSOd6. 
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7.2.9.5 The effect of metal ion on the 1H and 13CNMR chemical shifts of the triazole 
moiety for [Zn(L3)2Cl2] and [Cd(L
3)2Cl2] 
 
 
The 1H-, 13C-NMR data for the Zn(II) and Cd(II) complexes with L3 are displayed as 
an overlay in Figures 7.20 and 7.21, respectively. Although the Zn(II) and Cd(II) ions 
have the same electronic configuration (d10), they are lying in different transition 
metals series in the 3d-block and 4d-block, respectively.  
 
The chemical shift (δ) of the 1H-(C-H) and 13C-NMR (C=CH) for the triazole moiety 
of the Zn(II) and Cd(II) complexes are listed in Tables 7.7 and 7.8. It is clear that there 
is a detectable shift in the 1H- (C-H) and 13C-NMR (C=CH) for the triazole moiety 
upon complexation, compared with that in the free ligand.  
 
However, the chemical shifts between Zn(II) and Cd(II) complexes appear to be very 
close to each other. This may be related to the fact that the Zn(II) and Cd(II) ions in 
these complexes are adopting similar octahedral geometries with (2+) oxidation state. 
 
On the other hand, Zn(II) and Cd(II) complexes with various ligands (L2-L9), which 
contain several substituents (electron donating and electron withdrawing groups) on 
the phenyl ring, manifested itself in shifts in the C-H-triazole peak of the 1H-1,2,3-
triazole system, which was in the range of 9.06 - 9.46ppm for the 1H-NMR and in the 
range of 120.54-121.56ppm in the 13C-NMR spectra. These values are listed in Tables 
7.7 and 7.8, and display different chemical shifts in the 1HNMR spectra and 13C-NMR 
spectra due to the nature of the substituents. 
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Figure 7.20: The overlay of the (C-H) triazole from the 1H NMR for L3 in Zn(II) 
and Cd(II) complexes in DMSO-d6. 
 
Figure 7.21: The overlay 13C NMR of the (C=CH) triazole for L3 in CDCl2 and 
its Zn(II) and Cd(II) complexes in DMSO-d6. 
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Table 7.7: 1HNMR and 13CNMR chemical shifts of the Zn(II) complexes with 
ligands L2–L9 in DMSO-d6 solutions and the corresponding Hammett 
substituent constants. 
 
Table 7.8: 1HNMR and 13CNMR chemical shifts of the Cd complexes with 
ligands L2-L9 in DMSO-d6 solution and the corresponding to Hammett 
substituent constants. 
Complex σρ constant (-σρ ) Substituent 1H-NMR δ(C-H) 
(triazole) 
13CNMR(=CH) 
(triazole) 
[Cd(L2)2Cl2] -0.17 ρ-CH3 9.36 121.16 
[Cd(L3)2Cl2] -0.27 ρ-OCH3 9.08 120.82 
[Cd(L4)2Cl2]  0.45 ρ-COOH 9.39 121.22 
[Cd(L5)2Cl2]  0.06 ρ-F 9.27  121.40 
[Cd(L6)2Cl2]  0.23 ρ-Cl 9.33  121.32 
[Cd(L7)2Cl2]  0.66 ρ-CN 9.45 121.41 
[Cd(L8)2Cl2]  0 H 9.30 121.16 
[Cd(L9)2Cl2]  0.54 ρ-CF3 9.45 121.51 
 
The 1HNMR and 13CNMR spectra data for the Zn(II) and Cd(II) with ligands L2-L9 
are presented in Appendix 2. 
 
 
 
Complex σρ constant (-σρ ) Substituent 1H-NMR δ(C-H) 
(triazole) 
13CNMR(=CH) 
(triazole) 
[Zn(L2)2Cl2] -0.17 ρ-CH3 9.33 121.02 
[Zn (L3)2Cl2] -0.27 ρ-OCH3 9.06 120.75 
[Zn (L4)2Cl2] 0.45 ρ-COOH 9.38 121.21 
[Zn (L5)2Cl2] 0.06 ρ-F 9.32 121.56 
[Zn (L6)2Cl2] 0.23 ρ-Cl 9.31 121.23 
[Zn (L7)2Cl2] 0.66 ρ-CN 9.36 120.54 
[Zn (L8)2Cl2] 0 ρ-H 9.27 121.05 
[Zn (L9)2Cl2] 0.54 ρ-CF3 9.44 121.42 
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7.2.10 X-ray crystallography diffraction data analysis of the metal complexes 
During the course of this project, X-ray diffraction investigations of single crystals 
have been used extensively to confirm the formation of the titled complexes. These 
include X-ray single crystal diffraction analyses of the different metal ions and ligands 
complex systems.  The aim of the varying ligand systems and metal ions was to 
investigate: (i) the effect of the ligand system on the coordination sphere of a specific 
ion, and (ii) the influence of varying metal ions on the coordination sphere upon 
binding with a specific type of ligand. Due to the large number of complexes 
determined using X-ray single crystals, i.e. 20 complexes, L3 ligand were chosen as 
an example to show the influence of the metal ions on the coordination sphere of 
complexes.  On the other hand, the Cu(II) ion was chosen to study the impact of 
varying ligand systems on the coordination sphere of the complexes. Other X-ray 
molecular structures are presented in the Appendix 2. 
 
7.2.10.1 Structure determination 
Single crystal X-ray diffraction measurements for [Mn(L3)2Cl2], [Fe(L
3)2Cl2],  
[Co(L3)2Cl2], [Ni(L
3)2Cl2], [Cu(L
3)Cl2]n, [Cd(L
3)Cl2]n, [Cu(L
2)2Cl2], [Cu(L
6)2Cl2], 
[Cu(L7)2Cl2], [Cu(L
8)2Cl2] and [Cu(L
9)2Cl2], were performed using a Rigaku Saturn 
724+ area detector mounted at the window of an FR-E+ rotating anode generator with 
a (Mo Kα, λ=0.71075Å), while the data for the complex [Cu(L2)2Cl2] as collected 
using a Nonius-Kappa CCD area detector mounted at the window of an FR591 
rotating anode generator (Mo Kα, λ=0.71073A). The crystals were mounted on glass 
fiber and the data were collected at 120K under nitrogen flow from an Oxford 
Cryosystems cryostream 700 device. The data for the complex [Cu(L9)2Cl2] as 
collected at 100K and with a rotating anode generator (Mo Kα, λ=0.68890Å). On the 
other hand, the data for the complex [Cu(L8)2Cl2] was collected at 293K and with a 
rotating anode generator (Mo Kα, λ=0.71075Å). An empirical absorption correction 
was carried out using SADABS and the structures were solved by direct methods 
using SUPERFLIP [26]. Data were processed and empirical absorption corrections 
were also done using Crystal Clear SM-Expert, with the unit cell parameters refined 
against all data [27]. The structures were solved by direct methods using SHELXS-
97 with in OLEX2 [28]. All refinements on Fo
2 by full-matrix least squares refinement 
were solved using the SHELXL-97 program package [29]. All non-hydrogen atoms 
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were refined by isotropic displacement parameters and hydrogen atoms were added 
at calculated positions. Further refinement was done using a riding model with C-H 
(aromatic) 0.95Å UISO = 1.5Ueq (C); C-H (methyl) 0.98Å UISO = 1.5Ueq (C) [30]. The 
crystallographic data for the complexes are summarised in Table 7.9, while selected 
bond lengths, selected bond angles and selected torsion angles are presented in Tables 
7.10, 7.11, 7.12 and 7.13, respectively. 
7.2.10.2 X-ray crystallography diffraction data analysis of the metal complexes with 
ligand L3 
7.2.10.2.1 Single-crystal structure determinations of the metal complexes of [M:L-
1:2] 
 
The molecular structure of the four complexes [Mn(L3)2Cl2], [Fe(L
3)2Cl2], 
[Co(L3)2Cl2] and [Ni(L
3)2Cl2] are generally similar. The overall structures can be 
described as distorted octahedral. As expected, two triazole ligands are coordinated 
to the metal centre and lie in the equatorial plane, while the two chloro ligands are in 
the axial positions trans to each other. However, in [Mn(L3)2Cl2], the two chloro 
ligands are adopting the cis positions around the Mn centre. 
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Table 7.9: Crystallographic data for the ligand L3 and the complexes. 
Compound L3 [Mn(L3)2Cl2] [Fe(L3)2Cl2] [Co(L3)2Cl2] [Ni(L3)2Cl2] [CuL3) Cl2]n [Cd(L3)nCl2] 
Empirical formula C14H12N4O C28H24Cl2MnN8O2 C28H24Cl2FeN8O2 C28H24Cl2CoN8O2 C28H24Cl2NiN8O2 C14H12Cl2CuN4O C14H14CdCl2N4O 
Mr 252.28 630.39 631.30 634.38 634.16 386.72 451.60 
Temp/K 100(2) 100 K 100(2) K 100(2) K 100(2) K 100(2) K 100(2) K 
Cryst. syst. Triclinic Orthorhombic Monoclinic Monoclinic Monoclinic Orthorhombic Monoclinic 
Space group P1 Pbcn P21/c P21/c P21/c Pbca P121/c1 
a/Å 3.7837(4) 13.4618(9) 10.3599(7) 10.3480(10) 10.459(15) 7.1833(5) 24.2917(18) 
b/Å 10.8502(16) 9.2130(6) 13.1029(8) 12.9032(12) 12.968(17) 15.0954(11) 9.1879(7) 
c/Å 15.2200(17) 22.9298(16) 10.2300(6) 10.1969(9) 10.350(15) 27.0358(19) 7.0472(5) 
α/° 109.226(11) 90.00 90.00 90.00 90.00 90.00 90.00 
β/° 97.056(6) 90.00 96.161(7) 95.772(7)° 95.61(3) 90.00 92.144(5) 
γ/° 91.514(9) 90.00 90.00 90.00 90.00 90.00 90.00 
V/Å3 584.03(12) 2843.8(3) 1380.65(15) 1354.6(2) 1397(3) 2931.6(4) 1571.76(18) 
Z 2 4 2 2 2 8 4 
Rint 0.0617 0.1012 0.0387 0.2085 0.1445 0.084 0.094 
Dcalcd/g cm-3 1.435 1.472 1.519 1.555 1.508 1.752 1.908 
Refln (all/ind) 6395/ 
2617 
12965/ 
3242 
6581/ 
3143 
15422/ 
3098 
7036/ 
3134 
25308/ 
3354 
9891/ 
7737 
μ/mm-1 0.096 1.000-0.092 0.783 0.875 0.928 1.860 1.740 
R1/wR2 
(obsd data: F2>2σ(F2))a 
0.0534/ 
0.1074 
0.0597/ 
0.1345 
0.0398/ 
0.1021 
0.0466/ 
0.0762 
0.0928/ 
0.1629 
0.0496/ 
0.1127 
0.1210/ 
0.2914 
R1/wR2 (all data)a 0.0734/ 
0.1161 
0.1127/ 
0.1624 
0.0458/ 
0.1063 
0.1516/ 
0.0886 
0.1772/ 
0.2084 
0.0731/ 
0.1236 
0.1668/ 
0.3280 
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Table 7.10: Selected bond lengths in (Å) for the complexes with L3 ligand. 
Bond distance(Å) L3 [Mn(L3)2Cl2] [Fe(L3)2Cl2] [Co(L3)2Cl2] [Ni(L3)2Cl2] [CuL3)Cl2]n [Cd(L3)Cl2]n 
Empirical formula C14H12N4O C28H24Cl2MnN8O2 C28H24Cl2FeN8O2 C28H24Cl2CoN8O2 C28H24Cl2NiN8O2 C14H12Cl2CuN4O C14H14CdCl2N4O 
C7C11 1.362(6) 1.371(5) 1.375(3) 1.360(4) 1.361(9) 1.368(5) 1.39(3) 
N8N9 1.302(4) 1.305(4) 1.311(2) 1.309(4) 1.331(7) 1.323(4) 1.31(2) 
N9N10 1.355(4) 1.358(4) 1.354(2) 1.362(3) 1.368(7) 1.360(4) 1.35(2) 
N8C7 1.365(5) 1.365(4) 1.360(2) 1.360(3) 1.370(8) 1.359(4) 1.36(3) 
MN(PY) 1  2.330(3) 2.2018(15) 2.127(2) 2.1015(19) 2.066(3) 2.359(17) 
MN(PY)  1i  2.330(3) 2.2018(15) 2.127(2) 2.1015(19)   
MN(triazole)1  2.324(3) 2.1838(16) 2.105(3) 2.0739(19) 2.024(3) 2.391(18) 
MN(triazole)1i  2.324(3) 2.1838(16) 2.105(3) 2.0739(19)   
MCl1  2.4544(11) 2.4456(5) 2.4398(10) 2.4123(6) 2.6195(9) 2.563(5) 
MCl1i  2.4544(11) 2.4456(5) 2.4398(10) 2.4123(6) 2.2382(10) 2.667(6) 
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           Table 7.11: Selected bond angles [°] for the complexes with the L3 ligand 
Bonds Mn(L3)2Cl2] [Fe(L3)2Cl2] [Co(L3)2Cl2] [Ni(L3)2Cl2] [Cu(L3)Cl2]n [Cd(L3)Cl2]n 
N(PY) 1 MN (PY) 1i 178.89(16) 180.0 179.999(1) 179.999(1)   
N (triazole) 1i MN (triazole) 1 87.13(15) 180.0 179.999(1) 179.999(1)   
N(PY) 1MN (triazole) 1i 108.95(11) 104.10(6) 102.93(10) 101.3(2)   
N(PY) 1 MN (triazole) 1 71.90(10) 75.90(6) 77.07(10) 78.7(2) 79.78(12) 70.0(6) 
N(PY) 1M Cl 1 91.05(8) 89.80(4) 90.32(8) 90.28(15) 85.78(9) 94.5(4) 
N(PY) 1i M Cl 1 88.30(8) 90.20(4) 89.68(8) 89.72(15)   
N (triazole) 1i M Cl 1 155.71(8) 90.20(4) 90.25(9) 89.36(18)   
N (triazole) 1M Cl 1 86.19(8) 89.80(4) 89.75(9) 90.64(18) 107.97(8) 159.3(4) 
Cl 1 i M Cl 1 108.66(6) 180.0 179.999(1) 180.0 95.72(3) 103.30(18) 
N(PY) 1 MCl2     174.27(9) 159.6(4) 
N(triazole) 8 MCl2     94.50(9) 94.7(4) 
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Table 7.12: Selected torsion angles [°] for the complexes with the L3 ligand. 
 
Bonds [Mn(L3)2(Cl)2] [Fe(L3)2(Cl)2]              [Co(L3)2(Cl)2]             [Ni(L3)2(Cl)2]               
N(t) 1iMN(p)1C2 96.3(3) 0.6(3) 0.23(17) 1.7(6) 
N(t)) 1MN(p) 1C2 176.6(3) 179.4(3) 179.77(17) 178.3(6) 
Cl 1iMN(p) 1 C2 10.9(3) 89.1(3) 90.07(15) 92.3(5) 
Cl 1MN(p) 1C2 97.8(3) 90.9(3) 89.93(15) 87.7(5) 
N(t) 1iMN(t) 1N9 75.5(3) 101(16) 74(7) 21(6) 
N(p) 1MN(t) 1N9 173.5(4) 179.6(4) 179.5(2) 179.7(6) 
N(p) 1iMN(t) 1N9 5.8(4) 0.4(4) 0.5(2) 0.3 
Cl 1iMN(t) 1N9 149.7(3) 90.8(4) 90.40(18) 90.4(6) 
Cl 1MN(t) 1N9 81.1(3) 89.2(4) 89.60(18) 89.6(6) 
MN(t) 1N9N10 160.6(3) 177.0(3) 179.13(13) 176.7(4) 
N8N9N10C11 0.4(4) 0.4(4) 0.1(2) 179.7(5) 
N8N9N10C12 179.8(3) 179.1(3) 179.67(16) 0.7(10) 
 
Table 7.13: Selected torsion angles [°] for the Cu and Cd complexes with the 
ligand L3  
 
Bonds [Cu(L3)Cl2]n [Cd(L3)Cl2]n 
Cu1N1C6C7 4.4(4) 1(2) 
Cu1N8N9N10 174.8(2) 166.3(15) 
Cu1N1C6C7 4.4(4) 1(2) 
Cu1N8C7C6 3.5(4) 13(2) 
N8N9N10C12 179.4(3) 179.4(18) 
C7N8N9N10 0.3(4) 1(2) 
N9N10C12C17 144.8(3) 169(2) 
N1C6C7N8 5.2(5) 10(3) 
N8N9N10C12 179.4(3) 179.4(18) 
N8N9N10C11 1(2) 0.5(4) 
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7.2.10.2.2 The X-ray Crystal structure of dichloro 2-(1-(4-methoxyphenyl)-1H-1,2,3-
triazol-4-yl)pyridinenickel(II) [Ni(L3)2Cl2] 
 
The X-ray molecular structure of [Ni(L3)2Cl2] is depicted in Figure 7.22. The X-ray 
quality crystal of the molecule [Ni(L3)2Cl2] was obtained by slow evaporation in a hot 
mixture of DMSO: acetonitrile =1:9 solutions under ambient conditions. It crystallises 
in the monoclinic P21/c space group Table 7.9 indicates two molecules per unit cell 
as Z = 2 of the [Ni(L3)2Cl2] complex. Crystallographic data are presented in Table 7.9. 
Selected bond lengths, bond angles and torsion angles are provided in Tables 7.10, 
7.11, and Table 7.12, respectively. The nickel centre in the [Ni(L3)2Cl2] is in a 
distorted octahedral coordination arrangement, which includes two of the 2-(1-(4-
methoxy-phenyl)-1H-1,2,3-triazol-4-yl) pyridine ligands coordinated via the N8TA 
and N1PY atoms from the two different ligands L
3. N8eq –Ni–N1eq and N1ieq–Ni–N8ieq 
are lying in an equatorial plane with angles 78.7(2)°. In the equatorial plane, the 
pyridine N1PY and N8TA donors from the two ligands are mutually trans to each other. 
The angles for N8eq –Ni–N8ieq and N1eq –Ni–N1ieq are 179.999(1)°.   
 
Furthermore, the axial positions are occupied by two chloride ions Cl1ax–Ni–Cl1i ax, 
and the angle is 180.0°.  The angles in the plane containing the two L3 ligands are 
slightly deviated from 90° angles, because of the chelating nature of the two ligands 
L3. The bond lengths of N8–N9, N9–N10 and N8–C7 of the 1,2,3-triazole ring are 
1.331(7)Å, 1.368(7)Å and 1.370(8)Å, respectively. These values are slightly higher 
in the [Ni(L3)2Cl2] (by approximately 0.028Å), compared with the free ligand, where 
N8–N9 1.302(4)Å, N9–N10 1.355(4)Å and N8–C7 1.365(5)Å, respectively for the 
free ligand, and other reported Ni(II) pyridyl-triazole complexes [19]. Both chloro 
moieties show bond lengths of 2.454(3) Å, confirming terminal chloro ligands. The 
Ni–NPY bond lengths are ranging from 2.110(6)–2.111(6)Å, while the Ni–NTA bond 
lengths are 2.091(5)Å. This is consistent with the formation of the high-spin d8 Ni(II) 
metal centre. The metal-triazole bond length is slightly shorter than the metal pyridine 
bond length (by approximately 0.019Å). This is possibly due to π-back donation from 
the Ni(II) centre into the triazole ring. Such elongation of the N–N double bond has 
been previously observed and the value is for metal complexes containing substituted 
“azo” ligands [31]. Additionally, this may be because of the greater trans influence of 
the N8 of the triazole nitrogen with respect to N1 of the pyridyl nitrogen [32], and to 
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the better electron donating properties of the 1,2,3-triazole ring compared with the 
pyridine ring. Similar trends were observed and the value is in agreement with those 
previously reportedin metal complexes of other azole ligands containing a 2-pyridyl 
substituent [1, 33-35].   
 
The twisting angles between the pyridine plane and the triazolering and the triazole 
plane and the substituted phenyl ring are 114.8(6)° and 119.2(5)°, respectively.  As a 
result of conjugation, the triazole ring and the phenyl unit are essentially co-planar. 
The dihedral angle between the plane of the pyridyl moiety and the mean plane of the 
triazole ring is 2.3(8)°, while the dihedral angle between the plane of the methoxy 
phenyl group and the plane of the triazole moiety is tilted by 14.6(9)°. According to 
the literature, the values generally range from 3 to 14° [2, 36-37]. The bite angles of 
N1–Ni–N8 and N1i–Ni–N8 are ranging from 78.7(2)° to 101.3(2)°,  and the torsion 
angles between Ni1–N8–C7–C6, Ni–N1–C6–C7, Ni1-N1-C5-C6 and Ni1-N8-N9-
N10  are 4.7(7)°, 1.3(7)°, 178.1(5)° and 176.7(4)°, respectively.  Other torsion angles 
are presented in Table 7.12. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.22: The molecular structure of [Ni(L3)2Cl2]. The thermal ellipsoids are 
drawn at a 50% probability.  
 
Moreover, there are no classic hydrogen bonds observed. The value is typical of 
extensive weak hydrogen bonding interactions [38, 39]. It generates a 3D 
supramolecular sheet in the solid state, as indicated by Table 7.14 and Figure 7. 23. 
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The crystal structure shows the involvement of the chloro moieties in the formation 
of hydrogen bonds, by acting as accepters or donors.  This hydrogen bonding can be 
described as follows: The C4–H4 group of the pyridyl ring and   C18–H18C of the 
methoxy group are hydrogen–bonded to the chloro ligands of the next molecule in the 
same layer. The second chloro ligand forms hydrogen bonds to the acidic triazole 
C11–H11 group on a triazole ring of the next layer. The bond length of the H11...Cl 
distance is 2.611Å and is well below the Van der Waals radius of H and Cl (3Å) [40]. 
Furthermore, in all cases the angle is located at 165° degrees out of the plane of the 
C–H bond. This value is closer to those values of hydrogen–bonding interactions 
reported for nickel complexes [1, 19, 41]. The angles between Ni–Cl...H4, Ni–
Cl...H11 and Ni–Cl...H18C are 108.57(6)°, 107.09(6)° and 97.78(5)°, respectively.  
X-ray crystallography of [Ni(L3)2Cl2] established that the crystal structure is governed 
by short C–H...N interactions. 
 
The atoms of involved are C–H (C–H18A) of the methoxy group as donors, and the 
N9 atoms of the triazole units as accepters. These hydrogen – bonded chains are linked 
with the chains from the other layer by [C–H and H...N-triazole], as shown in Figure 
7.23. The H...N distances 2.665(7)Å are quite long and  > 2.5Å.  In all these C–H...N 
contacts the distance between the protons and the donor atomsare shorter than the sum 
of their van der Waals radius (2.75Å), and are comparable with published results in 
the literatur [39, 40]. These molecules adopt a head-to-tail orientation as shown in 
Figure 7.23. This head to tail arrangements are in accordance with those reported 
recently for Ni(II) and Pd(II) complexes with pyridyl-triazole ligands [19, 31, 32]. 
 
 
  
 175 
 
 
Figure 7.23: A 3D supramolecular sheet in [Ni(L3)2Cl2] complex showing intermolecular hydrogen bonding interactions (C–H…Cl and 
C–H…N).  
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The overlap between the triazole N8N9N10C7C11 and pyridine N1C2C3C4C5C6 rings of 
the neighbouring molecules resulted in face–to–face and slipped-type parallel 
alignment. That means the rings are parallel displaced with respect to one another, 
exhibiting a centroid–centroid distance of 3.589Å, which is stabilised by triazole -
pyridine π…π stacking and suggests the presence of some weak interactions. The 
adjacent pyridine ring is perfect coplanar, and the centroid - centroid distance is 
3.589Å. This distance is comparable to the previously reported bond separations of a 
typical π…π stacking [44-47]. The centroid - plane perpendicular distance is 3.288Å 
and the angle between the two planes is 2.88° (see Figure 7.24). 
 
 
Figure 7.24: The overlap between the triazole and pyridine rings in [Ni(L3)2Cl2] 
complex showing the intermolecular π…π stacking interactions. 
 
The complex is stabilised by hydrogen bonding interactions and intermolecular π…π 
stacking between the triazole and pyridyl rings. The molecules of [Ni(L3)2Cl2] are 
arranged in infinite hydrogen-bonded chains via C–H...N triazole, CH...Cl and C–
H...Cl and intermolecular π…π stacking between the pyridine and the triazole rings.  
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Table 7.14: Weak hydrogen bonding interactions parameters; D= donor and A= 
acceptor (Å, °) in the complex [Ni(L3)2Cl2]. 
 
D-H...A/interactions D–H (Å) H–A (Å) D–A (Å) Angle (  ͦ) 
C11–H11...Cl1 0.950(7) 2.611(3) 3.540 (8) 165.8(4) 
C4–H4...Cl1 0.951(7) 2.944(4) 3.552 (7) 122.9(4) 
C18–H18C...Cl1 0.980(1) 2.947(3) 3.787(8) 144.4(4) 
C18–H18A...N9 0.980(9) 2.665(7) 3.420(1) 134.5(4) 
 
7.2.10.2.3 X-ray Crystal structure of dichloro-2-(1-(4-methoxyphenyl)-1H-1,2,3-
triazol-4-yl)pyridinemanganese(II) [Mn(L3)2Cl2] 
 
The molecular structure of [Mn(L3)2Cl2] is depicted in Figure 7.25. The complex 
crystallised in an orthorhombic space group Pbcn.  Crystallographic data listed in 
Table 7.9 indicates four molecules per unit cell as Z = 4 of the [Mn(L3)2Cl2] complex. 
Selected bond lengths, bond angles and torsion angles are provided in Tables 7.10, 
7.11and 7.12, respectively. The geometry about the Mn atom is essentially a distorted 
octahedral coordination arrangement. The octahedral basal plane is formed by the two 
Cl atoms Cl1 and Cl1i, which are arranged in the cis position to each other and two 
nitrogen atoms N8 and N8i. The remaining two vacant sites on the metal centre are 
occupied by the nitrogen atoms N1 and N1i of the pyridyl moieties adopting a trans 
position with a 178.89(16)° angle between N1axMn1N1iax. 
 
The metal-ligand angles in the Mn(II) complex deviate significantly from the ideal 
value of 90° or 180° (characteristic of a regular octahedron). Consequently, the 
ligands fold around the metal ion using cis conformation of the Cl anions and 
allowing the N triazoles to from an equatorial plane with the Cl anions (angles 
between N8eq–Mn–C1eq and N8ieq–Mn–C1ieq are 88.30(8)° and 155.71(8)°, 
respectively). Completing the remaining sites on the manganese atom are the N atoms 
of the pyridyl moieties.  
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Figure 7.25: A labelled molecular structure diagram of [Mn(L3)2Cl2] with 
displacement thermal ellipsoids drawn at 50% probability. 
 
The bite angle between N8–Mn–N1 is 71.90(10)°. Furthermore, the angle between 
Cl1–Mn1–Cl1 is 108.66(6)°, slightly higher thanthe angles for the Mn(II) complex 
having cis chloride atoms [48]. The bond lengths of the terminal chloro groups, Mn–
Cl1 and Mn–Cl1i, are 2.4544(11)Å and 2.4543(11)Å, respectively [49]. The bond 
lengths of N8–N9, N9–N10 and N8–C7 of the 1,2,3-triazole segment are 1.305(4)Å, 
1.358(4) and 1.365(5)Å, respectively. These distance values are similar to the 
distances for the free ligand. The Mn–NPY and Mn–NTA bond lengths of 2.330(3)Å 
and .324(3)Å are fairly standard [50-52].  The metal-triazole bond length is slightly 
shorter than the metal pyridine bond (by approximately 0.006Å), and similar 
reasoning to that mentioned in section 7.2.10.2.2 can be used to explain it [32, 35].  
The angles between the pyridine plane and the triazole ring and between the triazole 
plane and the substituted phenyl ring are 115.4(3)° and 120.5(3)°, respectively.  The 
dihedral angle between the plane of the pyridyl moiety and the mean plane of the 
triazole ring is 5.4(5)°.  Furthermore, the dihedral angle between the plane of methoxy 
phenyl group and the plane of the triazole moiety is tilted by 38.6(5)°.  
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Figure 7.26: The overlap between the phenyl rings showing intermolecular π…π 
stacking and C–H…Cl hydrogen bonding interactions.  
 
The overlap of the whole structure of molecules in the crystal shows weak (π…π) 
interactions causing stacking of the molecules, as shown in Figure 7.26. This resulted 
in an offest-slipped parallel alignment, which is stabilised by phenyl-phenyl 
π…πinteractions between the (C12C13C14C15C16C17) and the (C12C13C14C15C16C17) 
phenyl rings. The overlap shows the centroid – centroid distance is 3.985Å, while the 
centroid – plane perpendicular distance is 3.680Å.  On the other hand the chelated 
(trizole) segment, which does not take part in the π…π interactions, is involved in a 
(D–H...A) interaction.  
 
There are no classic hydrogen bonds, but there are intermolecular interactions of the 
type D–H...A, which include C–H...Cl, C–H...O and C–H...N hydrogen bonds (see 
Figure 7.27). Distances and angles are listed in Table 7.15. The C–H...Cl hydrogen 
bonds can be described as [CH3] C3-H3...O1, [C–H18] C18–H18A...Cl1, [C–H11] 
C11–H11...Cl1, [C–H4] C4–H4...N9 and [C–H5] C5–H5A...Cl1, according to 
Brammer et al [53]. Such < M–Cl…H angles prefer values ranging from 90° to 130° 
[53, 54]. It is observed < M–Cl…H angles listed in Table 7.15 and in all the cases of 
intermolecular hydrogen bonds, most of the intermolecular hydrogen bonds fit this 
rule.  
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Table 7.15: Hydrogen bonding interactions parameters; D= donor and A= 
acceptor (Å, °) in the complex [Mn(L3)2Cl2]. 
 
D–H...A D–H H–A D–A Angle 
C3–H3...O1 0.950(4) 2.510(3) 3.540 (8) 159.0(2) 
C18–H18A...Cl1 0.981(4) 2.882(9) 3.700(4) 141.4(2) 
C5–H5...Cl1 0.950(3) 2.685(1) 3.620 (4) 168.3(2) 
C4–H4... N9 0.949(4) 2.947(3) 3.787(8) 128.3(2) 
C11–H11... Cl1 0.950(4) 2.599(8) 3.490(1) 156.2(4) 
Mn–Cl...H5    96.75(4) 
Mn–Cl...H11    115.89(4) 
Mn–Cl...H18A    91.59(3) 
 
In the crystal the molecules are arranged in infinite hydrogen-bonded 3D 
supramolecular chains along the b-axis direction, and within the chains are weak 
intermolecular π…π interactions and C–H...Cl hydrogen bonding interactions [55]. 
 
 
 
Figure 7.27: A 3D supramolecular sheet in [Mn(L3)2Cl2] showing intermolecular 
hydrogen bonding interactions C–H...Cl and (π…π) stacking interactions. The 
complex is viewed along the crystallographic b-axis. 
 181 
 
7.2.10.3 Single-crystal structure determinations of the metal complexes of [M:L 1:1] 
obtained from [M:L 1:2] complexes 
Crystals of the complexes [Cu(L3)Cl2]n, and [Cd(L
3)Cl2]n were obtained by slow 
evaporation of a hot mixture of CH3OH: CH3CN in a 1:1 ratio solution under ambient 
conditions. The [Cu(L3)Cl2]n crystallised in the orthorhombic Pbcn space group 
(according to Table 7.9 ) which indicates eight molecules per unit cell as Z = 8 of the 
[Cu(L3)Cl2]n complex. The [Cu(L
3)Cl2]n complex adopted a distorted trigonal 
bipyramidal geometry with a coordination number of five around the metal atom. The 
[Cd(L3)Cl2]n crystallised in the monoclinic Pb/caspace group, (see table 7.9) which 
indicates four molecules per unit cell as Z = 4 of the [Cd(L3)Cl2]n complex. The latter 
adopted a distorted octahedral geometry with a coordination number of six around the 
metal atom. The crystal structural data are listed in Tables 7.9, 7.10, 7.11 and 7.13 
and presented in Figures 7.28 and 7.31. These crystals were obtained from 
recrystallised complexes having a molar ratio of [M:L = 1:2]. The two complex 
formulas both adopted a one – dimensional infinite polymeric chain. 
7.2.10.3.1 X-ray crystal structure of a one-dimensional infinite polymeric chains of 
(µ--chlorido)-(2-(1-(4-methoxyphenyl)-1H-1,2,3-triazol-4-yl)pyridinecupper(II) 
dichloride complex C42H36Cl6Cu3N12O3 
 
The crystallographic data of the complex is given in Table 7.9; selected bond lengths, 
bond angles and torsion angles are provided in Tables 7.10, 7.11 and 7.13.  
 
 
 
 
 
 
 
 
 
Figure 7.28: Molecular structure of the monomeric [Cu(L2)Cl2] with 
displacement thermal ellipsoids drawn at 50% probability level and H atoms are 
shown as small spheres of arbitrary size.Solventmolecules have been omitted for 
clarity. 
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The copper centre in the complex [Cu(L3)Cl2]n is in a distorted trigonal bipyramidal 
coordination environment which includes the N8TA and N1PY atoms from one ligand 
L3 in the equatorial plane Figure 7.28. The axial positions are taken up by the bridging 
chlorine atoms Cl2 and the terminal free chlorine atoms Cl1 appeared upward and 
downward from each other. The X-ray crystal structure analysis of the Cu-complex 
reveals the formation of an infinite 1D chain link coordination polymer. A perspective 
view of the title compound showing the numbering scheme is given in Figure 7.29. 
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Figure 7.29: Perspective view of the one-dimensional infinite polymeric chain structure of the [Cu(L3)Cl2]n complex linked by Cl2. The 
Cu−Cu distance in the one dinuclear core is 4.070Å. The Cu(II) complex is viewed along the crystallographic b-axis. 
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The geometry around the copper(II) ion can be described as highly distorted square 
pyramidal geometry, with the basal plane formed by two nitrogen atoms (N1 and N8) 
of the ligand and two chloride atoms Cl1 and Cl2. The Cu–N1 distances are 
2.064(8)A˚ and Cu–N8 2.046(8)A˚ respectively and the Cu–Cl distances are (Cu–Cl1) 
2.240(3)A˚ and Cu–Cl2 2.295(3)A˚. The apical position is occupied by a symmetry-
related image of Cl2iat a distance of Cu–Cl2i 2.629(3)A˚ from the copper ion. The 
N1–Cu– Cl1 angle of the base plane is 174.6(2)° with N8–Cu– Cl2 155.3(2)°. The 
distortion of the five-coordinate sphere can be described by the trigonality parameter 
τ, which is defined as: (φ1 – φ2)/60 where φ1 and φ2 are the two largest L-Cu-L angles 
of the coordination sphere. The calculated τ for the Cu(II) ion site is 0.321, which 
confirms the tetragonal pyramidal character [56]. The difference in the Cu-Cl bond 
lengths, at the apical position which is considerable, is clearly related to the Jahn–
Teller distortion. The angle between the pyridine plane and the triazole ring is only 
113.9(8)°. The twisting angle between the triazole plane and the substituted phenyl 
ring is 118.5(9)°. The phenyl ring of the triazole ligand is twisted from the 
neighbouring triazole ring with the dihedral angle of 38.8(13)°, while the pyridine 
ring twisted from the neighbouring triazole ring has a dihedral angle of 3.5(12)°. Upon 
complexation, the resulting zig-zag chain of Cu1 and Cl2 is the backbone of a 
polynuclear array running parallel to the crystallographic b-axis. 
 
The angle between Cu1Cl2Cu1ii is 111.75o, and the array is stabilised by π…π 
stacking of the triazole ring containing N8 on a symmetry-related image of the ring 
containing N1 (see Figure 7.30). The Cu–Cl2–Cu bridge is formed by the atoms Cu, 
Cl2, Cl2i and Cuii. The Cu–Cl distances in the bridging unit are 2.295(3) and 
2.629(3)Å, and shows a symmetrical bridging of high degree compared to the present 
complex. The Cu(− Cl2)Cu core has each Cu(II) atom bond to a bridging chloride 
( − Cl2) (Figure 7.30). The bond length of Cu−Cl2 = 2.295(3)Å  is longer than that 
for Cu−Cl1 (by approximately 0.055Å) at Cu−Cl1 = 2.240(3)Å. The bond length of 
Cu−Cl2i = 2.629(3)Å is longer thanCu−Cl2 (by approximately 0.334Å). The local 
arrangement for each copper indicates a tetragonal pyramidal geometry τ for the 
Cu(II) ion of 0.321. The equatorial plane is formed by one bidentate triazole ligand, a 
bridging chloride, and a terminal chloride. The Cu−Cu distance in each dinuclear 
Cu(II) core is 4.070(1)Å. 
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It was reported that a Cu(II) complex similar to this polymeric chain has a five and 
six coordinate environment around the Cu(II) which leads to a distorted square 
pyramidal symmetry [57, 58]. The packing diagram and hydrogen bonding 
interactions were analysed by Mercury software. The packing and hydrogen bonding 
interactions are viewed along b-axis and are shown in Figure 7.30 B. The crystal 
structure can be described as an infinite chain that develop in a zigzag pattern along 
the b-axis via weak hydrogen bonds of type C3–H3...O1, C–H...O1 and C–H...Cl. 
These chains are interconnected, through hydrogen bonds via C–H...O and C–H...Cl. 
The complex displayed no classic strong hydrogen bonds of a D–H...A type (Table 
7.16) [38]. 
 
Table 7.16: Hydrogen bonding parameters; D= donor and A= acceptor (Å, °) in 
the complex [Cu(L3)Cl2]n chain. 
D–H...A D–H H–A D–A Angle 
C3–H3...O1 0.93 (1) 2.541(8) 3.27 (1) 135.4(6) 
C13–H13...O1 0.96 (1) 2.554(7) 3.45 (1) 161.9(6) 
 
The triazole ring C11–H(11)–Cl2 displayed an interaction with Cl2. The hydrogen 
bonding distances and angles are (D–H…A), (D–H) C11–H11= 0.929(9), (H–A) 
H11–Cl2= 2.880 and (D–A) C11–Cl2= 3.458Å, respectively. Table 7.17 and Figure 
7.30 B show that they are very similar to the bond lengths and angles for C–H...Cl 
which have been published recently [1]. These types of hydrogen bonding triazole C–
H...Cl– have been reported previously in literature [53, 59-61]. 
 
Table 7.17: Hydrogen bonding parameters; D= donor and A= acceptor (Å, °) in 
the complex [Cu(L3)Cl2]n chain. 
D–H...A D–H H–A D–A Angle 
C11–H11...Cl2 0.929(9) 2880(2) 3.46 (1) 149.3(6) 
C11–H11...Cl2i 0.929(9) 2.626(2) 3.46 (1) 149.3(6) 
C2–H2...Cl2 0.93(1) 2.719(2) 3.24 (1) 116.5(6) 
C6–N1...Cl2i 1.37(1) 3.110(7) 4.389(9) 154.2(6) 
C6–N1...Cl2 1.37(1) 3.210(7) 4.037(8) 154.2(6) 
C5–H5...Cl1 0.929(9) 2.855(3) 3.55 (1) 132.9(2) 
C18–H18...Cl1 0.96(1) 2.774(3) 3.71(1) 165.9(7) 
C11–H11...Cl2i 0.929(9) 2.880(2) 3.45(1) 121.2(6) 
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In addition to these hydrogen bond interactions, stacking molecules adopt a face-to-
face parallel alignment due to (π…π) weak interactions. The value between the 
pyridine - triazole, centroid (N1C2C3C4C5C6) pyridine ring and the centroid of the (N8 
N9C7C4N10C11) triazole ring of the adjacent molecule, is 3.495 [1], and the centroid–
plane perpendicular distance is 3.280Å (Table 7.18, Figure 7.30A). The angle between 
the two planes is 6.00°.  
 
Table 7.18: The π…π stacking interactions in the molecular structure of the 1D 
[Cu(L3)Cl2]n chain. 
 
Ring( triz) → Ring( py) 
of centroid 
Distance of centroid 
(tri) from ring (py) (Å) 
Centriods-plane 
perpendicular distances (Å) 
Ring(PY)→ Ring(TA) 3.647 3.280 
Ring(PY)→ Ring(TA) 3.900 3.280 
Ring(TA)→ Ring(PY) 3.628 3.466 
Ring(PY)→ Ring(TA) 3.495 3.458 
 
The molecular structure of the complex [Cu(L3)Cl2]n is stabilised by non-standard 
weak hydrogen bonds, via C–H...Cl and C–H...O1 atoms with intermolecular 
hydrogen bonds and π … π stacking interactions. 
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                                   (A)                                                                                           (B) 
Figure 7.30: Molecular structure of 1D chain [Cu(L3)Cl2]n ; (A)-showing the overlap layer of the complex arranged about a connected 
centre of symmetry. (B)- Schematic representation of the crystal structure showing the hydrogen bonding interactions (in blue line) via 
C–H...Cl and C–H...O1 atoms. The Cu(II) complex is viewed along the crystallographic b-axis. 
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7.2.10.3.2 X-ray crystal structure of a one-dimensional infinite polymeric chains of 
(µ--chlorido)-(2-(1-(4-methoxyphenyl)-1H-1,2,3-triazol-4-yl)pyridinecadmium(II) 
dichloride complex C42H36Cl6Cd3N12O3 
Crystallographic details of the complex are given in Table 7.9. Selected bond lengths, 
torsion angles and bond angles are provided in Tables 7.10, 7.11 and 7.13. 
 
 
 
 
 
 
 
 
Figure 7.31: Molecular structure diagram of the monomeric [Cd(L2)Cl2]. 
Displacement thermal ellipsoids are drawn at 50% probability level and H 
atoms are shown as small spheres of arbitrary size. Solventmolecules have been 
omitted for clarity. 
 
The bond length in Cd1−N1PY is 2.359(17)Å.  However this bond length is slightly 
longer than those that were observed for the ligand complex bridges from mercapto-
triazole ligands that have recently been published in literature and are around 
2.319(4)Å [62]. The Cd–NPY bond distances are similar to the literature reports for 
the [Cd3(pybta)4I6]n complex of 2.356(4)Å [63]. The bond length of Cd1−N8(NTA) is 
2.391(3)Å, this is among the shortest reported yet. In a synthesis and structural study 
of divalent Cu, Zn, Cd and Pd complexes with 1,2,3-triazole-based chalcogen ligands, 
the reported bond length was 2.249(3)Å [64], and for cadmium complexes bearing 
1,2,3-triazole ligands, including [(CdCl2)2(1,2-bis(benzotriazole)ethane)2] it ranged 
from 2.320 to2.328Å [65].The complex displays a 1D stranded chain structure 
consisting of tri nuclear [Cd(PYTA)Cl2]3 subunits. Within each tri nuclear subunit, 
three cadmium atoms are linked by one (PYTA) ligand and four chlorido ligands to 
form the basal plane in a zigzag conformation to complete the geometry around the 
metal and form an infinite 1D chain-like coordination polymer. Along the b-axis 
direction, each Cd(1) centre is double bridged by one pair of (PYTA) ligands and four 
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chlorido ligands. The (PYTA) molecule exhibits distorted conformation and the 
molecules are wrapped around the metal centre and are held together by Cd(1) atoms 
forming a one dimensional stranded chain structure as depicted Figure 7.32. 
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Figure 7.32: Perspective view of the one dimensional infinite polymeric chain structure of the [Cd(L3)Cl2]n complex linked by Cl2. The 
Cd−Cd distance in one dinuclear core is 3.875Å. The Cd(II) complex is viewed along the crystallographic b-axis. 
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The complex [Cd(L3)Cl2]n is in a distorted octahedral coordination environment, 
which includes the N8-triazole and pyridyl N1 atoms from one  ligand L3 in the 
equatorial plane, which participate with two chloride ions Cl1 and Cl2 in the bonding 
process. The angles between N8eqCd1Cl2eq and N1eqCd1Cl1eq are 94.7(4)° and 
94.5(4)°, respectively.  The axial positions of the Cd(II) centre are occupied by two 
bridging chloride atoms that are trans to each other [Cd1Cl1i= 2.667(6)Å, Cd1Cl2ii 
= 2.702(6)Å]. These distances are longer than that of non-bridged Cd-Cl bonds (by 
approximately 0.104 and 0.160Å respectively). The angle between the 
Cl1iexCd1Cl2iiex is 174.35(18)°, a value which is similar to one observed 
previously for a triazole-bridged cadmium coordination polymer [64-65]. The 
chloride bonds Cd−Cl1=2.563(5)Å and Cd−Cl2=2.542(6)Å are comparable to Cd-Cl 
bonds that was reported previously for a di- µ-dichlorido bridged cadmium(II) [67, 
68] (Figure 7.33). The bond angles of N8eqCd1Cl2eq and N1eqCd1Cl1eq are 
94.7(4)° and 94.5(4)°, respectively and angle between the Cl1iax-Cd1-Cl1iiax is 
174.35(18)°, suggesting a distorted octahedral geometry in the complex.   
The twisted angles of two chloride groups are 103.30(18)° of Cl2-Cd1-Cl1 and 
98.46(19)° of Cl2−Cd1−Cl2ii, respectively. The Cd−Cd distance in each dinuclear 
Cd(II) core is 3.875Å. There is an interesting change in the distance of the bond length 
for the C7–C11 triazole ring, and it appears that in the Cd(II) complex it is slightly 
longer than in the free ligand (by approximately 0.028Å). The values of C7–C11 in 
the triazole ring for the Cd(II) complex and the L3 are 1.39(3) and 1.362(6)Å, 
respectively. These changes confirm the complexation between the metal and the 
ligand. In the Cd(II) complex, the metal-triazole bond length is slightly longer than 
the metal pyridine bond i.e. Cd–N8 = 2.391(19) and Cd–N1 = 2.359(17)Å, 
respectively (a change of approximately 0.032Å).  These bonds are longer in the 
Cd(II) complex compared to others previously reported for the Cu(pyta) and the 
Pd(pyta) complexes [35, 38, 69-71]. From the experimental results it can be deduced 
that the N8 atom of the 1,2,3-triazole group is a more effective donor to coordinate 
with the metal than the N9 atom, due to its much higher electron density [72-73].  
In the complex the length of the Cd(1)-N(1) bond is 2.359(17)Å, which is 
approximately is 0.032Å shorter than the Cd(1)-N(8) bond of 2.391(18)Å. This also 
confirms that the N8 atom has a stronger coordinating ability than the N9 atom. The 
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chelating N1–M–N8 bite angle is 70.0(6)° which is similar in the complex compared 
the same angle in the polymeric Cd(II) complex (see Table 7.11). After complexation 
the pyridine ring is twisted with respect to the triazole ring, and the twisting angle is 
equal to 114.0(19)°. The twisting angle between the triazole plane and the substituted 
phenyl ring is 119.4(17)°, whereas, the plane of the pyridine ring exhibits a dihedral 
angle of 10(3)° with the mean plane of the triazole ring.   
In contrast, the dihedral angle between the triazole plane and the aromatic group plane 
is 11(3)°. The crystal structure of the complex shows an extensive chain that develops 
in a zigzag pattern along the b-axis via weak hydrogen bonds of the type D–H...A, 
through the C–H...O and C–H...Cl.  The relevant distances and angles are summarised 
in Table 7.19 and Figure 7.33B. Non-classic strong hydrogen bonds of the (D–H...A) 
type are observed and the value in the molecular structure of [Cd(L3)Cl2]n for the C–
H...O distances are C-H = 0.9500 Å, H...O = 2.60(2)Å and C14–O18 = 3.51(3)Å with 
an angle of 161(2)° for C14–H14...O18. These values are smaller than those 
previously reported for hydrogen bonds interactions [74, 75]. 
Moreover, as a result of these hydrogen bond interactions, weak interactions π…π 
type stacking interactions in the complex is observed. The distance between the 
centroid (N1, C2, C3, C4, C5, C6) pyridine ring and the centroid-centroid of (C12, C13, 
C14, C15, C16, C17) of the adjacent molecule is 3.666Å [22]. The centroid-plane 
perpendicular distance is 3.398-3.413Å (see Figure 7.33A). The angle between the 
two planes is 6.00°. 
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Table 7.19: Hydrogen bonding parameters (Å, °); D= donor and A= acceptor in 
the complex [Cd(L3)Cl2]n chain. 
D–H...A D–H H–A D–A Angle 
C4–H4...Cl1 0.9500(2) 2.845(5) 3.470 (2) 125.0(1) 
C5–H5...Cl1 0.9500(2) 2.892(5) 3.480 (2) 121.0(1) 
C11–H11...Cl2 0.9500(2) 2.677(6) 3.530 (2) 150.0(1) 
C17–H17...Cl2 0.9500(3) 2.824(5) 3.760(3) 168.0(1) 
Cd–H4...Cl1    135.6(2) 
Cd–H5...Cl1    94.2(2) 
Cd–H11...Cl2    122.5(2) 
Cd–H17...Cl2    149.1(2) 
CS–H1S...N9 0.9900(7) 2.590(2) 3.160(7) 117.0(4) 
CS–H1S... Cl2 0.9900(7) 2.885(5) 3.400(7) 113.0(4) 
C13–H13...O1S 0.9500(3) 2.560(5) 3.460(6) 158.0(2) 
 
Where: CS, H1S and O1S are referred to the molecules of solvent CH3OH  
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Figure 7.33: Partial view of the molecular structure of the 1D chain [Cd(L3)Cl2]n ; (A): showing the overlap between the phenyl 
rings as a result of intermolecular π…π stacking interaction. (B): Schematic representation of the crystal structure showing the 
hydrogen bonding interactions (in blue lines) via C–H...Cl and C–H...O1 atoms. The Cd(II) complex is viewed along the 
crystallographic b-axis.
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7.2.10.4 The effect of the nature of the 1,2,3-triazole substituent ligands in the 
crystal structure of the various Cu(II) complexes 
X-ray single-crystal diffraction analysis was used to determine the molecular 
structures of the complexes formed with ligands L2, L6, L7, L8 and L9 and are depicted 
in Figures 7.34 and 7.37. It shows perspective views of the structure of the copper(II) 
complexes formed with bidentate ligands and two chloride ions as a coligands. The 
single crystals of the complexes [Cu(L2)2Cl2], [Cu(L
6)2Cl2], [Cu(L
7)2Cl2], 
[Cu(L8)2Cl2] and [Cu(L
9)2Cl2], were grown by slow evaporation of methanol or 
methanol/acetonitrile in a ratio of 1:2 solvents. Unit cell data collection and structure 
refinement details are provided in Table 7.21 and selected bond lengths, angles and 
torsion angles are listed in Table 7.22, 7.23 and 7.24. Both the complexes [Cu(L2)2Cl2] 
and [Cu(L8)2Cl2] crystallised in the monoclinic space group P21/c.  
 
The complexes [Cu(L6)2Cl2] and [Cu(L
9)2Cl2] crystallised in an orthorhombic space 
groups of Pccn and Pca21, respectively. The complex [Cu(L7)2Cl2] crystallised in 
triclinic space group P-1. In all the Cu(II) complexes, the copper ion adopt the usual 
distorted octahedral coordination geometry with bond lengths and angles within the 
typical range found for copper complexes based on bidentate 2-pyridyl-1,2,3-triazole 
derivatives.  
 
The structures are very similar to the one that was reported for the [Cu(pyta)2Cl2] 
complex [2]. The copper(II) ion in the centre of complexes displays a Jahn - Teller 
distorted octahedral coordination, which includes two of the 2-pyridyl-1,2,3-triazole 
derivatives (L2= CH3, L
6= Cl, L7= CN, L8= H and L9= CF3ligand substituents) 
coordinated to the copper atom, through the N-triazole and N-pyridyl atoms from two 
different ligands which are lying in the equatorial plane mutually trans to each other. 
Furthermore, the axial positions are occupied by two chloride ions that are also trans 
to each other.  
 
The angles in the plane containing the two ligands deviate from 90° because of the 
chelating nature of the ligands. However, the 180o angles are intact in the case of the 
complexes [Cu(L2)2Cl2], [Cu(L
6)2Cl2] and [Cu(L
8)2Cl2], while this angle is distorted 
in the [Cu(L7)2Cl2] and [Cu(L
9)2Cl2] complexes. The pyridine and the chloride donor 
unite to adopt a square planar array around the Cu(II) ion. This angle ranges between 
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90.47(9)°-88.0(2)° see Table 7.23. The triazole rings and pyridine are coordinated to 
the copper core, leading to neutral mononuclear complexes. The most significant bond 
lengths of the C=C triazole and N=N inside the 1,2,3-triazole ring for each complex 
are changeable and depend on the electron donating or electron withdrawing nature 
of the substituent on the phenyl group. Interestingly, these substituents on the phenyl 
ring, if attached to a PYTA ligand does not affect the geometry of structures around 
the Cu(II) (see Figures 7.34 and 7.37). The [Cu(L2)2Cl2] complex is selected as an 
example to discuss its X-ray crystallography. 
 
7.2.10.4.1 The X-ray crystallography of di-chloro-bis (2-(1-(p-tolyl)-1H-1,2,3-
triazol-4-yl)pyridinecopper(II) 
 
X-ray crystallography was used to determine the molecular structure of the complex. 
Figure 7.34 shows a perspective view of the structure of the copper(II) complex 
formed with bidentate ligands and two chloride ions as co-ligands. Single crystals of 
the complex [Cu(L2)2Cl2] were grown from CH3OH.Crystallographic data are 
presented in Table 7.21 indicates two molecules per unit cell as Z = 2 of complex and 
selected bond lengths, angles and torsion angles are listed in Table 7.22, 7.23 and 
7.24. It crystallises in a monoclinic space group P21/c. The copper ion adopt the usual 
distorted octahedral coordination geometry with bond lengths and angles within the 
typical range found for copper complexes based on bidentate 2-pyridyl-1,2,3-triazole 
derivatives. This structure is very similar to that reported for a related [Cu(pyta)2Cl2] 
complex [2]. 
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Figure 7.34: Labelled Ortep plot of the [Cu(L2)2Cl2].  The thermal ellipsoids are 
drawn at 50% probability level and H atoms are shown as small arbitrary 
spheres. 
 
The copper(II) ion centre in the complex displays a Jahn - Teller distorted octahedral 
coordination. It includes two L2 ligands, where L2= bis(2-(1-(p-tolyl)-1H-1,2,3-
triazol-4-yl)pyridine, coordinated to the copper atom, through the NTA and NPY atoms 
from two different ligands which are lying in the equatorial plane and are mutually 
trans to each other. The angles for N4eq–Cu–N4ieq and N1eq–Cu–N1ieq are 180.0(19)° 
and 180.0(1)°, while the angles between N1eqCuN4eq and N1ieqCuN4ieq are 
similar to each other at 78.06(12)°. In addition, the axial positions are located by two 
chloride ions that are trans to each other at an angle of Cl1exCuCl1iex= 180.0°. The 
angles in the plane containing the two ligands deviate from 90° because of the 
chelating nature of the ligands. The 180o angles are intact in the case of the 
[Cu(L2)2Cl2] complex. The planar bidentate sites of the L
2 ligands constitute a square 
planar array around the Cu(II) ion - centred octahedron see the angles in Table 7.23. 
The chelating N1–Cu–N8 bite angle at 78.06(12)o is found to be lower than that 
reported for analogous structures around the metal centre [1, 2, 69-71].  
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The most significant result in the Cu(II) examples, is that the metal-triazole bond 
length is shorter than the metal pyridine bond: (by approximately 0.436Å) Cu-NTA = 
1.992(3)Å and Cu-NPY = 2.428(3)Å. This is due to of the greater trans influence of 
the triazole nitrogen versus the pyridyl nitrogen [32], which is evidence for the 
stronger electron donating properties of the 1,2,3-triazole ring compared to the 
pyridine ring, as was observed previously [33-35]. The bond lengths of both 
monodentate chloride ions show that CuCl1 is 2.3394(10)Å, similar to one that was 
observed and reported previously in literature [33]. The angle between Cl1Cu1Cl1i 
is 180.0o. The dihedral angle between the pyridine plane and the mean of the triazole 
ring is 1.3(6)°, while the 4-substituted aromatic group exhibits a dihedral angle of 
0.2(7)° with the mean plane of the triazole ring [32].  The angle between the pyridine 
plane and the triazole ring is 116.8(3)o, while the angle between the triazole plane and 
the substituted phenyl ring is 121.8(3)o.   
 
X-ray crystallography of the [Cu(L2)2Cl2] complex established that the crystal 
structures are governed by extensive hydrogen bonding C–H...Cl interactions which 
between the chloride ligands that are bound to the copper centres and the C–H group 
(see Figure 7.35). The molecules involved both of (1)- the C–H (C7–H7) atoms of the 
triazole ring, (2)- the C–H (C4–H4) atoms of the pyridine ring, (3)- the C–H (C9–
H9), (4)- C–H (C14–H14) atoms as a donor, while the acceptors for the hydrogen 
bonds are the Cl- ions and the chloride ligand bonded to C–H group of the 
neighbouring molecule (the next molecule in the same layer) in the crystal structure 
of the [Cu(L2)2Cl2] complex. The second chloride ligand forms hydrogen bonds to 
these C–H groups of the next layer. Relevant distances and angles are listed in Table 
7.20. These hydrogen - bonded chains are linked with the chains from the next layer 
by C–H...Cl hydrogen bonds as shown in Figure 7.35.  
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                      Figure 7.35: A 3D supramolecular sheet in [Cu(L2)2Cl2] complex showing intermolecular hydrogen bonding interactions. 
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In these C–H...Cl contacts the distances between the proton and the acceptor atoms 
are longer than the sum of their van der Waals radius (2.75Å), but the C–H...Cl 
linkages of the triazole rings displayed shorter distances than the sum of their van der 
Waals radius (2.75Å) [42-43]. The molecules of the [Cu(L2)2Cl2] are arranged in 
infinite hydrogen-bonded chains with (C–H...Cl) distances in the molecules of 
[Cu(L2)2Cl2] adopting a head-to-tail orientation as shown in Figure 7.35. 
 
Table 7.20: Hydrogen bonding parameters; D= donor and A= acceptor (Å) in 
the complex [Cu(L2)Cl2].  
D–H...A D–H H–A D–A Angle( ͦ) 
C7–H7...Cl1 0.950(4) 2.430(9) 3.373(4) 172.3(2) 
C4–H4...Cl1 0.950(4) 2.925(2) 3.864(4) 169.8(2) 
C9–H9...Cl1 0.950(4) 2.850(9) 3.794(4) 172.2(2) 
C14–H14...Cl1 0.980(5) 2.884(9) 3.675(5) 138.3(3) 
Cu–Cl–H7    107.03(4) 
Cu– Cl –H4    98.55(3) 
Cu– Cl –H9    105.23(4) 
Cu– Cl –H14    102.02(4) 
 
This generates a 3D supramolecular sheet, which form an infinite chain in the solid 
state, which are governed by hydrogen bonding. The complex is stabilised by 
hydrogen bonding interactions and intermolecular π…π stacking between the triazole 
and pyridyl rings in the solid state. Similar head to tail arrangements have been 
reported in the literature recently for Ni(II) and Pd(II) complexes with pyridyl-triazole 
ligands [19, 32]. 
 
The overlap between a triazole and -phenyl of the neighbouring adjacent molecules 
adoptan offset-slipped parallel displacedversion. Thegeometry is stabilised by 
triazole-phenyl interactions, where the centroid-centroid distance is 4.105Å. This 
distance is comparable to the previously reported bond separation of a typical π…π 
stacking [44-47]. The centroid - plane perpendicular distance is 3.508Å and the angle 
between the two planes is 10.83o (see Figure 7.36).  
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Figure 7.36: A pair of complexes arranged about a centre of symmetry. Dashed 
lines indicate intermolecular hydrogen bonds between C–H...Cl atoms and the 
π…π stacking interactions. The complex is viewed along the crystallographic b-
axis of the molecules of the [Cu(L2)2Cl2] complex. 
 
Figure 7.37: A labelled ellipsoids diagram of [Cu(L6)2Cl2], [Cu(L7)2Cl2] 
[Cu(L8)2Cl2] and [Cu(L9)2Cl2] complexes. The thermal ellipsoids are drawn at a 
50% probability level and H atoms are shown as small spheres of arbitrary size.  
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                    Table 7.21: Crystallographic data of Cu(II) with L2, L6, L7, L8 and L9 ligands. 
Complex [Cu(L2)2Cl2] [Cu(L6)2Cl2] [Cu(L7)2Cl2 [Cu(L8)2Cl2] [Cu(L9)2Cl2] 
Formula C28H24Cl2CuN8 C26H18Cl4Cu1N8 C28H20Cl2CuN10O C26H20Cl2CuN8 C28H18Cl2CuN8F6 
Mr 606.99 647.84          646.98 578.94 714.94 
Temp/K 120(2)K 100 K 100(2) K 293(2) K 100(2) K 
Wavelength Å 0.71073 0.71075 0.71075 0.71075 0.68890 
Cryst. syst. Monoclinic Orthorhombic triclinic Monoclinic Orthorhombic 
Space group P21/c Pccn          P1  P21/c Pca21 
a/Å 11.3032(7) 12.5664(12) 11.2493(8) 10.4068(7) 9.544(11) 
b/Å 12.7346(8) 25.691(3) 11.5300(8) 12.7681(6) 12.724(14) 
c/Å 9.8024(5) 9.7169(9) 12.0137(8) 9.4738(5) 22.54(3) 
α/° 90.00 90.00 110.065(8)° 90.00 90.00 
β/° 108.759(4)° 90.00 99.450(7)° 107.058(8) 90.00 
γ/° 90.00 90.00 105.122(7)° 90.00 90.00 
V/Å3 1336.02(14) 3137.0(6) 1356.5(3) 1203.45(12) 2738(5) 
Z 2 4 2 2 4 
Rint 0.0586 0.0950 0.081 0.0351 0.1333 
Dcalcd/g cm-3 1.509 1.372 1.584 1.598 1.735 
 
Refln (all/ind) 
12104/ 
3036 
7213/ 
2863 
16775/ 
16760 
6760/ 
2718 
17238/ 
4620 
μ/mm-1 1.052 1.066 1.047 1.164 1.072 
R1/wR2 
(obsd data: F2>2σ(F2))a 
0.0637/ 
0.1140 
0.0879/ 
0.2132 
0.0778/ 
0.1875 
0.0378/ 
0.0801 
0.1135/ 
0.2970 
R1/wR2 (all data)a 0.0958/ 
0.1300 
0.1882/ 
0.2614 
0.1350/ 
         0.2192 
0.0513/ 
0.0878 
0.1266/ 
0.3128 
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                 Table 7.22: Selected bond lengths (Å) of Cu(II) with in L2, L6, L7, L8 and L9 ligands 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bond distance(Å) [Cu(L2)2Cl2] [Cu(L8)2Cl2] [Cu(L6)2Cl2] [Cu(L7)2Cl2 [Cu(L9)2Cl2] 
 C28H24Cl2CuN8 C26H20Cl2CuN8 C26H18Cl4Cu1N8 C28H20Cl2CuN10O C28H18Cl2CuN8F6 
C7C11 1.367(6) 1.371(3) 1.363(10) 1.378(8) 1.393(16) 
N8N9 1.312(5) 1.308(3) 1.299(9) 1.338(7) 1.295(12) 
N9N10 1.358(5) 1.354(3) 1.361(9) 1.350(7) 1.349(13) 
N8C7 1.356(5) 1.362(3) 1.360(9) 1.357(7) 1.371(15) 
N1C6 1.344(5) 1.356(3) 1.363(10) 1.347(8) 1.286(15) 
MN(PY) 1 1.992(3) 1.997 (18) 2.010(6) 2.045(5) 1.976(10) 
MN(PY)  1i 1.992(3) 1.9970(18) 2.010(6) 2.051(5) 1.938(10) 
MN(triazole)1 2.428(3) 2.3724(19) 2.130(7) 2.051(5) 2.363(9) 
MN(triazole)1i 2.428(3) 2.3724(19) 2.130(7) 2.047(5) 2.381(9) 
MCl1 2.3394(10) 2.3711(6) 2.565(2) 2.8024(19) 2.563(5) 
MCl1i 2.3394 (10) 2.3710(6) 2.565(2) 2.5922(18) 2.667(6) 
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                      Table 7.23: Selected angles [°] of Cu(II) with L2, L6, L7, L8 and L9 ligands 
 
Bonds [Cu(L2)2Cl2] [Cu(L6)2 Cl2] [Cu(L7)2Cl2] [Cu(L8)2Cl2] [Cu(L9)2Cl2] 
N(PY) 1 MN (PY) 1i 180.000(1)    180.0 177.8(2) 180.00(2) 179.2(5) 
N (triazole) 1i MN (triazole) 1 180.00(19) 180.0(2) 92.42(14) 180.00(8) 178.7(4) 
N(PY) 1MN (triazole) 1i 101.94(12) 99.8(3) 92.57(15) 101.89(7) 103.8(4) 
N(PY) 1 MN (triazole) 1 78.06(12) 80.2(3) 176.80(6) 78.11(7) 77.4(3) 
N(PY) 1M Cl 1 90.47(9) 89.50(19) 84.52(14) 89.01(6) 88.0(2) 
N(PY) 1i M Cl 1 89.53(9) 90.50(19) 91.77(15) 90.99(6) 92.0(3) 
N (triazole) 1i M Cl 1 88.44(10) 88.28(5) 91.77(15) 88.28(5) 89.7(3) 
N (triazole) 1M Cl 1 91.56(10) 92.11(18) 86.01(15) 91.72(5) 90.1(3) 
Cl 1 i M Cl 1         180.0         180.0 80.24(19) 179.999(10) 179.03(13) 
N(PY) 1 MCl2 89.53(9) 90.50(19) 99.60(19) 90.99(6) 91.4(2) 
N (triazole) 1 MCl2 88.44(10) 87.89(18)        176.1(2) 88.28(5) 90.6(3) 
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                        Table 7.24: Torsion angles [°] of the Cu and complexes with L2, L6, L7, L8 and L9 ligands 
 
Bonds [Cu(L2)2(Cl)2] [Cu(L6)2(Cl)2] [Cu(L7)2(Cl)2] [Cu(L8)2(Cl)2] [Cu(L9)2(Cl)2] 
Cu1N1C6C7  1.3(5) 2.3(9) 1.6(7) 1.3(3) 0.0(12) 
Cu1N8N9N10 177.5(4) 172.8(6) 178.0(4) 169.6(2) 170.5(10) 
Cu1N8C7C6 0.6(4) 6.2(8) 2.6(7) 6.4(3) 4.7(12) 
N8N9N10C12 178.2(4) 177.9(7) 177.7(5) 179.2(2) 177.4(9) 
C7N8N9N10 0.6(5) 0.0(8) 0.8(7) 0.2(4) 2.7(12) 
N9N10C12C17 0.2(7) 177.8(7) 8.3(9) 178.1(2) 173.5(10) 
N1C6C7N8 -1.3(6)            2.9(10)  0.7(9) 4.3(3) -3.9(15) 
N8N9N10C12 178.2(4) 1.0(8) 177.7(5) 179.2(2) 177.4(9) 
N8N9N10C11 0.5(5) 177.9(7) 0.1(7) 0.0(3) 2.7(12) 
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The plot in Figure 7.38 shows a concave downwards deviation (ignoring one point 
involving Cl), with a positive slope for the electron donating groups. This indicates 
that increased electron density results in the C7-C11 triazole bond length becoming 
shorter and enhancing the double bond character of the bond. Electron withdrawing 
groups with a negative slope reduce the double bond character of the C7-C11 triazole 
bond and causing it to become longer. A concave downwards deviation in the 
Hammett plot as depicted in Figure 7.38 is characteristic [25]. The plot displayed the 
relationship between the bond lengthsC7-C11 in A˚ for the triazole carbon against the 
Hammett σρ substituent constant of the Cu(II) complexes with L2, L6, L7, L8 and L9 
ligands. This means that the X-ray structures can be used as a sensitive probe for the 
electron density on the metal centre [25].  
 
 
Figure 7.38: A plot of bond lengthsC7-C11 in A˚ for the triazole carbon against 
the Hammett σρ substituent constant of Cu(II) complexes with L2, L6, L7, L8 and 
L9 ligands. 
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7.3. General Experimental Procedures and Characterisation of Dichloro 
bis 1H-1,2,3-triazol metal complexes 
7.3.1 Synthesis and characterisation of the metal complexes with ligand L2 
 
7.3.1.1 Synthesis and characterisation of Dichloro(bis{2-[1-(4-methylphenyl)-1H-
1,2,3-triazol-4-yl-kN3]pyridine-kN})manganese(II) 
The [Mn(L2)2Cl2] complex, was prepared by stirring a solution of anhydrous MnCl2 
(0.041g, 0.32mmol) in CH3OH (10ml). Asolution of the ligand L
2 (0.15g, 0.65mmol, 
2eq) in CH2Cl2 (10ml), was added dropswise to it. A resulting pale yellow precipitate 
was obtained after stirring for 8-10h at RT. The solvent was then reduced in volume 
by a half under vacuum distillation before it was filtered and washed twice with cold 
methanol and then diethyl ether. A pale yellow solid, was obtained and isolated to 
yield a precipitate that give (0.195g, 0.32mmol, yielded 80%), mp. 324-326°C. IR: 
ῡ(cm-1): 3068, 3055, 3022, 1606, 1595, 1575, 1521, 1473, 1446, 1253, 1253, 1062, 
1044, 1011, 1000, 979, 861, 812, 784, 719. UV-Vis (DMSO) λmax: The Mn(II) 
complex showed absorption bands at 257nm, εmax = 88450dm3mol-1cm-1, 287nm, εmax 
= 40200dm3mol-1cm-1, 682nm, εmax = 13dm3mol-1cm-1. The complex with L2 showed 
a value of µeff = 5.62 B.M. HRMS TOF (ESI+) (water: acetonitrile = 1:3) withthe 
highest molecular weight ion peak matching, was observed atm/z = 562.1202 (80%) 
and is related to [M-Cl]+. The calculated value for [C28H24ClMnN8]
+ is 562.1193. ɅM 
(DMSO) = 50Ω-1cm2mol-1. 
7.3.1.2 Synthesis and characterisation of Dichloro(bis{2-[1-(4-methylphenyl)-1H-
1,2,3-triazol-4-yl-kN3]pyridine-kN})iron(II) 
For the preparation of [Fe(L2)2Cl2], the method used was analogous to that for 
[Mn(L2)2Cl2]. An amount of 0.041g, 0.32mmol of anhydrous FeCl2 and 0.15g, 
0.65mmol of L2 were used, and an identical work-up procedure gave the required 
compound as a bright yellow solid. The isolated precipitate gave (0.20g, 0.33mmol, 
yield 83%), mp. 310-312 °C. IR: ῡ(cm-1); 3063, 3047, 3025, 1605, 1595, 1571, 1522, 
1473, 1448, 1267, 1258, 1063, 1054, 1015, 1004, 886, 815, 786, 553. UV-Vis 
(DMSO) λmax: The Fe(II) complex showed absorption bands at259nm, εmax = 65500 
dm3mol-1cm-1, 287nm, εmax = 52000dm3mol-1cm-1, 326nm, εmax = 4783dm3mol-1cm-1, 
908nm, εmax = 85dm3mol-1cm-1. The complex with L2 showed a value of µeff = 5.26 
B.M. HRMS TOF (ESI+) (water: acetonitrile = 1:3) with the highest molecular weight 
ion peak matching, was observed at m/z = 563.1135 (80%) and is attributed to [M-
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Cl]+. The calculated value for [(C28H24N8MnCl)]
+ is 563.1162. ɅM (DMSO) = 43Ω-
1cm2 mol-1. 
7.3.1.3 Synthesis and characterisation of Dichloro(bis{2-[1-(4-methylphenyl)-1H-
1,2,3-triazol-4-yl-kN3]pyridine-kN})cobalt(II) 
For the preparation of [Co(L2)2Cl2], the method used was analogous to that for 
[Mn(L2)2Cl2]. An amount of 0.060g, 0.25mmol of CoCl2.6H2O and 0.11g, 0.50mmol 
of L2 were used, and an identical work-up procedure gave the required compound as 
a bright pink solid. The isolated precipitate gave (0.11g, 0.18mmol, yield 73%), mp. 
346-348°C. IR: ῡ(cm-1); 3045, 3024, 1609, 1595, 1574, 1521, 1475, 1450, 1262, 1245, 
1065, 1056, 1018, 1005, 871, 814, 786, 755. UV-Vis (DMSO): The Co (II) complex 
showed absorption bands at 252nm, εmax = 45200dm3mol-1cm-1, 257nm, εmax = 
77100dm3mol-1cm-1, 287nm, εmax = 26967dm3mol-1cm-1, 615nm, εmax = 56dm3mol-
1cm-1, 678nm, εmax = 89 dm3mol-1cm-1.  The complex with L2 showed a value of µeff 
= 3.00 B.M. HRMS TOF (MALDI) with the highest molecular weight ion peak 
matching, was observed at m/z = 566.1 (100%) and is related to [M-Cl]+. The 
calculated value for [(C28H24N8FeCl)]
+ is 566.1. ɅM (DMSO) λmax = 48Ω-1cm2mol-1. 
7.3.1.4 Synthesis and characterisation of Dichloro(bis{2-[1-(4-methylphenyl)-1H-
1,2,3-triazol-4-yl-kN3]pyridine-kN})nickel(II) 
For the preparation of [Ni(L2)2Cl2], the method used was as described for 
[Mn(L2)2Cl2]. An amount of 0.050 g, 0.25 mmol of NiCl2.6H2O and 0.10 g, 0.42mmol 
of L2 were used, and an identical work-up procedure gave the required compound as 
a pale blue solid. The isolated precipitate gave (0.11g, 0.18mmol, yield 73%), mp. 
340°C (decomp.). IR: ῡ(cm-1); 3038, 3021, 3010, 1612, 1596, 1577, 1521, 1476, 
1451, 1264, 1247, 1067, 1058, 1007, 874, 813, 786, 756, 720. UV- Vis (DMSO) λmax:  
The Ni (II) complex showed absorption bands at 257nm, εmax = 102150dm3mol-1cm-
1, 285nm, εmax = 42300dm3mol-1cm-1, 408nm, εmax = 18dm3mol-1cm-1, 668nm, εmax = 
9dm3mol-1cm-1. Thecomplex with L2 showed a value of µeff = 3.00 B.M. HRMS TOF 
(ESI+) (water: acetonitrile = 1:3) withthe highest molecular weight ion peak 
matching, was observed at m/z = 565.1167 (40%) and is related to [M-Cl]+. The 
calculated value for [(C28H24N8NiCl)]
+ is 565.1166. A good single crystal for X-ray 
structural analysis was obtained by slow evaporation of a hot DMSO: CH3CN = 1:9 
solution of the complex. ɅM (DMSO) = 45Ω-1cm2mol-1. 
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7.3.1.5 Synthesis and characterisation of Dichloro(bis{2-[1-(4-methylphenyl)-1H-
1,2,3-triazol-4-yl-kN3]pyridine-kN})copper(II) 
For the preparation of [Cu(L2)2Cl2], the method used was similar to that for 
[Mn(L2)2Cl2]. An amount of 0.062g, 0.46mmol of anhydrous CuCl2 and 0.21g, 
0.92mmol of L2 were used, and an identical work-up procedure gave the required 
compound as a pale green solid. The isolated precipitate gave (0.24g, 0.39mmol, yield 
91%), mp. 274-276°C.  IR: ῡ(cm-1); 3068, 3058, 3025, 1606, 1594, 1575, 1516, 1477, 
1449, 1267, 1250, 1063, 1042, 1029, 862, 817, 779, 754, 716. UV-Vis (DMSO) λmax: 
The Cu (II) complex showed absorption bands at 257nm, εmax = 52222 dm3mol-1cm-
1, 286nm, εmax = 35556dm3mol-1cm-1, 908nm, εmax = 85dm3mol-1cm-1. The complex 
with L2 showed a value of µeff = 1.70 B.M. HRMS (P+NSI); (CH3OH)/(NH4OAC) 
withthe highest molecular weight ion peak matching, was observed at m/z = 594.1547 
(45%) and is attributed to [(Cu(L2)2)
+ + (CH3COO
-)]+. The calculated value for 
[C28H24CuN8]
+ +(CH3COO
-)]+ is 594.1540.A good single crystal for X-ray structural 
analysis was obtained by slow evaporation of a hot CH3OH solution of the complex.  
ɅM (DMSO) = 31Ω-1cm2mol-1. 
7.3.1.6 Synthesis and characterisation of Dichloro(bis{2-[1-(4-methylphenyl)-1H-
1,2,3-triazol-4-yl-kN3]pyridine-kN})zinc(II) 
For the preparation of [Zn(L2)2Cl2], the method used was as described for that of the 
[Mn(L2)2Cl2]. An amount of anhydrous ZnCl2 of 0.19g, 0.80 mmol and 0.19g, 
0.80mmol of L2 were used, and an identical work-up procedure gave the required 
compound as a white solid. The isolated precipitate gave (0.18g, 0.39mmol, yield 
78%), mp. 318-320°C. IR: ῡ(cm-1); 3064, 3041, 3021, 1607, 1570, 1517, 1475, 1448, 
1270, 1239, 1073, 1057, 1075, 1006, 864, 812, 774, 754, 718. UV-Vis (DMSO) λmax: 
The Zn (II) complex showed absorption bands at 258nm, εmax = 47931dm3mol-1cm-1, 
288nm, εmax = 31379dm3mol-1cm-1. 1HNMR data δH/ppm (400MHZ, DMSO-d6): 9.23 
(1H, s, H8), 8.66-8.65 (1H,d, JHH = 4.12Hz, H14), 8.11-8.09 (1H, dd, 
1JHH = 7.79Hz, 
2JHH = 0.92Hz, H11), 7.97-7.92 (1H, dt, 
1JHH = 7.79 Hz, 
2JHH = 1.83Hz, H12), 7.89-7.87 
(2H, d, JHH = 8.24Hz, Ar-H2,6), 7.43-7.38 (3H, m, H13 and Ar-H3,5), 3.22 
(3H,s,CH3,H7); 
13CNMR (100.63MHZ, D6MSO-d6) δC/ppm: 20.49 (C7), 119.83 (C11), 
120.09 (C2, C6), 121.13 (C8), 123.25 (C13), 130.14 (C3, C5), 134.26 (C4), 137.31 (C12), 
138.49 (C1), 148.80 (C9), 149.33 (C14), 149.54 (C10). These assignments were 
confirmed using DEPT 13C (135°), 1H-1H COSY and 1H-13CHMQC two dimensional 
correlation spectroscopy. HRMS TOF (ESI+) (water: acetonitrile = 1:3) with the 
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highest molecular weight ion peak matching, was at m/z = 571.1129 (80%) and is 
related to [M-Cl]+. The calculated value for [(C28H24N8ZnCl)]
+ is 571.1104. A good 
single crystal for X-ray structural analysis was obtained by slow evaporation of a hot 
CH3OH solution of the complex. ɅM (DMSO) = 8 Ω-1cm2mol-1. 
7.3.1.7 Synthesis and characterisation of Dichloro(bis{2-[1-(4-methylphenyl)-1H-
1,2,3-triazol-4-yl-kN3]pyridine-kN})cadmium(II) 
For the preparation of [Cd(L2)2Cl2], the method used was as described for that of the 
[Mn(L2)2Cl2]. An amount of anhydrous CdCl2 of 0.15 g, 0.65 mmol and 0.15g, 
0.65mmol of L2 were used, and an identical work-up procedure gave the required 
compound as a white solid, and the isolated precipitate gave (0.18g, 0.27mmol, yield 
78%), mp. 306-308°C. IR: ῡ(cm-1); 3102, 1627, 1607, 1572, 1521, 1469, 1449, 1264, 
1239, 1062, 1015, 1004, 815, 781, 749, 720. UV-Vis (DMSO) λmax: The Cd (II) 
complex showed absorption bands at 256nm, ε max = 33448 dm3mol-1cm-1, 260nm, ε 
max = 31724dm
3mol-1cm-1, 287nm, εmax = 29655dm3mol-1cm-1. 1HNMR data δH/ppm 
(400MHZ, DMSO-d6): 9.26 (1H, s, H8), 8.66-8.67 (1H, d, JHH = 4.12Hz, H14), 8.11-
8.10 (1H, dd, 1JHH = 7.73Hz, H11), 7.98-7.95 (1H, dt, 
1JHH = 7.79Hz, 
2JHH = 1.83Hz, 
H12), 7.89-7.87 (2H, d, JHH = 8.24Hz, Ar-H2,6), 7.43-7.41 (3H, m, H13 and Ar-H3,5), 
3.23 (3H, s, CH3); 
13CNMR (100.63MHZ, D6MSO-d6) δC/ppm: 20.50 (C7),119.98 
(C11), 120.12 (C2, C6), 121.27 (C8), 123.39 (C13), 130.17 (C3, C5), 134.23 (C4), 137.52 
(C12), 138.58 (C1), 148.47 (C9), 148.97 (C14), 149.50 (C10). These assignments were 
confirmed using DEPT 13C (135°), 1H-1H COSY and 1H-13C HMQC two dimensional 
correlation spectroscopy. HRMS TOF (ESI+) (water: acetonitrile = 1:3) withthe 
highest molecular weight ion peak matching, was observed atm/z = 621.0856 (100%) 
and is assigned to [M-Cl]+ The calculated value for [(C28H24N8CdCl)]
+ is 621.0846. 
ɅM (DMSO) = 16 Ω-1cm2mol-1. 
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7.3.2 Synthesis and characterisation of the metals complexes with ligand L3 
 
7.3.2.1 Synthesis and characterisation of Dichloro(bis{2-[1-(4-methoxyphenyl)-1H-
1,2,3-triazol-4-yl-kN3]pyridine-kN})Manganese(II) 
For the preparation of [Mn(L3)2Cl2], the method used was similar to that for 
[Mn(L2)2Cl2]. An amount of anhydrous MnCl2 of 0.14g, 0.55mmol and 0.14g, 
0.55mmol of L3 were used, and an identical work-up procedure gave the required 
compound as a pale yellow solid. The isolated precipitate gave (0.14g, 0.22mmol, 
yield 82%), mp. 310-312°C. IR: ῡ(cm-1): 3049, 3025, 2966, 2873, 1604, 1569, 1518, 
1471, 1452, 1259, 1203, 1174, 1117, 1066, 1055, 1017, 1001, 980, 864, 827, 786, 
751, 718. UV-Vis (DMSO) λmax: The Mn(II) complex showed absorption bands at 
258nm, εmax = 17780dm3mol-1cm-1, 291nm, εmax = 19480dm3mol-1cm-1, 352nm, εmax 
= 32 dm3mol-1cm-1, 369nm, εmax = 30dm3mol-1cm-1, 390nm, εmax = 21dm3mol-1cm-1. 
The complex with L3 showed a value of µeff = 5.32 B.M. HRMS TOF (ESI+) (water: 
acetonitrile = 1:3) withthe highest molecular weight ion peak matching, was observed 
at m/z = 594.1069 (90%) and is attributed to [M-Cl]+. The calculated value for 
[(C28H24ClMnN8O2)]
+ is 594.1091. A good single crystal for X-ray structural analysis 
was obtained by slow evaporation of a hot methanol solution of the complex. ɅM 
(DMSO) = 52Ω-1cm2mol-1. 
 
7.3.2.2 Synthesis and characterisation of Dichloro(bis{2-[1-(4-methoxyphenyl)-1H-
1,2,3-triazol-4-yl-kN3]pyridine-kN})iron(II) 
For the preparation of [Fe(L3)2Cl2], the method used was similar to that for 
[Mn(L2)2Cl2]. An amount of anhydrous FeCl2 of 0.167g, 0.63mmol and 0.040g, 0.31 
mmol of L3 were used, and an identical work-up procedure gave the required 
compound as a pale yellow solid.  The isolated precipitate gave (0.167g, 0.46mmol, 
yield 83%), mp. 308-310°C; IR: ῡ(cm-1); 3054, 3032, 3012, 2965, 2865, 2838, 1606, 
1571, 1518, 1469, 1448, 1289, 1261, 1182, 1065, 1055, 1017, 1002, 979, 858, 825, 
786, 719. UV-Vis (DMSO) λmax: The Fe(II) complex showed absorption bands at 
256nm, εmax = 35500dm3mol-1cm-1, 291nm, εmax = 17500dm3mol-1cm-1, 333nm, εmax 
= 3810dm3mol-1cm-1, 922nm, εmax = 65dm3mol-1cm-1. The complex with L3 showed a 
value of µeff = 5.07 B.M. HRMS TOF (ESI+) (water: acetonitrile = 1:3) with the 
highest molecular weight ion peak matching, was observed at m/z = 595.1055 (88%) 
and is attributed to [M-Cl]+. The calculated value for [(C28H24ClFeN8O2)]
+ is 
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595.1060. A good single crystal for X-ray structural analysis was obtained by slow 
evaporation of a hot DMSO:CH3CN = 1:9 solution of the complex. ɅM(DMSO) = 
54Ω-1cm2mol-1. 
7.3.2.3 Synthesis and characterisation of Dichloro(bis{2-[1-(4-methoxyphenyl)-1H-
1,2,3-triazol-4-yl-kN3]pyridine-kN})cobalt(II) 
For the preparation of [Co(L3)2Cl2], the method used was similar to that for 
[Mn(L2)2Cl2]. An amount of CoCl2.6H2O 0.045g, 0.16 mmol and 0.071g, 0.32mmol 
of L3 were used, and an identical work-up procedure gave the required compound as 
a pale pink solid, and the isolated precipitate gave (0.091g, 0.14mmol, yield 77%), 
mp. 340°C (decomp.). IR: ῡ(cm-1): 3068, 3052, 3030, 3014, 2966, 2839, 1609, 1597, 
1574, 1518, 1471, 1453, 1320, 1261, 1204, 1175, 1067, 1058, 1019, 1003, 979, 860, 
825, 786, 752, 720. UV-Vis (DMSO) λmax: The Co (II) complex showed absorption 
bands at 257nm, εmax = 26625dm3mol-1cm-1, 292nm, εmax = 11000dm3mol-1cm-1, 
615nm, εmax = 38dm3mol-1cm-1, 677nm, εmax = 61dm3mol-1cm-1. The complex with L3 
showed a value of µeff = 3.97 B.M. HRMS TOF (ESI+) (water: acetonitrile = 1:3) with 
the highest molecular weight ion peak matching, was observed at m/z = 598.1048 
(90%) and correspond to [M-Cl]+. The calculated value for [(C28H24ClCoN8O2)]
+ 
observed 598.1043. A good single crystal for X-ray structural analysis was obtained 
by slow evaporation of a hot DMSO: CH3CN = 1:9 solution of the complex. ɅM 
(DMSO) = 42 Ω-1cm2mol-1. 
7.3.2.4 Synthesis and characterisation of Dichloro(bis{2-[1-(4-methoxyphenyl)-1H-
1,2,3-triazol-4-yl-kN3]pyridine-kN})nickel(II) 
For the preparation of [Ni(L3)2Cl2], the method used was similar to that for 
[Mn(L2)2Cl2]. An amount of NiCl2.6H2O of 0.037g, 0.15mmol and 0.08g, 0.31mmol 
of L3 were used, and an identical work-up procedure gave the required compound as 
a pale blue solid, and the isolated precipitate gave (0.073g, 0.11mmol, yield 74%), 
mp. 345°C (decomp.). IR: ῡ(cm-1); 3073, 3052, 3030, 2985, 2839, 1612, 1597, 1575, 
1519, 1473, 1455, 1322, 1263, 1176, 1070, 1060, 1020, 1005, 980, 862, 825, 787, 
754, 721. UV-Vis (DMSO) λmax: The Ni (II) complex showed absorption bands at 
257nm, εmax= 3602dm3mol-1cm-1, 291nm, εmax= 3653dm3mol-1cm-1, 407nm, εmax= 
61dm3 mol-1cm-1, 660nm, εmax= 43dm3mol-1cm-1. The complex with L3 showed a value 
ofµeff = 2.73 B.M. HRMS TOF (ESI+) (water: acetonitrile = 1:3) with the highest 
molecular weight ion peak matching, was observed at m/z = 597.1086 (80%) and is 
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related to [M-Cl]+. The calculated value for [(C28H24ClNiN8O2)]
+ is 597.1064. A good 
single crystal for X-ray structural analysis was obtained by slow evaporation of a hot 
DMSO: Acetonitrile = 1:9 solution of the complex. ɅM (DMSO) = 54 Ω-1cm2mol-1. 
7.3.2.5 Synthesis and characterisation of Dichloro(bis{2-[1-(4-methoxyphenyl)-1H-
1,2,3-triazol-4-yl-kN3]pyridine-kN})copper(II) 
For the preparation of [Cu(L3)2Cl2], the method used was similar to that for 
[Mn(L2)2Cl2]. An amount of anhydrous CuCl2 of 0.042g, 0.31mmol of and 0.16g, 
0.74mmol of L3 were used, and an identical work-up procedure gave the required 
compound as a pale green solid. The isolated precipitate gave (0.18g, 0.28mmol, yield 
91%), mp. 278-280°C.  IR: ῡ(cm-1); 3126, 3103, 3080, 2962, 2939, 2843, 1618, 1609, 
1596, 1585, 1517, 1465, 1454, 1441, 1317, 1277, 1249, 1184, 1112, 1068, 1026, 1001, 
983, 839, 819, 783, 722: UV-Vis (DMSO) λmax: The Cu (II) complex showed 
absorption bands at 257nm, εmax = 39200dm3mol-1cm-1, 287nm, εmax = 16433dm3mol-
1cm-1, 892nm, εmax = 97dm3mol-1cm-1. The complex with L3 showed a value of µeff = 
1.69 B.M. HRMS TOF (ESI+) (water: acetonitrile = 1:3) with the highest molecular 
weight ion peak matching, was observed at m/z = 602.1007(10%) and is related to 
[M-Cl]+. The calculated value for [(C28H24ClCuN8O2)]
 + is 602.0985. ɅM (DMSO) = 
24Ω-1cm2mol-1. 
7.3.2.6 Synthesis and characterisation of Dichloro(bis{2-[1-(4-methoxyphenyl)-1H-
1,2,3-triazol-4-yl-kN3]pyridine-kN})zinc(II) 
For the preparation of [Zn(L3)2Cl2], the method used was similar to that for 
[Mn(L2)2Cl2]. An amount of anhydrous ZnCl2 of 0.040g, 0.29mmol and 0.15g, 
0.66mmol of L3 were used, and an identical work-up procedure gave the required 
compound as a white solid, with the isolated precipitate that gave (0.14g, 0.21mmol, 
yield 77%), mp. 322-324°C. IR: ῡ(cm-1); 3079, 3014, 2935, 2837, 1610, 1594, 1573, 
1514, 1472, 1456, 1305, 1253, 1204, 1172, 1073, 1058, 1019, 1001, 983, 828, 778, 
720. UV-Vis (DMSO) λmax: The Zn (II) complex showed absorption bands at 258nm, 
εmax = 64267dm3mol-1cm-1, 285nm, εmax = 32033dm3mol-1cm-1. 1HNMR data δH/ppm 
(400MHZ, DMSO-d6): 9.05 (1H, s, H11), 8.63 (1H, d, J= 2.29Hz, H2),  8.09-8.07 (1H, 
d, JHH = 8.24Hz, H5), 7.92-7.90 (1H, d, 
1JHH = 1.37Hz, 
2JHH = 7.79 Hz, H4), 7.89-7.86 
(2H,d, JHH= 8.70Hz, H13,17), 7.37-7.34 (1H, dd, 
1JHH = 5.04Hz, 
2JHH = 6.64 Hz, H3), 
7.15-7.12 (2H,d, JHH= 9.16Hz, H14,16), 3.85 (3H, s, CH3, H19); 
13CNMR (100.63MHZ, 
D6MSO-d6) δC/ppm: 55.69 (C19), 115.02 (C14, C16-Ar), 119.79 (C5), 121.14 (C11), 
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121.99 (C13, C17), 123.03 (C3), 130.16 (C12), 137.05    (C4), 148.06 (C7), 149.56 (C2), 
149.82 (C6), 159.60 (C15). These assignments were confirmed using DEPT 
13C 
(135°),1H-1H COSY and 1H-13C HMQC two dimensional correlation spectroscopy. 
HRMS TOF (ESI+) (water: acetonitrile = 1:3) with the highest molecular weight ion 
peak matching, was observed at m/z = 603.1002 (50%) and is attributed to [M-Cl]+. 
The calculated value for [(C28H24ClZnN8O2)]
+ is 603.1005. A good single crystal for 
X-ray structural analysis was obtained by slow evaporation of a hot CH3OH solution 
of the complex.  ɅM (DMSO) = 12Ω-1cm2mol-1. 
7.3.2.7 Synthesis and characterisation of Dichloro(bis{2-[1-(4-methoxyphenyl)-1H-
1,2,3-triazol-4-yl-kN3]pyridine-kN})cadmium(II) 
For the preparation of [Cd(L3)2Cl2], the method used was similar to that for 
[Mn(L2)2Cl2]. An amount of anhydrous of anhydrous CdCl2 of 0.035g, 0.19mmol and 
0.10g, 0.39mmol of L3 were used, and an identical work-up procedure gave the 
required compound as a white solid. The isolated precipitate gave (0.10g, 0.14mmol, 
yield 80%), mp. 322-324°C. IR: ν (cm-1); 3097, 1631, 1611, 1602, 1572, 1518, 1469, 
1452, 1268, 1204, 1185, 1064, 1030, 1016, 1001, 981, 827, 781, 720. UV-Vis 
(DMSO) λmax: The Cd (II) complex showed absorption bands at 258nm, εmax = 
41933dm3mol-1cm-1, 286nm, εmax = 29167dm3mol-1cm-1. 1HNMR data δH/ppm 
(400MHZ, DMSO-d6): 9.07 (1H, s, H11), 8.64-8.61 (1H,d, JHH = 4.58Hz, H2), 8.09-
8.07 (1H, d, JHH = 7.79Hz, H5), 7.94-7.91 (1H, dd, 
1JHH = 7.79Hz, 
2JHH = 1.83Hz, H4), 
7.90-7.84 (2H, d, JHH = 9.16Hz, Ar-H13,17), 7.38-7.35 (1H, ddd, 
1JHH = 1.37Hz, 
2JHH 
= 4.58Hz, 3JHH = 7.33Hz, H3), 7.16-7.12 (2H, J= 9.16Hz, Ar-H14,16), 3.85 (3H, S, CH3, 
H19); 
13CNMR (100.63MHZ, D6MSO-d6): δC/pmm; 55.69 (C19), 115.03 (C14,C16 -Ar), 
119.85 (C5), 121.20 (C11), 122.00 (C13,C17 -Ar), 123.10 (C3), 130.13 (C12) , 137.16 
(C4), 147.90 (C7), 149.55 (C2), 149.65 (C6), 159.63 (C15). These assignments were 
confirmed using DEPT 13C (135°), 1H-1H COSY and 1H-13C two dimensional 
correlation spectroscopy. HRMS TOF (ESI+) (water: acetonitrile = 1:3) with the 
highest molecular weight ion peak matching, was observed at m/z = 653.0744 (10%) 
and is related to [M-Cl]+. The calculated value for [(C28H24ClCdN8O2)]
+  is  653.0744. 
ɅM (DMSO) = 18Ω-1cm2mol-1. 
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7.3.2.8 Synthesis and characterisation of Dichloro(bis{2-[1-(4-methoxyphenyl)-1H-
1,2,3-triazol-4-yl-kN3]pyridine-kN}) platinum (II) 
For the preparation of [Pt(L3)2Cl2]. To a solution of K2[PtCl4] (0.062g, 0.14mmol) in 
C2H5OH-H2O 8:2 (10mL) was added dropwise to a solution of L
3 (0.085g, 0.33mmol) 
in CH3CN (5mL). The resulting was stirred for 15mint at r.t and then the mixture 
allowed refluxing for 24h. The suspension was allowed to cool to r.t and then solvent 
was then reduced in volume by a half under vacuum distillation and a solid formed 
was filtered and washed twice with cold methanol and then diethyl ether, gave a 
yellow solid. The isolated precipitate gave (0.088g, 0.11mmol, yielded 78%), mp. 
252-254°C. IR: ῡ(cm-1); 3103,3067, 2921, 1616, 1601, 1576, 1511, 1464, 1456, 1257, 
1168, 1110, 1071, 1014, 980, 835, 804,773, 748, 723. 1HNMR data δH/ppm 
(400MHZ, DMSO-d6): 9.80 (1H, s, H11), 9.04-9.02 (1H,d, JHH = 5.04Hz, H2), 8.41-
8.37 (1H, td, 1JHH = 7.79Hz, 
2JHH = 1.73Hz, 
3JHH = 7.79Hz,  H5), 8.20-8.18 (1H, d,JHH 
= 7.73Hz, H4), 7.88-7.86 (2H, d, JHH = 8.70Hz, Ar-H13,17), 7.79-7.75 (1H, td, 
1JHH = 
1.37Hz, 2JHH = 5.95Hz, 
3JHH = 7.33Hz, H3), 7.29-7.25 (2H, J= 9.16Hz, Ar-H14,16), 3.91 
(3H, S, CH3, H19); 
13CNMR (100.63MHZ, D6MSO-d6): δC/pmm; 56.75 (C19), 116.15 
(C14,C16 -Ar), 122.79 (C5), 123.01 (C11), 123.93  (C13,C17 -Ar), 125.13 (C3), 126.75 
(C12) , 129.99 (C4), 142.56 (C7), 149.13 (C2), 150.59 (C6), 161.59 (C15).  These 
assignments were confirmed using DEPT 13C (135°), 1H-1H COSY and 1H-13C two 
dimensional correlation spectroscopy. HRMS TOF (ESI+) (water: acetonitrile = 1:3) 
with the highest molecular weight ion peak matching, was observed atm/z = 725.1413 
(100%) and is assigned to [M-Cl]+ The calculated value for [(C28H24N8PtCl)]
+ is 
725.1437. ɅM (DMSO) = 18 Ω-1cm2mol-1. 
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7.3.3 Synthesis and characterisation of the metals complexes with ligand L4 
 
7.3.3.1 Synthesis and characterisation of Dichloro(bis{4-[4-(pyridin-2-yl-kN)-1H-
1,2,3-triazol-1-yl-kN3]benzoic acid})manganese(II) 
For the prepation of [Mn(L4)2Cl2]. An amount of MnCl2 (0.028g, 0.22mmol) was 
stirred in a solution of anhydrous methanol (10ml). A solution of ligand L4 (0.12g, 
0.45mmol) in DMSO (10ml) was added dropwise to it and the mixture allowed to 
stirred for 15mint at r.t and then the mixture allowed to reflux for 24h while being 
stirred at rt. The solvent was reduced in volume by a half under vacuum distillation 
and crush ice was added to the solution. A resulting pale yellow precipitate was 
obtained and filtered before being washed twice with cold methanol and then diethyl 
ether. A pale yellow solid was isolated. The isolated precipitate gave (0.124g, 
0.18mmol, yield 78%), mp. 306–308°C. IR: ῡ(cm-1); 3436, 3073, 1714, 1673, 1603, 
1560, 1514, 1467, 1449, 1375, 1258, 1154, 1062, 1013, 1003, 979, 868, 783, 706. 
UV-Vis (DMSO) λmax:  The Mn(II) complex showed absorption bands at 258 nm, εmax 
= 117800dm3mol-1cm-1, 290nm, εmax = 68467dm3mol-1cm-1, 352nm, εmax = 1113 
dm3mol-1cm-1, 370nm, εmax = 1581dm3mol-1cm-1, 390 nm, εmax = 1280dm3mol-1cm-1.  
The complex with L4 showed a value of µeff = 5.62 B.M. HRMS TOF (MALDI) 
withthe highest molecular weight ion peak matching, was observed at m/z = 622.1 
(5%) and is assigned to [M-Cl]+. The calculated value for [C28H20N8MnO4Cl]
+ is 
observed and the value is 622.1. ɅM (DMSO) = 50 Ω-1cm2mol-1. 
7.3.3.2 Synthesis and characterisation of Dichloro(bis{4-[4-(pyridin-2-yl-kN)-1H-
1,2,3-triazol-1-yl-kN3]benzoic acid})iron(II) 
For the preparation of [Fe(L4)2Cl2], the method used was similar to that for 
[Mn(L4)2Cl2]. An amount of anhydrous FeCl2 of 0.027g, 0.21mmol and 0.11g, 
0.42mmol of L4 were used, and an identical work-up procedure gave the required 
compound as a pale yellow solid. The isolated precipitate gave (0.096g, 0.14mmol, 
yield 73%), mp. 348-350°C. IR: ῡ(cm-1); 3085, 1724, 1604, 1589, 1514, 1471, 1450, 
1406, 1372, 1254, 1173, 1104, 1055, 1018, 1004, 978, 857, 774. UV-Vis (DMSO) 
λmax: The Fe (II) complex showed absorption bands at 258nm, εmax = 181600dm3mol-
1cm-1, 291nm, εmax = 86500dm3mol-1cm-1, 332nm, εmax = 7053dm3mol-1cm-1. The 
complex with L4 showed a value of µeff = 5.1 B.M. HRMS TOF (MALDI) withthe 
highest molecular weight ion peak matching, was    observed at m/z = 623.1 (100%) 
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and is related to [M-Cl]+. The calculated value for [C28H20N8FeO4Cl]
+ is 623.1. ɅM 
(DMSO) = 34Ω-1cm2mol-1. 
7.3.3.3 Synthesis and characterisation of Dichloro(bis{4-[4-(pyridin-2-yl-kN)-1H-
1,2,3-triazol-1-yl-kN3]benzoic acid})cobalt(II) 
For the preparation of [Co(L4)2Cl2], the method used was analogous to that for 
[Mn(L4)2Cl2]. An amount of CoCl2.6H2O of 0.028g, 0.11mmol and 0.082g, 0.30mmol 
of L4 were used, and an identical work-up procedure gave the required compound as 
a pale pink solid. The isolated precipitate gave (0.071g, 0.10mmol, yield 71%), mp. 
348°C (decomp.). IR: ῡ(cm-1); 3045, 3024, 1609, 1595, 1574, 1521, 1475, 1450, 1262, 
1245, 1065, 1056, 1018, 1005, 871, 814, 786, 755. UV-Vis (DMSO) λmax: The Co(II) 
complex showed absorption bands at 258nm, εmax = 95650 dm3mol-1cm-1, 290nm, εmax 
= 49900dm3mol-1cm-1, 532nm, εmax = 50dm3mol-1cm-1. The complex with L4 showed 
a value ofµeff = 3.68 B.M. HRMS TOF (MALDI) with the highest molecular weight 
ion peak matching, was observed at m/z = 626.1 (5%) and is related to [M-Cl]+. The 
calculated value for [C28H20N8CoO4Cl]
+  is 626.1.  ɅM (DMSO) = 39Ω-1cm2 mol-1. 
7.3.3.4 Synthesis and characterisation of Dichloro(bis{4-[4-(pyridin-2-yl-kN)-1H-
1,2,3-triazol-1-yl-kN3]benzoic acid})nickel(II) 
For the preparation of [Ni(L4)2Cl2], the method used was similar to that for 
[Mn(L4)2Cl2]. An amount of NiCl2.6H2O of 0.030g, 0.12mmol and 0.080g, 0.30mmol 
of L4 were used, and an identical work-up procedure gave the required compound as 
a pale blue solid, with the isolated precipitate giving (0.06g, 0.090mmol, yield 77%), 
mp. 350°C (decmop.). IR: ῡ(cm-1); 3068, 3015, 1722, 1662, 1606, 1575, 1515, 1476, 
1451, 1376, 1260, 1220, 1106, 1065, 1007, 980, 875, 784, 764, 676. UV-Vis (DMSO) 
λmax:  The Ni (II) complex showed absorption bands at 258nm, εmax = 102900dm3mol-
1cm-1, 291nm, εmax = 48500dm3mol-1cm-1, 408nm, εmax = 47dm3mol-1cm-1, 662nm, 
εmax = 20dm3mol-1cm-1. The complex with L4 showed a value ofµeff = 2.68 B.M.   
HRMS TOF (MALDI) withthe highest molecular weight ion peak matching, was 
observed at m/z = 625.1(55%) and is attributed to [M-Cl]+.The calculated value for 
[C28H20N8NiO4Cl]
+ 625.1. A good single crystal for X-ray structural analysis was 
obtained by slow evaporation of hot DMSO: Acetonitrile = 1:9 solution of the 
complex. ɅM (DMSO) = 47Ω-1cm2mol-1. 
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7.3.3.5 Synthesis and characterisation of Dichloro(bis{4-[4-(pyridin-2-yl-kN)-1H-
1,2,3-triazol-1-yl-kN3]benzoic acid})copper(II) 
For the preparation of [Cu(L4)2Cl2], the method used was analogous to that for 
[Mn(L4)2Cl2]. An amount of anhydrousCuCl2 of 0.034g, 0.25mmol and 0.14g, 
0.52mmol of L4 were used, and an identical work-up procedure gave the required 
compound as a green solid. The isolated precipitate gave (0.168g, 0.25mmol, yield 
85%), mp. 315-317°C. IR: ῡ(cm-1): 3068, 3058, 3025, 1606, 1594, 1575, 1516, 1477, 
1449, 1267, 1250, 1063, 1042, 1029, 862, 817, 779, 754, 716. UV-Vis (DMSO) λmax:  
The Cu (II) complex showed absorption bands at 258nm, εmax = 119500dm3mol-1cm-
1, 291nm, εmax = 44000dm3mol-1cm-1, 907nm, εmax = 88dm3mol-1cm-1. The complex 
with L4 showed a value of µeff = 1.69 B.M. HRMS TOF (MALDI) with the highest 
molecular weight ion peak matching, was observed at m/z = 630.1 (12%) and is 
assigned to [M-Cl]+. The calculated value for [C28H20CuO4Cl]
+ is 630.1. ɅM (DMSO) 
= 24Ω-1cm2mol-1. 
7.3.3.6 Synthesis and characterisation of Dichloro(bis{4-[4-(pyridin-2-yl-kN)-1H-
1,2,3-triazol-1-yl-kN3]benzoic acid})zinc(II) 
For the preparation of [Zn(L4)2Cl2], the method used was as described for 
[Mn(L4)2Cl2] An amount of anhydrousZnCl2of 0.075g, 0.55mmol and 0.30g, 
0.11mmol check it of L4 were used, and an identical work-up procedure gave the 
required compound as a white solid, the isolated precipitate gave (0.114g, 0.17mmol, 
yield 74%), mp. 332-334 °C. IR: ῡ(cm-1); 3116, 1699, 1683, 1603, 1572, 1517, 1474, 
1458, 1441, 1302, 1240, 1277, 1163, 1152, 1091, 1038, 1020, 1014, 991, 856, 804, 
785, 770, 692. UV-Vis (DMSO) λmax: The Zn (II) complex showed absorption bands 
at 258nm, εmax = 176000dm3mol-1cm-1, 292nm, εmax = 4600dm3mol-1cm-1. 1HNMR 
data δH/ppm (400MHZ, DMSO-d6): 13.12 (1H, sb, H18), 9.38 (1H, s, H11), 8.67-8.65 
(1H, ddd, 1JHH = 0.92Hz, 
2JHH = 1.83 Hz,
3JHH = 4.58Hz, H2), 8.20-8.11(5H, m, H5, 
Ar-H,13,17,14,16), 7.96-7.92 (1H, dt, 
1JHH = 1.83Hz, 
2JHH = 7.63Hz, H4), 7.42-7.38 (1H, 
ddd, 1JHH = 1.22Hz, 
2JHH = 4.88Hz, 
2JHH = 7.78Hz, H3); 
13CNMR (100.63MHZ, 
D6MSO-d6): δC/pmm: 119.87 (C5), 119.95 (C14,C16), 121.33 (C11), 123.33 (C3), 
130.82 (C15),  130.93 (C13, C17), 137.22 (C4), 139.44 (C12), 148.42 (C7), 149.64 (C2), 
149.31 (C6), 166.23 (C18).These assignments were confirmed using DEPT 
13C (135°), 
1H-1H COSY and 1H-13C HMQC two dimensional correlation spectroscopy. HRMS 
TOF (MALDI) with the highest molecular weight ion peak matching, was observed 
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at m/z = 631.1 (20%) and is assigned to [M-Cl]+. The calculated value for 
[C28H20N8ZnO4Cl]
+ is 631.1. ɅM (DMSO) = 8Ω-1cm2mol-1. 
 
7.3.3.7 Synthesis and characterisation of Dichloro(bis{4-[4-(pyridin-2-yl-kN)-1H-
1,2,3-triazol-1-yl-kN3]benzoic acid})cadmium(II) 
For the preparation of [Cd(L4)2Cl2], the method used was similar to that for 
[Mn(L4)2Cl2]. An amount of anhydrous CdCl2 of 0.035g, 0.19mmol and 0.10g, 
0.38mmol of L4 were used, and an identical work-up procedure gave the required 
compound as a white solid. The isolated precipitate gave (0.099g, 0.16mmol, yield 
85%), mp. 340°C.  IR: ῡ(cm-1); 3142, 3072, 1695, 1604, 1572, 1517, 1473, 1450, 
1271, 1162, 1062, 1093, 1063, 1015, 1007, 992, 857, 783, 771, 693. UV-Vis (DMSO) 
λmax: The Cd (II) complex showed absorption bands at 258nm, εmax = 166667 dm3 
mol-1cm-1, 293nm, εmax = 57333 dm3mol-1cm-1. 1HNMR data δH/ppm (400MHZ, 
DMSO-d6): 12.89 (1H, sb -H18) 9.39 (1H, s, H11), 8. 66 (1H, S, H2), 8.21-8.12 (5H, 
m. H5, Ar-H13,17,14,16), 7.97-7.93 (1H, dt, 
1JHH = 1.46Hz, 
2JHH = 8.05Hz, H4), 7.42-
7.39 (1H, dd, 1JHH = 4.39Hz, 
2JHH = 7.32Hz, H3); 
13CNMR (100.63MHZ, D6MSO-d6) 
δC/pmm: 120.09 (C14, C16,), 120.43(C5), 121.83 (C11), 123.86 (C3), 131.57 (C13, C17), 
135.77 (C15), 137.80 (C4), 138.73 (C12), 148.87(C7), 150.00 (C2), 150.22 (C6), 170.88 
(C18). These assignments were confirmed using DEPT 
13C (135°), 1H-1H COSY and 
1H-13C two dimensional correlation spectroscopy. HRMS TOF (MALDI) with the 
highest molecular weight ion peak matching, was observed atm/z = 681.0 (85%) and 
is assigned to [M-Cl]+. The calculated value for [C28H20CdN8O4Cl]
+ is 681.0.  ɅM 
(DMSO) = 14Ω-1cm2mol-1. 
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7.3.4 Synthesis and characterisation of the metals complexes with ligand L5 
 
7.3.4.1 Synthesis and characterisation of Dichloro (bis{2-[1-(4-fluorophenyl)-1H-
1,2,3-triazol-4-yl-kN3]pyridine-kN})manganese(II) 
For the preparation of [Mn(L5)2Cl2], the method used was similar to that for 
[Mn(L2)2Cl2]. An amount of anhydrous MnCl2 of 0.027g, 0.21mmol and 0.10g, 
0.43mmol of L5, and an identical work-up procedure gave the required compound as 
a pale yellow solid. The isolated precipitate gave (0.10g, 0.158mmol, yield 78%), mp. 
306-308°C. IR: ῡ(cm-1); 3078, 1617, 1606, 1575, 1515, 1469, 1450, 1412, 1322, 1239, 
1058, 1013, 1002, 980, 837, 781, 720. UV-Vis (DMSO) λmax: The Mn(II) complex 
showed absorption bands at 258nm, εmax = 134000dm3mol-1cm-1, 285nm, εmax 
=70000dm3mol-1cm-1, 335nm, εmax = 64dm3mol-1cm-1, 353nm, εmax =38dm3mol-1cm-1, 
560nm, εmax = 6dm3mol-1cm-1. The complex with L5 showed a value of µeff = 5.82 
B.M.  HRMS (P+NSI) withthe highest molecular weight ion peak matching, was 
observed at m/z = 570.0686 (93%) and is attributed to [M-Cl]+. The calculated value 
for [C26H18F2N8MnCl]
+  is 570.0684. ɅM (DMSO) = 52Ω-1cm2mol-1. 
 
7.3.4.2 Synthesis and characterisation of Dichloro(bis{2-[1-(4-fluorophenyl)-1H-
1,2,3-triazol-4-yl-kN3]pyridine-kN})iron(II) 
For the preparation of [Fe(L5)2Cl2], the method used was analoguouse to that for 
[Mn(L2)2Cl2]. An amount of anhydrous FeCl2 of 0.030g, 0.23mmol and 0.11g, 
0.47mmol and of L5 were used, and an identical work-up procedure gave the required 
compound as a pale yellow solid. The isolated precipitate gave (0.10g, 0.16mmol, 
yield 75%), mp. 258-260°C. IR: ῡ(cm-1); 3065, 3041, 3026, 1605, 1578, 1515, 1472, 
1453, 1412, 1333, 1239, 1258, 1159, 1061, 1015, 1005, 979, 837, 788, 718. UV-Vis 
(DMSO) λmax: The Fe(II) complex showed absorption bands at 257nm, εmax = 
69630dm3mol-1cm-1, 286nm, εmax = 3111dm3mol-1cm -1, 329nm, εmax = 3380dm3mol-
1cm-1. The complex with L5 showed a value of µeff = 4.87 B.M. HRMS TOF 
(MALDI)withthe highest molecular weight ion peak matching, was observed at m/z 
= 571.0635 (35%) and is assigned to [M-Cl]+. The calculated value for 
[C26H18F2N8MnCl]
+  is 571.0660.  ɅM (DMSO) = 37Ω-1cm2mol-1. 
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7.3.4.3 Synthesis and characterisation of Dichloro(bis{2-[1-(4-fluorophenyl)-1H-
1,2,3-triazol-4-yl-kN3]pyridine-kN})cobalt(II) 
For the preparation of [Co(L5)2Cl2], the method used was as described for 
[Mn(L2)2Cl2]. An amount of CoCl2.6H2O of 0.035g, 0.15mmol and 0.076g, 0.30mmol 
of L5 were used, and an identical work-up procedure gave the required compound as 
a pale pink solid. The isolated precipitate gave (0.065g, 0.10mmol, yield 73%), mp. 
348-350°C. IR: ῡ(cm-1): 3072, 3041, 3013, 1610, 1585, 1517, 1478, 1455, 1313, 1241, 
1161, 1064, 1056, 1020, 1006, 979, 873, 838, 790, 757, 720. UV-Vis (DMSO) λmax:  
The Co (II) complex showed absorption bands at 258nm, εmax = 67000dm3mol-1cm-1, 
286nm, εmax = 30000dm3mol-1cm-1, 615nm, εmax = 73dm3mol-1cm-1, 678nm, εmax = 
118dm3mol-1cm-1.  The complex with L5 showed a value of µeff = 3.92 B.M. HRMS 
(P+NSI) withthe highest molecular weight ion peak matching, was observed at= 
m/z598.1070 (100%) and is attributed to [M + CH3COO]
+. The calculated value for 
[C26H18F2N8Co + CH3COO]
+  is 598.1082.  ɅM (DMSO) = 54Ω-1cm2mol-1. 
7.3.4.4 Synthesis and characterisation of Dichloro(bis{2-[1-(4-fluorophenyl)-1H-
1,2,3-triazol-4-yl-kN3]pyridine-kN})nickel(II) 
 
For the preparation of [Ni(L5)2Cl2], the method used was as described for 
[Mn(L2)2Cl2]. An amount of NiCl2.6H2O of 0.035g, 0.14mmol and 0.075g, 0.29 mmol 
of L5 were used, and an identical work-up procedure gave the required compound as 
a pale blue solid. The isolated precipitate gave (0.07g, 0.11mmol, yield 75%), mp. 
340°C (decomp.). IR: ῡ(cm-1); 3073, 3053, 3014, 1612, 1577, 1513, 1472, 1458, 1302, 
1264, 1229, 1158, 1069, 1057, 1022, 1007, 982, 835, 788, 752, 722. UV-Vis (DMSO) 
λmax:  The Ni (II) complex showed absorption bands at 258nm, εmax = 52667dm3mol-
1cm-1, 283nm, εmax = 31000dm3mol-1cm-1, 409nm, εmax = 14dm3mol-1cm-1, 670nm, 
εmax = 46dm3mol-1cm-1, 890nm, εmax = 33dm3mol-1cm-1. The complex with L5 were 
used showed a value of µeff = 2.88 B.M. HRMS (P+NSI) withthe highest molecular 
weight ion peak matching, was observed at m/z= 597.1095 (100%) and is assigned to 
[M + CH3COO]
+. The calculated value for [C26H18F2N8Ni + (CH3COO)
-]+  is 
597.1104. ɅM (DMSO) = 58Ω-1cm2mol-1. 
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7.3.4.5 Synthesis and characterisation of Dichloro(bis{2-[1-(4-fluorophenyl)-1H-
1,2,3-triazol-4-yl-kN3]pyridine-kN})copper(II) 
For the preparation of [Cu(L5)2Cl2], the method used was similar to that for 
[Mn(L2)2Cl2]. An amount of anhydrous CuCl2 of 0.030g, 0.22mmol and 0.11g, 
0.44mmol of L5 were used, and an identical work-up procedure gave the required 
compound as a pale green solid. The isolated precipitate gave (0.13g, 0.21mmol, yield 
92%), mp. 240-242°C. IR: ῡ(cm-1); 3060, 3045, 3025, 1617, 1608, 1578, 1517, 1477, 
1454, 1319, 1252, 1064, 1040, 1000, 982, 845, 782, 756, 693. UV-Vis (DMSO) λmax:  
The Cu(II) complex showed absorption bands at 257nm, εmax = 73333dm3mol-1cm-1, 
286nm, εmax = 29000dm3mol-1cm-1, 908nm, εmax = 87 dm3mol-1cm-1. The complex 
with L5 showed a value ofµeff = 1.63 B.M.  HRMS (P+NSI); with the highest 
molecular weight ion peak matching, was observed at m/z= 578.602 (100%) which is 
assigned to [M-Cl]+. The calculated value for [C26H18F2N8CuCl]
+  is 578.602.  ɅM 
(DMSO) = 33Ω-1cm2mo-1. 
 
7.3.4.6 Synthesis and characterisation of Dichloro(bis{2-[1-(4-fluorophenyl)-1H-
1,2,3-triazol-4-yl-kN3]pyridine-kN})zinc(II) 
For the preparation of [Zn(L5)2Cl2], the method used was analogous to that for 
[Mn(L2)2Cl2]. An amount of anhydrous ZnCl2 of 0.036g, 0.26mmol and 0.14g, 
0.55mmol of L5 were used, and an identical work-up procedure gave the required 
compound as a white solid. The isolated precipitate gave (0.14g, 0.22mmol, yield 
77%), mp. 318-320°C. IR: ῡ(cm-1); 3080, 3023, 1614, 1575, 1511, 1472, 1473, 1453, 
1322, 1274, 1239, 1166, 1133, 1057, 1062, 1007, 982, 839, 785, 722, 695. UV-Vis 
(DMSO) λmax: The Zn(II) complex showed absorption bands at 257nm, εmax = 
60333dm3mol-1cm-1, 287nm, εmax = 28333dm3mol-1cm-1. 1HNMR data δH/ppm 
(400MHZ, DMSO-d6): 9.32 (1H, s, H7), 8.66-8.65 (1H, d, JHH = 4.12Hz, H13), 8.12-
8.10 (1H, d, JHH = 7.79Hz, H10), 8.08-8.04 (2H,d, JHH = 9.16Hz, Ar-H2,6), 7.97-7.93 
(1H, dt,1JHH = 7.79Hz,
2JHH= 1.73Hz, H11), 7.51-7.44 (2H,d, JHH = 8.70Hz, Ar-H3,5), 
7.42-7.39 (1H, dd, 1JHH = 6.41Hz,
2JHH = 5.04Hz, H12); 
13CNMR (100.63MHZ, 
D6MSO-d6) δC/pmm: 116.53-116.77, (2JC-F = 23.96Hz, C3, C5, Ar), 119.73 (C10), 
121.47 (C7), 122.44 - 122.52 ( d, J
3
C-F  = 8.63Hz, C2,C6), 123.32 (C12), 133.02 (C1), 
137.31 (C11), 148.06 (C8), 149.27 (C9), 149.56 (C13), 162.88-160.44 (J
1
C-F = 
245.37Hz, C4). These assignments were confirmed using; DEPT 
13C (135°), 1H-1H 
COSY and 1H-13C HMQC two dimensional correlation spectroscopy. HRMS 
(P+NSI); with the highest molecular weight ion peak matching, was observed at = m/z 
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579.0598 (43%) and is related to [M-Cl]+. The calculated value for calculated value 
for [C26H18F2N8ZnCl]
+  is 579.0597.  ɅM (DMSO) = 10Ω-1cm2mol-1. 
7.3.4.7 Synthesis and characterisation of Dichloro(bis{2-[1-(4-fluorophenyl)-1H-
1,2,3-triazol-4-yl-kN3]pyridine-kN})cadmium(II) 
For the preparation of [Cd(L5)2Cl2], the method used was similar to that for 
[Mn(L2)2Cl2]. An amount of anhydrous CdCl2 of 0.036g, 0.17mmol and 0.088g, 0.38 
mmol of L5 were used, and an identical work-up procedure gave the required 
compound as a white solid. The isolated precipitate gave (0.10g, 0.15mmol, yield 
83%), mp. 316-318°C.  IR: ῡ(cm-1); 3103, 1617, 1602, 1574, 1517, 1470, 1452, 1334, 
1248, 1239, 1125, 1075, 1057, 1015, 1004, 983, 824, 780, 749, 720, 695.  UV-Vis 
(DMSO) λmax: The Cd(II) complex showed absorption bands at 258nm, ε max = 
35333dm3mol-1cm-1, 287nm, εmax = 30667dm3mol-1cm-1. 1HNMR data δH/ppm 
(400MHZ, DMSO-d6): 9.27 (1H, s, H7), 8.67-8.65 (1H, ddd, 
1JHH  = 0.92Hz, 
2JHH = 
1.83Hz, 3JHH = 5.50Hz H13), 8.12-8.11 (1H, td, JHH = 7.79Hz, H10), 8.08-8.03 (2H,d = 
JHH = 9.16Hz, Ar-H2,6), 7.97-7.92 (1H, dt, 
1JHH = 7.79Hz, 
2JHH = 1.83Hz, H11), 7.48-
7.44 (2H, d, JHH = 8.70Hz, Ar-H3,5), 7.42-7.39 (1H, ddd, 
1JHH  = 0.92Hz, 
2JHH = 
4.58Hz, 3JHH = 7.79Hz, H12);  
13CNMR (100.63MHZ, D6MSO-d6) δC/pmm: 116.50 - 
116.74, (2JC-F = 23.96Hz, C3, C5, Ar), 119.81 (C10), 121.50 (C7), 122.63- 122.53( d, 
J3C-F = 9.58 Hz, C2,C6), 123.28 (C12), 133.10 (C1), 137.28 (C11), 148.02 (C8), 149.30 
(C13), 149.56 (C9), 162.96-160.51 (J
1
C-F = 246.33Hz, C4). These assignments were 
confirmed using DEPT 13C (135°), 1H-1H COSY and 1H-13C HMQC two dimensional 
correlation spectroscopy.  HRMS (P+NSI) withthe highest molecular weight ion peak 
matching, was observed at m/z =629.0337 (55%) and is attributed to [M-Cl]+. The 
calculated value for [C26H18F2N8CdCl]
+  is 629.0338.  ɅM (DMSO) = 16Ω-1cm2mol-
1. 
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7.3.5 Synthesis and characterisation of  the metals complexes with ligand L6 
 
7.3.5.1 Synthesis and characterisation of Dichloro(bis{2-[1-(4-chlorophenyl)-1H-
1,2,3-triazol-4-yl-kN3]pyridine-kN})manganese(II) 
For the preparation of [Mn(L6)2Cl2], the method used was similar to that for 
[Mn(L2)2Cl2]. An amount of anhydrous MnCl2 of 0.030g, 0.24mmol and (0.12g, 
0.47mmol of L6 were used, and an identical work-up procedure gave the required 
compound as a pale yellow solid. The isolated precipitate gave 0.123g, 0.19mmol, 
yield 81%), mp. 312-314°C.  IR: ῡ(cm-1); 3090, 3055, 1607, 1574, 1518, 1472, 1452, 
1409, 1286, 1259, 1158, 1141, 1062, 1053, 1024, 1007, 978, 856, 845, 825, 782, 718. 
UV-Vis (DMSO) λmax: The Mn (II) complex showed absorption bands at 258nm, εmax 
=46923dm3mol-1cm-1, 289nm, εmax =33846dm3mol-1cm-1, 502nm, εmax =33dm3mol-
1cm-1. The complex with L
6 showed a value of µeff = 5.98 B.M. HRMS TOF (ESI+) 
(water: acetonitrile = 1:3) with the highest molecular weight ion peak matching, was 
observed at m/z = 602.0092 (30%) and is related to [M-Cl]+. The calculated value for 
[C26H18N8MnCl3]
+ is 602.0100.  ɅM (DMSO) = 50Ω-1cm2mol-1.  
 
7.3.5.2 Synthesis and characterisation of Dichloro(bis{2-[1-(4-chlorophenyl)-1H-
1,2,3-triazol-4-yl-kN3]pyridine-kN})iron(II) 
For the preparation of [Fe(L6)2Cl2], the method used was analogous to that for 
[Mn(L2)2Cl2]. An amount of anhydrous FeCl2 of 0.033g, 0.26mmol and 0.13g, 
0.52mmol of L6 were used, and an identical work-up procedure gave the required 
compound as a pale yellow solid. The isolated precipitate gave (0.097g, 0.15mmol, 
yield 79%), mp. 258-260°C. IR: ῡ(cm-1); 3051, 3023, 3005, 1606, 1591, 1570, 1502, 
1472, 1448, 1405, 1267, 1257, 1151, 1134, 1095, 1061, 1052, 1013, 1003, 977, 860, 
825, 808, 789, 711. UV-Vis (DMSO) λmax: The Fe(II) complex showed absorption 
bands at 258nm, εmax = 58571dm3mol-1cm-1, 287nm, εmax = 47143dm3mol-1cm-1, 
332nm, εmax = 4060dm3mol-1cm-1, 386nm, εmax = 2020dm3mol-1cm-1. The complex 
with L6 showed a value of µeff = 5.10 B.M. HRMS (ESI+) (water: acetonitrile = 1:3) 
with the highest molecular weight ion peak matching, was observed at m/z =603.0050 
(75%) and is related to [M-Cl]+. The calculated value for [C26H18N8MnCl3]
+  
is603.0069.  ɅM (DMSO) = 39Ω-1cm2mol-1. 
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7.3.5.3 Synthesis and characterisation of Dichloro(bis{2-[1-(4-chlorophenyl)-1H-
1,2,3-triazol-4-yl-kN3]pyridine-kN})cobalt(II) 
For the preparation of [Co(L6)2Cl2], the method used was similar to that for 
[Mn(L2)2Cl2]. An amount of anhydrous CoCl2.6H2O of 0.040g, 0.16mmol and 0.086g, 
0.33mmol of L6 were used, and an identical work-up procedure gave the required 
compound as a pale pink solid. The isolated precipitate gave (0.084g, 0.13mmol, yield 
78%), mp. 332-334°C. IR: ῡ(cm-1); 3065, 3052, 1606, 1570, 1502, 1472, 1448, 1405, 
1268, 1257, 1151, 1134, 1095, 1061, 1052, 1013, 1003, 977, 825, 789, 756, 711. UV-
Vis (DMSO) λmax: The Co(II) complex showed absorption bands at 257nm, εmax = 
3407dm3mol-1 cm-1, 287nm, εmax = 3550dm3mol-1cm-1, 615nm, εmax = 56dm3mol-1cm-
1, 678nm, εmax = 93dm3mol-1cm-1. The complex with L6 showed a value ofµeff = 4.12 
B.M. HRMS (ESI+) (water: acetonitrile = 1:3) withthe highest molecular weight ion 
peak matching, was at m/z = 606.0030 (100%) and is attributed to [M-Cl]+. The 
calculated value for [C26H18N8CoCl3]
+  is 606.0052. ɅM (DMSO) = 47Ω-1cm2mol-1. 
 
7.3.5.4 Synthesis and characterisation of Dichloro(bis{2-[1-(4-chlorophenyl)-1H-
1,2,3-triazol-4-yl-kN3]pyridine-kN})nickel(II) 
For the preparation of [Ni(L6)2Cl2], the method used was analogous to that for 
[Mn(L2)2Cl2]. An amount of NiCl2.6H2O of 0.031g, 0.13mmol and 0.075g, 0.29mmol 
of L6 were used, and an identical work-up procedure gave the required compound as 
a pale blue solid. The isolated precipitate gave (0.06g, 0.093mmol, yield 72%), mp. 
347°C (decomp.). IR: ῡ(cm-1); 3048, 3010, 1612, 1577, 1502, 1475, 1452, 1408, 1274, 
1262, 1141, 1096, 1064, 1058, 1013, 1022, 1006, 978, 866, 826, 789, 758, 712. UV-
Vis (DMSO) λmax: The Ni(II) complex showed absorption bands at 257nm, εmax = 
63333dm3mol-1cm-1, 287nm, εmax = 41905dm3mol-1cm-1, 408nm, εmax = 15dm3mol-
1cm-1, 670nm, εmax = 44dm3mol-1cm-1. The complex with L6 showed a value of µeff = 
2.73 B.M.  HRMS (ESI+) (water: acetonitrile = 1:3) with the highest molecular weight 
ion peak matching, was observed at m/z = 605.0100 (18%) and is related to [M-Cl]+. 
The calculated value for [C26H18N8NiCl3]
+  is 605.0073. ɅM (DMSO) = 58Ω-1cm2mol-
1. 
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7.3.5.5 Synthesis and characterisation of Dichloro(bis{2-[1-(4-chlorophenyl)-1H-
1,2,3-triazol-4-yl-kN3]pyridine-kN})copper(II) 
For the preparation of [Cu(L6)2Cl2], the method used was as described for 
[Mn(L2)2Cl2]. An amount of anhydrous CuCl2 of 0.03g, 0.24mmol and 0.13g, 
0.50mmol of L6 were used, and an identical work-up procedure gave the required 
compound as a green solid. The isolated precipitate gave (0.135g, 0.20mmol, yield 
89%), mp. 274-276°C. IR: ῡ(cm-1): 3068, 3043, 3022, 1607, 1572, 1501, 1474, 1450, 
1407, 1280, 1250, 1157, 1092, 1064, 1040, 1027, 1013, 998, 861, 824, 779, 781, 711. 
UV-Vis (DMSO) λmax: The Cu(II) complex showed absorption bands at 252nm, εmax 
= 34583dm3mol-1cm-1, 260nm, εmax = 41250dm3mol-1cm-1, 288nm, εmax = 
44167dm3mol-1cm-1, 876nm, εmax = 71dm3mol-1cm-1. The complex with L6 showed a 
value of µeff = 1.70 B.M. HRMS TOF (ESI+) (water: acetonitrile = 1:3) with the 
highest molecular weight ion peak matching, was observed at m/z= 610.0009 (100%) 
and is corresponding to [M-Cl]+. The calculated value for [C26H18N8CuCl3]
+ is 
610.0016. A good single crystal for X-ray structural analysis was obtained by slow 
evaporation of hot methanol: Acetonitrile = 1:1solution of the complex.  ɅM (DMSO) 
= 24Ω-1cm2mol-1. 
7.3.5.6 Synthesis and characterisation of Dichloro(bis{2-[1-(4-chlorophenyl)-1H-
1,2,3-triazol-4-yl-kN3]pyridine-kN})zinc(II) 
For the preparation of [Zn(L6)2Cl2], the method used was similar to that for 
[Mn(L2)2Cl2]. An amount of anhydrous ZnCl2 of 0.033g, 0.24mmol and 0.126g, 
0.49mmol of L6 were used, and an identical work-up procedure gave the required 
compound as a white solid. The isolated precipitate gave (0.122g, 0.18mmol, yield 
78%), mp. 328-330°C.  IR: ῡ(cm-1): 3048, 3024, 3010, 1611, 1593, 1577, 1502, 1474, 
1452, 1407, 1274, 1262, 1140, 1095, 1064, 1058, 1021, 1014, 1006, 978, 865, 825, 
788, 757, 788, 712. UV-Vis (DMSO) λmax: The Zn(II) complex showed absorption 
bands at 258nm, εmax = 53333dm3mol-1cm-1, 286nm, εmax = 44286dm3mol-1cm-1. 
1HNMR data δH/ppm (400MHZ, DMSO-d6): 9.31 (1H, s, H11), 8.65 (1H, ddd, 1JHH = 
0.92Hz, 2JHH = 1.71Hz,
 3JHH = 4.12Hz, H2), 8.12-7.92  (3H, m, H5, Ar-H13,17), 7.97-
7.92 (1H, dt, 1JHH = 1.83Hz,  
2JHH = 7.79Hz, H4), 7.70-7.67 (2H, d, JHH = 9.16Hz, Ar-
H14,16), 7.41-7.38 (1H, ddd,
 1JHH = 0.92Hz, 
2JHH = 1.37Hz,
 3JHH = 7.33Hz, H3); 
13CNMR(100.63MHZ, D6MSO-d6) δC/pmm: 119.71 (C5), 121.20 (C11), 121.88 
(C13,C17-Ar), 123.19 (C3), 129.64 (C14,C16-Ar), 133.01 (C12), 135.23 (C15), 137.13 
(C4), 148.12 (C7), 149.20 (C6), 149.49 (C2). These assignments were confirmed using; 
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DEPT 13C (135°), 1H-1H COSY and 1H-13C HMQC two dimensional correlation 
spectroscopy. HRMS TOF (ESI+) (Water: acetonitrile = 1:3) with the highest 
molecular weight ion peak matching, was observed at m/z = 611.0039 (100%) and is 
related to [M- Cl]+. The calculated value for [C26H18N8CdCl3]
+  is 611.0011.   ɅM 
(DMSO) = 12 Ω-1cm2mol-1. 
7.3.5.7 Synthesis and characterisation of Dichloro(bis{2-[1-(4-chlorophenyl)-1H-
1,2,3-triazol-4-yl-kN3]pyridine-kN})cadmium(II) 
For the preparation of [Cd(L6)2Cl2], the method used was analogous to that for 
[Mn(L2)2Cl2]. An amount of anhydrous CdCl2 of 0.035g, 0.19mmol and 0.11 g, 0.42 
mmol of L6 were used, and an identical work-up procedure gave the required 
compound as a white solid. The isolated precipitate gave (0.11g, 0.15mmol, yield 
83%), mp. 316-318°C. IR: ῡ(cm-1): 3090, 3090, 3052, 1613, 1602, 1570, 1500, 1466, 
1451, 1401, 1283, 1248, 1159, 1134, 1096, 1061, 1012, 1004, 981, 828, 783, 749, 
714. UV-Vis (DMSO) λmax: The Cd(II) complex showed absorption bands at 256nm, 
εmax = 57083dm3mol-1cm-1, 287nm, εmax = 36250dm3mol-1cm-1. 1HNMR data δH/ppm 
(400MHZ, DMSO-d6): 9.33 (1H, s, H11), 8.67-8.66 (1H, ddd,
 1JHH = 0.92Hz,  
2JHH = 
1.71Hz , 3JHH = 4.12Hz, H2), 8.12-8.10  (2H, dd, 
1JHH = 0.92Hz, 
2JHH = 7.79Hz, H5), 
8.08-8.01 (2H, d, JHH = 8.70Hz, Ar-H13,17), 7.98-7.93 (1H, dt, 
1JHH = 1.83Hz, 
2JHH = 
7.79Hz, H4), 7.70-7.67 (2H, d, JHH = 9.16Hz, Ar-H14,16), 7.43-7.40 (1H, ddd,
 1JHH = 
1.37Hz, 2JHH = 4.58Hz,
 3JHH = 7.33Hz, H3); 
13CNMR (100.63MHZ, D6MSO-d6) 
δC/pmm: 119.80 (C5), 121.32 (C11), 121.83 (C13,C17-Ar), 123.28 (C3), 129.66 (C14,C16-
Ar), 133.05 (C12), 135.20 (C15), 137.26 (C4), 147.91 (C7), 149.05 (C6), 149.48 (C2). 
These assignments were confirmed using; DEPT 13C (135°), 1H-1H COSY and 1H-
13C HMQC two dimensional correlation spectroscopy. HRMS TOF (ESI+) (water: 
acetonitrile = 1:3) with the highest molecular weight ion peak matching, was observed 
at m/z = 660.9731; (70%) and is assigned to [M-Cl]+. The calculated value for 
[C26H18N8CdCl3]
+  is 660.9754.  ɅM (DMSO) = 18Ω-1cm2mol-1. 
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7.3.5.8 Synthesis and characterisation of Dichloro(bis{2-[1-(4-chlorophenyl)-1H-
1,2,3-triazol-4-yl-kN3]pyridine-kN})platnium(II) 
For the preparation of [Pt(L6)2Cl2], the method used was similar to that for 
[Pt(L3)2Cl2]. To solution of L
6 (0.060g, 0.23mmol) in CH3CN (5mL) was added 
dropswise a solution of K2[PtCl4] (0.075g, 0.096mmol) in C2H5OH-H2O 8:2 (10mL). 
A yellow solid was isolatedgiving (0.10g, 0.13mmol, yielded 78%), mp. 282-284°C. 
IR: ῡ(cm-1); 3131, 3057, 1614, 1602, 1589, 1570, 1550, 1501, 1473, 1400, 1237, 1146, 
1038, 1012, 997, 990, 823, 780, 740. 1HNMR data δH/ppm (400MHZ, DMSO-d6): 
9.41(1H, s, H11), 8.70-8.69 (1H, d,
 1JHH = 54.58Hz, H2), 8.17-8.15  (1H, dd, 
1JHH = 
8.24Hz, H5), 8.13-8.10 (2H, d, JHH = 8.70Hz, Ar-H13,17), 8.01-7.97 (1H, dt, 
1JHH = 
1.83Hz, 2JHH = 7.79Hz, H4), 7.75-7.72 (2H, d, JHH = 8.70Hz, Ar-H14,16), 7.47-
7.4340.45 (1H, ddd, 1JHH = 0.92Hz, 
2JHH = 5.04Hz,
 3JHH = 7.33Hz, H3); 
13CNMR 
(100.63MHZ, D6MSO-d6) δC/pmm: 119.73 (C5), 121.32 (C11), 121.82 (C13,C17-Ar),  
123.33(C3), 129.76 (C14,C16-Ar), 133.02 (C12), 135.26 (C15), 137.27 (C4), 148.21 (C7), 
149.25 (C6), 149.59 (C2). These assignments were confirmed using; DEPT 
13C (135°), 
1H-1H COSY and 1H-13C HMQC two dimensional correlation spectroscopy. HRMS 
TOF (ESI+) (water: acetonitrile = 1:3) with the highest molecular weight ion peak 
matching, was observed at m/z = 742.0359 (30%) and is assigned to [M-Cl]+. The 
calculated value for [C26H18N8PtCl3]
+  is 742.0368.  ɅM (DMSO) = 8Ω-1cm2mol-1. 
7.3.6 Synthesis and characterisation of the metals complexes with ligand L7 
7.3.6.1 Synthesis and characterisation of Dichloro (bis {4-[4-(pyridin-2-yl-kN)-1H-
1,2,3-triazol-1-yl-kN3]benzonitrile})manganese(II) 
For the preparation of [Mn(L7)2Cl2], the method used was similar to that for 
[Mn(L2)2Cl2]. An amount of anhydrous MnCl2 of 0.032g, 0.25mmol and 0.13g, 
0.52mmol of L7 were used, and an identical work-up procedure gave the required 
compound as a pale yellow solid. The isolated precipitate gave (0.125g, 0.20mmol, 
yield 80%), mp. 318-320°C. IR: ῡ(cm-1); 3070, 3057, 3007, 2233, 1630, 1603, 1590, 
1570, 1518, 1471, 1448, 1409, 1285, 1255, 1158, 1061, 1050, 1016, 1005, 978, 851, 
812, 783, 717. UV-Vis (DMSO) λmax: The Mn(II) complex showed absorption bands 
at 261nm, εmax = 76000dm3mol-1cm-1, 294nm, εmax = 89000dm3mol-1cm-1, 743nm, εmax 
= 4dm
3mol-1cm-1. The complex with L7 showed a value of µeff = 5.78 B.M.  HRMS 
TOF (ESI+) (water: acetonitrile = 1:3) with the highest molecular weight ion peak 
matching, was observed at m/z = 584.0770 (100%) and is attributed to [M-Cl]+. The 
calculated value for [C28H18N10ClMn]
+  is 584.0785. ɅM (DMSO) = 52Ω-1cm2mol-1. 
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7.3.6.2 Synthesis and characterisation of Dichloro(bis{4-[4-(pyridin-2-yl-kN)-1H-
1,2,3-triazol-1-yl-kN3]benzonitrile})iron(II) 
For the preparation of [Fe(L7)2Cl2], the method used was analogous to that for 
[Mn(L2)2 Cl2]. An amount of anhydrous FeCl2 of 0.028g, 0.22mmol and 0.12g, 
0.48mmol of L7 were used, and an identical work-up procedure gave the       required 
compound as a pale yellow solid. The isolated precipitate gave (0.113g, 0.18mmol, 
yield 83%), mp. 308-310°C.  IR: ῡ(cm-1); 3071, 3057, 3025, 3012, 2233, 1604, 1591, 
1572, 1514, 1471, 1451, 1410, 1287, 1258, 1259, 1140, 1061, 1052, 1016, 1006,977, 
846, 787, 717. UV-Vis (DMSO) λmax: The Fe(II) complex showed absorption bands 
at 256nm, εmax = 138750dm3mol-1cm-1, 289nm, εmax = 56250dm3mol-1cm-1, 950nm, 
εmax = 45dm3mol-1cm-1. The complex with L7 showed a value of µeff = 4.26 B.M. 
HRMS TOF (ESI+) (water: acetonitrile = 1:3) with the highest molecular weight ion 
peak matching, was observed at m/z 585.0738 (70%) and is assigned to [M-Cl]+. The 
calculated value for [C28H18N10ClFe]
+ is 585.0754.  ɅM (DMSO) = 39Ω-1cm2mol-1. 
7.3.6.3 Synthesis and characterisation of Dichloro(bis{4-[4-(pyridin-2-yl-kN)-1H-
1,2,3-triazol-1-yl-kN3]benzonitrile})cobalt(II) 
For the preparation of [Co(L7)2Cl2], the method used was as described for 
[Mn(L2)2Cl2]. An amount of 0.042g, 0.17mmol of CoCl2.6H2O and 0.13g, 0.50mmol 
of L7 were used, and an identical work-up procedure gave the required compound as 
a pale pink solid. The isolated precipitate gave (0.081g, 0.12mmol, yield 74%), mp. 
350-352°C. IR: ῡ(cm-1); 3077, 3059, 3041, 3013, 2232, 1630, 1603, 1591, 1575, 1518, 
1472, 1451, 1410, 1286, 1261, 1245, 1144, 1061, 1053, 1018, 1006, 978, 849, 824, 
794, 718. UV-Vis (DMSO) λmax: The Co(II) complex showed absorption bands at 
256nm, εmax = 53750dm3mol-1cm-1, 295nm, εmax = 49375dm3mol-1cm-1, 615nm, εmax 
= 45dm3mol-1cm-1, 677nm, εmax = 97dm3mol-1cm-1.  The complex with L7 showed a 
value of µeff = 3.80 B.M. HRMS TOF (ESI+) (water: acetonitrile = 1:3) with the 
highest molecular weight ion peak matching, was observed at m/z = 588.0740 (25%) 
and is related to [M- Cl+. The calculated value for [C28H18N10ClCu]
+ is 588.0736. ɅM 
(DMSO) = 44Ω-1cm2mol-1. 
  
 230 
 
7.3.6.4 Synthesis and characterisation of Dichloro(bis{4-[4-(pyridin-2-yl-kN)-1H-
1,2,3-triazol-1-yl-kN3]benzonitrile})nickel(II) 
For the preparation of [Ni(L7)2Cl2], the method used was similar to that for 
[Mn(L2)2Cl2]. An amount of NiCl2.6H2O of 0.033g, 0.14mmol and of 0.075g, 
0.34mmol of L7 were used, and an identical work-up procedure gave the required 
compound as a pale blue solid. The isolated precipitate gave (0.062g, 0.099mmol, 
yield 72%), mp. 346°C (decomp.). IR: ῡ(cm-1); 3078, 3059, 3021, 3016, 2232, 1631, 
1603, 1592, 1578, 1518, 1476, 1473, 1454, 1410, 1288, 1262, 1159, 1146, 1063, 1055, 
1021, 1008, 979, 848, 824, 794, 756, 719. UV-Vis (DMSO) λmax: The Ni(II) complex 
showed absorption bands at 256nm, εmax = 55417dm3mol-1cm-1, 292nm, εmax = 
37083dm3mol-1cm-1, 408nm, εmax = 14dm3mol-1cm-1, 682nm, εmax = 5dm3mol-1cm-1. 
The complex with L7 showed a value ofµeff = 2.77 B.M. HRMS (ESI+) (water: 
acetonitrile = 1:3) with the highest molecular weight ion peak matching, was observed 
at m/z 587.0751 (5%) and is related to [M-Cl]+. The calculated value for 
[C28H18N10ClNi]
+  is 587.0758. ɅM (DMSO) = 50Ω-1cm2mol-1. 
 
7.3.6.5 Synthesis and characterisation of Dichloro(bis{4-[4-(pyridin-2-yl-kN)-1H-
1,2,3-triazol-1-yl-kN3]benzonitrile})] copper(II) 
For the preparation of [Cu(L7)2Cl2], the method used was similar to that for [Mn (L
2)2 
Cl2]. An amount of anhydrous CuCl2 of 0.036 g, 0.26 mmol of and 0.13g, 0.53mmol 
of L7 were used, and an identical work-up procedure gave the required compound as 
a green solid. The isolated precipitate gave (0.136g, 0.21mmol, yield 90%), mp. 292-
294°C.   IR: ῡ(cm-1); 3077, 3038, 3004, 2232, 1634, 1616, 1601, 1594, 1579, 1516, 
1475, 1449, 1456, 1411, 1371, 1288, 1279, 1161, 1149, 1061, 1010, 978, 858, 826, 
797, 720. UV-Vis (DMSO) λmax: The Cu(II) complex showed absorption bands at 
258nm, εmax = 57278dm3mol-1cm-1, 299nm, εmax = 48636dm3mol-1cm-1, 922nm, εmax 
= 121dm3mol-1cm-1. The complex with L7 showed a value of µeff = 1.64 B.M. HRMS 
TOF (ESI+) (water: acetonitrile = 1:3) with the highest molecular weight ion peak 
matching, was observed at m/z = 592.0712 (75%) and is related to [M-Cl]+. The 
calculated value for [C28H18N10ClCu]
+ is 592.0700. A good single crystal for X-ray 
structural analysis was obtained by slow evaporation of a hot (methanol: acetonitrile 
=1:1) solution of the complex. ɅM (DMSO) = 26Ω-1cm2mol-1. 
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7.3.6.6 Synthesis and characterisation of Dichloro(bis{4-[4-(pyridin-2-yl-kN)-1H-
1,2,3-triazol-1-yl-kN3]benzonitrile})zinc(II) 
For the preparation of [Zn(L7)2Cl2], the method used was similar to that for 
[Mn(L2)2Cl2]. An amount of anhydrous ZnCl2 of 0.025g, 0.18mmol and 0.10g, 
0.40mmol of L7 were used, and an identical work-up procedure gave the required 
compound as a white solid. The isolated precipitate gave (0.088g, 0.14mmol, yield 
77%), mp. 288-290°C.   IR: ῡ(cm-1); 3076, 3052, 3010, 2228, 1631, 1602, 1591, 1574, 
1518, 1472, 1452, 1409, 1286, 1259, 1158, 1141, 1062, 1053, 1024, 1007, 978, 856, 
845, 825, 782, 718. UV-Vis (DMSO) λmax: The Zn(II) complex showed absorption 
bands at 256nm, εmax = 17400dm3mol-1cm-1, 300nm, εmax = 17200dm3mol-1cm-1. 
1HNMR data δH/ppm (400MHZ, DMSO-d6): 9.31 (1H, S, H16), 8.63 (1H,s, H14), 8.18-
8.16 (2H, d, JHH = 8.25Hz, Ar-H3,11),  8..07-7.97 (3H, m, H15, Ar-H7,10), 7.91-7.88 
(1H, t, 1JHH = 7.15Hz,  
2JHH = 7.15Hz, H18), 7.36-7.35 (1H, d, JHH = 4.67Hz, H19); 
13CNMR (100.63MHZ, D6MSO-d6) δC/pmm: 111.37(C12), 118.12 (C5), 120.15 (C15), 
120.84 (C3,C11-Ar), 121.54 (C16), 123.68 (C19), 134.29 (C7,C10-Ar), 137.52(C18), 
139.52 (C6), 148.58 (C17), 149.06 (C9), 149.79 (C14).These assignments were 
confirmed using DEPT 13C (135), 1H-1H COSY and 1H-13C HMQC two dimensional 
correlation spectroscopy. HRMS TOF (ESI+) (water: acetonitrile = 1:3) with the 
highest molecular weight ion peak matching, was observed at m/z = 593.0675 (80%) 
and is related to [M-Cl]+. The calculated value for [C28H18N10ClZn]
+ is 593.0696. ɅM 
(DMSO) = 6Ω-1cm2mol-1. 
7.3.6.7 Synthesis and characterisation of Dichloro(bis{4-[4-(pyridin-2-yl-kN)-1H-
1,2,3-triazol-1-yl-kN3]benzonitrile})cadmium(II) 
For the preparation of [Cd(L7)2Cl2], the method used was analogous to that for 
[Mn(L2)2Cl2]. An amount of anhydrous CdCl2 of 0.029g, 0.15mmol and 0.10g, 
0.40mmol of L7 were used, and an identical work-up procedure gave the required 
compound as a whitesolid. The isolated precipitate gave (0.089g, 0.13mmol, yield 
83%), mp. 280-282°C. IR: ῡ(cm-1); 3092, 3055, 2234, 1631, 1602, 1571, 1568, 1510, 
1468, 1450, 1406, 1285, 1269, 1248, 1158, 1141, 1062, 1058, 1032, 1014, 1005, 981, 
839, 782, 719. UV-Vis (DMSO) λmax: The Cd(II) complex   showed absorption bands 
at 258nm, εmax = 16800dm3mol-1cm-1, 300nm, εmax = 20200dm3mol-1cm-1. 1HNMR 
data δH/ppm (400MHZ, DMSO-d6): 9.45 (1H, s, H16), 8.68-8.67 (1H, d, JHH = 4.12Hz, 
H14), 8.28-8.26 (2H, d, JHH = 6.60Hz, Ar-H3,11), 8.12-8.09 (3H, m, H15, Ar-H7,10), 
7.98-7.94 (1H, t, 1JHH = 7.42Hz, 
2JHH = 7.70Hz, H18), 7.42-7.40 (1H, t, 
1JHH = 6.32Hz, 
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2JHH = 4.95Hz, H19); 
13CNMR (100.63MHZ, D6MSO-d6) δC/pmm: 111.12 (C12), 
117.84 (C5), 119.81 (C15), 120.55 (C3,C11-Ar), 121.41 (C16), 123.34 (C19), 134.04 
(C7,C10-Ar), 137.20 (C18), 139.34 (C6), 148.35 (C17), 148.94 (C9), 150.23 (C14). These 
assignments were confirmed using DEPT 13C (135°), 1H-1H COSY and 1H-13C 
HMQC two dimensional correlation spectroscopy. HRMS TOF (ESI+) (water: 
acetonitrile = 1:3) with the highest molecular weight ion peak matching, was observed 
at m/z = 643.0438 (90%) and is attributed to [M-Cl]+. The calculated value for 
[C28H18N10ClCd]
+ is 643.0422. ɅM (DMSO) = 13Ω-1cm2mol-1. 
 
7.3.7 Synthesis and characterisation of the metals complexes with ligand L8 
 
7.3.7.1 Synthesis and characterisation of Dichloro{bis[2-(1-phenyl-1H-1,2,3-triazol-
4-yl-kN3)pyridine-kN]}manganese(II) 
For the preparation of [Mn(L8)2Cl2], the method used was similar to that for 
[Mn(L2)2Cl2]. An amount of 0.040g, 0.31mmol of anhydrous MnCl2 and 0.14g, 
0.62mmol of L8 were used, and an identical work-up procedure gave the required 
compound as a pale yellow solid. The isolated precipitate gave (0.15g, 0.26mmol, 
yield 82%), mp. 318-320°C. IR: ῡ(cm-1); 3068, 3011, 2970, 1607, 1596, 1577, 1504, 
1471, 1444, 1285, 1255, 1063, 1046, 1010, 1001, 978, 911, 857, 790, 757, 725, 683. 
UV-Vis (DMSO) λmax: The Mn(II) complex showed absorption bands at 257nm, εmax 
= 72500 dm
3mol-1cm-1, 286nm, εmax = 33214dm3mol-1cm-1, 773nm, εmax = 278dm3mol-
1cm-1, 910nm, εmax = 143dm3mol-1cm-1. The complex with L8 showed a value of µeff = 
5.52 B.M. HRMS TOF (ESI+) (water: acetonitrile = 1:3) with the highest molecular 
weight ion peak matching, was observed at m/z = 534.0861 (80%) and is attributed to 
[M-Cl]+. The calculated value for [C26H20N8ClMn]
+ is 534.0861. X-Ray quality bright 
yellow crystals were obtained by slow evaporation of a hot (CH3OH:CH3CN: 1:1) 
solution of the complex. ɅM (DMSO) = 52Ω-1cm2mol-1. 
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7.3.7.2 Synthesis and characterisation of Dichloro{bis[2-(1-phenyl-1H-1,2,3-triazol-
4-yl-kN3)pyridine-kN]}iron(II) 
For the preparation of [Fe(L8)2Cl2], the method used was analogous to that for 
[Mn(L2)2Cl2]. An amount of anhydrous of anhydrous FeCl2  of 0.030g, 0.23mmol 
and 0.10g, 0.40mmol of L8 were used, and an identical work-up procedure gave the 
required compound as a pale yellow solid. The isolated precipitate gave (0.11g, 
0.19mmol, yield 81%), mp. 336-338°C. IR: ῡ(cm-1): 3064, 3053, 3026, 3009, 1606, 
1594, 1575, 1504, 1471, 1444, 1267, 1259, 1063, 1054, 1016, 1004, 977, 913, 861, 
815, 785, 756, 725, 686. UV-Vis (DMSO) λmax: The Fe(II) complex showed 
absorption bands at 258nm, εmax= 62593dm3mol-1cm-1, 286nm, εmax= 32963dm3mol-
1cm-1, 333nm, εmax= 52917dm3mol-1cm-1, 522nm, εmax= 190dm3mol-1cm-1, 756nm, 
εmax= 885dm3mol-1cm-1. The complex with L8 showed a value of µeff = 4.66 B.M. 
HRMS TOF (ESI+) (water: acetonitrile = 1:3) with the highest molecular weight ion 
peak matching, was observed at m/z = 535.0835 (60%) and is related to [M-Cl]+. The 
calculated value for [C26H20N8ClFe]
+ is 535.0849. ɅM (DMSO) = 46Ω-1cm2mol-1. 
7.3.7.3 Synthesis and characterisation of Dichloro{bis[2-(1-phenyl-1H-1,2,3-triazol-
4-yl-kN3)pyridine-kN]}cobalt(II) 
For the preparation of [Co(L8)2Cl2], the method used was similar to that for 
[Mn(L2)2Cl2]. An amount of anhydrous CoCl2.6H2O of 0.050g, 0.21mmol and 0.094g, 
0.21mmol of L8 where used, yielding a pale pink solid. The isolated precipitate gave 
(0.09g, 0.15mmol, yield 75%), mp 350-352°C. IR: ῡ(cm-1);  3050, 3027, 3013, 1610, 
1594, 1579, 1505, 1474, 1447, 1271, 1263, 1065, 1057, 1019, 1006, 978, 914, 885, 
785, 755, 685 UV-Vis (DMSO) λmax: The Co(II) complex showed absorption bands 
at 258nm, εmax= 60690dm3mol-1cm-1, 286nm, εmax= 28966dm3mol-1cm-1, 615nm, εmax=  
44dm3mol-1cm-1, 678nm, εmax=72dm3mol-1cm-1.The complex with L8 showed a value 
ofµeff = 3.49 B.M. HRMS TOF (ESI+) with the highest molecular weight ion peak 
matching, was observed at m/z= 538.0851 (70%) is related to [M-Cl]+. The calculated 
value for [C26H20N8ClCo]
+ is 538.0831. ɅM (DMSO) = 44Ω-1cm2mol-1. 
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7.3.7.4 Synthesis and characterisation of Dichloro{bis[2-(1-phenyl-1H-1,2,3-triazol-
4-yl-kN3)pyridine-kN]}nickel(II) 
For the preparation of [Ni(L8)2Cl2], the method used was as described for 
[Mn(L2)2Cl2]. An amount of NiCl2.6H2O of 0.040g, 0.16mmol and 0.075g, 0.33mmol 
of L8 where used, and an identical work-up procedure gave the required compound as 
a pale blue solid. The isolated precipitate gave (0.075g, 0.13mmol, yield 78%), mp. 
340°C (decomp.). IR: ῡ(cm-1): 3041, 3026, 3015, 1613, 1595, 1582, 1505, 1475, 1448, 
1273, 1264, 1140, 1066, 1059, 1007, 978, 914, 888, 785, 756, 727, 685. UV-Vis 
(DMSO) λmax: The Ni(II) complex showed absorption bands at 258nm, εmax= 
80000dm3mol-1cm-1, 286nm, εmax= 46818dm3mol-1cm-1, 400nm, εmax= 20dm3mol-1cm-
1, 668nm, εmax= 8dm3mol-1cm-1. The complex with L8 showed a value ofµeff = 3.00 
B.M. HRMS TOF (ESI+) (water: acetonitrile = 1:3) with the highest molecular weight 
ion peak matching, was observed at m/z = 537.0834 (40%) and is attributed to[M-
Cl]+. The calculated value for [C26H20N8ClNi]
+ is 537.0853. ɅM (DMSO) = 50Ω-
1cm2mol-1. 
7.3.7.5 Synthesis and characterisation of Dichloro{bis[2-(1-phenyl-1H-1,2,3-triazol-
4-yl-kN3)pyridine-kN]}copper(II) 
For the preparation of [Cu(L8)2Cl2], the method used was analogous to that for 
[Mn(L2)2Cl2]. An amount of anhydrous CuCl2 of 0.055g, 0.40mmol and 0.18g, 
0.81mmol of L8 where used, and an identical work-up procedure gave the required 
compound as a green solid. The isolated precipitate gave (0.22g, 0.38mmol, yield 
93%), mp. 282-284°C. IR: ῡ(cm-1); 3059, 3028, 3014, 1608, 1595, 1574, 1505, 1475, 
1467, 1448, 1269, 1254, 1065, 1047, 1028, 1002, 973, 912, 858,783, 757, 733, 685. 
UV-Vis (DMSO) λmax: The Cu(II) complex showed absorption bands at 258nm, εmax 
= 44286dm
3mol-1cm-1, 285nm, εmax= 31429dm3mol-1cm-1, 908nm, εmax = 13dm3mol-
1cm-1. The complex with L
8 showed a value ofµeff = 1.71 B.M. HRMS TOF (ESI+) 
(water: acetonitrile = 1:3) with the highest molecular weight ion peak matching, was 
observed at m/z 542.0817 (20%) and is related to [M-Cl]+. The calculated value for 
[C26H20N8ClCu]
+ is 542.0795. A good single crystal for X-ray structural analysis was 
obtained by slow evaporation of hot (CH3OH) solution of the complex. ɅM (DMSO) 
= 26Ω-1cm2mol-1. 
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7.3.7.6 Synthesis and characterisation of Dichloro{bis[2-(1-phenyl-1H-1,2,3-triazol-
4-yl-kN3)pyridine-kN]}zinc(II) 
For the preparation of [Zn(L8)2Cl2], the method used was similar to that for 
[Mn(L2)2Cl2]. An amount of anhydrous ZnCl2 of 0.035g, 0.25mmol and 0.11g, 
0.51mmol of L8 where used, and an identical work-up procedure gave the required 
compound as a white solid. The isolated precipitate gave (0.12g, 0.20mmol, yield 
81%), mp. 246-248°C. IR: ῡ (cm-1); 3039, 3024, 3011, 1608, 1594, 1577, 1574, 1505, 
1474, 1467, 1446, 1271, 1261, 1097, 1064, 1058, 1048, 1020, 1010, 1006, 978, 913, 
869, 786, 756, 726, 686. UV-Vis (DMSO) λmax: The Zn(II) complex showed 
absorption bands at 257nm, εmax= 142222dm3mol-1cm -1, 287nm, εmax= 58333dm3mol-
1cm-1.  1HNMR data δH/ppm (400MHZ, DMSO-d6): 9.27 (1H, s, H1), 8.66-8.65 (1H, 
d,1JHH = 2.75Hz, H7), 8.13-8.11  (1H, d,
1JHH = 7.79Hz, H4), 8.03-8.00 (2H, d, JHH = 
7.33Hz, Ar-H9,13), 7.96-7.92 (1H, dt, 
1JHH = 1.83Hz, 
2JHH = 7.79Hz, H5), 7.65-7.60 
(2H, d, JHH = 7.33Hz, Ar-H10,12), 7.54-7.50 (1H, td,
 1JHH = 0.92Hz,  
2JHH = 1.37Hz,
 
3JHH = 1.83Hz, H11), 7.41-7.39 (1H, ddd,
 1JHH = 0.92Hz, 
2JHH = 5.04Hz,
 3JHH = 7.79Hz, 
H6); 13CNMR (100.63MHZ, D6MSO-d6) δC/pmm: 119.89 (C4), 120.22 (C9,C13-Ar),  
120.22 (C1), 123.32 (C6), 128.81 (C11), 129.81 (C10,C12-Ar), 136.52 (C5), 137.36 (C8), 
147.87 (C2), 149.22 (C3), 149.50 (C7). These assignments were confirmed using 
DEPT 13C (135°), 1H-1H COSY and 1H-13C HMQC two dimensional correlation 
spectroscopy. HRMS (ESI+) (water: acetonitrile = 1:3) with the highest molecular 
weight ion peak matching, was observed at m/z 543.0780 (60%) and is related to [M-
Cl]+. The calculated value for [C26H20N8ClZn]
+ is 543.0791. ɅM (DMSO) = 8Ω-
1cm2mol-1. 
7.3.7.7 Synthesis and characterisation of Dichloro{bis[2-(1-phenyl-1H-1,2,3-triazol-
4-yl-kN3)pyridine-kN]}cadmium(II) 
For the preparation of [Cd(L8)2Cl2], the method used was analogous to that for 
[Mn(L2)2Cl2]. An amount of anhydrous CdCl2 of 0.037g, 0.20mmol and 0.10g, 
0.45mmol of L8 where used and an identical work-up procedure gave the required 
compound as a white solid. The isolated precipitate give (0.12g, 0.19mmol, yield 
81%), mp. 294-296°C.  IR: ῡ(cm-1); 3102, 3066, 3011, 1624, 1604, 1597, 1574, 1504, 
1486, 1447, 1267, 1250, 1064, 1016, 1010, 1002, 913, 859, 781, 753, 724, 718, 685. 
UV-Vis (DMSO) λmax: The Cd(II) complex showed absorption bands at 257nm, εmax= 
58095dm3mol-1cm-1, 287nm, εmax= 25000dm3mol-1cm-1. 1HNMR data δH/ppm 
(400MHZ, DMSO-d6):  9.30 (1H, s, H1), 8.67-8.66 (1H, ddd, 
1JHH = 0.92Hz, 
2JHH = 
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1.83Hz, 3JHH = 5.04Hz, H7), 8.13-8.11(1H, td, 
1JHH = 0.92Hz, 
2JHH = 1.37Hz, 
3JHH = 
8.24Hz, H4), 8.03-8.00 (2H, d = 7.73Hz, Ar-H9,13),7.98-7.94(1H, td, 
1JHH = 1.83Hz, 
2JHH = 7.79Hz,  H5), 7.65-7.60 (2H, d, JHH = 7.78Hz, Ar-H10,12), 7.54-7.50 (1H, dt,
 
1JHH = 0.92Hz,  
2JHH = 1.37Hz,
 3JHH = 1.83Hz, H11), 7.43-7.40 (1H, ddd,
 1JHH = 0.92Hz, 
2JHH = 5.04Hz,
 3JHH = 7.79Hz, H6); 
13CNMR (100.63MHZ, D6MSO-d6) δC/pmm: 
119.89 (C4), 120.22(C9,C13-Ar),  121.28 (C1), 123.32 (C6), 128.81 (C11), 129.81 
(C10,C12-Ar), 136.52 (C5), 137.36 (C8), 147.87 (C2), 149.22 (C3), 149.55 (C7). These 
assignments were confirmed using DEPT 13C (135°), 1H-1H COSY and 1H-13C 
HMQC two dimensional correlation spectroscopy. HRMS TOF (ESI+) (water: 
acetonitrile = 1:3) with the highest molecular weight ion peak matching, was observed 
at m/z = 593.0507 (10%) and is attributed to [M-Cl]+. The calculated value for 
[C26H20N8ClCd]
+ is 593.0533. ɅM (DMSO) = 16Ω-1cm2mol-1. 
7.3.7.8 Synthesis and characterisation of Dichloro{bis[2-(1-phenyl-1H-1,2,3-triazol-
4-yl-kN3)pyridine-kN]}platinum(II) 
For the preparation of [Pt(L8)2Cl2], the method used was similar to that for 
[Pt(L3)2Cl2]. To a solution of L
8 (0.085g, 0.38mmol) in CH3CN (5mL) was added 
dropswise a solution of K2[PtCl4] (0.070g, 0.16mmol) in C2H5OH-H2O 8:2 (10mL). 
A yellow solid, was isolated giving (0.094g, 0.13mmol, yielded 80%), mp. 246-
248°C. IR: ῡ(cm-1); 3186, 3051, 1600, 1592, 1578, 1540, 1520, 1502, 1470, 1464, 
1447, 1280, 1237, 1146, 1091, 1035, 999, 840, 841, 791, 757, 722. 1HNMR data 
δH/ppm (400MHZ, DMSO-d6): 9.38 (1H, s, H1), 8.71-8.69 (1H, ddd, 1JHH = 0.92Hz, 
2JHH = 1.83Hz, 
3JHH = 5.04Hz, H7), 8.18-8.15(1H, td, 
1JHH = 0.92Hz, 
2JHH = 1.37Hz, 
3JHH = 7.79Hz, H4), 8.09-8.06 (2H, d = 8.24Hz, Ar-H9,13), 8.01-7.97(1H, dt, 
1JHH = 
1.83Hz, 2JHH = 7.79Hz, H5), 7.69-7.64 (2H, d, JHH = 8.24Hz, Ar-H10,12), 7.58-7.54 (1H, 
tt, 1JHH = 0.92Hz,  
2JHH = 1.37Hz,
 3JHH = 7.79Hz, H11), 7.47-7.43 (1H, ddd,
 1JHH = 
0.92Hz, 2JHH = 4.58Hz,
 3JHH = 7.79Hz, H6);
 13CNMR (100.63MHZ, D6MSO-d6) 
δC/pmm: 120.34 (C4), 120.71(C9,C13-Ar),  121.78 (C1), 123.90 (C6), 129.38 (C11), 
130.44 (C10,C12-Ar), 137.09 (C5), 137.90 (C8), 148.74 (C2), 150.02 (C3), 150.21 (C7). 
These assignments were confirmed using DEPT 13C (135°), 1H-1H COSY and 1H-13C 
HMQC two dimensional correlation spectroscopy. HRMS TOF(ESI+) (MALDI) with 
the highest molecular weight ion peak matching, was observed at m/z = 675.1 (25%) 
and is attributed to [M-Cl]+. The calculated value for [C26H20N8ClPt]
+ is 675.1. ɅM 
(DMSO) = 8Ω-1cm2mol-1. 
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7.3.8 Synthesis and characterisation of the metals complexes with ligand L9 
7.3.8.1 Synthesis and characterisation of Dichloro[bis(2-{1-[4-
(trifluoromethyl)phenyl]-1H-1,2,3-triazol-4-yl-kN3}pyridine-kN)]manganese(II) 
For the preparation of [Mn(L9)2Cl2], the method used was similar to that for 
[Mn(L2)2Cl2]. An amount of anhydrous MnCl2 of 0.055g, 0.43mmol and 0.25g, 
0.86mmol of L9 where used, and an identical work-up procedure gave the required 
compound as a pale yellow solid. The isolated precipitate gave (0.24g, 0.34mmol, 
yield 80%), mp. 306-308°C. IR: ῡ(cm-1); 3068, 3055, 3022, 1606, 1595, 1575, 1521, 
1473, 1446, 1253, 1253, 1067, 1019, 1006, 861, 812, 784, 719. UV-Vis (DMSO) λmax: 
The Mn(II) complex showed absorption bands at 258nm, εmax = 87059dm3mol-1cm-1, 
286nm, εmax = 51765dm3mol-1cm-1, 526nm, εmax = 570dm3mol-1cm-1, 677nm, εmax = 
135dm3mol-1cm-1. The complex with L9 showed a value of µeff = 5.66 B.M. HRMS 
TOF (ESI+) with the highest molecular weight ion peak matching, was observed at 
m/z = 670.0613 (55%) and is related to [M-Cl]+. The calculated value for 
[C28H18ClF6N8Mn]
+ is 670.0622.  ɅM (DMSO) = 56Ω-1cm2mol-1. 
7.3.8.2 Synthesis and characterisation of Dichloro[bis(2-{1-[4-
(trifluoromethyl)phenyl]-1H-1,2,3-triazol-4-yl-kN3}pyridine-kN)]iron(II) 
For the preparation of [Fe(L9)2Cl2], the method used was analogue to that for 
[Mn(L2)Cl2]. An amount of anhydrous FeCl2 0.050g, 0.43mmol and 0.25g, 0.86mmol 
of L9, and an identical work-up procedure gave the required compound as a pale 
yellow solid with (0.20 g, 0.28 mmol, yielded 83%), mp. 274-276 °C. IR: ῡ(cm-
1);3063, 3047, 3025, 1605, 1595, 1571, 1522, 1473, 1448, 1267, 1258, 1060, 1049, 
1015, 1005, 886, 815, 786. UV-Vis (DMSO) λmax: The Fe (II) complex showed 
absorption bands at 258nm, εmax = 58947dm3 mol-1cm-1, 288nm, εmax = 48947dm3mol-
1cm-1, 326nm, εmax = 4511dm3mol-1cm-1, 566 nm, εmax = 461dm3mol-1cm-1, 590nm, 
εmax = 453dm3mol-1cm-1 respectively. The complex with L9 showed a value of µeff = 
4.72 B.M. HRMS TOF (MALDI) with the highest molecular weight ion peak 
matching, was observed at m/z = 671.1 (100%) and is attributed to [M-Cl]+. The 
calculated value for [C28H18ClF6N8Fe]
+  is 671.1.  ɅM (DMSO) = 48 Ω-1cm2mol-1. 
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7.3.8.3 Synthesis and characterisation of Dichloro[bis(2-{1-[4-
(trifluoromethyl)phenyl]-1H-1,2,3-triazol-4-yl-kN3}pyridine-kN)]cobalt(II) 
For the preparation of [Co(L9)2Cl2], the method used was as described for 
[Mn(L2)2Cl2]. An amount of CoCl2.6H2O of 0.040g, 0.16mmol and 0.097g, 0.33mmol 
of L9 where used, and an identical work-up procedure gave the required compound as 
a pale pink solid. The isolated precipitate gave (0.085g, 0.12mmol, yield 70%), mp. 
336-338°C. IR: ῡ(cm-1); 3069, 3040, 3012, 1610, 1579, 1517, 1475, 1441, 1321, 1261, 
1258, 1062, 1053, 1020, 1006, 886, 818, 818, 786, 757, 720.  UV-Vis (DMSO) λmax: 
The Co(II) complex showed absorption bands at 258nm, εmax= 952944dm3mol-1cm-1, 
286nm, εmax= 52353dm3mol-1cm-1, 615nm, εmax= 84dm3mol-1cm-1, 679nm, εmax= 
138dm3mol-1cm-1. The complex with L9 showed a value of µeff = 3.62 B.M. HRMS 
(P+NSI) with the highest molecular weight ion peak matching, was observed at m/z = 
674.0565 (10%) is assigned to [M-Cl]+. The calculated value for [C28H18ClF6N8Co]
+ 
is 674.0574. ɅM (DMSO) = 46Ω-1cm2mol-1. 
7.3.8.4 Synthesis and characterisation of Dichloro[bis(2-{1-[4-
(trifluoromethyl)phenyl]-1H-1,2,3-triazol-4-yl-kN3}pyridine-kN)]nickel(II) 
For the preparation of [Ni(L9)2Cl2], the method used was as described for 
[Mn(L2)2Cl2]. An amount of NiCl2.6H2O of 0.052g, 0.21mmol and 0.12g, 0.42mmol 
of L9 where used, and an identical work-up procedure gave the required compound as 
a pale pink solid. The isolated precipitate gave (0.11g, 0.12mmol, yield 73%), mp. 
350 °C(decomp.).  IR: ν (cm-1); 3075, 3051, 3012, 1613, 1588, 1580, 1518, 1477, 
1456, 1313, 1260, 1243, 1066, 1057, 1022, 1008, 876, 838, 806, 759, 752, 721. UV-
Vis (DMSO) λmax:  The Ni (II) complex have shown absorption bands at 259nm, εmax= 
41579 dm3mol-1cm-1, 287nm, εmax= 40000 dm3mol-1cm-1, 408nm, εmax= 13 dm3mol-1 
cm-1, 686nm, εmax= 4 dm3mol-1cm-1, complex with L9 showed a value of µeff = 3.62 
B.M. HRMS TOF (MALDI); the molecular ion peak observed atm/z = 673.1 (100%); 
is related for [M-Cl]+, calculated value for [C28H18ClF6N8Ni]
 +; observed 673.1.  ɅM 
(DMSO) = 48 Ω-1cm2mol-1. 
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7.3.8.5 Synthesis and characterisation of Dichloro[bis(2-{1-[4-
(trifluoromethyl)phenyl]-1H-1,2,3-triazol-4-yl-kN3}pyridine-kN)]copper(II) 
For the preparation of [Cu(L9)2Cl2] the method used was similar to that for 
[Mn(L2)2Cl2]. An amount of anhydrous CuCl2 of 0.055g, 0.40mmol and 0.23g, 
0.80mmol of L9 where used and an identical work-up procedure gave the required 
compound as a pale green solid. The isolated precipitate gave (0.24g, 0.33mmol, yield 
82%), mp. 248-250°C.  IR: ῡ(cm-1); 3060, 3044, 3026, 1617, 1608, 1577, 1526, 1518, 
1478, 1453, 1332, 1274, 1251, 1065, 1038, 1028, 1015, 865, 844, 782, 757, 732. UV-
Vis (DMSO) λmax: The Cu(II) complex showed absorption bands at 258nm, εmax = 
58947dm3mol-1cm-1, 287nm, εmax = 47368dm3mol-1cm-1, 496nm, εmax = 62dm3mol-
1cm-1, 888nm, εmax = 62dm3mol-1cm-1, The complex with L9 showed a value of µeff = 
1.60 B.M.  HRMS (P+NSI) with the highest molecular weight ion peak matching, was 
observed at m/z = 678.0532 (100%) and is attributed to [M-Cl]+. The calculated value 
for [C28H18ClF6N8Cu]
+ is 678.0538. A good single crystal for X-ray structural 
analysis was obtained by slow evaporation of a hot CH3OH solution of the complex.  
ɅM (DMSO) = 28Ω-1cm2mol-1. 
7.3.8.6 Synthesis and characterisation of Dichloro[bis(2-{1-[4-
(trifluoromethyl)phenyl]-1H-1,2,3-triazol-4-yl-kN3}pyridine-kN)]zinc(II) 
For the preparation of [Zn(L9)2Cl2], the method used was as described for 
[Mn(L2)2Cl2]. An amount of anhydrous ZnCl2 of 0.040g, 0.29mmol and 0.17g, 
0.58mmol of L9 where used, and an identical work-up procedure gave the required 
compound as a white solid. The isolated precipitate gave (0.20g, 0.28mmol, yield 
72%), mp. 280-282°C. IR: ῡ(cm-1); 3131, 3067, 3026, 1615, 1597, 1571, 1514, 1472, 
1447, 1323, 1296, 1274, 1065, 1038, 1028, 1015, 1251, 825, 779, 740, 717. UV-Vis 
(DMSO) λmax: The Zn(II) complex showed absorption bands at 256nm, εmax= 
32880dm3mol-1cm-1, 286nm, εmax= 31660dm3mol-1cm-1, respectively. 1HNMR data 
δH/ppm (400MHZ, DMSO-d6):  9.44 (1H, s, H11),  8.67 (1H, S, H2), 8.34-8.24 (2H, d, 
JHH = 8.70Hz, Ar-H13,17), 8.14-8.09 (1H, d, 
1JHH = 7.79Hz, H5),  8.04-7.92 (3H, m, H4, 
Ar-H14,16), 7.43-7.40 (1H, t,
1JHH = 5.50Hz, 
2JHH = 7.33Hz, H3); 
13CNMR 
(100.63MHZ, D6MSO-d6) δC/pmm: 119.90 (C5), 120.72 (C13, C17-Ar), 119.69, 
122.40, 125.11, 127.82 (q, J1C-F = 270.20Hz, C-F3 (C18)), 121.53 (C11), 123.40 (C3), 
127.13, 127.09, 127.05, 127.09 (q, J3C-F = 3.83Hz, C14, C16-Ar), 128.37, 128.68, 
129.01, 129.33 (q, J2C-F = 32.59Hz, C-CF3 (C15)), 137.26 (C4), 139.34 (C12), 148.42 
(C7), 149.17 (C6), 149.67 (C2). These assignments were confirmed using DEPT 
13C 
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(135°), 1H-1H COSY and 1H-13C two dimensional correlation spectroscopy.  HRMS 
((P+NSI) with the highest molecular weight ion peak matching, was observed atm/z 
= 716.9202 (5%) and is assigned to [M+H]+. The calculated value for 
[C28H18ClF6N8Zn]
+ is 716.0333.  ɅM (DMSO) = 12Ω-1cm2mol-1.  
7.3.8.7 Synthesis and characterisation of Dichloro[bis(2-{1-[4-
(trifluoromethyl)phenyl]-1H-1,2,3-triazol-4-yl-kN3}pyridine-iN)]cadmium(II) 
For the preparation of [Cd(L9)2Cl2], the method used was similar to that for 
[Mn(L2)2Cl2]. An amount of anhydrous CdCl2 of 0.045g, 0.24mmol and 0.14g, 
0.49mmol of L9, and an identical work-up procedure gave the required compound as 
a white solid. The isolated precipitate gave (0.13 g, 0.17 mmol, yield 68%), mp. 344-
346°C. IR: ῡ(cm-1); 3107, 3063, 1618, 1601, 1597, 1523, 1471, 1450, 1331, 1285, 
1266, 1251, 1066, 1034, 1017, 845, 724, 704, 694. UV-Vis (DMSO) λmax: The Cd(II) 
complex showed absorption bands at 258nm, εmax= 27850dm3mol-1cm-1, 288nm, εmax= 
26733dm3mol-1cm-1, respectively. 1HNMR data δH/ppm (400MHZ, DMSO-d6): 9.52 
(1H, s, H11), 8.69-8.67 (1H, td, 
1JHH = 0.95Hz, 
2JHH = 1.83Hz, 
3JHH = 4.58Hz, H2),  
8.31-8.29 (2H, d, JHH = 8,70Hz, Ar-H13,17), 8.15-8.12 (1H, dt, 
1JHH = 0.95Hz, 
2JHH = 
1.37Hz, 3JHH = 7.79Hz, H5), 8.02-8.00 (2H, d, JHH = 8,70Hz, Ar-H14,16), 7.99-7.95 
(1H, dt,1JHH = 1.83Hz, 
2JHH = 7.79Hz, H4), 7.45-7.41 (1H, ddd, 
1JHH = 1.37Hz, 
2JHH = 
5.04Hz, 3JHH = 7.33Hz, H3); 
13CNMR (100.63MHZ, D6MSO-d6) δC/pmm: 119.97 
(C5), 120.71 (C13, C17-Ar), 119.81, 122.47, 125.17, 127.88 (q, J
1
C-F = 270.20Hz, C-F3 
(C18)), 121.64 (C11), 123.59 (C3), 127.11, 127.14, 127.18, 127.21 (q, J
3
C-F = 3.83Hz, 
C14, C16-Ar), 129.32, 129.00, 128.66, 128.36 (q, J
2
C-F = 32.59Hz, C-CF3 (C15)), 137.51 
(C4), 139.33 (C12), 148.36 (C7), 149.08 (C6), 149.73 (C2). These assignments were 
confirmed using DEPT 13C (135°), 1H-1H COSY and 1H-13C HMQC two dimensional 
correlation spectroscopy. HRMS (P+NSI) with the highest molecular weight ion peak 
matching, was observed at m/z = 729.0279 (45%) and is attributed to [M-Cl]+. The 
calculated value for [C28H18ClN8F6Cd]
+ is 729.0275. ɅM (DMSO) = 20Ω-1cm2mol-1.  
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7.4 Conclusion 
In conclusion, new metal complexes with di (trans or cis) chloro as coligands, having 
the general formula [M(Ln)2(Cl)2] (where; M= Mn(II), Fe(II), Co(II), Ni(II), Cu(II),  
Zn(II) and CdII), and Ln = [bis-(PYTA)-1H-1,2,3-triazol-4-yl)pyridine] (where; Ln : 
n = 2 = CH3, 3 = OCH3, 4 = COOH, 5 = F, 6 = Cl, 7 = CN, 8= H, 9 = CF3) have been 
successfully prepared  and characterised by FT-IR, UV-Vis and fluorescence 
spectra,HRMS TOF (MALDI), NMR, magnetic moment measurements, conductivity 
and X-ray crystallography. The structural analysis indicates that the complexes of the 
type [M(L3)2(Cl)2] are a rare example of the coexistence of two trans coordinated Cl 
anions in the axial position or cis position in the mononuclear triazole-based 
octahedral configuration. This is an interesting finding, which deserves further 
investigation. 
 
In summary, eight bidentate 2-pyridyl-1,2,3-triazole ligands bearing a 4-substituted 
phenyl group and their corresponding metal complexes were designed and 
synthesised through a convenient click chemistry strategy. In this study, it was 
demonstrated that the direct connection at the N8 position of the triazolyl ring of a 4-
substituted phenyl group has a significant influence on the geometry of both the 
ligands and their corresponding M-complexes. The co-planarity of the organic 
framework led to slip-stacked π–π interactions between two molecules of the 
complex. Additionally, it was shown that the nature of the pendant group (X = CH3, 
OCH3, COOH, F, Cl, CN, H, CF3) could affect the electronic properties of the M(II)-
complexes. The methoxy- or phenyl moieties do not modify the photophysical 
properties of the complexes, but the presence of a cyanophenyl group (electron 
withdrawing groups) quenched the luminescence due to a high probability of non-
radiative deactivation. 
These first results were considered particularly significant, as they open up new 
prospects for the modulation of the photophysical properties of PYTA derivatives 
directly connected to a π-conjugated system. Further studies were conducted 
concerning the extension of the π-backbone of the PYTA core with other substituted 
aromatic or heteroaromatic moieties, as well as the study of the relationship between 
the natures of the π-conjugated arm vs. the electronic properties of the M-complexes. 
These complexes displayed weak fluorescence intensity with low quantum yield.  In 
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this work, it has been establish that the PYTY ligand L3 was found to bind the Fe(II), 
Co(II) and Ni(II) in a similar manner. The metal-Ntriazole bond was slightly shorter 
than metal-N pyridine bond. The pyridine and triazole rings occupied the equatorial 
plane, whereas the metal-Cl atoms were in the axial plane. Only in the Mn(II) and 
Cd(II) complexes, was it found that the metal-Cl atoms lie in the equatorial plane.  All 
these complexes have a distorted octahedral geometry. Structural characterisation of 
all of the complexes showed that the bis-chelating ligands are in the equatorial plane 
of the octahedron, and the triazole and pyridine nitrogens from each of the ligands are 
trans to each other.  Weak intermolecular interactions via C–H–Cl, C–H...N and C–
H...O are observed in the solid state. This result in an ordered three-dimensional 
supramolecular structure in which the molecules adopted a head-to-tail orientation 
that are stabilised by hydrogen bonding and π…π stacking. The Cu(II) and Cd(II) 
complexes displayed one-dimensional infinite polymeric chain structures of the 
[M(L3)Cl2]n complexes, as well as stabilisation of these by hydrogen bonding and 
π…π stacking. These crystals were obtained from recrystallised complexes having an 
initial molar ratio of [M:L 1:2]. This metal – ligand stoichiometry gave these 
structures a molar ratio of [M:L 1:1] in the polymeric chains. In the case of Cu(II) 
with different ligands L2, L6 L7, L8 and L9, the molecular structure of these complexes 
showed a distorted Jahn-Teller octahedral coordination arrangement.  This can be 
deduced from the fact that the metal-N triazole bonds are longer in the vertical 
equatorial plane than the metal-NPY bonds that formed in the equatorial plane. It was 
also observed that the coordinated Cl- ions occupied positions in the axial plane. The 
most significant finding in the Cu(II) complexes was that the bond lengths of the C=C 
in the triazole ring and the N=N inside the 1,2,3-triazole ring for each complex are 
changeable depending on the presence of electron donating or electron withdrawing 
substituents on the phenyl group. Interestingly, such a substituent on the phenyl ring 
attached to a PYTY ligand does not affect the geometry of the structures around the 
Cu(II) metal atom, as can be seen from the data in Table 7.22. Figure 7.38 displayed 
a linear correlation between the bond lengthsC7-C11 of the triazole carbons against the 
Hammett σρ substituent constant of Cu(II) complexes with L2, L8 and L9 ligands. 
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Chapter 8 : THE SYNTHESIS AND SUBSTITUTION 
REACTIONS OF NOVEL ISOTHIOCYANATE 
COMPLEXES OF 2-[1-(4-METHOXY-PHENYL)-1H-
1,2,3-TRIAZOL-4-YL]-PYRIDINE LIGAND 
 
8.1 Introduction 
 
Since ruthenium complexes containing isothiocyanate ligands such as N719 (Cis-
bis(isothiocyanato)-bis(2,2′-bipyridyl-4,4′-dicarboxylic acid)ruthenium(II)) [1], and 
the black dye BD (tri(isothiocyanato)(2,2′;6′,2′′-terpyridyl-4,4′,4′′ tricarboxylic acid) 
ruthenium(II) [2] are the best wideband synthesised solar dyes identified to date 
(higher power conversion), it is reasoned that it would be interesting to synthesise 
some metal isothiocyanate complexes by exchange of the chloro ligand (L3 ligand) 
with an isothiocyanato. These metal isothiocyanate complexes would be tested to see 
if there is improved photosensitiser properties. The aim was also to replace the 
ruthenium dyes with alternative low-cost metal complexes.  
 
A range of novel complexes of [(bis-isothiocyanato)-bis-2-(1-(4-methoxy-phenyl)-
1H-1,2,3-triazol-4-yl)pyridine]metal(II), were successfully prepared based on the 
replacement of the chloro groups of [M(L3)2(Cl)2] complexes which were prepared in 
(Chapter 7), with isothiocyanate ligands [M(L3)2(NCS)2]. The effect of the 
isothiocyanate group was investigated on the photophysical properties of the 
complexes, in particular absorbance, the molecular geometries and fluorescence 
behaviour.  The complexes were prepared in good yields of between 72-84 %, (see 
experimental section additional details section 8.3, Table 8.10), from the reaction of 
one equivalent of the metal complex, [M(L3)2(Cl)2], dissolved in DMSO, with an 
excess potassium isothiocyanate (KNCS) dissolved in CH3OH, as shown in Scheme 
8.1. The complexes prepared were characterised by FT-IR, magnetic moments, 
conductivity measurements, melting points, mass spectra, NMR spectroscopy and X-
ray crystallography in addition to their spectroscopic properties. 
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Scheme 8.1: Synthesis route of metal isothiocyanate complexes by coligand 
exchange in DMSO. 
 
8.2 Results and Discussion 
8.2.1 FT-IR spectral data for the complexes [Fe(L3)2(NCS)2], [Co(L
3)2(NCS)2], 
[Zn(L3)2(NCS)2] and [Cd(L
3)2(NCS)2] 
An overlay for the IR spectra of various L3 metal complexes with isothiocyanate as 
coligands is presented in Figure 8.1.  The plot aims to show differences between the 
spectra with regard to the shifts of functional groups on complex formation. 
 
 
Figure 8.1: FT-IR spectra of the various metal complexes showing characteristic 
bands of NCS-, C=Npy and C=CAr for [Fe(L3)2(NCS)2], [Co(L3)2(NCS)2], 
[Zn(L3)2(NCS)2] and [Cd(L3)2(NCS)2]. 
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The IR spectra of the title complexes display mainly bands due to the C≡N streeting 
vibrations for the trans–coordinated NCS−groups at ῡ2073-2087cm-1. This was 
observed for all complexes indicating that the two trans-(NCS−) anions are bound to 
the centre metal atom [3, 4], as shown in Scheme 8.1. The peak observed for the C≡N 
stretching band occurs at higher frequency than a typical C≡N stretching band, which 
indicates that the N atom is bound to the metal atom in the complex (near and below 
2100cm-1) [5, 6]. This is supported by the X-ray structure (Figure 8.27 and 8.33). The 
ν(C=N) stretching band of the pyridine moiety is observed around 1601-1609 cm-1 for 
the complexes, which is consistent with coordination of the nitrogen atom of the 
pyridine moiety with the metal atom.  The ν(C=C) bands of the phenyl ring of the 
complexes usually appear as two absorption peaks at around 1597- 1595cm-1 and 1516 
-1517cm-1. The ν(C=N) absorption band of the triazole moiety is at around 1574 - 
1571cm-1 in the metal complexes. 
 
Table 8.1: IR frequencies (cm-1) of the bis-isothiocyanato coligands in the (L3) 
complexes.  
 
 
 
 
 
 
 
 
Compound ν(N=C=S) ν(C=N)py, 
ν(C=C)Ar,ν(C=N)triaz conj. 
ν(N-N)triaz ν(C=C)Ar 
[Fe(L3)2(NCS2)] 2076 1606, 1597, 1574 1176,1064 1517 
[Co(L3)2(NCS)2] 2073 1609, 1597, 1575 1176,1065 1516 
[Zn(L3)2(NCS)2] 2087 1607, 1597, 1575 1179,1065 1517 
[Cd(L3)2(NCS)2] 2076 1601, 1571 1179,1088 1517 
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8.2.2 Magnetic moments, electronic spectra, and conductivity measurements for the 
complexes [Fe(L3)2(NCS)2], [Co(L
3)2(NCS)2], [Zn(L
3)2(NCS)2] and [Cd(L
3)2(NCS)2] 
8.2.2.1 UV-Vis Spectral data for bis-isothiocyanato of L3 metals complexes 
The UV-Vis spectral data of the [M(Ln)2(NCS)2] complexes (M= Fe(II), Co(II), Zn(II) 
and Cd(II)) were recorded over a wide range of concentrations of 10-3 M to 10-6 M in 
DMSO at room temperature (294K) using wavelength scan of 245nm to 950nm to 
facilitate the observation of low intensity forbidden d-d transitions.  The UV-Vis 
spectra of the complexes are depicted in Figures 11.14 -11.17. (See Physical 
Appendix Chapter 11) and the data summarised in Table 8.2. 
 
8.2.2.2 Magnetic moments and the conductivity measurements  
The magnetic moments and the conductivity measurements for these metal complexes 
have shown similar behaviour to the complexes of the chlorido ions that are described 
in chapter 7 (see chapter 7 Table 7.3 and sections 7.2.5 and 7.2.6). The data is 
summarised in Table 8.2. 
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Table 8.2: UV-Vis spectral data of L3 complexes in DMSO solutions. 
Compound Band Position 
λmax (nm) 
Band Position 
   λmax (cm-1) 
Extinction coefficient 
ɛmax (dm3mol-1 cm-1) 
Assignment µeffB.M Conductivity 
M (Ω-1 cm2mol-1) 
[Fe(L3)2(NCS)2] 258, 286 
351 
38760, 34965 
30030 
63333, 78666 (1.5x10-6M) 
664 (1x10-4M) 
Intra – ligand, π→π*, n→π* 
CT 
5.36 48 
[Co(L3)2(NCS)2] 258, 288 
538 
38760, 34246 
18587 
61250, 40000 (2.4x10-6M) 
14 (1x10-4M) 
Intra – ligand,  π→π*, n→π* 
4T1g (F)  → 4T1g (P) 
4.56 37 
[Zn(L3)2(NCS)2] 257, 288 38910,34722 57500, 38750 (2.4x10-6M) Intra – ligand,  π→π*, n→π* diamagnetic 12 
[Cd (L3)2(NCS)2] 257, 288 38910, 34722 48519, 36296 (2.7x10-6M) Intra – ligand,  π→π*, n→π* diamagnetic 18 
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8.2.3 Fluorescence emission spectral data for the complexes [Fe(L3)2(NCS)2], 
[Co(L3)2(NCS)2], [Zn(L
3)2(NCS)2] and [Cd(L
3)2(NCS)2] 
The fluorescence spectra of the triazole-based ligands and its various metal M(II) 
complexes with isothiocyanate NCS− coligands, with [M = Fe(II), Co(II), Zn(II), 
Cd(II)], were investigated in DMSO at room temperature (294K), The fluorescence 
and quantum yield were determined by comparison with 1,1':4'1"-p-terphenyl; (PTP) 
dye as a reference. The complexes and the reference dye were both excited at 276nm, 
whilst maintaining a nearly equal absorbance (0.095). The emission spectra were 
recorded from 285 to 550nm. All experiments were carried out at absorbance values 
below (0.1). 
The fluorescence emission spectra of the complexes with the general formula 
[M(L3)2(NCS)2], where M = Fe(II), Co(II), Zn(II) and, Cd(II), are depicted   in Figure 
8.2. The complexes showed weak fluorescence and low quantum yields relative to the 
standard PTP and the corresponding chloride complexes. The emission spectra of the 
complexes were characterised by their photoluminescence spectra, which were found 
to be red shifted from 345-346nm to 379-435nm in the isothiocyanate complexes. 
This indicates that the emission spectra may possibly originate from ligand-to-metal 
charge transfer (LMCT) [7, 8], which is distinctly different from those of the chloride 
complexes [M(L3)2Cl2], as can be seen in Figures 8.2 and 8.3.  The intensity, emission 
peaks, Stokes shifts and quantum yields for the various complexes are summarised in 
Table 8.3. These peaks originate from LLCT (ligand-to-ligand charge transfer) and 
LMCT (ligand-to-metal charge transfer) [9-11]. 
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(A)                                                                             (B) 
Figure 8.2: Fluorescence spectra of chloro metal complexes (A): [M(L3)2Cl2] and the corresponding isothiocyanate complexes (B): 
[M(L3)2(NCS)2]. 
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Figure 8.3: UV-Vis and Fluorescence intensity, for various metal complexes samples with isothiocyanate (-NCS) coligands.  
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The introduction of the isothiocyanate group into the chlorido complex had little effect 
on the UV spectra but red shifted and broadened the fluorescence spectra (see Figure 
8.2). In Figure 8.2B showing the fluorescence spectra of the isothiocyanate 
complexes, the scale was expanded (2.4 x) compared to that used for Figure 8.2A in 
order to illustrate the reduced fluorescence and quantum yield (Φf) of these complexes 
(see Table 8.3). The reduced fluorescence of the isothiocyanate complexes suggests 
inefficient ligand-to-metal charge transfer (LMCT) which may be a result of the 
structure of the complex.  
Table 8.3: Photoluminescence spectra of the various complexes in DMSO (10-6 
M); samples were excited at λmax (ex) = 276 nm. 
 
Quantum yields were calculated using the same method described in chapter (6): 
Φ (Co) = Φ (PTP) x (Area (Co) / (Area (PTP)) x (ABS (PTP)) / (ABS (Co)) x (η2 (DMSO) / η2 
(DMSO)) 
(Φf)Co=1.0 x  
𝟓𝟎𝟑𝟗.𝟔𝟎𝟗
𝟏𝟐𝟏𝟏𝟒𝟑.𝟎𝟓𝟖
  x  
𝟎.𝟎𝟗𝟓𝟒
𝟎.𝟎𝟗𝟔𝟎
  x  
𝟏.𝟒𝟕𝟕𝟎
𝟏.𝟒𝟕𝟕𝟎
 
(Φf)Co= 0.0416 x 0.994 = 0.04 % 
Compound Intensity 
 
Emissions 
  ( λem) nm, c=1 x 
10-6 M 
 
Stokes 
shift 
(Δλ)nm 
 
Quantum   
yield 
(Φf) 
PTP 
2720 
2218 
332 
345 
56 
69 
1.0 
[Co(L3)2(NCS)2] 
46 
32 
24 
16 
329 
381 
404 
435 
55 
105 
128 
154 
 
 
 
0.04 
[Fe(L3)2(NCS)2] 
30 
31 
29 
20 
13 
7 
304 
330 
343 
379 
398 
439 
28 
54 
67 
103 
122 
163 
 
 
 
 
 
0.026 
[Zn(L3)2(NCS)2] 
32 
33 
13 
9 
332 
345 
412 
436 
56 
69 
136 
160 
 
 
 
0.027 
[Cd(L3)2(NCS)2] 
20 
8 
5 
347 
410 
435 
71 
134 
159 
 
 
0.016 
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8.2.4 Mass spectra for the complexes [Fe(L3)2(NCS)2], [Co(L
3)2(NCS)2], 
[Zn(L3)2(NCS)2] and [Cd(L
3)2(NCS)2] 
Positive ion TOF-MOLDI-MS was the most satisfactory technique used for the 
analysis and measurement of these poorly soluble, high MW metal complexes. 
However, the molecular ion peak [M(L3)2(NCS)2]
+,  corresponding to the molecular 
weight of the metal complexes, was not observed due to the poor stability of the 
complex.  Only a secondary fragment ion was observed after the loss of one or more 
of the NCS-anions, the ligand or the metal atom when using this technique (Figure 
8.4). The high resolution mass spectra (HRMS) therefore was undertaken on the 
highest MW secondary fragment ion peak [M(L3)2NCS]
+, as can be seen in Figure 8.5 
produced after the loss of anisothiocyanate NCS- anion from the molecular ion via 
pathway (A) (see Scheme 8.2), as reported in literature [3, 12]. The second significant 
fragment ion peak [M(L3)2]
+ was formed with the loss of a (NCS-)2group from the 
molecular ion via pathway (B) in Scheme 8.2. Table 8.4 show the molecular weight 
and relative abundances of each species identified for the four metal complexes. 
 
Scheme 8.2: The major fragments observed in mass spectra for metal complexes 
of general formula [M(L3)2(NCS)2]. 
 
 
Table 8.4:  MS (TOF-MOLDI-MS) species observed for complexes. 
 
Compound [M- (NCS)]+ [M- (NCS)2]+ Other fragments 
[Fe(L3)2(NCS)2] 618.1 (100) % 560.1(3%)  
[Co(L3)2(NCS)2] 621.0 (100) % 563.1(15%)  
[Zn(L3)2(NCS)2] 626.0 (100) %   
[Cd(L3)2(NCS)2] 
 
676.1 (100) % 
618.1(40%) 
501.2(30%) 
422(15%) 
 
[M(L3)2Py(NCS)]
+ 
[M(L3) (NCS)]+ 
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Figure 8.4: TOF-MS-ES (+) mass spectrum of the complex [Fe(L3)2(NCS)2].  
 
Figure 8.5: The calculated mass spectrum of complex [Fe(L3)2(NCS)2]. 
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Figure 8.6: TOF-MS-ES mass spectrum of the complex [Co(L3)2(NCS)2]. 
 
Figure 8.7: The calculated mass spectrum of the complex [Co(L3)2(NCS)2].
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Figure 8.8: TOF-MS-ES (+) mass spectrum of complex [Zn(L3)2(NCS)2]. 
 
Figure 8.9: The calculated mass spectrum of complex [Zn(L3)2(NCS)2]. 
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Figure 8.10: TOF-MS-ES (+) mass spectrum of complex [Cd(L3)2(NCS)2]. 
 
Figure 8.11: The calculated mass spectrum of complex [Cd(L3)2(NCS)2] 
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8.2.5 1H, 13C, HMQC two dimensional correlation spectroscopy and DEPT NMR 
spectra for the complexes 
All assignments were confirmed using DEPT 13C (135°); 1H-1H COSY and 1H-13C 
HMQC two dimensional correlation spectroscopy. The 1H-13C and DEPT NMR 
analysis was used to characterise the structure of the [M(L3)2(NCS)2] complexes. 
8.2.5.1 1H and 13CNMR spectra for [Zn(L3)2(NCS)2] and [Cd(L
3)2(NCS)2] 
The 1H and 13C NMR data for the complexes [Zn(L3)2(NCS)2] and [Cd(L
3)2(NCS)2] 
are displayed in Figures 8.12-8.19. The 1H-NMR spectra and 13C spectra for each 
complex were supported by 2-dimensional spectra (1H–1HCOSY, 13C–1H HMQC) to 
confirm the proposed assignments. The chemical shifts (δ) of the 1H- (C-H) and 13C-
NMR (C=CH) of the complexes have been tabulated in Tables 8.5. 
8.2.5.1.1 1H NMR spectra for the complex [Zn(L3)2(NCS )2] and [Cd(L
3)2(NCS )2] 
The 1H NMR spectrum for the complexes [Zn(L3)2(NCS)2] and [Cd(L
3)2(NCS)2] in 
DMSO-d6 solution is overlaid in Figure 8.12. The spectra display a lack of multiplicity 
of peaks, indicating the presence of only one isomer. The spectra in Figures 8.13 and 
8.18 show a significant downfield chemical shift for the triazole proton (C11;11-H), i.e.  
δ = 9.293 and δ = 9.269 ppm (1H, s) for the Zn(II) and Cd(II) isothiocyanate 
complexes, relative to the corresponding chlorido complexes. This shift is a 
consequence of the effect of the isothiocyanate group M-N+≡C-S ̶ and it resonance 
contributors that reduce the electron density of the coordinated [M2+] atom via 
electron withdrawal. This occurs through back-bond donation from the metal d-orbital 
to the p-π* anti-bonding orbital of the ligand N+≡C-S ̶  [13].  Another factor affecting 
the chemical shift is that complex formation reduces the electron density of the 
triazole ring (the lone electron pair on the triazole nitrogen combines with the metal). 
This observation is consistent with the coordination between the triazole group and 
metal moiety. The proton resonances of the pyridine group are shifted in accordance 
with its proximity to the metal centre, and the proton H2 closest to the M(II) centre is 
shifted downfield due the pyridine nitrogen atom binding to the metal.  This signal is 
slightly shifted downfield compared to that detected in the free ligand and in the 
[Zn(L3)2Cl2] and [Cd(L
3)2Cl2] complexes. Other significant signals are summarised 
in Table 8.5, and are similar to observations reported before in chapter 7 (see Table 
7.7 and 7.8). 
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8.2.5.1.2 13C NMR spectra and DEPT spectra for the complexes [Zn(L3)2(NCS)2] 
and [Cd(L3)2(NCS)2] 
The 13C NMR spectra for [Zn(L3)2(NCS)2] and [Cd(L
3)2(NCS)2] are depicted in 
Figures 8.18 and 8.23. These figures shown significant chemical resonance shift in 
the range δ = 133.58ppm and δ = 132.28ppm in 13CNMR.  These shifts are attributed 
to the trans NCS carbon isothiocyanate ligands and indicates the binding of the 
isothiocyanate with the Zn(II) and Cd(II) ions [14,15]. The peaks at δ = 121.20 ppm 
and δ = 121.17ppm are assigned to the (C11, triazole) for the Zn(II) and Cd(II) 
complexes, respectively. This gives a value of Δδ = 0.63ppm in comparison with the 
chemical shift of L3. The peaks at δ = 121.73 and 114.79ppm usually are common 
characteristic features observed in para benzene substitutions (C14, C16; C13, C17).  
These two signals are equivalent to four carbons in the same environments, and are 
attributed to para benzene substitution.  The chemical shift of the CH3 group of the 
methoxy moiety appears as expected up field in the range at δ = 55.61-55.62ppm [16, 
17]. The results are summarised in Table 8.5.  A sample 1H-13C HMQC correlation 
and COSY spectra of [Zn(L3)2(NCS)2] and [Cd(L
3)2(NCS)2] in DMSO-d6 are 
displayed in Figures 8.16-8.17 and 8.21-8.22 respectively. 
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Table 8.5: 1H NMR data for the complexes measured in DMSO-d6 and chemical 
shift in ppm (δ). 
Compound Functional group δ (PPM) δ (PPM) 13C 
L3 C(11; 11)-H 8.53, s, 1H 120.57 
 C(2; 2)- H 8.64,1H, d, J= 2.29Hz 149.99 
[Zn(L3)2Cl2] C(11; 11)-H 9.06, s,1H, 120.75 
 C(2; 2)- H 
8.69-8.64,1H, d, JHH = 
4.58Hz 
149.43 
[Cd(L3)2Cl2] C(11; 11)-H 9.08, s,1H 120.82 
 C(2; 2)- H 
8.69-8.64,1H, d, JHH = 
4.58Hz 
149.26 
 C-NCS  133.58 
[Zn(L3)2(NCS)2] C(11; 11)-H 9.29 H, s, 1H 121.20 
 C(2; 2)- H 
8.69-8.68,1H, d, JHH = 
4.12Hz 
149.46 
[Cd(L3)2(NCS)2] C(11; 11)-H 9.26 H, s, 1H 121.17 
 C(2; 2)- H 
8.69-8.68,1H, d, JHH = 
4.58Hz 
149.52 
 C-NCS  132.28 
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Figure 8.12: The overlay of the 1H NMR for the isothiocyanato complexes of   L3 
with Zn(II) and Cd(II), highlighting in each the C-H triazole peak. 
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    Figure 8.13: 1H NMR spectrum of [Zn(L3)2(NCS)2] in DMSO-d6. 
 
Figure 8.14: 13C NMR spectrum of [Zn(L3)2(NCS)2] in DMSO-d6. 
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Figure 8.15: 13C NMR and DEPT NMR spectrum of [Zn(L3)2(NCS)2] in DMSO-
d6. 
 
Figure 8.16: 2D 1H-1HCOSYcorrelation spectrum of [Zn(L3)2(NCS)2] in DMSO-
d6. 
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Figure 8.17: 2D 1H-13C HMQC correlation spectrum of [Zn(L3)2(NCS)2] in 
DMSO-d6. 
 
Figure 8.18: 1H NMR spectrum of [Cd(L3)2(NCS)2] in DMSO-d6. 
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Figure 8.19: 13C NMR spectrum of [Cd(L3)2(NCS)2] in DMSO-d6. 
 
Figure 8.20: 13C NMR and dept NMR spectrum of [Cd(L3)2(NCS)2] in DMSO-d6. 
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Figure 8.21: 2D 1H-1HCOSYcorrelation spectrum of [Cd(L3)2(NCS)2] in DMSO-
d6. 
 
Figure 8.22: 13C NMR and DEPT NMR spectrum of [Cd(L3)2(NCS)2] in DMSO-
d6. 
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8.2.6 X-ray crystallographic diffraction of the metal various complexes 
8.2.6.1 Structure determination 
The single crystal X-ray diffraction measurements for [Zn(L3)2(NCS)2] and 
[Cd(L3)2(NCS)2] were performed using a Rigaku Saturn 724+ area detector mounted 
at the window of an FR-E+ rotating anode generator with Mo Kα, λ= 0.71070Å and 
Mo Kα, λ= 0.71075Å for [Cd(L3)2(NCS)2] complex at 100K. The crystals were 
mounted on glass fibres and the data were collected at 120K under nitrogen flow from 
an Oxford Cryosystems cryostream 700 device. An empirical absorption correction 
was carried out using SADABS and the structures were solved by direct methods 
using SUPERFLIP software [18]. Data were processed and empirical absorption 
corrections were carried out using Crystal Clear SM-Expert with the unit cell 
parameters refined against all data [19]. The structures were solved by direct methods 
using SHELXS-97 with OLEX2 [20]. All structures were refined on Fo
2 by full-matrix 
least squares refinement using the SHELXL-97 program package [21]. All non-
hydrogen atoms were refined by isotropic displacement parameters and hydrogen 
atoms were added at calculated positions and refined using a riding model with C-H 
(aromatic) 0.950Å UISO = 1.5 Ueq (C); C-H (methyl) 0.980 Å UISO = 1.5 Ueq (C) [22]. 
The crystallographic data for the complexes are summarised in Table 8.6. 
 
8.2.6.2 X-ray crystallography diffraction analysis of bis-isothiocyanato metal 
complexes with the L3 ligand 
 
8.2.6.2.1 Single-crystal structure determinations of [Zn(L3)2(NCS)2] and 
[Cd(L3)2(NCS)2] complexes 
The molecular structure of the two complexes [Zn(L3)2(NCS)2] and [Cd(L
3)2(NCS)2] 
were confirmed by X-ray crystallography analysis. The crystal structures of these 
complexes are generally similar. As expected, the two-triazole ligands are coordinated 
to the metal centre and lying in the same equatorial plane, while the two-
isothiocyanate ligands are located in the axial positions that are trans to each other. 
These crystal structures have a six coordination number with distorted octahedron 
geometry typical of M(II) complexes. The X-ray diffraction data analysis of the 
complexes [Zn(L3)2(NCS)2] and [Cd(L
3)2(NCS)2] are listed in Table 8.6, while 
selected bond lengths, bond angles and torsion angles are depicted in Tables 8.7 and 
8.8. 
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Table 8.6: Crystallographic data for the complexes [Zn(L3)2(NCS)2] and 
[Cd(L3)2(NCS)2]. 
Compound L3 [Zn(L3)2(NCS)2] [Cd(L3)2(NCS)2] 
Formula C14H12N4O C30H24N10O2S2Zn C30H24N10O2S2Cd  
Mr 252.28 686.08 451.60 
Temp/K 100(2) 100(2) K 100(2) K 
Cryst. syst. Triclinic Triclinic Triclinic 
Space group P1 P1 P1 
a/Å 3.7837(4) 6.8984(4) 6.8526(5) 
Wavelenght Å 0.71075 0.71070 0.71075 
b/Å 10.8502(16) 9.6078(7) 9.5938(7) 
c/Å 15.2200(17) 12.2677(8) 12.6921(9) 
α/° 109.226(11) 98.399(7) 101.567(13) 
β/° 97.056(6) 95.666(6) 94.308(12) 
γ/° 91.514(9) 110.914(5) 110.645(14) 
V/Å3 584.03(12) 741.29(8) 755.23(12) 
Z 2 1 1 
Rint 0.0617 0.0342 0.1444 
Dcalcd/g. cm
-3 1.435 1.537 1.612 
Refln (all/ind) 6395/2617 7374/3387 6527/3384 
μ/mm-1 0.096 1.018 None 
R1/wR2 
(obsd data: 
F2>2σ(F2))a 
0.0534/ 
0.1074 
0.0331/ 
0.0852 
0.0635/ 
0.1366 
R1/wR2 (all data)a 0.0734/ 
0.1161 
0.0431/ 
0.0889 
0.0875 / 
0.1483 
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Table 8.7: Selected bond lengths Å and angles [°] for the complexes [Zn(L3)2(NCS)2] and [Cd(L3)2(NCS)2]. 
Bond distance(Å) L3 [Zn(L3)2(NCS)2] [Cd(L3)2(NCS)2] angles (°) [Zn(L3)2(NCS)2] [Cd(L3)2(NCS)2] 
Empirical formula C14H12N4O C30H24N10O2S2Zn C30H24N10O2S2Cd  C30H24N10O2S2Zn C30H24N10O2S2Cd 
C7C11 1.362(6) 1.364(2) 1.370(6) N(PY) 1 MN (PY) 1i 180.0(6) 180.0 
N8N9 1.302(4) 1.312(2) 1.308(6) N (tz) 1i MN (tz) 1 180.0(4) 180.0 
N9N10 1.355(4) 1.345(2) 1.345(5) N(PY) 1MN (tz) 1i 102.25(5) 107.31(14) 
N8C7 1.365(5) 1.353(2) 1.352(6) N(PY) 1 MN (tz) 1 77.75(5) 72.62(14) 
MN(PY) 1  2.1745(15) 2.348(4) N(PY) 1M N1CS 88.80(6) 88.39(16) 
MN(PY)  1i  2.1745(15) 2.348(4) N(PY) 1iM  N1CSi 91.20(6) 91.61(16) 
MN(triazole)1  2.1556(14) 2.309(4) N (tz) 8i M N1CSi 89.94(6) 88.39(16) 
MN(triazole)1i  2.1556(14) 2.309(4) N (tz) 8M N1CS 90.06(6) 91.61(16) 
MN1S  2.1298(17) 2.307(5) N1SMN1Si 180.0 180.0 
MN1Si  2.1298(17) 2.307(5) N1SC1SS1S 179.24(17) 179.0(5) 
N1SC1S  1.154(3) 1.149(7) C1S N1SM 174.71(15) 167.3(4) 
S1SC1S  1.639(2) 1.634(6)    
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Table 8.8: Selected torsion angles [°] for the complexes [Zn(L3)2(NCS)2] and 
[Cd(L3)2(NCS)2]. 
 
Angles [Zn(L3)2(NCS)2] [Cd(L3)2(NCS)2] 
N(t) 1i MN(p)1C2 15.8(16) 1.7(4) 
N(t)) 1MN(p) 1C2 178.42(16) 175.1(3) 
N1Si MN(p) 1 C2 88.74(15) 90.6(4) 
N1SMN(p) 1C2 91.26(15) 90.6(4) 
N(p) 1MN(t) 1N9 0.47(19) 1.6(5) 
N(p) 1i MN(t) 1N9 179.53(19) 1.6(5) 
N1SiMN(t) 1N9 88.29(18) 90.2(5) 
N1SMN(t) 1N9 91.71(18) 90.2(5) 
MN(t) 1N9N10 176.81(13) 174.8(3) 
N8N9N10C11 0.4(2) 1.5(5) 
N8N9N10C12 174.98(15) 177.0(4) 
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8.2.6.2.2 The X-ray crystal structure of bis-(isothiocyanato-N)(bis{2-[1-(4-
methoxyphenyl)-1H-1,2,3-triazol-4-yl-kN3]pyridine-kN})]zinc(II) [Zn(L3)2(NCS)2] 
The molecular structure of the complex [Zn(L3)2(NCS)2] as confirmed by single-
crystal X-ray diffraction is depicted in Figure 8.23. The crystals of the molecule 
[Zn(L3)2(NCS)2] were obtained by slow evaporation in a hot mixture of 
CH3OH:CH3CN= 1:2 under ambient conditions. It crystallises in the triclinic P-1 
space group, which indicates one molecule per unit cell as Z=1of [Zn(L3)2(NCS)2] 
complex (see Figure 8.28). The zinc centre in the [Zn(L3)2(NCS)2] complex is in a 
distorted octahedral coordination arrangement, which includes two of the 2-(1-(4-
methoxy-phenyl)-1H-1,2,3-triazol-4-yl)pyridine L3 ligands coordinated to the zinc 
atom, via the N8trz and N1py  atoms from the two different ligands. The N8eq–Zn–
N1eq and N1
i
eq–Ni–N8ieq atomic bands are lying in the equatorial plane with angles 
of 77.75(5)°.  In the equatorial plane the pyridine N1py and N8trz donor atoms from 
the two ligands are mutually trans to each other, and the angles for N8eq–Zn–N8ieq 
and N1eq–Zn–N1ieq are 180.00(4)° and 180.00(6)°, respectively. Furthermore, the 
axial positions are occupied by two isothiocyanate ions that are trans to each other, 
with the N1Sex –Zn–N1Sex at an angle of 180.0°.  
 
Figure 8.23: The molecular structure of [Zn(L3)2(NCS)2]. The thermal ORTEP 
diagram is drawn at a 50% probability level and the H atoms are shown as small 
spheres of arbitrary size. 
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The angles in the plane between these two L3 ligands slightly deviated from 90°. The 
angle is distorted because of the chelating nature of the ligands L3, but the 180° angles 
are intact. The N8–N9 bond length inside the 1,2,3-triazole ring is 1.302(4) Å, while 
the N9–N10 and N8–C7 bond lengths for the free ligand are 1.355(4) and 1.365(5)Å, 
respectively. The distances of the bond lengths between N8–N9 1.312(2) Å, N9–N10 
1.345(2)Å and N8–C7 1.353(2)Å respectively, are slightly higher in the 
[Zn(L3)2(NCS)2] complex (by approximately 0.010Å) when compared with the free 
ligand and another M(II)pyridyl-triazole complex published recently [23].  Both the 
monodentate isothiocyanate ion ligands shown bond lengths for the connection M–
NCS of 2.1298(17)Å.  
The C–N and C–S bond length values are 1.154(3) Å and 1.639(2) Å, respectively. 
These bond lengths are comparable to those bond lengths of NCS- observed 
previously in the literature [24, 25].  In the complex, the metal-isothiocyanate chain 
indicates a π-delocalization along to the Zn–N–C angles at 174.7(2), while the angle 
between N1SZn1N1Si is 180.0°. This provides evidence that the NCS- anion is a 
perfect linear group, which is in good agreement with reports found for M(II) 3d 
complexes having bent terminally bonded NCS ligands (141°-174°) [25, 26]. The 
angles around the metal centre are listed in Table 8.7. In the Zn(II) complex, the metal-
triazole bond length is slightly shorter at 2.1556(14)Å than the metal pyridine bond 
length at 2.1745(15)Å (by approximately 0.0189Å). These distances are normal and 
comparable with distances in other complexes containing the PYTA type ligands, 
because of the greater trans influence of the triazole nitrogen N8 with respect to the 
pyridyl nitrogen N1 [26, 27].  
After complexation, the twisting angle between the pyridine plane and the triazolering 
is only 114.50(15)°, while the twisting angle between the triazole plane and the 
substituted phenyl ring is 120.87(14)°. The dihedral angle between the plane of the 
pyridyl moiety and the mean plane of the triazole ring is 0.5(2)°, whereas the dihedral 
angle between the plane of the methoxy phenyl group and the plane of the triazole 
moiety is tilted by 9.8(2)°. From the overlay of the structure shown in Figure 8.24, 
extensive weak hydrogen bonding interactions were observed.  
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This generates a 3D supramolecular network sheet of infinite chains in the solid state. 
It can be deduced that there are four kinds of weak intermolecular hydrogen bonds of 
type (D–H…A), which include. (1)- C11–H11...S1S and C11–H11...S1Si occurring 
via the H-triazole (H11) from a neighbouring layer with (S) from the monodentate 
trans isothiocyanate NCS ligand, and from another H-triazole (H11) on another 
neighbouring second layer with (Si) from the second monodentate trans 
isothiocyanate NCSi ligand from the same layer, (2)-C16–H16...O1, where these 
intermolecular hydrogen bonds occur via the H-phenyl ring (H16) from the main layer 
with O1 from the methoxy group linkage to the phenyl ring of the second layer (3)-
C3–H3...C1S and C1Si, (4)-C17–H17...C1S and C1Si. These intermolecular hydrogen 
bonds are summarised in Table 8.9. These values of hydrogen bonds are in agreement 
with values reported previously in literature [28, 29]. In the complex [Zn(L3)2(NCS)2], 
it was observed that these intermolecular hydrogen bonds play the roles of the 
hydrogen bond donors and acceptors. 
 
Table 8.9: Weak hydrogen bonding interaction parameters; D= donor and A= 
acceptor (Å, °) in the complex [Zn(L3)2(NCS)2]. 
 
D-H...A/interactions D–H (Å) H–A (Å) D–A (Å) Angle (  ͦ) 
C11–H11...S1S 0.9300 2.777(5) 3.592 (2) 146.8(1) 
C11–H11... S1Si 0.9300 2.777(5) 3.592 (2) 146.8(1) 
C16–H16...O1 0.9300 2.532(2) 3.396 (3) 154.6(1) 
C3–H3...C1S 0.9300 2.762(3) 3.451(3) 131.6(1) 
C3–H3...C1Si 0.9300 2.763(2) 3.451(3) 131.6(1) 
C17–H17...C1S 0.9300 2.821(2) 3.642(3) 147.8(1) 
C17–H17...C1Si 0.9300 2.821(2) 3.642(3) 147.8(1) 
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Figure 8.24: Schematic representation of a 3D supramolecular sheet, showing intermolecular hydrogen bonding interactions in 
an extended complex [Zn(L3)2(NCS)2]. The molecules are linked in a layered manner viaC17–H17…S1S andC17–H17…S1Si, 
C3–H3...S1S, C3–H3...S1Si and C16–H16...O1 interactions. The complex is viewed along the crystallographic b-axis.
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Notably, one offset face-to-face π…π interaction exists between two parallel 
coordinated pyridyl rings composed of the (N12C2C3C4C5C6) and (N12C2C3C4C5C6) 
molecules. The adjacent molecules adopt an offset-slipped face-to-face parallel 
alignment, where the adjacent pyridine ring is perfectly coplanar. The centroid – 
centroid distance is 3.877Å, with a plane–plane distance of 3.046Å and an angle 
between the planes of 2.23° (see. Figure 8.25). This distance is comparable to the 
previously reported bond separation of a typical π…π stacking [4]. Another π…π 
stacking interaction exists between two parallel phenyl rings, with a plane–plane 
distance of 3.534Å [43, 30] and a centroid–centroid distance of 3.345Å, as is 
presented in Figure 8.26. Finally, it was also observed π…π stacking interactions 
occurring between two parallel coordinated pyridyl rings with phenyl rings in the 
crystal structure of the complex [Zn(L3)2(NCS)2]. Here the plane–plane distance is 
3.325Å and the centroid–centroid distance is 3.940Å (see Figure 8.27) [31, 34].  These 
π…π interactions are continuous throughout the [Zn(L3)2(NCS)2] complex and result 
in a 3D infinite supramolecular structure Figure.8.24. 
 
Figure 8.25: A pair of connected complexes arranged about a centre of 
symmetry, showing the overlap between the two pyridine rings due to 
intermolecular π…π interaction in molecule [Zn(L3)2(NCS)2]. The complex is 
viewed along the crystallographic b-axis. 
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Figure 8.26: A pair of connected complexes arranged about a centre of 
symmetry, showing the overlap between the two phenyl rings due to 
intermolecular π…π interaction in the molecule [Zn(L3)2(NCS)2]. The complex is 
viewed along the crystallographic b-axis. 
 
 
Figure 8.27: A pair of connected complexes arranged about a centre of 
symmetry, showing the overlap between the two parallel pyridyl rings and 
phenyl rings due to intermolecular π…π interactions in the molecule 
[Zn(L3)2(NCS)2]. The complex is viewed along the crystallographic b-axis. 
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Figure 8.28: The unit cell, viewed along the crystallographic b – axis.  A capped 
stick model of the molecular structure packing of [Zn(L3)2(NCS)2]. H atoms are 
shown as small spheres of arbitrary size. 
 
The complex [Zn(L3)2(NCS)2] is stabilised by four intermolecular hydrogen bonding 
interactions andthree intermolecular π…π interactions.  The π…π stacking can be 
described as occurring in the solid state between (1)- the pyridyl - pyridyl rings, (2) - 
triazole - triazole rings and (3)- phenyl-phenyl rings. In the crystal structure, the 
molecules of the [Zn(L3)2(NCS)2] complex are arranged in infinite chains forming a 
3D supramolecular network sheet. The molecules of [Zn(L3)2(NCS)2] adopt a head-
to-tail orientation (see Figure 8.24).  
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 8.3 General Experimental Procedures and Characterisation of Bis-
Isothiocyanato bis 1H-1,2,3-triazol Metal Complexes 
 
8.3.1 Synthesis and characterisation of bis-isothiocyanato of L3 metal complexes 
The general procedure referred to above and described in detail for the first complex 
synthesis, was used to prepare the following complexes by using the indicated 
amounts of each reagent. 
Table 8.10: Bis-isothiocyanate Metal-L3 complexes synthetised and 
characterised during the investigation. 
[M(L3)2(Cl)2] KNCS amount Yield (%) MP (oC) 
0.072g, 0.11mmol 
 [Fe(L3)2(NSC)2] 
0.5g, 7.68mmol 
KNCS 
0.056g,0.082mmol, 
72% 
238 - 240 
0.081g, 0.12mmol 
[Co(L3)2(NSC)2] 
0.45g, 6.91mmol 
KCNS 
0.076g,0.091mmol, 
76% 
310 - 312 
0.084g, 0.13mmol 
[Zn(L3)2(NSC)2] 
0.60g, 9.21mmol 
KNCS 
0.072g,0.10mmol, 
 80% 
314 - 316 
0.090g, 0.13mmol 
[Cd(L3)2(NSC)2] 
0.60g, 9.21mmol 
KNCS 
0.080g,10mmol,  
84% 
308-310 
 
8.3.1.1 Synthesis and characterisation of Bis(isothiocyanato-N)(bis{2-[1-(4-
methoxyphenyl)-1H-1,2,3-triazol-4-yl-N3]pyridine-kN})]iron(II) 
The [Fe(L3)2(NCS)2] complex was synthesised by dissolving (0.072g, 0.11mmol), of 
the complex [Fe(L3)2(Cl2)] in DMSO (10ml). The mixture was allowed to stir for 15 
min, and then a solution of KNCS (0.5g, 7.68mmol) in a mixture of H2O (5ml) and 
CH3OH (20ml) was slowly added. The mixture was refluxed for 24h, and then 
allowed to stir at room temperature for 30min. The solvent was reduced under vacuum 
to about half its original volume, and then crushed ice was added to the solution. The 
resulting precipitate was filtered, washed with several volumes of cold methanol and 
diethyl ether to yield a pale yellow solid. The isolated product gave a yield of 72%, 
(0.056g, 0.082mmol), mp, 238 - 240°C. IR ῡ(cm-1): 3123, 3087, 2956, 2921, 2851, 
2851, 2834, 2076, 1606, 1574, 1514, 1471, 1467, 1442, 1309, 1253, 1176, 1064, 1028, 
1017, 1001, 983, 836, 792, 789, 719. UV-Vis (DMSO) λmax: 258nm, εmax = 63333 
dm3mol-1cm-1, 286nm, εmax = 78666 dm3mol-1cm-1, 351nm, εmax = 664 dm3mol-1cm-1. 
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The complex showed a value of µeff = 5.36 B.M:  HRMS TOF (MALDI) with the 
highest molecular weight peak matching, observed at m/z = 618.1 (100%) is attributed 
to [M-NCS]+. The calculated value for [C29H24N9O2SFe]
+ is 618.1. The second 
fragment observed is at 560.1(3%) and is referred to as [M]+. The calculated value for 
[C28H24N8O2Fe]
+  is observed at a value of  = 560.1. ɅM (DMSO) = 48Ω-1cm2mol-1 
[35-37]. 
8.3.1.2 Synthesis and characterisation of Bis(isothiocyanato-N)(bis{2-[1-(4-
methoxyphenyl)-1H-1,2,3-triazol-4-yl-kN3]pyridine-kN})]cobalt(II) 
IR ῡ(cm-1):  3128, 3088, 2932, 2851, 2833, 2073, 1606, 1575, 1516, 1470, 1467, 1442, 
1308, 1253, 1176, 1064, 1029, 1019, 1001, 983, 827, 791, 789, 720. UV-Vis (DMSO) 
λmax: The Co(II) complex have shown absorption bands at 258nm, εmax = 61250 
dm3mol-1cm-1, 288nm, εmax = 40000dm3mol-1cm-1, 538nm, εmax = 14dm3mol-1cm-1. 
The complex showed a value of µeff = 4.56 B.M:  HRMS TOF (MALDI) with the 
highest molecular weight peak matching, observed at m/z = 621.0 (100%), is assigned 
to [M-NCS]+. The calculated value for [C28H24N7O2SCo]
+  is 621.0. The second 
fragment observed at 563.1(20%) is referred to as [M]+. The calculated value for 
[C28H24N8O2Co]
+ is observed at a value of 563.1. ɅM (DMSO) = 37Ω-1cm2mol-1[3-5]. 
8.3.1.3 Synthesis and characterisation of Bis(isothiocyanato-N)(bis{2-[1-(4-
methoxyphenyl)-1H-1,2,3-triazol-4-yl-kN3]pyridine-kN})]zinc(II) 
IR ῡ(cm-1):  3122, 3088, 2955, 2934, 2834, 2081, 1608, 1575, 1517, 1470, 1455, 1442, 
1309, 1253, 1177, 1065, 1028, 1017, 1002, 983, 836, 789, 769, 720. UV-Vis (DMSO) 
λmax: The Zn(II) complex have shown absorption bands at 257nm, εmax = 
57500dm3mol-1cm-1, 288nm, εmax = 38750dm3mol-1cm-1. 1HNMR data δH/ppm 
(400MHZ, DMSO-d6): 9.25 (1H, s, H11),   8.65-8.64 (1H,d, JHH = 4.58Hz, H2), 8.12-
8.10 (1H, d, JHH = 7.79Hz, H5), 7.98-7.89 (3H, m, H4, Ar-H13,17), 7.42-7.39 (1 H, dd, 
JHH = 5.04H3), 7.17-7.13 (2H, J= 9.16Hz, Ar-H14,16), 3.84 (3H, s, CH3, H19); 
13CNMR 
(100.63MHZ, D6MSO-d6) δc/ppm: 55.62 (C19), 114.81 (C14,C16 -Ar), 119.76 (C5), 
121.20 (C11), 121.73 (C13,C17 -Ar) 123.38 (C3), 129.74 (C12) , 133.58 (NCS), 137.53 
(C4), 147.45 (C7), 149.01 (C2), 149.46 (C6), 159.28 ( C15): These assignments were 
confirmed using DEPT 13C (135°), 1H-1H COSY and 1H-13C HMQC two dimensional 
correlation spectroscopy. HRMS TOF (MALDI) with the highest molecular weight 
peak matching, observed at m/z = 626.0 (100%), is assigned to [M-NCS]+. The 
calculated value for [C29H24N9O2SZn]
+ is 626.1. The crystals of the molecule 
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[Zn(L3)2(NCS)2] were obtained by slow evaporation in the hot mixture of CH3OH: 
CH3CN in a ratio of 1:2 solutions. ɅM (DMSO) = 10Ω-1cm2mol-1 [35-37]. 
8.3.1.4 Synthesis and characterisation of Bis(isothiocyanato-N)(bis{2-[1-(4-
methoxyphenyl)-1H-1,2,3-triazol-4-yl-kN3]pyridine-kN})]cadmium(II) 
IR ῡ(cm-1):  3140, 3110, 3086, 2958, 2934, 2835, 2075, 1601, 1571, 1517, 1489, 1454, 
1440, 1311, 1253, 1177, 1065, 1027, 1017, 1002, 983, 838, 796, 774, 718.  UV-Vis 
(DMSO) λmax: The Cd(II) complex have shown absorption bands at 258nm, εmax = 
48519dm3mol-1cm-1, 288nm, εmax = 36296 dm3mol-1cm-1. NMR data (ppm), δH 
(400MHZ, D6MSO-d6)
 1HNMR data δH/ppm (400MHZ, DMSO-d6): 9.22 (1H, s, 
H11), 8.66-8.64 (1H,d, JHH = 4.12Hz, H2), 8.11-8.09 (1H, d, JHH = 7.79Hz, H5), 7.96-
7.91 (4H, m, H4, Ar-H13,17), 7.41-7.39 (1 H, dd, JHH = 5.04 H3), 7.17-7.13 (2H, J= 
9.16 Hz, Ar-H14,16), 3.84 (3H, s, CH3, H19); 
13CNMR (100.63MHZ, D6MSO-d6) 
δc/ppm: 55.61 (C19), 114.79 (C14,C16 -Ar), 119.72 (C5), 121.17 (C11), 121.71 (C13,C17 
-Ar) 123.33 (C3), 129.74 (C12), 132.23 (NCS), 137.44 (C4), 147.66 (C7), 149.21 (C2), 
149.52 (C6), 159.24 C18): These assignments were confirmed using DEPT 
13C (135°), 
1H-1H COSY and 1H-13C HMQC two dimensional correlation spectroscopy. 100%. 
X-ray quality white crystals were obtained by slow evaporation of hot (CH3OH).  
HRMS TOF (MALDI) with the highest molecular weight peak matching, observed at 
m/z = 676.1 (95%), is assigned to [M-NCS]+. The calculated value for 
[C29H24N9O2SCd]
+  is 676.1. The second fragment observed at 618.1(40%) is assigned 
to [M]+. The calculated value for [C28H24N8O2Cd]
+ is the peak at 501.2(30%) and is 
attributed to[Cd(L3)py(NCS)]+. The calculated value for [C20H17N6OCdS]
+ is 
observed at a value of 501.2.  The peak at 422.2(15%) is attributed to [Cd(L3)(NCS)]+. 
The calculated value for [C15H12N9OCdS]
+ is 422.2.  ɅM (DMSO) = 12 Ω-1cm2mol-1 
[35-37]. 
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8.4 Conclusion 
In conclusion, new complexes with trans-isothiocyanato as coligands, having the 
general formula [M(L3)2(NCS)2], (where; M= Fe(II), Co(II), Zn(II) and Cd(II), and 
L3 = [bis-2-(1-(4-methoxy-phenyl)-1H-1,2,3-triazol-4-yl)pyridine] have been 
successfully prepared and characterised using FT-IR, UV-Vis and fluorescence 
measurements, HRMS TOF (MALDI), NMR, magnetic moments, conductivity and 
X-ray crystallography. The structural analysis indicates that the complexes of 
[Zn(L3)2(NCS)2] and [Cd(L
3)2(NCS)2] are rare examples of the coexistence of two 
trans – coordinated NCS¯ anions in the axial position in the mononuclear triazole-
based octahedral configuration. The substitution of the chlorido ligand by an 
isothiocyanato group in the triazole complexes in order to enhance the fluorescence 
of these complexes failed to produce the desired effect. This could be related to the 
structure of these complexes.  It was noted that the above substitution had very little 
effect of the geometry of the complex.  One major difference between the triazole 
structure and that found in wide band ruthenium photosensitsers such as N3 and N719 
which both are efficient photosensitsers is the geometry of the isothiocyanato groups 
which is trans- in the triazole complexes studied by us and cis- in the ruthenium 
complexes investigated in the literature by Grätzel et al [1-2]. The ruthenium 
complexes have a net dipole moment with respect to the isothiocyanato groups, which 
is absent in the triazole complexes described here. The cis-geometry could result in 
cooperative effects in relation to the MCLT properties of the complex.  
Further work to address this issue could involve the substitution of the Mn and Cd-
triazole chloride complexes with ligand L8, by an isothiocyanate group in view of the 
fact that the chloride complexes of these metals adopt a cis configuration (see Figure 
8.29).  
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Figure 8.29: The molecular structures of cis configuration of the complexes (A) 
[Mn(L3)2Cl2), (B) [Mn(L8)2Cl2] and(C) [Cd(L8)2Cl2]. 
 
If there is a cis effect with respect to the properties of these complexes, then should 
be observe an enhancement in the fluorescence properties of these complexes with 
respect to their chlorido counterparts. 
 
In summary, the click reaction has proved to be a versatile reaction for the preparation 
of a diverse range of cis and trans organometallic complexes as well as polymeric 
structures with a range of metal ions.  The replacement of phenyl azide derivatives 
with azides prepared from known fluorescent compounds could result in the 
preparation of triazoles with enhanced fluorescent properties and improved solubility 
in organic solvents that would result in greater fluorescence, in view of the effect of 
solvent polarity on fluorescence and through the conjugation identified in these 
derivatives. The identification of triazole ligands that adopt cis and trans 
configurations with particular metal ions should allow us to choose appropriate 
transition metals and ligands to engineer photosensitsers with enhanced fluorescent 
properties and organic solvent solubility.  The work undertaken here can contribute 
to the development of a new generation of low cost highly fluorescent sensitisers for 
investigation in dye based solar cells.  The next chapter describes the evaluation of 
the synthesised complexes to date as potential anti-cancer agentes.  
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Chapter 9 : BIOLOGICAL AND MEDICINAL 
EVALUATION OF METAL-LIGAND COMPLEXES 
 
9.1 Introduction 
Since compounds similar to the ones synthesised in this investigation were 
reported in literature to show medicinal properties [1, 2], it was decided to 
conduct a preliminary assessment of the potential biological activity of selected 
compounds produced in the first part of this thesis. Potential anti-cancer 
properties could open lucrative applications of such compounds and extend 
their applications to areas wider than possible dye solar cell compounds. This 
part of the work was carried out at the University of Salford under supervision 
of Dr Ragazzon. 
 
9.2 Human cell Lines 
The antitumor screenings were carried out on two human tumour cell lines, 
HepG2: Hepatoma Cells (hepatic carcinoma from a 15 years old child) 
(Cyprotex) and HCT116: Colorectal Cancer Cell (gift from KidsCan). 
 
9.3 Materials and experimental methods 
RPMI sterile media, PBS (sterile phosphate buffer), FBS (foetal bovine serum) and 
sterile plastic ware were obtained from Fisher UK. NEAA (non-essential aminoacids), 
L-glutamine, trypsin, chlorpromazine and streptomycin/penicillin were obtained from 
Sigma-Aldrich UK. MTT was obtained from Alfa-Aesar UK. Pipettes and tips were 
obtained from Anachem UK. 
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9.3.1 Methods 
 
9.3.2.1 MTT Assay 
In 1983, Mosmann developed the MTT assay (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide assay) and is a method of measuring the survival of 
mammalian cells, in which the yellow 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) is reduced to the purple formazan in living cells (Scheme 
9.1) [3, 4]. In metabolically active cells, MTT is reduced by the mitochondrial enzyme 
succinate dehydrogenase to form insoluble formazan crystals that are subsequently 
solubilised, and the optical density (OD) measured spectrophotometrically. This 
method is commonly used to illustrate inhibition of cellular proliferation. The 
absorbance of this coloured solution can be quantified by measuring at a certain 
wavelength (usually between 500 and 600 nm) by a scanning multi-well 
spectrophotometer [5-8].  
 
 
Scheme 9.1: Chemical structure of MTT and its reduced formazan product 
The MTT assay is a cell-based assay often used for screening collections of 
compounds to determine if the test molecules have effects on cell proliferation or 
show direct cytotoxic effects that eventually lead to cell death. The MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium reduction assay 
was the first homogeneous cell survival assay developed for a 96-well format that was 
suitable for high throughput screening (HTS) [9]. The MTT substrate is prepared in a 
physiologically balanced solution, added to cells in culture and incubated. The 
quantity of formazan (presumably directly proportional to the number of viable cells) 
is measured by recording changes in absorbance at 570 nm using a plate reading 
spectrophotometer. A reference wavelength of 630 nm is sometimes used, but is not 
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necessary for most assay conditions. Viable cells with active metabolism convert 
MTT into a purple coloured formazan product with an absorbance maximum near 570 
nm. When cells die, they lose the ability to convert MTT into formazan, thus colour 
formation serves as a useful and convenient marker of only the viable cells. The exact 
cellular mechanism of MTT reduction into formazan is not well understood, but likely 
involves reaction with NADH or similar reducing molecules that transfer electrons to 
MTT [10]. 
 
The formazan product of the MTT tetrazolium accumulates as an insoluble precipitate 
inside cells as well as being deposited near the cell surface and in the culture medium. 
The formazan must be solubilised prior to recording absorbance readings. The amount 
of signal generated is dependent on several parameters including: the concentration 
of MTT, the length of the incubation period, the number of viable cells and their 
metabolic activity. All of these parameters should be considered when optimizing the 
assay conditions to generate a sufficient amount of product that can be detected above 
background levels [9]. 
 
The conversion of MTT into formazan by cells in culture is time dependent. Longer 
incubation time will result in accumulation of colour and increased sensitivity up to a 
point. However, the incubation time is limited because of the cytotoxic nature of the 
detection reagents which utilize energy (reducing equivalents such as NADH) from 
the cell to generate a signal [9]. For cell populations in a log phase growth, the amount 
of formazan product is generally proportional to the number of metabolically active 
viable cells. 
 
Chlorpromazine, a DNA intercalating agent with antipsychotic properties, was used 
as positive controls to assess the assays have worked. DMSO and media were used as 
negative controls [11]. 
 
9.3.2.2 Cells and cell culture conditions 
For cytotoxicity determination, two different human cancer cell lines were used: 
HCT116 (colorectal cancer cells, gift from KidsCan) and HepG2 (hepatoma cells, gift 
from Cyprotex). Cell culture media and reagents were purchased from Fisher 
scientific, UK. Cells were grown as an adherent monolayer culture in 75cm2 flasks in 
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RPMI 1640 medium supplemented with 10%, heat inactivated foetal bovine serum, 
1% v/v nonessential amino acids (from 100× ready-to-use stock), 2mM L-glutamine 
and 115 units/mL of penicillin G, 115 μg/mL of streptomycin at 37 °C under a 
humidified atmosphere containing 5% CO2 and 95% air. 
9.3.2.3 IC50 determination: 
A total of 15 compounds were chosen for IC50 determination based on the screening 
at single high dose results, and structural variation between the synthesised 
compounds in order to get more in depth information about the structural activity 
relationship. The selected compounds were tested at a range of concentrations (20, 
10, 5, 2.5, 1.25, 0.625μM) on two different cancer cell lines (HepG2 and HCT116), 
and cell death percentage was determined by the colorimetric MTT [3-(4,5-dimethyl-
2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide] micro-culture assay.  HCT and 
hepG2 cancer cell lines were chosen because they are the third most prevalent cancer 
in the UK. Cells were detached from the 75cm2 flasks (at a confluence of 70%) by 
trypsinisation, seeded in 100μL aliquots into 96-well clear micro-culture plates. Cell 
densities of 3.0 × 103 cells/well for 72 hours of incubation, were chosen in order to 
ensure exponential growth of untreated controls throughout the experiment. Cells 
were allowed to adhere into the 96-well micro-culture plate for 24 hours prior to 
dosing. Stock solutions of the test compounds in DMSO were appropriately diluted 
in complete culture media to make up the required concentrations, and then added in 
25μL aliquots into the 96-well micro-culture plate. Cells were exposed to the test 
compounds for 72 hours. Plates were maintained at 37°C in a humidified atmosphere 
containing 95% air and 5% CO2. At the end of the incubation period 30μL/well MTT 
solution in phosphate-buffer (3 mg/mL) were added, and then incubated for further 3 
hours. After the end of the incubation, the supernatants containing medium and MTT 
were removed and the formazan crystals formed by viable cells were dissolved in 
100μL of DMSO per well. Optical densities at λ = 540 nm were measured with a 
LUMIistar Omega multi-mode plate reader. The colorimetric MTT assay was used to 
determine the cell death percentage at serial diluted concentration of the tested 
compounds (range of concentrations 20-0.625μM), and the IC50 (the concentration at 
which 50% of cell growth was inhibited as compared to the control wells which did 
not contain any drug) was determined from dose response curve using OriginPro 9.1 
data analysis and graph software [12]. 
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9.4 Results and discussion 
9.4.1 Results of screening for anticancer activity at single high dose 100μM using 
the effect of the ligand nature on the (R) group substitutes in HepG2 and HCT116 
cancer cell Lines 
Experiments were performed in duplicates as a proof of concept and to obtain 
statistical errors.  More number of experiments is needed to establish the results.  Only 
the ligands and the complexes were screened. It is necessary to screen the metal 
chlorides too in order to complete the control experiments. The in-vitro of activity of 
60 compounds (free ligands (L2-L9) and their metal complexes), were investigated 
against liver carcinoma (HepG2) and colon carcinoma (HCT116). In this study, a 
family of neutral bidentate 1,4-substituted pyridyl-1,2,3-triazole-phenyl ligands with 
pendent phenyl functional groups, was included, bearing different substituents on the 
phenyl-triazole moieties by using various (R) groups with different substituents such 
as electron withdrawing and electron donating (L2-L9) ligands, Scheme 9.2. 
Where: 
L2 = CH3,  
L3 = OCH3, 
L4 = COOH,  
L5 = F,  
L6 = Cl,  
L7 = CN,  
L8 = H and  
L9 = CF3 
 
 
In these complexes, Metal = Mn(II), Fe(II), Co(II), Ni(II), Cu(II), Zn(II), Cd(II) and 
Pt(II). The compounds were screened and evaluated for their cytotoxicity activity, 
after a period of time ranging from 24 and 72 hr of incubation at 100μM concentration. 
It was observed that all free ligands are non-toxic with an order of activity classified 
as: CN > COOH > H > CF3 > Cl > CH3> OCH3> F. The collected data is summarised 
in Table 9.1. It was found that the metal complexes exhibited variable cytotoxicity.  
The preliminary results show the significance of the presence of the metal, especially 
Co(II) and Cu(II), for coordination topyridyl-1,2,3-triazole. It was observed that (11) 
compounds displayed higher levels of cytotoxicity than the control, having cell 
 
Scheme 9.2: The chemical structure of the ligands L2-L9.  
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survival rate less than 20%. Only a few compounds exhibited cell survival rates of 
less than 10%. Tables and Figures are presented in the Appendix 3. When the survival 
is higher than 100%, it can mean: 
1) The compound can stimulate growth 
2) There is the possibility of contamination by bacteria in the well 
As the testing was also performed at different times (data not shown), and growth was 
not observed it can be safely assumed there was a contamination in that particular 
well. 
*SD: Standard deviation obtained from 2 replicates  
N=2 Screening was performed as high-throughput and then active compounds taken 
for further assessment. 
Table 9.1: In-vitro cytotoxicity of the ligands (L2-L9) against HepG2 and 
HCT116 human cancer cells (represented the cell survival rate after exposure to 
24 and 72 hours) at 100 μM concentrations, respectively. 
 
Compound 
code 
(100 μM) 
% cell 
survival 
HepG2 
24 hr 
*SD % cell 
survival 
HepG2 
72 hr 
*SD % cell 
survival 
HCT116 
24 hr 
*SD % cell 
survival 
HCT116 
24 hr 
*SD 
Control 100   0.03* 100   0.07* 100   0.06* 100   0.24* 
L2 64.1 0.06 173.1 0.05 69.2  0.08 118.6 0.06 
L3 65.1  0.10 176.8  0.03 76.0  0.03 108.2  0.08 
L4 47.7 0.00 151.5 0.04 62.8  0.03 92.3  0.05 
L5 78.6  0.01 175.2  0.02 72.8  0.06 124.5  0.04 
L6 61.7  0.02 195.7  0.05 67.4 0.03 94.5  0.02 
L7 44.3  0.08 141.8  0.03 57.4  0.06 77.6  0.02 
L8 53.4  0.09 137.2  0.04 71.9  0.00 93.6  0.14 
L9 59.6  0.12 136.6  0.07 71.0  0.07 90.3  0.12 
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Figure 9.1: In-vitro cytotoxicity of the ligands (L2-L9) and chlorpromazine 
against HepG2 and HCT116 human cancer cells at various exposure time of 24 
and 72 h. 
 
9.4.2: Results of screening for anticancer activity at single high dose 100μM using 
colon carcinoma (HepG2) cell lines. 
In general, new drugs are expected to have an IC50 lower than 20μM before taking 
them for chemical optimisation; as our initial panel included 60 compounds, it was 
decided a one top concentration of 100μM as cut off would give us an indication if 
there was any compound worth taking it forward. It is noticeable that after the 
complexation between the metal ions with different ligands, the compounds CoL3-2, 
CoL6-2, CoL7-2, CoL8-2, CuL2-2, CuL8-2 and CuL9-2 displayed cell survival rates 
of less than 20%, while CoL8-2, CoL9-2, CuL2-2 and CuL9-2 exhibited cell survival 
rates of less than 10%. The compounds with metal ions Co(II) and Cu(II) showed 
stronger cytotoxicity, and the improvement of anti-proliferation activity by metal 
complexes can be attributed to an increased in the lipophilicity. Therefore, they can 
infiltrate into the cells more easily [13]. Tables 9.2- 9.3 and Figures 9.2-9.3, revealed 
the order of cytotoxicity at 72 hours on HepG2 to be CuL9-2 > CuL2-2 > CoL6-2 > 
CoL3-2 > CoL8-2 > CoL7-2.  
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Table 9.2: In-vitro cytotoxicity of Co(II) complex with ligands (L2-L9) against 
HepG2 and HCT116 human cancer cells (represented the cell survival rate after 
exposure to 24 and 72 hours) at 100 μM concentrations, respectively. 
 
Compound 
code 
(100 μM) 
% cell 
survival 
HepG2 
24 hr 
*SD % cell 
survival 
HepG2 
72 hr 
*SD % cell 
survival 
HCT116 
24 hr 
*SD % cell 
survival 
HCT116 
24 hr 
*SD 
Control 100   0.03* 100   0.07* 100  0.06* 100  0.24* 
CoL2-2 19.4 0.03 30.9 0.02 15.6 0.04 86.8  0.05 
CoL3-2 15.0  0.01 14.1  0.02 22.6  0.10 4.7  0.02 
CoL4-2 49.7  0.08 142.8  0.05 66.0  0.08 60.6  0.09 
CoL5-2 18.4  0.01 65.9  0.14 11.9 0.02 18.6 0.07 
CoL6-2 10.3  0.00 10.8  0.03 5.9 0.01 5.3  0.00 
CoL7-2 15.4  0.00 15.5  0.01 11.6  0.01     43.2   0.03 
CoL8-2 8.1  0.00 15.5  0.00 22.3  0.07 3.7  0.00 
CoL9-2 9.7 0.00 133.7  0.06 46.4  0.15 20.7  0.20 
 
 
 
Figure 9.2: Cell survival rate of the Co(II) complex with ligands (L2-L9) and 
chlorpromazine tested on the cell lines HepG2 and HCT116 after exposed for 24 
and 72 h.  
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Table 9.3: In-vitro cytotoxicity of Cu(II) complex with ligands (L2-L9) against 
HepG2 and HCT116 human cancer cells (represented the cell survival rate after 
exposure to 24 and 72 hours) at 100 μM concentrations, respectively. 
 
Compound 
code 
(100 μM) 
% cell 
survival 
HepG2 
24 hr 
*SD % cell 
survival 
HepG2 
72 hr 
*SD % cell 
survival 
HCT116 
24 hr 
*SD % cell 
survival 
HCT116 
24 hr 
*SD 
Control 100   0.03* 100   0.07* 100   0.06* 100   0.24* 
CuL2-2 12.7 0.01 8.5 0.00 6.5  0.00 2.2 0.00 
CuL3-2 49.5  0.06  167.7  0.04 70.4  0.01 100.2  0.05 
CuL4-2 41.7  0.05  160.7  0.04 45.0  0.05  90.1  0.02 
CoL5-2 18.4  0.01 65.9  0.14 5.6   0.01  3.1  0.00 
CuL6-2 32.1  0.02 79.0  0.05 38.4 0.04 21.9  0.00 
CuL7-2 31.9  0.03 93.1  0.14 40.3  0.03 21.8  0.05 
CuL8-2 13.9  0.01 121.1  0.11 8.9   0.00 17.5  0.16 
CuL9-2 9.5  0.00 7.7  0.00 4.8  0.01 1.9  0.00 
 
 
 
 
Figure 9.3: Cell survival rate of the Cu(II) complex with ligands (L2-L9) and 
chlorpromazine tested on the cell lines HepG2 and HCT116 after exposed for 24 
and 72 h.  
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9.4.3: Results of screening for anticancer activity at single high dose 100μMusing 
colon carcinoma (HCT116) cell lines. 
In colon carcinoma (HCT116) cell line it was observed CoL3-2, CoL5-2, CoL6-2, 
CoL8-2, CuL2-2, CuL5-2, CuL8-2 and CuL9-2 are more effective on HCT116. The 
compounds CoL5-2 and CuL8-2have cell survival rates of less than 20%. While the 
compounds CoL3-2, CoL6-2, CoL8-2, CuL2-2, CuL5-2 and CuL9-2 exhibited cell 
survival rates below 10%. CoL9-2, CuL2-2, CoL5-2 and CoL6-2 were showed to be 
more effective on this cell line. The copper complex of the ligand L9 having 
(trifluoride carbon) group and with code CuL9-2 displays higher cytotoxicity than 
other the copper and cobalt analogues complexes. 
9.4.4: Results of screening for anticancer activity at single high dose 100μM 
concentrations on the liver carcinoma (HepG2) and colon carcinoma (HCT116) cell 
lines. 
Interesting discoveries came from the analysis, which indicate a preference for the 
colon cancer cell line in order of activity as follows: CuL9-2 > CuL2-2 > CuL5-2 > 
CoL6-2, while on hepatic cancer cell line the order for activity is: CuL9-2 > CuL2-2 
> CoL6-2 > CoL8-2. 
 
9.4.5 The influence of different metal ions on one particular ligand and how this 
impacts on the cell viability 
In the metal 1,4-substituted pyridyl-1,2,3-triazole-phenyl complexes, besides the 
central metal ion, pyridyl-1,2,3-triazole-phenyl platform plays a key role in 
determining the biological activities. The most effective complexes on liver 
carcinoma (HepG2) and colon carcinoma (HCT116) are CoL6-2 and CuL9-2. These 
results are displayed in Figures 9.4 - 9.5 and Tables 9.4 - 9.5. The rest of the Figures 
and Tables for other complexes are presented in the Appendix 3. 
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Table 9.4: In-vitro cytotoxicity of ligand (L6) and their complexes against HepG2 
and HCT116 human cancer cells (represented the cell survival rate after 
exposure to 24 and 72 h. 
 
Compound 
code 
(100 μM) 
% cell 
survival 
HepG2 
24 hr 
*SD % cell 
survival 
HepG2 
72 hr 
*SD % cell 
survival 
HCT116 
24 hr 
*SD % cell 
survival 
HCT116 
24 hr 
*SD 
Control 100   0.03* 100    0.07* 100   0.06* 100   0.24* 
MnL6-2 51.2  0.15 84.6  0.02 45.5 0.10 37.4  0.14 
FeL6-2 64.5  0.10 138.1 0.03 55.0 0.05 37.2  0.07 
CoL6-2 10.3  0.00 10.8  0.03 5.9 0.01 5.3  0.00 
NiL6-2 64.3  0.12 132.5  0.02 57.5 0.02 76.8  0.21 
CuL6-2 32.1  0.02 79.0  0.05 38.4 0.04 21.9  0.00 
ZnL6-2 47.5  0.05 51.4  0.03 65.7 0.03 13.1  0.02 
CdL6-2 46.1 0.08 98.5  0.05 38.2 0.02 42.5  0.16 
PtL6-2 33.8 0.01 144.7 0.01 65.1 0.10 72.0 0.08 
 
 
 
 
Figure 9.4: Cell survival rate of the metal(II) complexes with ligands (L6) and 
chlorpromazine tested on the cell lines HepG2 and HCT116 after exposed for 24 
and 72 h.  
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Table 9.5: In-vitro cytotoxicity of ligand (L9) and their complexes against HepG2 
and HCT116 human cancer cells (represented the cell survival rate after 
exposure to 24 and 72 h. 
 
Compound 
code 
(100 μM) 
% cell 
survival 
HepG2 
24 hr 
*SD % cell 
survival 
HepG2 
72 hr 
*SD % cell 
survival 
HCT116 
24 hr 
*SD % cell 
survival 
HCT116 
24 hr 
*SD 
Control 100   0.03* 100    0.07* 100   0.06* 100   0.24* 
MnL9-2 60.7  0.14 50.8  0.01 69.1  0.02 55.2  0.33 
FeL9-2 56.8  0.13 55.3  0.03 69.9  0.07 12.5  0.03 
CoL9-2 9.7 0.00 133.7  0.06 46.4  0.15 20.7  0.20 
NiL9-2 42.3  0.00 173.1  0.03 57.9  0.07 41.1  0.15 
CuL9-2 9.5  0.00 7.7  0.00 4.8  0.01 1.9  0.00 
ZnL9-2 40.8  0.08 147.0  0.09 50.8  0.02 59.9  0.15 
CdL9-2 47.5  0.09 92.7  0.03 53.1  0.01 33.4  0.09 
 
 
 
 
 
Figure 9.5: Cell survival rate of the metal(II) complex with ligands (L9) and 
chlorpromazine tested on the cell lines HepG2 and HCT116 after exposed for 24 
and 72 h.  
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9.4.6 The IC50 measurements of selected compounds on HepG2 cell lines at 72 
hours of incubation 
From the results of the first screening at 100 µM concentrations 14 compounds were 
selected: CoL2-2, CoL3-2, CoL5-2, CoL6-2, CoL7-2, CoL8-2, CoL9-2, 
Co(L3)2(NCS)2, CuL2-2, CuL3-2, CuL5-2, CuL6-2, CuL7-2, CuL9-2 and were tested 
for their IC50 levels. The IC50 represents the lowest concentration of a drug or 
chemical that is required for 50% inhibition under the experimental conditions; in 
other words, it is a measure of the effectiveness of a substance in inhibiting a specific 
biological or biochemical function [14]. The selected compounds were incubated at a 
range of concentration at 37ºC and 5% CO2 for 72 hours. The data was plotted into 
Origin V9.1 using a dose-dependent equation to determine the IC50 values, Table 9.6. 
 
Table 9.6: Cytotoxicity of pyridyl-triazole complexes on HepG2 cell lines at 72 
hours of incubation.  
Compounds IC50 μM (*SD onHepG2)  
CoL2-2 >20 
CoL9-2 >20 
[Co(L3)2 (NCS5)2] >20 
CoL3-2 >20 
CoL5-2 >20 
CoL7-2 >20 
CoL6-2 2.45 
CoL8-2 >20 
CuL6-2 >20 
CuL7-2 >20 
CuL5-2 >20 
CuL9-2 >20 
CuL2-2 >20 
CuL3-2 >20 
Chlorpromazine 11.94 
*SD: Standard deviation obtained from 2 replicates and obtained through Origin V9.1. 
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From the values in Table 9.6 it is clear that the majority of the tested compounds had 
an IC50>20 μM after 72 hours of incubation, while a single compound (CoL6-2) 
having chlorine on the pendent phenyl arm connected to the triazole ring showed 
excellent cytotoxic activity towards HepG2 (IC50 = 2.45μM). The chemical structure 
for the complex (CoL6-2) is presented in Figure 9.6.  
 
 
 
Figure 9.6: The chemical structure of the complex (CoL6-2). 
 
 
 
Figure 9.7: In-vitro cytotoxicity effects of complex CoL6-2 against human 
hepatic cancer cell line (HepG2) after 72 hours of incubation. 
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9.4.7 The IC50 measurements of selected compounds on HCT116 cell lines at 72 
hours of incubation 
CoL2-2, CoL3-2, CoL5-2, CoL6-2, CoL7-2, CoL8-2, CoL9-2, Co(L3)2(NCS)2, 
CuL2-2, CuL3-2, CuL5-2, CuL6-2, CuL7-2, CuL9-2) were screened for IC50 
determination on HCT116. The results of this screening are summarised in Table 9.7. 
The compounds CoL2-2, Co(L3)2(NCS)2, CoL3-2, CoL5-2, CoL7-2, CuL2-2, CuL7-
2 all had an IC50>20 μM after 72 hours in incubation, while CoL6-2, CoL8-2, CoL9-
2, CuL3-2, CuL5-2, CuL6-2, CuL9-2 demonstrated variable values of IC50 due to the 
different substituents on the phenyl-triazole moieties. The complex CuL5-2 (fluoride 
on the pendent phenyl arm connected to the triazole ring) displayed excellent 
cytotoxic activity toward HCT116 with an IC50 value of 0.0092 μM, CuL3-2 
(methoxy) exhibited an IC50 value of 2.48 μM, CuL9-2 (trifluoride carbon) showed 
an IC50 value of 5.09 μM (Figure 9.9), and lastly the CuL6-2 (chloride) showed an 
IC50 value of 10.08 μM. The IC50 values of the cobalt complexes could be arranged 
in the order of: CoL6-2 (chloride) displayed IC50 value of 4.64 μM Figure 9.10 and 
CoL9-2 (trifluoride carbon) with IC50 value of 5.03 μM. The chemical structures of 
these complexes are presented in Figure 9.8.   
 
 
 
Figure 9.8: The chemical structures of the complexes (CoL6-2, CoL9-2, CoL8-2 
CuL3-2, CuL5-2, CuL6-2 and CuL9-2). 
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Table 9.7: Cytotoxicity of pyridyl-triazole complexes on HCT116 cell lines at 72 
hours of incubation. 
Compounds IC50 μM (*SD <5%) on HCT 116 
CoL2-2 >20 
CoL9-2 5.03 
[Co(L3)2 (NCS5)2] >20 
CoL3-2 >20 
CoL5-2 >20 
CoL7-2 >20 
CoL6-2 4.64 
CoL8-2 3.18 
CuL6-2 10.08 
CuL7-2 >20 
CuL5-2 0.0092 
CuL9-2 5.09 
CuL2-2 >20 
CuL3-2 2.48 
Chlorpromazine 14.31 
 
*SD: Standard deviation obtained from 2 replicates and obtained through Origin V9.1. 
 
Figure 9.9: In-vitro cytotoxicity effects of complex CuL9-2 complex against 
human colon cancer cell line (HCT116) at 72 hour of incubation. 
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Figure 9.10: In-vitro cytotoxicity effects of complex CoL6-2 complex against 
human colon cancer cell line (HCT116) at 72 hour of incubation. 
9.5 Conclusion 
It was observed the free ligands are non-toxic towards the tested cell lines and the 
insertion of metal leads to considerable cytotoxicity. The study clearly indicates that 
the insertion of metal into a non-toxic pyridyl-triazole-phenyl moieties ligands 
functional group imparts cytotoxic activity to the compound. Among all these 
complexes the copper and cobalt complexes are the most effective. 
Upon analysis of the activities of all compounds on both cell lines representing hepatic 
and colon cancers, it was found the colon carcinoma HCT116 was more sensitive, 
therefore it can speculate the compounds are more active on colon cancer. From the 
detailed analysis of IC50 values it was discovered the compounds CoL6-2, CoL8-2, 
CoL9-2, CuL3-2, CuL5-2, CuL6-2, CuL9-2, were active on both cell lines but 
showing a marked preference for colon carcinoma HCT116.  
The compound (CoL6-2) showed a preference for HepG2, implying the compound 
has selectivity for hepatic cancer over colon cancer. The compounds CoL8-2, CoL9-
2, CuL3-2, CuL5-2, CuL6-2 and CuL9-2 have preference for the colon carcinoma 
HCT116 instead of the hepatic carcinoma. This selectivity can also imply the 
possibility of choosing one type of cancer, this can be extrapolated to assume in the 
case of CoL6-2, this theoretical treatment would target hepatic cancers but would not 
affect the intestine epithelial with less side effects for a treatment course. Also any 
derivatives based on compounds CoL5-2, CoL8-2, CuL5-2 and CuL8-2 would target 
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the colon carcinoma but would not affect the liver, which is generally a problem with 
chemotherapy.  
This difference could be based on compounds binding on targets that only appear on 
one cell line and not in both, as well as different metabolic functions in both types, in 
which the compounds could be activated or inactivated. 
In further work, the compounds CoL8-2, CuL8-2, CoL9-2, CoL5-2, CuL3-2, CuL5-
2, CoL6-2, CuL6-2 and CuL9-2should be studied for: 
 Metabolism, using hepatic enzymes in first instance, to see if there is any modification 
to the structure. 
 Toxicity in primary hepatic and colon cells. 
 Target validation through cell cycle analysis and fluorescence microscopy to 
determine the mode of action on both tumour and primary cells. 
 The compounds (CoL6-2 the lowest IC50 of Hepg2 and CuL5-2 the lowest IC50 of 
HCT116) could be taken as hits to explore further modifications to improve the 
anticancer activities. 
 Synthesis and characterisation of ruthenium complexes with theses ligands for 
studying the biological activities on liver carcinoma (HepG2) and the colon carcinoma 
(HCT116). 
 
As mentioned earlier, it is necessary to screen the metal chlorides too in order to 
complete the control experiments. In further work with the selected compounds from 
IC50 tests, it is recommended to assess the physico-chemical properties including pKa, 
lipophilicity and solubility. As the complexes can exhibit photodynamic properties 
when exposed to certain wavelengths, it is recommended to assess the complexes in 
different cell lines whilst exposed to light, to determine if the toxicity increases (IC50 
would decrease).  
 The investigation into the potential anti-cancer properties of the compounds initially 
intended simply as dye solar cell possibilities, open a new and exciting area of 
application and further exploration of these synthesised complexes. It also 
demonstrates the well-known experience of many researchers that one often discovers 
different applications and uses for compounds initially intended for other purposes if 
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one is willing to experiment think laterally and is aware of chemical similarities 
between different metal complexes. This latter part of the thesis work is most 
satisfying in the unexpectedly positive results it yielded. 
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Chapter 10 : Conclusions, Recommendations and 
Contributions 
 
10.1 Conclusions 
A series of bi-dentate 2-pyridyl-1,2,3-triazole ligands bearing a 4-substituted phenyl 
arm using a simple cycloaddition reaction (an example of click chemistry). were 
successfully synthesised. Furthermore, it has been demonstrated that different 
functional groups (electron rich and withdrawing substituents) on the triazole 
heterocycle affect the electronic properties of the triazole moiety and the formation of 
metal complexes.  In particular, direct connection at the N8 position of the triazolyl 
ring of a 4-substituted phenyl group has a significant influence on the geometry of 
both the ligands and their corresponding M-complexes. First row transition metal 
complexes (Mn(II), Fe(II), Co(II), Ni(II), Cu(II), Zn(II) and Cd(II)) were synthesised 
due their availability and cost effectiveness as alternative solar dyes compared to the 
popular ruthenium metal. During the characterisation and structural studies of the 
complexes it was found that [M(L3)2(Cl)2] type complexes show a rare example of the 
coexistence of two trans coordinated Cl anions in the axial position or cis position in 
the mononuclear triazole-based octahedral configuration. The fact that the electronic 
properties of the ligands can be controlled via electron donating or withdrawing 
groups clearly will be beneficial in designing bespoke solar dyes.  In an effort to 
increase fluorescence properties of the metal complexes it was decided to use 
isothiocyanates as co-ligands, alongside triazoles, with various metals (M= Fe(II), 
Co(II), Zn(II) and Cd(II)).  Interestingly, it was found that that the complexes of 
[Zn(L3)2(NCS)2] and [Cd(L
3)2(NCS)2] are rare examples of the coexistence of two 
trans – coordinated NCS¯ anions in the axial position in the mononuclear triazole-
based octahedral configuration.  Unfortunately, isothiocyanate substituted metal-
triazole-complexes did not produce an enhanced fluorescence possibly due to 
structural reasons (trans- orientation as opposed to cis-).   
 
Since a number of interesting metal complexes were avaible, it was envisaged their 
use within cancer therapy.  A collaboration with Dr. Ragazzon at Salford University 
was established to assist with this and it found that free ligands are non-toxic towards 
the tested cell lines and the insertion of metal leads to considerable cytotoxicity.  
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Using copper and cobalt complexes proved to be the most effective and cytotoxic 
towards the cell lines.  IC50 values have shown that the complexes are most active in 
colon cancers compared to hepatic cancers and is possibly due to differences in 
binding mechanisms.  
 
10.2 Further Work 
Further work should involve fabrication of DSSC cells with the synthesised metal 
complexes and testing their solar conversion.  It would be useful to address whether 
a cis – configuration is preferred in increasing solar efficiency compared to a trans - 
orientation of the ligands within these metal complexes.  An exploration of the 
electrochemistry of the synthesised dye solar compounds should be pursued and will 
surely yield some interesting results and maybe even application potential.  
In further work, selected complexes should also be studied for: 
 Metabolism, using hepatic enzymes in first instance, to see if there is any modification 
to the structure. 
 Toxicity in primary hepatic and colon cells. 
 Target validation through cell cycle analysis and fluorescence microscopy to 
determine the mode of action on both tumour and primary cells 
 The compounds CoL6-2 (the lowest IC50 of Hepg2) and CuL5-2 (the lowest IC50 of 
HCT116) could be explored and modified furthet to improve their anticancer 
activities. 
 Synthesis and characterisation of ruthenium complexes with theses ligands for 
studying the biological activities on liver carcinoma (HepG2) and the colon carcinoma 
(HCT116). 
 Establishing the mechanism of cancer cell killings by selected organometallic 
complexes. 
 Photodynamic investigation using the synthesised organometallic complexes. 
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10.3 Novelty and contribution to new knowledge  
The current investigation yielded several new and interesting contributions to the 
current field of knowledge in the area. 
 
 New compounds have been synthesised and characterised, including several new bi-
dentate 2-pyridyl-1,2,3-triazole ligands bearing a 4-substituted phrnyl arm with 
various electron withdrawing and electron donating groups (PYTA ligands) to 
produce several new novel organometallic compounds with two different types of co- 
ligands, namely Cl- and SCN-. There are currently one paper submitted to the arabain 
journal of chemistry on these molecules, with a further two papers in preparation.  
(See the Contributions from this research). 
 Proof of a unique crystal structure packing patten of the repeating unit cells in the 
PYTA ligand, on which a paper has been published in crystallographica B70, 379–
389 (2014). 
 Potential new solar cell compounds that have similar structures to commercial solar 
cell compounds, and which can be explored more and modified further. 
 Potential new anti - cancer compounds with promising and potential selective anti - 
cancer properties, which can be explored futher.  
 
10.4 Achieving the aims of the investigation 
The aims of the investigation, as set out in Chapter 1, were to accomplish the: 
1- Synthesis of transition metal complexes. 
2- Characterisation of the physical properties of the complexes.  
3- Characterisation of the optical, fluorescent and crystallographic properties of the 
complexes to predict their suitability or not for DSSC. 
4- Evolution of the complexes as potential anti - cancer agents.  
All these aims were successfully achieved and described in the thesis. Furthermore, 
the hypotheses that careful ligand design and systemic variation of the metal centre 
can tune and optimise the optical absorption properties of a new series of 
chromophores and produce potentially useful anti – cancer drugs, have been mainly 
proven correctly, although further electrochemical work is required to validate the 
first part. 
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Chapter 11 : Physical Appendices 
 
11.1 Appendix for Chapter 6 
 
11.1.1 UV-Vis Spectral data for ligands L2- L9 
The electronic spectra of a series of 2-pyridyl-1,2,3-triazole attached to the phenyl 
pendant arm are presented in (Figure 11.1) The ligands L2-L9 exhibit similar 
absorption bands spectrum of the free ligand, the absorption bands occur at 283-
292nm it can be assigned to the para substituent phenyl ring, which it can be assigned 
to overlap of π → π* and n → π* transitions of the aromatic and other functional 
groups present in the ligands (see Table 11.1) [1- 2].  
 
Figure 11.1: Electronic spectra of ligands L2-L9 in DMSO (C = 1x10-6M) at 
298K. 
 
A plot of the λ maxvs the σp substituent constant for all ligands gave a concave upward 
deviation in the Hammett plot with a neagtive slope for the electron donating groups 
and a positive slope for electron withdrawing groups. This is a change in mechanism 
in which electron donating groups decrease the positive charge at the triazole ring. 
However, electron withdrawing groups enhance the positive charge (see Figure 11.2) 
at this centre. There were three substituents (H, CF3 and COOH) which are outliers on 
the plot. 
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Figure 11.2:  Hammett plot of correlations of the λ max of L2-L9 ligands vs. σp 
values for the Hammett substituent parameters electron donor and withdrawing 
para substituents (R = H, Me, OMe, Cl, F, CN, COOH, and CN). 
 
 
 
 
Figure 11.3: Hammett plot of absorbance maximum of L2-L9 ligands vs. σp 
values for the electron donor and withdrawing para substituents (R = H, Me, 
OMe, Cl, F, CN, COOH, and CN). 
 
In the series L2-L9, the maximum absorption of both bands measured in DMSO (1x10-
6M), gives a linear correlation the between the Hammett σρ constant for the substituent 
on the p-position of the phenyl group (Figure 11.3). The two substituents which are 
outliers (COOH and CN) are not included in the plot. This suggests that compounds 
with these substituents act as stronger acids than one would have predicted from their 
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values. When electron withdrawing due to mesomeric effects can be extended to the 
reaction centre via “through conjugation”, the result is an even more stabilised 
species. These types of correlation between the Hammett σρ constant in relation to the 
substituent of the p-position and the relevant UV absorption frequencies were reported 
previously in literature [3, 4]. 
Table 11.1: The absorption maxima λ max vs the Hammett parameter of the σρ 
substituent correlation in DMSO (C= 1 X10-6M). 
 
Compound Substituent 
   in para 
postion 
σρ λ max(nm) Absorbance ε/10-6 M 
dm3. mol-1.cm-1 
L2 CH3 -0.17 283 0.1051 15100 
L3 OCH3 -0.27 285 0.1052 15200 
L4 COOH 0.45 291 0.0814 81400 
L5 F 0.06 283 0.0994 99400 
L6 Cl 0.23 284 0.0957 95700 
L7 CN 0.66 292 0.0975 97500 
L8 H 0 284 0.0975 97500 
L9 CF3 0.54 288 0.0932 93200 
 
11.2 Appendix for Chapter 7 
11.2.1 UV-Vis Spectral data for L3 ligand 
The electronic spectrum of L3 exhibits an intense absorption maximum at 285nm due 
to the overlap of π → π* and n → π* transitions, as shown in Figure 11.4. The 
electronic spectra of the complexes of L3 exhibited various extents of bathochromic 
shift of the bands related to the intraligand π → π* and n → π* transitions. Bands in 
the range of 352-389nm are related to the charge transfer transitions (CT), and were 
observed in the spectra data for the [M(Ln)2Cl2] complexes.  Complexes of the d
5-d9 
system display several bands in the visible region due to d-d transitions. The 
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assignments of these bands indicate octahedral geometries around the different metal 
atoms (see Table 7.3 page 138 for full assignments) [1-2]. 
 
Figure 11.4: UV-Vis spectrum of L3 at concentration of 1x10-6M. 
 
11.2.2 UV-Vis Spectrum for [Mn(L3)2Cl2)] 
The data of the [Mn(L3)2Cl2] complex with different concentrations in DMSO 
solutions are presented in chapter 7 Table 7.3 page 138. The spectrum of the Mn(II) 
complex in Figure 11.5 exhibits two bands at 258 nm, and 291 nm at concentration of 
5x10-6 M. These bands are related to the intraligand transitionsπ → π* and n → π*, 
respectively. High spin Mn(II)-complexes are very weakly coloured compounds due 
to spin forbidden d-d transitions. Therefore, it is difficult to identify the d-d bands of 
the Mn(II) complex. At higher concentrations of the Mn(II)-complex, e.g at a 
concentration of 1x10-3M, the complex displays several bands. The first band at 
352nm = 28409cm-1; εmax = 32dm3mol-1cm-1, is assignable to a n → π* transition. The 
metal-ligand charge transfer transition band is observed at 369nm = 27100cm-1; εmax= 
30 dm3 mol-1 cm-1. Lastly the band detected at 390nm = 25641cm-1; εmax = 21dm3mol-
1cm-1 could be attributed to a 4A1g → 4T1g transfer. The observed room temperature 
magnetic moment value 5.32 B.M is typical for a high spin (d5) configuration of 
Mn(II)-complexes, and confirm an octahedral geometry about Mn atom [5-7]. 
 
 314 
 
 
Figure 11.5: UV-Vis spectra of the [Mn(L3)2Cl2] complex in DMSO solutions.  
 
11.2.3 UV-Vis Spectrum data for [Fe(L3)2Cl2)] 
The UV-Vis spectrum of the [Fe(L3)2Cl2] complex gave a yellow colour in DMSO 
solution, and is shown in Figure 11.6. The spectrum reveals two absorption peaks at 
257nm and 291nm, which are assigned to the intraligand π → π* and n → π* 
transitions (red shift). The absorption peak at 333nm is related to the charge transfer 
transition. The peak detected at 922 nm is attributable to a 5T2g → 5E2g transfer. The 
magnetic moment of 5.07 B.M indicates a high spin octahedral geometry around the 
Fe atom [8-11]. 
 
Figure 11.6: UV-Vis spectra of the [Fe(L3)2Cl2] complex in DMSO solutions. 
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11.2.4 UV-Vis Spectral data for [Co(L3)2Cl2], [Ni(L
3)2(Cl2)] and [Cu(L
3)2(Cl2)] 
The spectra of [Co(L3)2(Cl2)], [Ni(L
3)2(Cl2)] and [Cu(L
3)2(Cl2)] complexes depicted 
in Figures 11.7 to 11.9, show intraligand transitions (see Table 7.3 page 138). The Co-
complex displays two additional bands in the visible region at 615 and 678nm, which 
are related to 4T1g
(F) → 4T2g(P) and 4T1g(F) → 4A2g(F) transitions respectively. This is 
characteristic for the distorted octahedral geometry around the Co atom. The magnetic 
measurement of the Co(II) complex, with the value 3.97 B.M, corresponds to three 
unpaired electrons. This value is in agreement with a high spin configuration and 
supports an octahedral environment around the Co(II) ion [12, 13]. 
 
Figure 11.7: UV-Vis spectra of the [Co(L3)2Cl2] complex in DMSO solutions. 
 
The spectrum of the [Ni(L3)2Cl2] displayed in Figure 11.8, displays peaks at 407 and 
660nm attributed to 3A2g
(F) → 3T1g(p) and 3A2g(F) → 3T1g(F) transitions, respectively. 
This is typical for a distorted octahedral geometry around the Ni atom [14]. The 
magnetic measurement value 2.73 B.M and corresponds to two unpaired electrons. 
This value is in agreement with a high spin configuration and confirmed the 
octahedral environment around the Ni(II) atom [15-17]. 
 
 316 
 
 
Figure 11.8: UV-Vis spectra of the [Ni(L3)2Cl2] complex in DMSO solutions. 
 
The electronic spectrum of the Cu(II) complex is depicted in Figure 11.9 and consists 
of a broad, low intensity shoulder band centred at 892nm, which is assigned to a 2B1g 
→ 2B2 g transition, which suggests a distorted octahedral configuration. This 
distortion can be such as to cause the three transitions, 2B1g → 2B2g, 2B1g → 2Eg, and 
2B1g → 2A1g, to remain unresolved in the spectra. It is concluded that all three 
transitions lie within the single broad envelope centred at the same range previously 
mentioned. This assignment is in agreement with the general observation that Cu(II) 
d-d transitions are normally close in energy. The magnetic moment measurement of 
the Cu(II) complex, with the value of 1.69 B.M, corresponds to one electron. This 
value is in agreement with a high spin configuration and of an octahedral environment 
around the Cu(II) atom [18, 20]. 
 
Figure 11.9: UV-Vis spectra of the [Cu(L3)2Cl2] complex in DMSO solutions. 
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Due to the Jahn-Teller (J-T) effect, the ground state 2Eg is further splitted into a 2B1g 
ground state and 2Ag excited state. 
 
 
 
Figure 11.10: Jahn-Teller distortion of the octahedral symmetry of Cu(II) and 
the 2Eg and 2T2g states of the octahedral Cu(II) ion (d9) split under the inﬂuence 
of tetragonal distortion [23]. 
11.2.5. UV-Vis Spectral data for [Zn(L3)2Cl2] and [Cd(L3)2(Cl2)] 
The electronic spectra of the [Zn(L3)2Cl2]and [Cd(L
3)2Cl2] complexes in Figure 11.11 
exhibit bands at 257nm, 291nm and 258, 286nm, respectively. These were assigned 
to intra-ligand transitions π → π* and n→ π* (see Table 7.3 page 138), which are 
related to d (10) electron configurations of the Zn(II) and Cd(II) metals respectively 
[21, 22]. 
 
Figure 11.11: UV-Vis spectra (A) of the [Zn(L3)2Cl2] and (B) the [Cd(L3)2Cl2] 
complexes in DMSO solution. 
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11.2.6 Introduction to Magnetic Susceptibility 
Magnetic susceptibility is measured using a sensitive instrument known as a magnetic 
susceptibility balance. The Gouy balance was used for determining the magnetic 
susceptibility of all the materials. The gram magnetic susceptibility for a substance 
can be calculated from the following equation.  
χg = (Cbal) (l) (R – Ro) / (109) (m)                                                      (11.1)  
Where; l = height of sample in the tube in units of centimetres 
            m = mass of the sample in units of grams 
            R = reading for tube plus sample 
            Ro = reading for the empty tube 
           Cbal = balance calibration constant = 1.0 
The molar magnetic susceptibility is then calculated from the gram magnetic 
susceptibility using Equation (11.2): 
 
χm = (χg) (molar mass)                                                                       (11.2) 
 
The magnetic susceptibility for a particular substance is not particularly useful in 
itself. However, the effective magnetic moment for a particular substance can be 
calculated from the gram magnetic susceptibility [23] using Equation (11.3):  
 
Ueff = 2.83 [(Χm) (T)] 1/2                                                                       (11.3)    
 
In this equation T represents the Kelvin temperature (294 K). 
 
11.2.7 Introduction to fluorescence measurements 
Fluorescence is the molecular absorption of light energy at one wavelength and its 
nearly instantaneous re-emission at another, usually longer, wavelength. Some 
molecules fluoresce naturally and others can be modified to become fluorescent 
compounds. Fluorescent compounds have two characteristic spectra: an excitation 
spectrum (the wavelength and amount of light absorbed) and an emission spectrum 
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(the wavelength and amount of light emitted). These spectra are often referred to as a 
compound's fluorescence signature or fingerprint. No two compounds have the same 
fluorescence signature. It is this principle that makes fluorometry a highly specific 
analytical technique. 
 
Fluorometry is the measurement of fluorescence. The instrument used to measure 
fluorescence is called a fluorometer or fluorimeter. A fluorometer generates the 
wavelength of light required to excite the analyte of interest. It selectively transmits 
the wavelength of light emitted, and then it measures the intensity of the emitted light. 
The emitted light is proportional to the concentration of the analyte being measured 
(up to a maximum concentration). Fluorometers employ monochromators (a 
spectrofluorometer), optical filters (a filter fluorometer), or narrow band light sources 
like LED’s or lasers to select excitation and emission wavelengths. 
 
Fluorometry is chosen for its extraordinary sensitivity, high specificity, simplicity, 
and low cost compared to other analytical techniques. Fluorometry is ordinarily 1000-
fold more sensitive than absorbance measurements. It is a widely accepted and 
powerful technique that is used for a variety of environmental, industrial, and 
biotechnology applications. It is a valuable analytical tool for both quantitative and 
qualitative analysis [24-25]. 
11.2.8. Jablonski diagram (diagram of electronic transitions) 
Absorption of light (photons) by a population of molecules stimulates electron 
transition from the singlet ground electronic level S0 to an excited state Sn (n > l). An 
excited molecule will return to the ground state S0 following two consecutive steps 
[26]. The molecule at Sn returns to the lowest excited state S1 by losing a part of its 
energy in the surrounding environment. This phenomenon is usually called internal 
conversion, and is shown in Figure: 11.12. 
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Figure 11.12: Jablonski diagram of electronic transitions. [27-28] 
 
2- From the excited state S1, the molecule will reach the ground state S0 via various 
competitive processes: 
• Emission of a photon (fluorescence) with a radiative rate constant (Kr). 
• Part of the absorbed energy is dissipated in the medium as heat. This type of energy 
is non-radiative and happens with a rate constant (Ki). 
• Excited molecules can release some of their energy to molecules located nearby. 
This energy transfer occurs with a rate constant Kq (collisional quenching), or with a 
rate constant Kt (energy transfer at distance). 
• A transient passage occurs to the excited triplet state T1 of energy lower than S1 with 
a rate constant Kisc (inter-system crossing). For each excited state S, there is an excited 
state T of lower energy. The triplet state is an excited state and so is energetically 
unstable. Therefore, de-excitation of the molecule from the triplet state occurs via 
competitive processes similar to those demonstrated for the de-excitation of the 
excited singlet state S1: 
 Emission of a photon with a rate constant K'p. This phenomenon is entitled 
phosphorescence. 
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 Dissipation of non-radiative energy with a rate constant K'i. 
 Transfer of energy to another molecule at distance (rate constant K't) or by collision 
(rate constant K'q). 
 
Generally, the main emissions of the metal-organic hybrid complexes can be divided 
into three types: 
1- The LLCT ( Ligand - to - Ligand charge transfer ) 
2- LMCT ( Ligand - to - metal  charge trainsfer ) 
3- MLCT (Metal - to -  Ligand  charge trainsfer ) [29-30] 
11.2.9 Fluorescence quantum yield 
Molecules in the fundamental ground state absorb light with intensity equal to I and 
reach an excited state Sn. Then, different competitive processes, including 
fluorescence, will compete with each other to de-excite the molecule. The rate 
constant (k) of the excited state is the sum of the kinetic constants of the competitive 
processes, as given in Equation (11.4): 
 
k = kr+ kisc+ ki                                                         (11.4) 
 
The fluorescence quantum yield ɸF is the number of photons emitted by the radiative 
way over that absorbed by the molecule, as shown in Equation (11.5): 
 
ɸ𝐅 =
𝐞𝐦𝐢𝐭𝐭𝐞𝐝 𝐩𝐡𝐨𝐭𝐨𝐧𝐬
 𝐚𝐛𝐬𝐨𝐫𝐛𝐞𝐝 𝐩𝐡𝐨𝐭𝐨𝐧𝐬
=
𝒌𝐫 
𝒌𝐫 + 𝒌𝐢𝐬𝐜 + 𝒌𝐢
                 (11.5) 
All the quantum yields have been referenced to the recrystalised standard p-terphenyl 
(λmax = 276 nm). The fluorescence measurement was carried out at 294 K and at low 
concentrations to avoid reabsorption. The solutions were purged with helium gas to 
prevent oxygen quenching of the emission spectra. The unknown quantum yield Φ(x) 
of the complex solutions relative to the quantum yield of the reference Φ(r) for the 
standard p-terphenyl was 1.0, as calculated by Equation 11.6: 
Φ(x) = Φ(r) x (Area(x) / (Area(r)) x (ABS(r) / (ABS (x)) x (η2(x) / η2(r))             (11.6)  
The area of the unknown and reference (Area (x and r)) were determined from the 
fluorescence spectra [31-34]. 
 322 
 
The absorbance terms in the equation are those of the unknown and reference (ABS 
(x and r)) at their appropriate excitation wavelengths, and the η2 is the refractive index 
for the solvent (DMSO) = 1.4770. Usually the refractive indices can be taken from a 
chemistry text [35]. The area of the emission spectrum was integrated using the 
software available in the instrument (FL solution software). As an example, below is 
the quantum yield for cobalt complex calculated by Equation 11.7: 
Φ (Co) = Φ (PTP) x (Area (Co) / (Area (PTP)) x (ABS (PTP) / (ABS (Co)) x (η2 (DMSO) / η2 
(DMSO))                                                                                                             (11.7)                          
11.2.10 Stokes shift 
Fluorescence energy is always less than the absorption energy for a given molecule. 
Thus, the emitted light is observed at longer wavelengths than the excitation, as shown 
in Figure 11.13. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11.13: Stokes shift between the peak absorbance and peak emission [36]. 
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1.3 Appendix for Chapter 8 
11.3.1 UV-Vis Spectrum data for the [Fe(L3)2(NCS)2] complex 
The UV-Vis spectrum of the [Fe(L3)2(NCS)2] complex in DMSO solution is yellow 
in colour (Figure 11.14). The spectrum reveals two absorption peaks at 258 and 
286nm, which are assigned to intra-ligand π → π* and n → π* transitions. The 
absorption peak at 351nm is attributed to a charge transfer transition. The magnetic 
moment for the complex of 5.07 B.M, indicates via the literature an assignment of a 
high spin octahedral environment (see Table 8.2). [10-15]. 
 
Figure 11.14: UV-Vis spectrum of [Fe(L3)2(NCS)2] complex in DMSO solution. 
 
11.3.2 UV-Vis Spectral data for the [Co(L3)2(NCS)2] complex 
The UV-Vis spectrum of the [Co(L3)2(NCS)2] complex is depicted in Figure 11.15. It 
shows intra-ligand transitions (see Table 8.2). The Co-complex displays bands in the 
visible region at 536nm, which are related to a 4T1g
 (F) → 4T2g (P) transfer.  Other bands 
at 258-288nm were assigned to the intra-ligand π → π* and n → π* transitions, 
respectively. This is characteristic of a distorted octahedral geometry around the Co 
atom. The magnetic measurement of the Co(II) complex of 3.97 B.M, corresponds to 
three unpaired electrons and is in agreement with a high spin configuration with an 
octahedral environment around the Co(II) ion [5, 8-10, 20, 22]. 
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Figure 11.15: UV-Vis spectrum of [Co(L3)2(NCS)2] complex in DMSO solution. 
11.3.3 UV-Vis Spectral data for the [Zn(L3)2(NCS)2] and[Cd(L
3)2(NCS)2] 
complexes 
The UV-Vis spectra of the [Zn(L3)2(NCS)2] and [Cd(L
3)2(NCS)2] complexes in 
Figures 11.16 and 11.17 exhibit bands at 257 nm and 288nm, respectively. These 
bands were assigned to intra-ligand π → π* and n→ π* transitions (see Table 8.2), 
and is related to the d10 electron configuration of the Zn(II) and Cd(II) metals, 
respectively [13-21]. 
 
Figure 11.16: UV-Vis spectrum of [Zn(L3)2(NCS)2] complex in DMSO solution. 
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Figure 11.17: UV-Vis spectrum of [Cd(L3)2(NCS)2] complex in DMSO solution. 
 
The magnetic moments and the conductivity measurements for these metal complexes 
have shown similar behaviour to the complexes of the chlorido ions that are described 
in chapter 7 (see section 7.2.5 and 7.2.6).  
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